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ABSTRACT
PART 1: DESIGN, SYNTHESIS, AND EVALUATION OF NOVEL
GRAM-POSITIVE ANTIBIOTICS
PART 2: SYNTHESIS OF DIHYDROBENZOFURANS VIA A NEW TRANSITION METAL
CATALYZED REACTION
PART 3: DESIGN, SYNTHESIS, AND EVALUATION OF BZ/GABAA α6 POSITIVE
ALLOSTERIC MODULATORS
by
Christopher Michael Witzigmann
The University of Wisconsin-Milwaukee, 2016
Under the Supervision of Distinguished Professor James M. Cook
Part 1. Lead compound SK-03-92 represents a new scaffold for antibiotic drug
discovery. Development of a new process for the synthesis of analogs has led to the
development of a number of new ligands with even more potent activity against gram-positive
bacteria, including drug-resistant strains of S. aureus. Compounds 36 and 38 represent some of
the most potent analogs developed thus far, and preliminary results indicate that they are also not
cytotoxic. Research into a Heck-mediated transition metal catalyzed pathway towards electronrich stilbenoid analogs has greatly expanded the scope of future SAR studies. This development
has led to 14 new analogs with minimum inhibitory concentrations (MICs) in pharmaceutically
acceptable ranges and it is presumed that further SAR expansion will lead to even more potent
compounds. Mechanism of action studies have shown that these compounds prove difficult to
induce mutations in bacteria that lead to drug-resistance. This has made determination of the
mechanism/mode of action difficult, and to date it is still not known, but is promising in that a
lack of developed resistance may show that these compounds act on pathways that are novel and
unlikely to form resistance. An enzyme catalyzed pathway involving tyrosinase is postulated as
a plausible mechanism for these stilbenoid compounds. This process would involve the
ii

formation of quinones, which might be toxic to the bacteria, causing the observed bactericidal
nature of these potent analogs. Further, this may explain some of the observed activity for a
number of analogs synthesized in this study. The need for new antibiotics is clear, and these
novel compounds represent a new scaffold for antibiotic drug discovery.
Part 2. Dihydrobenzofurans are an important class of compounds, a number of which are
natural products and/or biologically active. A new transition metal catalyzed pathway was
developed to synthesize novel dihydrobenzofurans. This new process was modified from the
Heck reaction developed in Part 1. Initially, the dihydrobenzofurans synthesized by the Heck
mediated process were in very low yields. Optimization of the conditions for this reaction were
successful in improving the conversion to nearly quantitative levels. A preliminary examination
of the scope of the reactions indicated that a number of electron-rich aryl bromides were well
tolerated and high yields for nearly all attempted aryl bromides were reported. The scope of
vinyl arenes includes both aryl and heteroaryl vinylic compounds, many of which were
conveniently synthesized from inexpensive starting materials. This reaction sequence is similar
to work reported by Larock, however differs in a number of significant ways.
Part 3. The α6 subunits of GABAA receptors exhibit a quite restricted regional
distribution in the brain. They are predominantly expressed in the granule cells of the
cerebellum, and in the cochlea nuclei. Our recent study revealed that the α6 GABAAR in the
cerebellum plays an important role in controlling the sensorimotor gating function, a deficit of
this function is manifested in several neuropsychiatric disorders, such as schizophrenia, tic
disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder. We have
designed a series of pyrazoloquinolinone ligands that are functionally selective for α6β2,3γ2
GABAA receptors and are positive allosteric modulators at this subtype. Preliminary data show
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analogs such as Compound 6 and Compound 11 are effective in an animal model with
sensorimotor gating deficit, reflecting the impairment of prepulse inhibition of the acoustic
startle response (PPI) induced by methamphetamine.
Recently, the α6 GABAAR was shown to be expressed in both neurons and satellite glia
of the trigeminal ganglia. The α6 subunit positive neuronal cell bodies in the trigeminal ganglia
project axons to the temporomandibular joint and likely to the trigeminal nucleus caudalis and
upper cervical region (Vc–C1), and might modulate orofacial pain and inflammatory
temporomandibular joint nociception and might modulate orofacial pain and inflammatory
temporomandibular joint nociception. Rats with 30% knock down of the α6 subunit of GABAA
receptors in trigeminal ganglia were hypersensitive to TMJ inflammation, measured by a prolong
meal time. The prevalence of TMJ disorders in the United States is estimated at 4.6% and these
disorders are the leading cause of chronic orofacial pain.
Importantly, trigeminal ganglia also send projections to the trigeminal nucleus caudalis
(TNC) and upper cervical region (Vc–C1), the trigeminal cervical complex. Activation of the
TNC plays an important role in the neuropathogenesis of migraine. In an animal model of
migraine, we have found a selective α6-GABAA receptor PAM, Compound 6, effectively
decreased the number of activated neurons in the TNC induced by intracisteral (i.c.) injection of
capsaicin. This suggests the potential of selective α6-GABAA receptor PAMs for the treatment of
migraine.
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Part 1
DESIGN, SYNTHESIS, AND EVALUATION OF NOVEL
GRAM-POSITIVE ANTIBIOTICS

1

CHAPTER ONE
INTRODUCTION TO ANTIBIOTICS
I.

HISTORY OF ANTIBIOTICS.
Throughout history infectious diseases have been among the most common ailments for

man.1 Historical epidemics such as the Bubonic plague, leprosy, and tuberculosis killed
hundreds of millions of people and were all caused by various bacterial strains.2-4 In the US,
many of these diseases are viewed as historical, yet they still persist and are major diseases in
many third-world countries to this day.5-7 This persistence is generally due to poor living
conditions, lack of access to clean water, and lack of access to antibiotics.8
Past countries have dealt with these epidemics through a variety of means. Usually the
most successful methods were improved living conditions and access to fresh water.
Quarantines were also routinely used to separate healthy individuals from the sick.9 These
methods, however, did little to help those already suffering from the disease. In fact, it wasn’t
until the early 20th century that the first antibiotics were discovered, the most successful of these
early antibiotics was Prontosil (Scheme 1-1).10 Prior to this discovery, vaccines were the most
successful method of avoiding epidemics, however a crude understanding of pathogenicity and
why vaccinations were successful led to both poor results and, similarly to recent perspectives on
vaccinations, an “anti-vax” sentiment among many populations.11 Vaccines were also not
applicable to people who had already contracted a specific disease and survival rates for some of
these diseases were very low. Because vaccinations were often not universal and because it was
not possible to vaccinate for many infectious diseases, the discovery of antibiotics was perhaps
one of the most important discoveries of the 20th century.12
2

Scheme 1-1: Prontosil and its activation to sulfanilamide.

Prior to the discovery of Prontosil, Paul Erhlich, an early pioneer in bacterial staining and
chemotherapeutic agents, discovered that methylene blue could be used to treat patients with
malaria.13 Methylene blue is described as the first fully synthetic drug, and it found use as an
antimalarial drug due to its ability to stain the pathogenic protozoans responsible for malaria.14
Erhlich’s hypothesis was that the ability of the drug to stain the pathogens blue may lead to
therapeutic potential. Indeed, when tested on two patients their fevers subsided and the parasites
disappeared from their bloodstream. Methylene blue was used for many years as an antimalarial
drug until the more successful chloroquine was discovered.15
Based on this early work by Erhlich, Gerhard Domagk continued research on dyes as
possible antibiotic agents. In the early 1930’s, Domagk discovered that Prontosil rubrum, named
due to its deep red color, was efficacious in treating mice infected with streptococci.16
Interestingly, the compound had no activity when used in vitro. Indeed, it was later found that
Prontosil was an early example of a pro-drug, a compound that breaks down to the active
component in vivo. In this case, Prontosil breaks down to sulfanilamide, a compound found to
have potent antibacterial activity (Scheme 1-1).17 Although this led to a rather short
pharmaceutical duration of Prontosil, because sulfanilamide was similarly efficacious in vivo,
this ushered in a new era of antibiotic research in the field of sulfa drugs.
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Unfortunately, this new paradigm shift in medicine came with an unfortunate side-effect,
bacterial resistance. Sulfanilamide resistance was reported as early as the late 1930’s, just a
few years after the discovery of Prontosil’s antibacterial activity.18 This has led to a back-andforth struggle to design new antibiotics that can treat the growing number of resistant strains.

II.

CURRENT ANTIBIOTICS.
Since the early pioneering days of antibiotic research, many new antibiotics have been

discovered. Advances in the fields of microbiology have allowed researchers to not only
discover new antibiotics, but also to assess the mechanisms by which these new antibiotics target
bacteria, they’re mode/mechanism of action (MOA).19-20
Although certainly not an exhaustive list, eight different current antibiotics will be
illustrated here. These include Gentamicin, Ampicillin, Oxacillin, Ciprofloxacin, Vancomycin,
Erythromycin, Tetracycline, and Rifampin. These eight drugs are all used in later chapters as
controls for compounds synthesized in this work.

1.

Gentamicin.

Figure 1-1: Structure of Gentamicin.

Gentamicin was discovered in 1963 as a fermentation product of the gram-positive
bacteria Micromonospora purpurea.21 Due to poor oral bioavailability, it is generally used either
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as a topical agent or intravenously.22-23 Gentamicin is a type of aminoglycoside which works by
stopping bacterial protein synthesis, this typically kills the bacterium and is known as a
bactericidal antibiotic.24 It is also listed by the World Health Organization (WHO) as an
essential medicine, one of the most important medications needed in a basic health system.
Gentamicin is generally used for gram-negative infections, especially blood-related
infections.25 Although certain gram-positive strains are susceptible to Gentamicin, most are not,
so in general it is not used to treat gram-positive infections. Unfortunately, Gentamicin has
several severe side-effects including nephrotoxicity (kidney damage) and ototoxicity (cochlea
toxicity) which limit its use as a treatment.22, 26 Recently due to the emergence of resistance in
many gram-negative strains, Gentamicin has found renewed use since it is still effective against a
number of these resistant strains.27 This lack of resistance is directly tied to its infrequent use in
the past rather than an inability for Gentamicin to confer resistance, as resistant strains are now
becoming more prevalent due to this resurgence.28

2.

Ampicillin.

Figure 1-2: Structure of Ampicillin.

Ampicillin is a drug related to penicillin and is in the ß-lactam family of antibiotics.29
These antibiotics inhibit transpeptidase, a protein necessary for cell wall synthesis.30 This often
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leads to cell lysis and death of the cell, so ß-lactam antibiotics are bactericidal.30-31 Ampicillin
was the first ‘broad-spectrum’ penicillin with activity against both gram-positive and gramnegative bacteria. It differs from penicillin G only with the inclusion of an amino group, which
helps Ampicillin penetrate gram-negative bacterial cell walls.32 It is also on the WHO’s list of
essential medicines for basic health systems.
Like other penicillins, Ampicillin is not effective against methicillin-resistant S.
aureus (MRSA). The effectiveness of penicillin analogs relies on their ability to both reach
penicillin-binding proteins (PBPs) and bind to the PBPs. Some bacteria are able to produce
enzymes that cleave the ß-lactam rings, known as ß-lactamase or penicillinase.33 Cleavage of the
ß-lactam rings leaves the resulting compound ineffective. Another method bacteria have
employed to gain resistance to ß-lactams is altering the PBPs. This is most notable in MRSA
strains in which the PBP is altered to such a degree that the ß-lactam ring is no longer able to
bind and the antibiotics are thus ineffective.33-34
In the case of ß-lactamases, it has been shown that ß-lactamase inhibitors such as
clavulanic acid can increase the potency of penicillin’s when co-administered.35 However,
treatment in this fashion can potentially lead to bacterial strains that possess higher levels of ßlactamase expression which can make future treatments with ß-lactams even less effective.36
Still, treatments with ampicillin or the closely related amoxicillin are among the most prescribed
treatments for bacterial infections.37

3.

Oxacillin.

Similarly to Ampicillin, Oxacillin is also a ß-lactam antibiotic. They differ greatly in that
Oxacillin is resistant to penicillinase38, however, this has led to extensive use against penicillin6

resistant S. aureus. Unfortunately, this led to the previously mentioned resistant strains in which
the PBPs active sites are altered in such a way that these ß-lactams can no longer bind, leaving
drugs like Oxacillin and the related Methicillin ineffective for MRSA strains.39
Figure 1-3: Structure of Oxacillin.

Despite these issues, Oxacillin remains a popular choice for treating bacterial infections
that are penicillin resistant.40 It is increasingly important, however, that these drugs are not over
prescribed and that patients adhere to the treatment protocols to slow the emergence of new
strains of MRSA.41

4.

Ciprofloxacin.

Ciprofloxacin, commonly known as simply Cipro, is a relatively modern antibiotic
released in 1987. It is also on the list of WHO’s essential medications for a basic health system.
It is used for both gram-positive and gram-negative infections and works by inhibiting DNA
gyrase and topoisomerase IV.42 This prevents bacterial DNA from separating and thus inhibits
cell division. Cipro has been shown to be bactericidal when used in higher concentrations,
however at its MIC it is bacteriostatic.43 It is thought this bactericidal nature is due to the release
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of DNA gyrase complexes leading to chromosomal DNA fragmentation, while at lower
concentrations the inhibitory effects just stop cell division.44
Figure 1-4: Structure of Ciprofloxacin.

Cipro is a second generation fluoroquinolone and is derived from the original antibiotic
quinolones discovered in the early 1960’s. In general, these fluoroquinolones are known to
quickly develop resistance, sometimes even within one course of treatment.45 This problem was
compounded with prescriptions for conditions not approved by the FDA and overuse in
veterinary medicine.46-47 Some bacteria developed efflux pumps that decrease intracellular
quinolone concentration and some others developed mutations to DNA gyrase and
topoisomerase IV that decreased binding affinity for quinolones.45
One literature source published in the late 1980’s reports that clinical oral dosage of
Cipro to 37 MRSA patients resulted in Cipro-resistant mutants which developed in 6 out of the
37 cases. While the article claims 91% of patients were clinically cured or their conditions
improved, this rate of resistance was alarming.48
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5.

Vancomycin.

Figure 1-5: Structure of Vancomycin.

Vancomycin is a gram-positive antibiotic biosynthesized by the bacteria Amycolatopsis
orientalis. It was first isolated in 1953 from a soil sample collected from the jungles of
Borneo.49 The mode of action is the inhibition of proper cell-wall synthesis leading to death of
the cell. Due to the difference in cell wall configurations, Vancomycin is ineffective in treating
bacterial infections from gram-negative bacteria.
Originally Vancomycin was developed as a solution to the penicillin-resistant S. aureus
infections mentioned earlier, however as Methicillin and Oxacillin were developed and were
both more efficacious and easier to dose, Vancomycin fell behind as a drug of last-resort. This
was due in part to its low oral bioavailability, which necessitated IV administration.50 Recently,
however, Methicillin and Oxacillin resistant S. aureus (MRSA) have necessitated Vancomycin
as a first-line treatment for a number of these infections.51 While IV injections are necessary for
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most infections, it can be orally administered for bowel or stomach infections since it has rather
poor oral absorption.52 It is now also on the WHO’s list of essential medications.
Vancomycin resistance, however, is becoming more prevalent, especially in hospital
settings.51, 53 If these infections are not identified as Vancomycin resistant early enough, patients
are at extreme risk. As these strains of Vancomycin-intermediate and Vancomycin-resistant S.
aureus (VISA and VRSA respectively) become more prevalent, a new antibiotic will necessarily
become the new first-line treatment for bacterial infections, with resistance likely to follow.

6.

Erythromycin.

Figure 1-6: Structure of Erythromycin.

Erythromycin is yet another antibiotic that was originally separated from a natural source,
in this case the bacteria Saccharopolyspora erythraea.54 It is also another antibiotic listed by the
WHO as an essential medication for a basic health system. It was first isolated in 1952 and was
found to be active against gram-positive bacterial strains. Erythromycin is in the antibiotic class
of macrolides, compounds that inhibit protein synthesis by binding to the 50S subunit of
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bacterial ribosomes, humans do not have 50S ribosomal units so these compounds act selectively
on the bacteria.55
Resistance to macrolides and Erythromycin is seen in many bacteria with mutations in
the 50S subunit which inhibits binding. MRSA strains, for example, are notoriously resistant to
Erythromycin and other macrolides.56-58 Growing resistance in other species is also an alarming
concern.

7.

Tetracycline.

Figure 1-7: Structure of Tetracycline.

Tetracycline was also originally isolated from bacteria, in this case strains of
Streptomyces produced the compound.59 It was first isolated in 1945 and was surprisingly
already prescribed as a drug as early as 1948.60 It is yet another antibiotic listed by the WHO as
an essential medicine.
Tetracycline acts by inhibiting protein synthesis by blocking the attachment of charged
aminoacyl-tRNA to the A site on the ribosome.61 Tetracycline binds to the 30S ribosomal
subunit of microbial ribosomes and also binds to the 40S subunit of mammalian ribosomes.
However, while bacteria actively pump Tetracycline into the cytoplasm, mammalian cells do not.
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The relatively small off-site effects in humans by Tetracycline can be explained by this 40S
binding.62 The inhibition of protein synthesis is reversible and thus bacteriostatic.59
Bacteria actively form resistance to Tetracycline by either encoding efflux pumps that
actively pump Tetracycline from the cytoplasm, or by ribosomal protection proteins that dislodge
Tetracycline from the ribosome.59, 63 Tetracyclines are sometimes prescribed for MRSA related
infections, however identification of the strain and its susceptibility to Tetracycline are important
factors considered before treatment.64-66

8.

Rifampin.

Figure 1-8: Structure of Rifampin.

As has been the case for most antibiotics discussed above, Rifampin was also first
isolated from another species of bacteria, in this case Amycolatopsis rifamycinica. It was first
discovered in 1957 and first sold as a medication in 1971.67 Along with most of the
aforementioned antibiotics, it is also on the WHO list of essential medications, particularly for
Tuberculosis (TB).68
Rifampin inhibits RNA polymerase halting bacterial RNA synthesis. It is extremely
potent in wild-type strains of M. Tuberculosis and many strains of MRSA; however, resistance is
12

easily conferred.69 Bacteria confer resistance through altered residues in the Rifampin binding
site on RNA polymerase.69-71 Rifampin resistant TB is one of the most dangerous microbes in
developing countries, with TB infecting nearly 10 million people in 2014 alone. It is estimated
that ~20% of all cases involve strains resistant to at least one medication.72-74 This often leads to
a ‘cocktail’ drug composed of, in many cases, three separate drugs (isoniazid, pyrazinamide, and
rifampin).75
Due to side-effects and the conference of resistance, Rifampin is generally not used to
treat MRSA infections, but when it is used, it is generally used in combination therapy to reduce
the likelihood of forming resistance.76

III.

THE NEED FOR NEW ANTIBIOTICS.

The eight aforementioned pharmaceutical drugs represent some of the most widely
prescribed medications for bacterial infections. It should be clear, however, that resistant strains
to every single one of these antibiotics has been observed. The early penicillins were the first to
lose effectiveness, followed closely by the penicillinase resistant methicillin/oxacillin drugs. The
explosion of new antibiotics in the mid-20th century slowed the spread of resistance, or at least
widened its scope, leaving a plethora of treatment options even for the deadliest infections. That
said, however, identification of strains is difficult and generally results in the use of the best
current first-line therapy to eradicate an infection and give the best chances of survival to the
patient. Indeed, choosing the wrong therapy is deadly in many cases, especially in MRSA
related infections.77
This problem is exacerbated since the first-line treatments slowly lose effectiveness and a
new first-line therapy is needed. Currently, Vancomycin is considered the first-line treatment for
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many identified MRSA infections78, as MRSA becomes more prevalent, the use of Vancomycin
will also become more prevalent. In the past decade we have seen a surprising explosion of
Vancomycin resistant related microbes, specifically VISA and VRSA.79
Currently, it is estimated that close to 19,000 patients die annually from MRSA related
infections in the United States alone.80-83 When VRSA becomes just as prevalent as MRSA is
today, those numbers could sky-rocket. This alone is an important reason for the development of
new antibiotics, but there is also a plethora of other related infections both from gram-negative
bacteria and mycobacterium that also require new medications and new treatments.84-87
Unfortunately, bacterial infections are less enticing for pharmaceutical companies as
treatment lengths are generally weeks as opposed to chronic diseases in which treatments could
last years. The costs necessary to take a drug from the bench to a prescription are prohibitive
with such short treatment cycles. Moreover, as current antibiotics are still effective to varying
degrees, competition in the market lowers the potential profits from a new drug.88
With this combination of factors involved, it is not surprising that the number of new
antibiotics approved by the Food and Drug Administration (FDA) has steadily declined since the
1980’s. It is also important to note that new antibiotics are generally from an already known
class of antibiotics, of which resistance patterns are already known. Recently the resurgence of
antimicrobial research has led to the discovery of the first new class of antibiotics in 30 years,
Teixobactin. Human trials of this new drug may not be started until 2017, however, and
although resistant strains have not been isolated in vitro, experts claim that it is still possible that
resistant strains will develop in clinical settings.89
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IV.

CONCLUSION.

The history of antibiotics spans just over one century. In the course of that century many
new drugs have been discovered that have become essential medications in treating often deadly
infections. More recently, however, the spread of resistance has led to the need for the discovery
of new antibiotics. Although the economic benefits of antimicrobial research limit the overall
throughput, it is exciting to see that the first new class of antibiotics in 30 years was recently
discovered with Teixobactin. It is hoped that this ushers in a new wave of antimicrobial research
that can potentially lead to discovery of many new novel classes of antimicrobials that are active
against resistant strains. Moreover, compounds that do not confer resistance could usher in a
new era of microbial treatment that no longer relies on the susceptibility patterns of different
strains.
Described in this thesis is a new class of antibiotics, stilbenoids, which have been found
to possess potent activity against gram-positive bacteria. These compounds were originally
derived from a natural product, but synthetically modified to increase potency. While these
stilbenoids exhibited potent activity against wild-type strains, it was also discovered that these
compounds possess potent activity against all resistant strains tested. Additionally, mutants from
a sub-lethal dosage of these agents were not observed over many trials, prompting the hypothesis
that these compounds might not confer resistance. Many of these small molecules were also
tested both in vitro and in vivo for cytotoxicity and were generally found to be well tolerated and
safe. The mode of action for these new stilbenoid derivatives is still elusive, due in part to their
lack of conference of resistance. The compounds described within this thesis may one day be
useful tools or medications for gram-positive bacterial infections.
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CHAPTER TWO
SYNTHESIS, SCALE-UP, AND BIOLOGICAL EVALUATION OF
SK-03-92 AND A SMALL SERIES OF DIRECT ANALOGS BASED ON AN
INTERESTING STILBENOID NATURAL PRODUCT SCAFFOLD
I.

INTRODUCTION AND BACKGROUND.
1.

Natural product identification and evaluation.

Due to the emergence of resistant pathogens, discovery of new and novel antibiotics is of
utmost priority. Natural products represent one of the greatest sources for novel compounds with
biological activity. These natural products can be modified and enhanced via synthetic
techniques to potential drug candidates. Our interdisciplinary research team has been engaged in
screening extracts of medicinal plants and fungi in search of new molecules with interesting
biological profiles. This research led to the identification of (E)-3-hydroxy-5-methoxystilbene
(Figure 2-1, 1) in the leaves of a shrub native to the great lakes region. This shrub, Comptonia
Peregrina, also known as “sweet fern”, has been used in traditional herbalism to treat a number
of medical issues. It is used as a tea to treat nausea or a poultice for skin conditions, which may
be directly related to the antimicrobial components of the plant.
Figure 2-1: Natural product from ‘sweet fern’.
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Further pharmacological testing of the essential oils of sweet fern indicated that the oil
was cytotoxic to mammalian cells.90 This cytotoxicity, however, was likely due to other major
components of the oil, for example methyl p-coumarate (Figure 2-2). The Michael-acceptor
nature of this molecule is likely the cause of this cytotoxicity, and it is important to note that the
compound of interest, 1, does not have any Michael-acceptor moieties. In other work we have
shown that related compounds with a Michael-acceptor moiety are both very active
antimicrobials while also cytotoxic to mammalian cell lines.91
Figure 2-2: Methyl p-coumarate as a Michael-acceptor.

Interestingly compound 1 was also identified in a number of other plant species including
Didymochlaena truncatula92 and Alpinia katsumadai93, however as far as one can determine the
antimicrobial activity was only investigated by the LaCrosse/UWM research team. Other
stilbenes have been investigated as antimicrobial agents and have been shown to exhibit activity
against both gram-positive bacteria and certain fungal strains, however these stilbenes are
multimeric derivatives of a basic stilbene structure. An example of such a compound is
“heyneanol A”, reported to have both cytotoxic character with potential use for cancer therapy as
well as antimicrobial activity specific for gram-positive bacteria. These multimeric compounds
may work by a similar mechanistic pathway to the natural product 1; however, it should be noted
that mechanism of action studies for both the compounds presented in this work, along with
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other similarly structured compounds, such as heyneanol A, have not been unequivocally
elucidated as of yet.
Figure 2-3: Structure of heyneanol A.
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2.

Initial SAR study.

Although analysis of crude extracts and extremely small heavily purified samples of a
product from natural sources may yield interesting biological data, it is imperative that these
molecules be prepared synthetically to confirm both the biological activity and also permit the
synthesis of novel analogs that may improve upon the biological activity of the parent natural
compound.
A broad SAR study was imagined that included synthesis of not only the parent
stilbenoid scaffold, but also the synthesis of analogous vinyl ethers, vinyl thioethers, and
enamines (Figure 2-4).94
Figure 2-4: Initial SAR targets.
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Compounds synthesized in these series were routinely assayed for Minimum Inhibitory
Concentrations (MICs) against eleven standard test strains of bacteria including two grampositive species (S. aureus and E. faecalis), two gram-negative species (P. aeruginosa and E.
coli), and seven mycobacterium strains (M. intracellulare, M. chelonae, M. fortuitum, M.
kansasii, M. avium, and M. smegmatis). In addition, some compounds were also tested against
B. cereus, a safer surrogate of the deadly and high priority B. anthracis which has potential use
as a biological weapon. M. smegmatis is a safer surrogate of the high risk pathogen M.
tuberculosis, which presents a major health epidemic in third world countries.
The original synthesis of the natural product 1 and other related stilbenoid compounds
was accomplished by utilizing a transition metal catalyzed Negishi cross-coupling reaction.
Negishi coupling forms a C-C bond between organic halides (or triflates) and organozinc
compounds with a relatively wide scope, thus it was envisioned that a wide variety of
compounds could be synthesized via this method. Detailed in Scheme 2-1 is the route towards
both the natural product and a number of new analogs.
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Scheme 2-1: Synthesis of stilbenoids, including the natural product 1.

Although this method was successful in the synthesis of the natural product and a number
of related analogs, several issues with the reaction were reported. First, the starting aldehyde 2
was both expensive and it was found that protection of the phenol to the TIPS derivative 3 was
necessary for the conversion to the vinyl iodide 4. Additionally, the vinyl iodide 4 was unstable
at room temperature and purification required column chromatography, thus large scale reactions
were difficult and sometimes resulted in little or no yield of the product. Storage of the vinyl
iodide at -40 ºC kept it relatively stable, however, enough impurities were present after several
days/weeks that re-purification was necessary to achieve high yields in the palladium catalyzed
cross-coupling reaction.
Synthesis of the organozinc complex 5 from aryl bromides generally proceeded with no
issue and the vast number of commercially available aryl bromides provided ample substitution
patterns in this aryl unit. Finally, deprotection of the TIPS group with TBAF in THF generally
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worked very well and in some cases could be done in a one-pot fashion prior to purification of
the protected compound 6.
In a similar fashion vinyl ethers, vinyl thioethers, and enamines were also synthesized
from the vinyl iodide 4 using a copper catalyzed process described below (Scheme 2-2, Scheme
2-3, and Scheme 2-4).
Scheme 2-2: Synthesis of vinyl ethers.

Scheme 2-3: Synthesis of vinyl thioethers.
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Scheme 2-4: Synthesis of enamines.

3.

Results and Discussion.

With a viable synthetic procedure in place for the synthesis of natural product 1, enough
compound was prepared to assay against of number of bacterial strains. Additional strains of
bacteria were also used in the assay of the natural product as it was of highest priority. The
results indicated that indeed the stilbenoid has antimicrobial properties and its activity should be
explored more thoroughly (Table 2-1).
Interestingly the natural compound 1 was found to have activity against both grampositive bacteria and mycobacterium, but no activity against gram-negative bacteria. This
interesting result led to the idea that perhaps the mechanism of action was related to the cell wall,
since the biggest difference between both gram-positive and mycobacterium to gram-negative
bacteria is indeed the construction of the cell wall. Some of the most interesting results from this
initial assay were the activity against strains that are resistant to some commercial antibiotics.
These include the results from E. faecium VRE 1 and VRE 14 (vancomycin resistant
enterococci) and S. aureus MRSA MC-1 and MC-4 (methicillin resistant). This was a surprising
result as both methicillin and vancomycin’s mode of action is directly tied to the bacterial cell
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wall, suggesting that if this natural product is also acting on the cell wall, it may be acting on a
novel mechanism of action.
Table 2-1: Antimicrobial assays for natural product 1.

Species
Bacillus anthracis
Bacillus megaterium
Bacillus cereus
Bacillus subtilis
Corynebacterium pseudodipthericum
Corynebacterium diphtheriae ToxCorynebacterium xerosis
Enterococcus faecium VRE 1
Enterococcus faecium VRE 14
Enterococcus faecalis ATCC 29212
Staphylococcus aureus ATCC 29213
Staphylococcus aureus ATCC 25923
Staphylococcus aureus MRSA MC-1
Staphylococcus aureus MRSA MC-4
Streptococcus mitis
Streptococcus aagalactiae
Streptococcus pyogenes
Streptococcus pneumoniae ATCC 49619
Listeria monocytogenes
Mycobacterium bovis BCG
Escherichia coli
Pseudomonas aeruginosa

Gram
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
N/A
–
–

MIC (µg/mL)
8
64
16
16
16
32
16
16
16
16
32
32
32
32
64
32
16
8
32
26
>128
>128

+: gram-positive, -: gram-negative, N/A: mycobacterium are neither + or -

Vinyl ethers, vinyl thioethers, and enamines also showed promise when assayed against
the primary targets (Table 2-2). Other compounds synthesized within these series had equal to or
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weaker activity then the compounds shown below. Because of this, more focus was put into the
synthesis of the stilbenoid compounds closely related to the natural product 1.
Table 2-2: Antimicrobial assays for vinyl ether, vinyl thioether, and enamine analogs.a
HO

O

Bacterial Strain

HO

7

8

OMe

a

S

OMe

S. aureus

64

16

32

E. faecalis

64

16

32

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

128

64

64

M. chelonae

>128

128

64

M. fortuitum

128

128

128

M. kansasii

>128

64

64

M. avium

128

128

64

M. smegmatis

128

128

32

M. marinum

>128

64

64

Values in µg/mL

Synthesis of a number of stilbenoid analogs, moreover, led to a far more interesting
analog in SK-03-92 (Table 2-3). Many other compounds in this series, however, were more
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similar in activity to the natural product 1, not potent enough for use as an antimicrobial drug
candidate.
Table 2-3: Activity of some novel stilbenoid compounds, including SK-03-92.a

HO

Bacterial Strain

S

SK-03-92
OMe

a

S. aureus

16

16

2

E. faecalis

32

16

2

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

64

64

32

M. chelonae

128

64

32

M. fortuitum

128

64

16

M. kansasii

128

64

32

M. avium

128

64

32

M. smegmatis

64

64

32

M. marinum

128

64

16

Values in µg/mL

With activities below the range of 10 µg/mL, SK-03-92 exhibited activity that was
similar to some mainstream antibiotics and thus served as an excellent lead compound for further
SAR studies.
25

II.

CHEMISTRY AND RESULTS.
1.

Scale up of SK-03-92.

Based on the initial SAR study, SK-03-92 (Table 2-3) was deemed the most promising
lead compound and therefore future study required a synthesis suitable for scale-up to gram
quantities. The original palladium-mediated Negishi cross-coupling reaction required not only
the use of expensive transition metals, but also the use of unstable intermediates which were
difficult to prepare in large quantities (Scheme 2-1). It was found that a Wittig-type approach
could be used to successfully scale up SK-03-92 to gram quantities through a less expensive yet
more laborious seven-step process beginning with 3,5-dihydroxybenzoic acid (Scheme 2-5).
Scheme 2-5: Scale-up of the synthesis of SK-03-92.
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The 3,5-dihydroxybenzoic acid (12) was converted into the methyl ester (13) and

subsequently protected as the dimethoxy derivative (14). It is worth noting that the conversion
from 12 to 14 could be accomplished in one step utilizing the same conditions as 13 to 14;
however, this leads to a slightly lower overall yield. The hydride reduction of 14 with lithium
aluminum hydride provided the alcohol (15) which was subsequently treated with phosphorous
tribromide to provide the alkyl bromide (16). The synthesis of the diethylphosphonate (17) was
accomplished by heating bromide 16 in neat triethylphosphite at 130 ºC. The
diethylphosphonate (17) and benzo[b]thiophene-2-carbaldehyde (18), in the presence of sodium
hydride, gave the corresponding stilbene (19) in good overall yields. Mono-demethylation was
accomplished by treating 19 with sodium ethanethiolate at 140 ºC to furnish the final stilbene,
SK-03-92, in an approximate overall yield of 50%. It should also be noted that the benzyl bromo
derivative (16) was not stable and decomposed readily on the benchtop, thus storage as the
alcohol (15) or conversion immediately to the more stable diethylphosphonate (17) was
preferred.
One significant hurdle to scale-up via this method, however, was the price of
thioaldehyde 18. The conversion of the much less expensive thionapthene 20 to 18 was
accomplished by lithiation of the 2-position with n-butyl lithium and subsequent treatment with
dimethylformamide to provide the aldehyde 18 in excellent yield (Scheme 2-6).
Scheme 2-6: Scale-up of the synthesis of aldehyde 18.
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Although this route was longer than the prior Negishi cross-coupling procedure, it was
successfully used to synthesize over 50 grams of SK-03-92 in a more economical and less
cumbersome manner. Purification was only necessary after synthesis of 19 (crystallized from
toluene) and although chromatography was usually necessary for small scale purification of SK03-92, on large scale it can be adequately purified by crystallization from isopropanol with
excellent recovery. This was a major improvement in the route.

2.

Synthesis of analogs starting from SK-03-92.

The initial SAR study employing the previously discussed Negishi cross-coupling
procedure focused exclusively on substitution (ring C) using a variety of aryl bromides (Figure
2-5, green portion), which left the ‘left-hand-side’ (Figure 2-5, red portion) substitution pattern
and bridged alkene (Figure 2-5, blue portion) moieties intact. After screening a number of
different aldehydes the benzo[b]thiophene moiety was found to be the most active, and thus the
goal of this research was to synthetically modify both the ‘left-hand-side’ and the bridge in an
attempt to gain more insight into the SAR of these novel stilbenoid compounds and perhaps get a
clinical candidate to treat MRSA infections.
Figure 2-5: Functionality evaluation of SK-03-92.
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Chemical Formula: C17H14O2S
Molecular Weight: 282.36
c Log P: 4.74
tPSA: 29.46

Since adequate amounts of SK-03-92 were available, direct modification of SK-03-92
was explored. The most convenient method of directly modifying the ‘bridge’ of SK-03-92 was
to hydrogenate it via Pd/C to the saturated analog 21 (Scheme 2-7).
Scheme 2-7: Hydrogenation of SK-03-92.

Based on the biological evaluation of this new analog, to be discussed in the upcoming
section, additional modifications to the bridge were not attempted.
SK-03-92 has relatively few sites for direction manipulation, however, the phenolic
group at the 3-position gave access to a few new analogs. Since the advent of transition metal
chemistry a number of reactions have been developed that replace aryl halides or triflates with
other desirable functionalities.95-99 Through the initial SAR it was shown that the dimethoxy
analog 19 (Scheme 2-5) was inactive and based on this it was assumed that the phenolic
functionality was essential for activity. However, for the same reason mono-demethylation was
successful, namely the symmetrical nature of 19, this would also allow substitution at the
phenolic site and subsequent demethylation of the methoxy group at position 5 to give structural
analogs of SK-03-92 (Figure 2-6).
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Figure 2-6: Phenolic substitution followed by demethylation.

From this study, synthesis of the triflate analog of SK-03-92 was followed by substitution
using transition metal catalysis. This was followed further by demethylation of the methoxy
group at position 5 giving rise to other interesting analogs. Synthesis of the triflate analog of
SK-03-92 from triflic anhydride proceeded smoothly in 98% yield (Scheme 2-8) and was found
to be adequately stable when stored in a freezer.
Scheme 2-8: Synthesis of the triflate analog of SK-03-92.
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With the triflate 22 in hand, the study focused on replacement with a functional group
similar in size and electronic character to the methoxy group at position 5 of SK-03-92. The first
interesting analog planned was conversion of the triflate group to a thiol (Scheme 2-9). A
number of methods existed for this transformation100-103, however, this work focused on a
method employing triisopropyl silane thiol and palladium tetrakis. Two analogs were envisioned
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from this route; first the thiol depicted in Scheme 2-9, and next the thiomethoxy 25 depicted in
Scheme 2-11.
Scheme 2-9: Triflate to thiol synthesis.
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Unfortunately, although the transition metal catalyzed reaction worked flawlessly, the
simple removal of the silyl group proved troublesome. In fact, the thiol analog was never
observed even in crude samples tested by NMR. On addition of TBAF, it was noted that starting
material abruptly disappears with formation of baseline material. This material was tested by
NMR, but revealed little information on the structure of the crude material. Though synthesis of
the thiol was halted, it was found that adding 2 equivalents of iodomethane to the TBAF
conditions resulted in the thiomethyl compound 24 (Scheme 2-10). Further demethylation of 24
led to the SK-03-92 thiomethyl analog 25 (Scheme 2-11).
Scheme 2-10: Synthesis of thiomethyl analog of 19.
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Scheme 2-11: Synthesis of the thiomethyl analog of SK-03-92.

Unfortunately, the methylation reaction took place in low yield leading to an overall poor
yield of the interesting SK-03-92 analog 25. The final reaction to compound 25 took advantage
of the electronic character of the thiomethyl group which was not as readily demethylated as
methoxy groups, an interesting reaction considering that the thiol itself was not stable enough to
isolate.
The next analog of interest was substitution of the triflate group with a nitrile group. A
nitrile group is of similar size to a methoxyl group, however, they have very different electronic
characteristics, so this substitution could give some insight into the SAR related to ring A of SK03-92. A number of methods are available for such a substitution104-106, however, in this case
we started with the well-known Rosenmund-von Braun reaction (Scheme 2-12).107 It was found
that under the harsh conditions, conversion to the nitrile via this process was not possible. It is
also possible that triflates are not suitable for this reaction since little literature support was
found for the substitution besides those of aryl halides.
Scheme 2-12: Rosenmund-von Braun reaction.
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Fortunately, there are many alternatives to such reactions and it was found that in a
similar manner to the thiol synthesis, palladium tetrakis was found to convert the triflate into the
corresponding nitrile in the presence of copper iodide and sodium cyanide (Scheme 2-13).
Scheme 2-13: Transition metal catalyzed nitrile synthesis.
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Unfortunately, low yields (35%) and difficulties in the synthesis of the phenol from the
nitrile analog 26 made synthesis of the nitrile analog of SK-03-92 difficult and it was not pursued
further (Scheme 2-14).
Scheme 2-14: Demethylation of the nitrile analog.
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It should be noted that it is presumed that the above reaction does work, however only a
small amount of 26 was synthesized and it may have decomposed under the harsh conditions of
demethylation Scheme 2-14. At this time, however, it was determined that a new synthetic
pathway was necessary for synthesis of analogs similar to SK-03-92. Although the triflate
pathway was successful for a small number of compounds, the necessity to demethylate many of
the possible analogs proved troublesome on such a small scale.
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One further analog was also synthesized from the diethylphosphonate (17) originally
discussed in Scheme 2-5. Thiophene-2-carbaldehyde (27) and diethylphosphonate were reacted
in a similar manner to Scheme 2-5 (step 6) to give the dimethoxy analog 28. Demethylation via
sodium ethane thiol gave the desired thiophene analog 29 (Scheme 2-15). Thiophene is a known
bioisostere of a benzene ring108-110 and given the activity of SK-03-92 with a thionapthene ring,
this compound is an isostere of the original natural product 1 and its activity was important to
compare to 1.
Scheme 2-15: Synthesis of the thiophene derivative of natural product 1.
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MIC results and discussion.

Minimum inhibitory concentrations (MICs) of new analogs were carried out according to
standard protocols.111 As previously discussed, the strains tested were two gram-positive strains,
two gram-negative strains, and a series of seven different mycobacterium strains. Although MIC
data for the mycobacterium strains was not within a drug-suitable range for any compounds
discussed analysis of the data, in some cases, reveal interesting SAR information. For example,
in some cases stilbenes exhibited activity against both gram-positive and mycobacterium strains,
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yet in other cases some only exhibited activity against gram-positive strains. This may relate to
the difference in the cell walls between gram-positive bacteria and mycobacterium.
Table 2-4: MIC results for compounds 22, 21, and 29.a

Bacterial Strain

a

S. aureus

>128

8

32

E. faecalis

>128

16

64

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

>128

128

64

M. chelonae

>128

>128

128

M. fortuitum

>128

128

>128

M. kansasii

>128

>128

64

M. avium

>128

128

128

M. smegmatis

>128

128

128

M. marinum

>128

>128

64

Values in µg/mL

Not surprisingly, triflate 22 was found to be inactive (Table 2-4). As discussed the
previous SAR indicated that a phenolic group was necessary, since dimethoxy analogs, prior to
demethylation, were found to be inactive in all cases tested. Importantly, however, examination
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of the MIC of the triflate analog indicated this lack of activity extended to groups other than
methoxy.
The saturated analog 21 was found to retain activity (Table 2-4), although it was ~4-fold
less active then the parent lead compound SK-03-92. From this it was concluded that the
olefinic bridge was important, but not absolutely necessary for activity, which may prove useful
for future SAR endeavors. However, rigid stilbenes with an olefinic bridge have exhibited more
potent activity and thus should be investigated first. It is hypothesized that the rigidity of the
unsaturated bridge may help these stilbenoid compounds penetrate the cell walls of the grampositive bacteria more readily. Only a subtle loss of activity when the bridge was saturated
supports this hypothesis. This may be of importance for later SAR advances as saturation of the
bridge can reduce the likelihood of side-effects similar to that of other stilbenoid pharmaceuticals
such as stilbestrol.112
Since thiophene is a bioisostere of benzene, it was felt the thiophene analog 29 should
have similar activity to the natural product 1 and that was the case (Table 2-4). Interestingly in
the previous SAR it was found that substitution of a naphthene group instead the thianaphthene
in SK-03-92 resulted in an 8-fold decrease in activity even though they are related bioisosteres.
This led one to believe that it was perhaps the change in geometric orientation from naphthene to
thianaphthene that led to the poorer MIC results (Figure 2-7). Interestingly, ring B 5-membered
thiophene rings form a conserved symmetry with respect to the alkene bridge when compared to
their 6-membered ring counterparts.
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Figure 2-7: Orientation of ring C in stilbenoid compounds.

Table 2-5: MIC results for compounds 24, 25, and 26.a

Bacterial Strain

a

S. aureus

>128

2

>128

E. faecalis

>128

8

>128

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

>128

128

>128

M. chelonae

>128

64

>128

M. fortuitum

>128

64

>128

M. kansasii

>128

64

>128

M. avium

>128

64

>128

M. smegmatis

>128

64

>128

M. marinum

>128

64

>128

Values in µg/mL
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As previously discussed the SAR predicted that lack of a phenolic group would result in a
lack of activity and ligand 24 with a thiomethyl group, devoid of a phenolic group, lacked
activity (Table 2-5). Similar results were seen with triflate 22; which indicated that the phenolic
nature in ring A is necessary for the antimicrobial activity as observed in compounds such as SK03-92.
Thiomethyl analog 25 retained activity and was as active as the parent SK-03-92 within
experimental error (Table 2-5). Analysis of this result indicated that although the phenol was a
necessary component for consistently potent compounds, there was room for synthetic
manipulation of the methoxy group of SK-03-92 to retain or enhance potency in ring A of the
stilbenoids.
Finally, the nitrile analog 26 lacked activity since it too lacked the necessary phenolic
group. Synthesis of the more interesting phenolic analog of 26 failed via the current methods
and was followed up in future studies to be discussed in Chapter 3.

4.

Biological and Pharmacokinetic data on SK-03-92.

Note: These data were gathered and compiled by Dr. Bill Schwan, UW-LaCrosse.
The gram quantities of SK-03-92 permitted a more robust experimental design that
included more in depth in vitro assays as well as in vivo assays in mice/rats.
The preliminary efficacy testing was performed using SK-03-92 in a murine thigh
abscess model.113 Briefly, murine thigh abscesses were established with a 1 x 106 CFU of S.
aureus MW2, a CA-MRSA strain. Three cohorts were established: a phosphate buffered saline
control (containing DMSO), a single-dose group of 3.2 µg SK-03-92 per gram mouse, and a
single-dose group of 160 µg SK-03-92 per gram mouse. On the day after the bacteria were
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injected into the mice (CA-MRSA), the mice were injected with either drug or control. Two
days after the drug dose (three days after injection of the bacteria), murine thighs were collected,
homogenized, and plated onto brain heart infusion agar. Colony counts were taken for the
homogenized thighs of the mice. Examination of the results indicated that the median CFU/thigh
was one log unit lower in the low-dose (3.2 µg per g) test group, and two log units lower in the
high-dose (160 µg per g) test group, as compared with the control group (Figure 2-8). It was
also important to note that no adverse effects were noted in any of the mice tested with SK-0392.
Figure 2-8: In vivo testing of SK-03-92 in a murine thigh abscess model.

These results were encouraging, however they also indicated that a more in-depth
pharmacokinetic profile of SK-03-92 was necessary.
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4.1: Determining the solubility of SK-03-92 in other solutions
Because SK-03-92 had low solubility in an aqueous solution, and solubilizing the drug in
DMSO would be inappropriate for oral or intravenous (IV) administration to humans, alternative
vehicles were examined. The solubility of SK-03-92 was determined using high performance
liquid chromatography (HPLC). The solubility of SK-03-92 in PBS was <0.0001 mg/mL, but
the solubility in other suitable vehicles ranged from 4.6 mg/mL for 20% Solutol HS 15/80% PBS
to 9.2 mg/mL for PEG 400. The Solutol HS 15/PBS solution was chosen for further development
of a dosing solution due to the potential for use in both IV and oral administration.
4.2: Safety/cytotoxicity testing of SK-03-92
To determine the approximate safety of SK-03-92 against tissue culture cells, an MTT [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was performed. The IC50 of
SK-03-92 was shown to be 125 μg/mL for all four tissue culture cell lines (J774A.1, U937, 292,
and T24), generating a promising relatively high therapeutic index (IC50/MIC) of 62.5 for 90% of
the S. aureus strains.
To determine if SK-03-92 was safe for use in vivo, an escalating dosing scheme in mice
(5, 50, 300, and 2000 mg/kg) was employed. None of the mice that received a single dose of the
highest drug concentration (2000 mg/kg) IP displayed any adverse effects over a two-week time
frame (e.g., altered gait, ungroomed, significant weight loss), demonstrating that SK-03-92 was
non-toxic at this highest dose. After initial dosing at 2000 mg/kg, a repeat dose of 2000 mg/kg
was administered a week later, and again, no overt toxicity was observed for the animals. High
doses of the related compounds, pterostilbene and resveratrol, have been shown to be non-toxic
in mice114, rats115, and humans116.
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4.3: Single dose PK analysis of SK-03-92
A single dose of SK-03-92 was given to mice to assess single dose PK parameters. The
observed area under the plasma concentration-time curve (AUCINF_obs), maximum plasma
concentration (Cmax), time to achieve Cmax (Tmax), oral clearance of drug observed (Cl_F_obs),
volume of distribution of drug observed (Vz_F_obs), and half-life were calculated.
Intraperitoneally administered SK-03-92 had a half-life of 22.46 min, a Tmax of 30 min, a Cmax of
1.64 μg/mL, a Cl_F_obs of 1.46 mL/min/g, a Vz_F_obs of 47.71 mL/g, and a AUCINF_obs of
70.15 min·mg/mL (Table 2-6). The Tmax of 30 min when given ip and 22 min when dosed orally
demonstrated rapid absorption of SK-03-92 in line with the rapid absorption of other stilbenoid
drugs.117 The maximal plasma concentration (Cmax) was somewhat low for orally administered
SK-03-92 (370 ng/mL), but was still detectable and was approximately 25% of the
Cmax observed with ip-administered drug (1.64 μg/mL). The Cmax and AUC0-inf values for SK-0392 fall between the values reported for resveratrol and pterostilbene118. After achieving the Cmax,
the SK-03-92 plasma concentrations dropped to negligible levels 75 min after oral gavage, which
was in line with the PK results that have been observed using other stilbenoid drugs.117-118 The
relatively short half-life of SK-03-92 (22 min for ip administered, 30 min for orally
administered) suggested that administration more than once a day would be needed to treat a S.
aureus infection. The concentration of SK-03-92 reached a high of 1.641 μg/mL after 30 min and
dropped to 0.149 μg/mL within 90 min of ip injection. All of the mice looked healthy, and no
overt toxicity (e.g., excessive weight loss, ungroomed, altered gait) was observed, mimicking the
mouse safety study above.
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Table 2-6. Summary of pharmacokinetic (PK) parameters by route and schedule.
Route
ip a
oral b

Half-Life
(min)
22.46 ±
17.81
30.40 ±
17.81

Tmax c
(min)
30.00 ±
0.00
21.43 ±
11.80

Cmax c
Cl_F_obs c
(µg/mL) (mL/min/g)
1.64 ±
1.46 ± 0.26
0.59
0.37 ±
21.00 ±
0.35
6.71

Vz_F_obs c
(mL/g)
47.71 ±
33.25
810.67 ±
173.87

AUCINF_obs c
(min*µg/mL)
70.15 ± 12.76
5.14 ± 1.87

a Mean ± standard deviation from three mice tested; b Mean ± standard deviation from three mice tested;
c Tmax (time to achieve Cmax), Cmax (maximum plasma concentration), Cl_F-obs (oral clearance of drug
observed), Vz_F-obs (volume of distribution of drug observed), and AUCINF_obs (area under the plasma
concentration-time curve observed).

4.4: Relative bioavailability of SK-03-92
To determine the relative bioavailability of the SK-03-92 lead compound, 100 μg/g of
Solutol HS 15/PBS formulated SK-03-92 was administered orally to the mice. After 15 min,
0.740 μg/g was detected in the mouse plasma, and by 30 min that level had dropped to 0.126
μg/g. All of the mice looked healthy, and no signs of toxicity were observed. The relative
bioavailability (AUCoral/AUCIP) was approximately 8%, which indicated that oral delivery of the
drug would not provide therapeutic concentrations for treating S. aureus infections. Other studies
that have examined stilbenoid compounds have also observed low to very low bioavailability for
those agents.117-119
4.5: Multi-dose effects and protein analyses of SK-03-92
Examination of the single dose PK analysis indicated that the SK-03-92 lead compound
was safe, but the plasma concentration was somewhat low. Multi-dose experiments were
performed to assess adverse effects associated with chronic dosing as well as pharmacokinetics.
Given that adverse effects do not correlate linearly with plasma concentrations, animals could
experience adverse effects when plasma concentrations were undetectable with repeated dosing.
Pharmacokinetic evaluations were performed to determine if changes in pharmacokinetic profiles
with chronic dosing (e.g., reduced clearance) were associated with adverse effects.
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To determine how multiple doses of SK-03-92 affected the health of the mice, as well as
the PK parameters, an extended five-day PK study was undertaken. Plasma concentrations
ranged from a high of 0.086 μg/mL after 15 min to a low of 0.027 μg/mL after 75 min. In the PK
study which extended to two-weeks following oral administration, the plasma SK-03-92
concentrations ranged from 0.144 μg/mL after 15 min to 0.01 μg/mL after 75 min. On average,
the treated mice lost about 1.5% of their weight after two-days, but after one week, the weight of
treated mice increased on average by 5.16% on day 9 and went up further to 9.75% by day 12.
Two doses of SK-03-92 given four hours apart for three days achieved a maximum SK-03-92
plasma concentration of only 2.12 μg/mL.
4.6: Protein binding by SK-03-92
The degree of protein binding by SK-03-92 in plasma was also determined. It was found
that 84.4% of the SK-03-92 drug bound to plasma proteins. Consequently, most of the SK-03-92
lead compound bound to plasma proteins, which could affect its bioavailability.
This was the first study to examine the PK properties of a new lead compound labeled SK-03-92.
Other studies have examined the PK properties of stilbenoid-based compounds, but none of these
other studies have done PK analysis with the expressed goal of using a drug with a stilbene
scaffold to treat bacterial infections. The absence of overt symptoms in mice following dosing
with SK-03-92 suggests that SK-03-92 may have a very good safety margin. High concentrations
of SK-03-92 given daily to mice did not appear to have gross adverse effects on the mice, which
is in line with animal studies done using resveratrol and pterostilbene.117 Both the SK-03-92 ip
and oral administration pharmacokinetic profiles were low; likewise, low plasma concentrations
of resveratrol (<1 μg/mL) and pterostilbene (<8 μg/mL) have been observed in animals. The
maximum SK-03-92 plasma concentration in the mice was only 2.12 μg/mL. Several properties
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of SK-03-92 probably contribute to its low plasma/tissue concentrations in mice. Aqueous
solubility appeared to be one of the barriers. Stilbene compounds are hydrophobic and generally
insoluble in aqueous solutions. The use of a Solutol HS 15/PBS solution improved the solubility
of SK-03-92, but the solubility was still less than 10%. Another property tied to the low
plasma/tissue availability of SK-03-92 was its high level of plasma protein binding (84.4%). Our
previous in vitro study demonstrated a much higher MIC against Streptococcus pneumoniae, and
this was probably due to SK-03-92 binding to the proteins found in the fetal calf serum added to
the wells of the microtiter plate. A myriad of proteins present in the bloodstream and tissues
would reduce the effective concentration of SK-03-92. Lastly, SK-03-92 exhibited a relatively
short half-life in the mice, breaking down into metabolic byproducts within 15 min after ip or
oral delivery. Resveratrol and pterostilbene also have short half-lives in animal plasma (15–60
min and 120 min, respectively) with substantial accumulation of metabolic byproducts.
New drugs with novel mechanisms of action are needed to keep abreast of antibiotic
resistance in S. aureus, one of the ESKAPE pathogens. The safety profile of SK-03-92 is highly
encouraging. Although the oral bioavailability of SK-03-92 may hinder use as an oral standalone treatment for S. aureus infections, the opportunity to employ it against drug resistant
strains of MRSA topically or embedded in a patch still exists. We are also analyzing microarrays
and performing additional assays to elucidate the mechanism(s) of action of SK-03-92.
Furthermore, we are currently assessing whether SK-03-92 has a synergistic effect when coadministered with clinically useful antimicrobials such as oxacillin, clindamycin, and
vancomycin. If the half-life and bioavailability problems can be solved, an analog of SK-03-92
may have a future in treating S. aureus skin and soft tissue infections.
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III.

CONCLUSION.

In summary, a method for the scale-up of SK-03-92, a new lead compound for
antimicrobial research, was completed in an overall yield of 50% from a total of seven synthetic
steps. This permitted gram scale synthesis of SK-03-92 which led to a compendium of
information on the biological and pharmacokinetic properties of SK-03-92.
Although initial results with SK-03-92 in vivo seemed promising, pharmacokinetic issues
involving its absorption as well as it is half-life indicate that as a pharmaceutical candidate it is
not ideal. However, it provides the impetus and direction for future synthetic endeavors
discussed in future Chapters of this work.
Since the mechanism of action of SK-03-92 and related analogs is still unknown, it is not
possible to design related drugs for a specific target, but rather continue with SAR studies to
attempt to find the optimal substitution patterns for activity. Once a catalog of active compounds
is constructed, more in depth PK analysis may lead to a novel candidate for an antimicrobial
pharmaceutical drug.
Synthesis of some new analogs was successful using transition metal catalyzed
substitution of a triflate group with other small nucleophiles, however the route took place in low
yield and required a difficult demethylation step after the penultimate palladium catalyzed
reaction. This was not ideal and was not seen as a long-term solution to advance the SAR of this
interesting class of compounds. Because of this, a new one-step route was investigated.

IV.
1.

EXPERIMENTAL.
In vitro and in vivo assays. (Completed by Dr. Bill Schwan, UW-LaCrosse)
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1.1: MIC assays.
In vitro minimum inhibitory concentration (MIC) determinations were performed
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines,115 for most of the
bacteria that were screened. Tetracycline, ciprofloxacin, and erythromycin controls were
included as control antibiotics for the gram-positive bacteria MICs and correlated with
established MIC values. All anti-mycobacterium activity evaluations (except for the antiMycobacterium tuberculosis assays) were performed using MIC assays in Middlebrook 7H9
broth with 10% oleic acid albumin dextrose complex (OADC) as previously described.120
Rifampin was used as the positive control for the mycobacterial MICs. All MIC numbers are a
compilation of the geometric means from three separate runs. For the broad characterization
against S. aureus, strains that have been typed by a variety of means were used.116
1.2: Mice.
The Institutional Animal Care and Use Committees at the University of Wisconsin-La
Crosse and the University of Wisconsin-Madison approved the study design and the animal
handling protocols of this pharmacokinetic study. The protocol number for UW-Madison was
M1732 with a start date of 23 April 2009, whereas the UW-La Crosse protocol was 3–8 with a
start date of 26 March 2008. Either female BALB/c (NCI) or Swiss Webster (Harlan) mice 5–9
weeks old were used in this study.
1.3: Cytotoxicity assays.
Initial in vitro safety testing of SK-03-92 was performed with an MTT [3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (9, American Type Culture
Collection) for several tissue culture cell lines (murine monocytic J774A.1, human monocytic
U937, human kidney epithelial 293, and human bladder epithelial T24) using mitomycin C
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(Sigma, St. Louis, MO, USA) and DMSO alone as positive and negative controls, respectively.
Assays were done a total of three times per tissue culture cell line.
1.4: Initial Safety Testing in Mice.
Three female 5–9 week old Swiss Webster mice (Harlan) per drug concentration were
injected intraperitoneally (ip) with increasing concentrations of SK-03-92: 5, 50, 300, and 2000
mg/kg according to OECD.115 The lowest concentration of drug was used first. Overt toxicity
(e.g., altered gait, ungroomed, significant weight loss) was monitored. If two of three mice
showed no overt toxicity, then the next dose of drug was given.
1.5: HPLC sssay development.
An HPLC method was developed on a Halo C18 4.6 × 1.0 mm, 2.7 μm column (MACMOD Analytical Inc., Chadds Ford, PA, USA) for the detection and quantitation of SK-03-92.
The method was developed using the information obtained from a scouting gradient of 5%–
100% acetonitrile over 35 min. A UV spectrum of SK-03-92 was obtained from the scouting
gradient and the observed maximum for SK-03-92 was 335 nm, with a local maximum of 224
nm also observed. The 335 nm maximum wavelength was used for the quantitation of SK-03-92,
and the 224 nm local maximum wavelength was used to monitor for possible formation of
degradation products not visible at the 335 nm wavelength. Flow rate was 0.750 mL/min and
injection volume was 10 μL. The mobile phase was 62% acetonitrile (Fisher, Hanover Park, IL,
USA):38% water (Milli-Q UV plus) and the isocratic program was 62% acetonitrile:38% water
for 20 min. Acquisition time was 10 min and room temperature retention time was 5.4 min.
Standards of SK-03-92 were prepared in acetonitrile at concentrations of 0.05–0.005 mg/mL.
1.6: Single Dose PK Assay.
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An initial single dose PK experiment was performed using 100 μg/g of formulated SK03-92 administered ip to twenty-one female, 5–6 week old BALB/c mice (7 per cohort for 3
cohorts, NCI) under parameters established previously. Three animals were used as a control
group and received blank vehicle, whereas three mice per time point received 100 μg/g SK-03-92
ip and were sacrificed with blood collected at the 15, 30, 45, 60, 75, and 90 min time points by
warming the tails of the mice in warm water, lancing the lateral saphenous tail vein, and
collecting the blood (up to 150 μL) into microvette tubes (Sarstedt) containing EDTA or terminal
bleed into vacucontainers containing EDTA as an anti-coagulant. Plasma was separated from
packed blood cells by centrifugation (600× g) and stored at −70 °C until needed for HPLC
analysis. Samples were analyzed with a Shimadzu Prominence HPLC system (Kyoto, Japan)
with a Halo C18 column (MAC-MOD Analytical Inc., Chadds Ford, PA, USA). A mobile phase
of 62% acetonitrile/38% water, isocratic program of 62% acetonitrile for 20 min, and flow rate
of 0.75 mL/min with an injection volume of 10 μL and a retention time of 5.4 min were used.
The standard curve for SK-03-92 was linear from 0.0098 to 2.5 μg/mL in plasma. Each
chromatogram was collected and integrated to estimate the peak area of analyte by EZ
Chrom® software (version.1.0, Agilent Technologies Inc., Santa Clara, CA, USA). The ratio of
peak area of SK-03-92 was calculated to estimate the drug concentration(s) using a pre-built
calibration curve. Major pharmacokinetic parameters were calculated using the
noncompartmental analysis module of WinNonlin® (version 5.1, Pharsight Corp., Princeton, NJ,
USA) under sparsely sampling mode.
1.7: Bioavailability assay.
A relative bioavailability study was performed using 100 μg/g of formulated SK-03-92
administered orally to six female 5–6 week old BALB/c mice (NCI) with three animals as the
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control group receiving blank vehicle by the oral route. Three mice per time point had blood
collected at 15 and 30 min after administration.
1.8: Multi-dose analysis.
First, a five-day PK study with SK-03-92 orally administered to female 5-6 week old
BALB/c mice was conducted. Three mice received 300 μL of blank vehicle by oral
administration. Doses of 100 μg/g SK-03-92 were given orally each day in the vehicle. Blood
was collected from three mice at time points 15, 30, 45, 60, 75, and 90 min after administration.
Body weight was monitored every day before SK-03-92 administration. Plasma was prepared
and stored at −70 °C until analyzed by HPLC. In an extension of this PK study to two-weeks
following oral administration of SK-03-92, six mice were dosed in the test (SK-03-92) arm and
six vehicle control mice in the other arm. Lastly, a multi-dosing PK analysis was done using two
51-μg/g doses of SK-03-92 per day (given four hours apart) over the course of three days in five
mice.
1.9 Protein binding assay.
Plasma collected from EDTA treated blood from six SK-03-92 dosed mice was added to
methyl tert-butyl ether (MTBE) to precipitate the proteins. The precipitated proteins were
separated from the remainder of the plasma by centrifugation (14,000× g for 20 min) through a
Microcon 10K filter (Millipore) and dried under a stream of nitrogen gas. The dried product was
suspended in 62% acetonitrile/38% ddH2O and the AUC was quantified and correlated with the
initial concentration of SK-03-92 present in the plasma by HPLC.

2.

Characterization data.

Both 1H and 13C NMR spectra were recorded on a Bruker DPX-300 or DRX-500
instrument where noted. HRMS scans were recorded with a Shimadzu LCMS-IT-TOF or similar
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instruments run at the Shimadzu Analytical Chemistry Center of Southeastern Wisconsin. In
silico cLogP values and topological polar surface area values (tPSA) were calculated with
ChemBioDraw Ultra v. 14.
(E)-3-(2-(Benzo[b]thiophen-2-yl)vinyl)-5-methoxyphenol (SK-03-92, Table 2-3, entry 3)

The NaH (60% dispersed in mineral oil, 3.6 g, 0.09 mol) was added to anhydrous DMF (100
mL) at 0° C. The CH3CH2SH (12.2 mL, 13.22 g, 0.12 mol) was then added dropwise and stirred
at 0° C for 30 min. The temperature of the reaction mixture was allowed to rise to rt and the
mixture stirred for 1 h. The temperature of the reaction mixture was raised to 140° C and (E)-2(3,5-dimethoxystyryl)benzo[b]thiophene (8.90 g, 0.03 mol) in dry DMF (30 mL) was added
dropwise to the reaction mixture. This mixture was held at 140° C and monitored by TLC (30%
EtOAc in hexanes). When the starting material was no longer present by TLC (~1 hr), the
reaction mixture was cooled to rt and quenched by addition of aq 0.5N HCl (500 mL). The
mixture was extracted with EtOAc (3 x 200 mL). The combined organic layers were washed
sequentially with aq 0.5N HCl (3x60 mL) and brine (3 x 60 mL). The organic layer was dried
over Na2S04 and the solvent was removed in vacuo. The crude solid was purified by flash
column chromatography (FCC) (20% EtOAc in hexanes) to afford the pure SK-03-92 in 92%
yield as a pale yellow solid (7.79g): 1H NMR (300 MHz, CD3COCD3) δ 8.43 (s, 1H), 7.89 – 7.77
(m, 2H), 7.52 – 7.34 (m, 4H), 6.97 (d, J = 15.9 Hz, 1H), 6.72 (m, 2H), 6.40 (t, J = 2.2 Hz, 1H),
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3.81 (s, 3H); 13C NMR (75 MHz, CD3COCD3) δ 161.3, 158.7, 142.7, 140.3, 138.6, 130.8, 124.8,
124.5, 123.6, 123.4, 122.4, 122.0, 106.2, 103.4, 101.5, 54.6; HRMS (ESI) (M + H), Calcd. for
C17H15O2S 283.0793; Found 283.0797.
(E)-3-(2-(Benzo[b]thiophen-2-yl)vinyl)-5-methoxyphenyl trifluoromethanesulfonate (22,
Table 2-4, entry 1)

The (E)-3-(2-(benzo[b]thiophen-2-yl)vinyl)-5-methoxyphenol (1.00g, 3.54mmol, 1eq) was
dissolved in 50mL DCM (freshly distilled) and the pyridine (310mg, 3.90mmol, 1.1eq) was
added in one portion. The solution was cooled to 0 ºC and trifluoromethanesulfonic anhydride
(1.1g, 3.90mmol, 1.1eq) was added dropwise at 0 ºC. The starting material was consumed after
10 min on analysis by TLC (20% EtOAc in hexanes) and the reaction was quenched with aq
0.5N HCl (50mL). DCM (40mL) was added and the organic layer extracted. The organic layer
was washed with brine (50mL) and dried over Na2SO4. The solvent was removed in vacuo
leaving a crude yellow solid. The solid was purified by flash column chromatography on silica
gel (10% EtOAc in hexanes) to provide the pure 22 in 98% yield as a white solid (1.44g): 1H
NMR (300 MHz, CDCl3) δ 7.80 (dd, J = 8.8, 4.8 Hz, 1H), 7.75 (dd, J = 6.1, 3.0 Hz, 1H), 7.41 –
7.30 (m, 4H), 7.28 (s, 1H), 7.04 (s, 2H), 6.92 (d, J = 16.0 Hz, 1H), 6.74 (t, J = 2.1 Hz, 1H), 3.89
(s, 3H), 1.57 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 160.97, 150.51, 141.74, 140.00, 139.80,
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139.16, 128.56, 125.24, 124.89, 124.72, 124.68, 123.73, 122.30, 112.00, 111.19, 106.59, 55.82;
HRMS (ESI) (M + H), Calcd. for C18H14F3O4S2 415.0286; Found 415.0291.
3-(2-(Benzo[b]thiophen-2-yl)ethyl)-5-methoxyphenol (21, Table 2-4, entry 2)

The (E)-3-(2-(benzo[b]thiophen-2-yl)vinyl)-5-methoxyphenol (100mg, 0.354mmol, 1eq) and
10% Pd/C (38mg, 10mol% Pd) were mixed in a sealed tube under argon. THF (4mL) was added
in one portion and the sealed tube was evacuated under vacuum and backfilled with argon three
consecutive times. The sealed tube was evacuated under vacuum and a balloon filled with
hydrogen was attached. The starting material was consumed after 2h (TLC, silica gel) and the
solution was filtered through a plug of celite. The solvent was removed in vacuo to leave a crude
yellow solid. The solid was purified by flash column chromatography on silica gel (10% EtOAc
in hexanes) to provide the pure 21 in 95% yield as a white solid (96 mg): 1H NMR (300 MHz,
CDCl3) δ 7.79 (d, J = 7.6 Hz, 1H), 7.68 (d, J = 7.3 Hz, 1H), 7.42 – 7.19 (m, 2H), 7.02 (s, 1H),
6.41 (s, 1H), 6.30 (dd, J = 5.9, 3.7 Hz, 2H), 4.83 (s, 1H), 3.77 (s, 3H), 3.33 – 3.11 (m, 2H), 3.11
– 2.83 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 160.95, 156.59, 145.28, 143.63, 140.08, 139.31,
124.12, 123.55, 122.82, 122.15, 120.93, 107.92, 106.84, 99.32, 55.29, 37.37, 32.32; HRMS
(ESI) (M + H), Calcd. for C17H17O2S 285.0949; Found 285.0947.
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(E)-3-Methoxy-5-(2-(thiophen-2-yl)vinyl)phenol (29, Table 2-4, entry 3)

The NaH (60% dispersed in mineral oil, 360 mg, 0.009 mol) was added to anhydrous DMF (10
mL) at 0° C. The CH3CH2SH (1.22 mL, 1.32 g, 0.012 mol) was then added dropwise and stirred
at 0° C for 30 min. The temperature of the reaction mixture was allowed to rise to rt and the
mixture stirred for 1 h. The temperature of the reaction mixture was raised to 140° C and (E)-2(3,5-dimethoxystyryl)thiophene (739 mg, 0.003 mol) in dry DMF (3 mL) was added dropwise to
the reaction mixture. This mixture was held at 140° C and monitored by TLC (30% EtOAc in
hexanes, silica gel). When starting material was no longer present by TLC (~2 h) the reaction
mixture was cooled to rt and quenched by addition of aq 0.5N HCl (50 mL). The mixture was
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed sequentially with
aq 0.5N HCl (3x15 mL) and brine (3 x 15 mL). The organic layer was dried (Na2S04) and the
solvent was removed in vacuo. The crude solid was purified by FCC (20% EtOAc in hexanes) to
afford the pure 29 in 62% yield as an off-white solid (432 mg): 1H NMR (300 MHz, CDCl3) δ
7.23 – 7.17 (m, 2H), 7.09 – 7.08 (m, 1H), 7.04 – 7.00 (m, 1H), 6.84 (d, J = 16.2 Hz, 1H), 6.63 (s,
1H), 6.57 (s, 1H), 6.36 (t, J = 2.1 Hz, 1H), 5.04 (s, 1H), 3.83 (s, 3H); 13C NMR (75 MHz,
CDCl3) δ 161.0, 156.7, 142.4, 139.3, 127.8, 127.5, 126.3, 124.5, 122.4, 105.7, 104.7, 101.0, 55.3;
HRMS (ESI) (M + H), Calcd. for C13H13O2S 233.0636; Found 233.0639.

53

(E)-2-(3-Methoxy-5-(methylthio)styryl)benzo[b]thiophene (24, Table 2-5, entry 1)

The (E)-3-(2-(benzo[b]thiophen-2-yl)vinyl)-5-methoxyphenyl trifluoromethanesulfonate
(250mg, 0.603mmol, 1eq) and tetrakis(triphenylphosphine)palladium(0) (35mg, 5mol%) were
mixed in a sealed tube under argon. Then degassed toluene (3mL), triisopropylsilanethiol
(138mg, 0.724mmol, 1.2eq), and triethylamine (80mg, 0.784mmol, 1.3eq) were added and the
sealed tube was heated to 100 ºC. After 2h the starting material was consumed (by TLC) and the
sealed tube was cooled to rt. The solution was filtered through a plug of celite and the celite
washed with EtOAc (10mL x 3). The organic layer was washed with water (10mL) and brine
(10mL), then dried over Na2SO4, and the solvent removed in vacuo. The crude solid was
dissolved in THF and iodomethane (171mg, 1.20mmol, 2eq) was added in one portion.
Tetrabutyl-ammonium fluoride trihydrate (381mg, 1.20mmol, 2eq) was added slowly in 3
portions. Analysis by TLC (20% EtOAc in hexanes, silica gel) confirms the reaction was
complete 0.5h after the addition. The reaction was quenched with water (10mL) and extracted
with EtOAc (10mL x 2). The organic layer was washed with brine (10mL) and dried over
Na2SO4. The solvent was removed in vacuo leaving an orange solid. The solid was purified by
flash column chromatography on silica gel (10% EtOAc in hexanes) to provide the pure 24 in
47% yield as a yellow solid (89 mg): 1H NMR (300 MHz, CDCl3) δ 7.85 – 7.76 (m, 1H), 7.76 –
7.69 (m, 1H), 7.42 – 7.24 (m, 4H), 7.00 (d, J = 10.2 Hz, 1H), 6.94 (d, J = 16.0 Hz, 1H), 6.84 (s,
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1H), 6.80 – 6.70 (m, 1H), 3.87 (s, 3H), 2.55 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 160.18,
142.58, 140.32, 140.15, 138.98, 138.36, 130.25, 124.88, 124.55, 123.69, 123.50, 123.18, 122.25,
117.29, 111.87, 108.61, 55.39, 15.77; HRMS (ESI) (M + H), Calcd. for C18H17OS2 313.0721;
Found 313.0718.
(E)-3-(2-(Benzo[b]thiophen-2-yl)vinyl)-5-(methylthio)phenol (25, Table 2-5, entry 2)

The NaH (60% dispersed in mineral oil, 40mg, 1.00 mmol, 8eq) was added to anhydrous DMF
(2 mL) at 0° C. Then CH3CH2SH (0.1 mL 1.39 mmol, 11eq) was added dropwise and stirred at
0° C for 30 min. The temperature of the reaction mixture was allowed to rise to rt and the
mixture stirred for 1 h. The temperature of the reaction mixture was raised to 140° C and (E)-2(3-methoxy-5-(methylthio)styryl)benzo[b]thiophene (38.7 mg, 0.124 mmol, 1eq) in dry DMF
(0.5 mL) was added dropwise to the reaction mixture. This mixture was held at 140° C and
monitored by TLC (30% EtOAc in hexanes). When the starting material was no longer present
by TLC (~1 hr) the reaction mixture was cooled to 0 ºC and quenched by addition of aq 0.5N
HCl (10 mL). The mixture was extracted with EtOAc (3 x 10 mL). The combined organic layers
were washed sequentially with aq 0.5N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic
layer was dried over Na2SO4 and the solvent was removed in vacuo. The crude solid was purified
by FCC (20% EtOAc in hexanes) to afford the pure product in 82% yield as a pale yellow solid
(30 mg): 1H NMR (300 MHz, CDCl3) δ 7.78 (dd, J = 7.9, 4.8 Hz, 1H), 7.75 – 7.66 (m, 1H), 7.40
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– 7.29 (m, 2H), 7.29 – 7.23 (m, 2H), 6.96 (s, 1H), 6.89 (d, J = 16.0 Hz, 1H), 6.76 (s, 1H), 6.68 (t,
J = 1.8 Hz, 1H), 2.52 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 160.52, 142.48, 140.46, 140.10,
138.76, 138.32, 130.22, 124.87, 124.45, 123.70, 123.40, 123.15, 122.20, 117.19, 111.67, 108.71,
15.57; HRMS (ESI) (M + H), Calcd. for C17H15OS2 299.0564; Found 299.0568.
(E)-3-(2-(Benzo[b]thiophen-2-yl)vinyl)-5-methoxybenzonitrile (26, Table 2-5, entry 3)

The (E)-3-(2-(benzo[b]thiophen-2-yl)vinyl)-5-methoxyphenyl trifluoromethanesulfonate
(250mg, 0.603mmol, 1eq), tetrakis(triphenylphosphine)palladium(0) (35mg, 5mol%), sodium
cyanide (59.10mg, 1.21mmol, 2eq), and copper iodide (11.5mg, 10mol%) were mixed in a sealed
tube under argon. Then degassed toluene (3mL) was added and the sealed tube was heated to
100 ºC. After 2hr the starting material was consumed (by TLC) and the sealed tube was cooled
to rt. The solution was filtered through a plug of celite and the celite washed with EtOAc (10mL
x 3). The organic layer was washed with water (10mL) and brine (10mL), dried over Na2SO4,
and the solvent removed in vacuo to furnish a red solid. The solid was purified by flash column
chromatography on silica gel (20% EtOAc in hexanes) to provide the pure 26 in 35% yield as a
yellow solid (61.5 mg): 1H NMR (300 MHz, CDCl3) δ 7.80 (dd, J = 8.6, 5.0 Hz, 1H), 7.77 – 7.70
(m, 1H), 7.46 – 7.29 (m, 5H), 7.22 (s, 1H), 7.05 (s, 1H), 6.89 (d, J = 16.0 Hz, 1H), 3.89 (s, 3H);
13

C NMR (75 MHz, CDCl3) δ 160.03, 141.69, 139.97, 139.36, 139.16, 128.11, 125.30, 124.98,
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124.81, 124.72, 123.76, 122.52, 122.31, 118.60, 116.83, 115.88, 113.65, 55.68; HRMS (ESI) (M
+ H), Calcd. for C18H14NOS 292.0796; Found 292.0792.
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CHAPTER THREE
DEVELOPMENT OF A NEW TRANSITITION METAL CATALYZED
REACTION FOR THE SYNTHESIS OF NOVEL ANALOGS OF SK-03-92:
EXPLORATION OF THE HECK REACTION
I.

INTRODUCTION AND BACKGROUND.
1.

Negishi and Wittig couplings.

As described in the previous Chapter, the two methods that were previously employed to
synthesize novel stilbenoid analogs had numerous shortcomings from a synthetic perspective
(Scheme 3-1).
Scheme 3-1: Negishi cross-coupling and Wittig-Horner type coupling procedures.

The Negishi cross-coupling procedure required synthesis of the unstable vinyl iodide 4
and while it was useful for synthesis of analogs in which ring A (see Figure 2-4) was static, it
was not very useful for a more comprehensive analysis of the SAR. It also required deprotection
of a silyl group, which while not very difficult nor low-yielding, still added another step to the
process. The Wittig-Horner type coupling was devised for scale-up purposes of SK-03-92 and
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similarly to the Negishi type coupling it was very useful when ring A was held static. However,
it also required a deprotection step; in this case a mono-demethylation which was rather lowyielding and troublesome when working on small scales. A reaction with a more comprehensive
scope for the synthesis of similar stilbenoid analogs was necessary.

2.

Retrosynthetic analysis.

As described earlier, it is helpful to identify and separate the three distinct structural
moieties observed in these analogs: the phenolic substituted ring A, the alkene “bridge”, and the
non-polar aromatic region of, in general, rings B and C (see Figure 2-4). Due to the reactivity of
phenols, prior synthetic procedures focused on protection, which of course resulted in the need
for deprotection, generally as a final step, to obtain the desired analog. The removal of this
deprotection step was a priority, directing research toward reactions that were tolerable to
phenolic substituents.
Because prior results indicated that benzo[b]thiophene was the most advantageous nonpolar aryl group which represented rings B and C in active analogs, it was determined that a
method that focuses on this moiety, while still with the capacity to change to different structural
analogs, was preferred.
The SAR also indicated that the alkene ‘bridge’, while not necessary for activity, seemed
to show improved potency for at least 1 analog. Taken together, these stipulations resulted in the
analysis illustrated in Scheme 3-2.
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Scheme 3-2: Retrosynthetic analysis.

The second option in the Figure above very much resembles the prior Negishi crosscoupling reaction. The first option, however, is more interesting for a number of reasons.
Firstly, aryl halides are generally commercially available and inexpensive. Secondly, if a desired
bromo/iodo phenol is not available, phenols can be readily brominated with commercially
available and inexpensive reagents such as Br2 or NBS. In addition, keeping the aryl side-chain
static as a benzo[b]thiophene moiety was the initial goal for the new SAR and synthesis of the
vinyl analog was trivial.
Both options, however, strongly imply a transition metal catalyzed reaction. One of the
most well-known transition metal reactions is the Heck-Mizoroki reaction, a reaction between an
aryl halide (usually electron-poor) and an unsaturated (usually activated) styrene.121 In this case,
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however, electron-rich phenolic bromides and unactivated styrenes are not ideal candidates for
such a reaction121-122, however it was still pursued due to the scope and ease of synthesis of the
starting materials.

3.

Heck-Mizoroki reaction.

3.1: Background.
In the early 1970’s both Heck and Mizoroki published a nearly identical synthesis of
stilbene (Scheme 3-3).123-124 This synthesis employed iodobenzene, styrene, base, and a
palladium (II) catalyst. This work was an extension of prior work done by both Fujiwara125-126
and Heck.127
Scheme 3-3: Original synthesis by Mizoroki (1971) and Heck (1972).

Heck greatly expanded the scope and utility of this reaction over the course of the next
few years and made many key discoveries including the use of phosphine ligands to enhance
reaction conditions.128 As one of the first palladium mediated coupling procedures, the Heck
reaction prompted the way to other widely known transition metal catalyzed reactions such as the
Suzuki reaction, Sonogashira coupling, and Negishi coupling reactions.129-131
3.2: Catalytic cycle.
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The catalytic cycle of the Heck reaction (Figure 3-1) generally starts with a palladium (II)
species which is subsequently reduced to palladium (0) via a phosphine ligand and through a
number of transformations, all discussed below, ends with a regeneration of the palladium (0)
species which gives rise to the catalytic nature of the process.
Figure 3-1: General catalytic cycle of the Heck reaction.

As discussed earlier a palladium (II) catalyst, if employed, is reduced to palladium (0),
prior to entering the catalytic cycle (Figure 3-1).132 While palladium (II) catalysts are routinely
used based on the relative stability of palladium (II) and the ability to store for long periods of
time on the benchtop, palladium (0) catalysts are also available and can be used directly without
the need for pre-catalyst activation.133-135 Many of these catalysts, including palladium tetrakis,
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are not air or temperature stable, however a growing number of air and/or temperature stable
palladium (0) catalysts have been discovered.134, 136-137
The next step, b (Figure 3-1), is the oxidative addition of a halide or triflate substituted
aryl group (Scheme 3-4). This reaction occurs in a concerted manner (b1) and though the cis and
trans isomers are in equilibrium (b2), it has been found that only the cis continues through the
catalytic cycle.138-140
Scheme 3-4: Concerted mechanism of oxidative addition (Figure 3-1 “b”).

Detailed in process c (Figure 3-1) is the migratory insertion of an alkene into the
palladium species (Scheme 3-5). Data suggests that this step also relies on a concerted
mechanism (c1), although other mechanisms may be possible depending on the
catalyst/ligand/reactants involved.141-142 The regioselectivity of the migratory insertion step is
generally determined by steric considerations, however when electron-rich alkenes are employed
in some cases electronic character can play a role.134, 143 Regioselectivity in the original
Heck/Mizoroki reaction relied exclusively on sterics due to the electron-poor nature of the alkene
(styrene).
Scheme 3-5: Migratory insertion of an alkene to palladium (Figure 3-1 “c”).
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The double bond is re-introduced by ß-hydride elimination, step d (Scheme 3-6). Steric
effects generally lead to only the E isomer; however, in some cases the Z isomer can be more
prevalent.134, 144 Base plays an essential role in reductively eliminating the remaining palladium
hydride species back to palladium (0), stopping re-insertion of the alkene and allowing the
catalytic cycle to continue, step e (Scheme 3-7).
Scheme 3-6: ß-hydride elimination (Figure 3-1 “d”).

Scheme 3-7: Base promoted dehydropalladation and reductive elimination (Figure 3-1 “e”).

As with almost all transition metal chemistry, the above schemes are a general case and
many factors may influence these micro-reactions to varying degrees. Many theories exist on the
exact mechanism of oxidative addition and reductive elimination; presented here are the most
well-regarded theories for a general palladium-phosphine directed reaction.134, 138, 143
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3.3: Scope.
The scope of the Heck reaction is wide and varied. Bimolecular reactions to
intramolecular reactions have been thoroughly explored over the last few decades. It was
generally thought that aryl (pseudo)halides were necessary; however, recent findings suggest that
even alkyl halides can undergo Heck reactions.145-147 With some 3rd generation phosphine
catalysts it is even possible to use aryl chlorides with varying degrees of success.148-150 The most
general considerations for a Heck reaction seem to be an organo-halide and an olefin, from there
careful selection of both catalyst and ligand, along with reaction conditions, can potentially lead
to the desired product.

II.

CHEMISTRY AND RESULTS.
1.

Heck reaction trials.

From examination of the original retrosynthetic analysis, it was determined that a Heck
reaction may be useful in the synthesis of analogs of SK-03-92. The original synthesis
envisioned the use of 3-bromo substituted phenols to give analogs with the same substitution
pattern as SK-03-92, however, 4-bromo substituted phenols were both easier to synthesize and
were generally more commercially available. For these reasons we started the original trials
using 1-(5-bromo-2-hydroxyphenyl)ethan-1-one (30, Scheme 3-8) which had been previously
purchased for another project.
Scheme 3-8: Proposed Heck reaction.

65

This reaction also hinged on the synthesis of the olefin 31. This was conveniently
accomplished starting from the aldehyde 18 (Scheme 3-9), previously synthesized and used for
the scale-up of SK-03-92. The synthesis of olefin 31 proceeded with little difficulty from a
Wittig reaction employing methyltriphenylphosphonium bromide and sodium methoxide.
Scheme 3-9: Synthesis of olefin 31.

Unlike the vinyl iodides previously used, the olefin 31 was sufficiently stable at room
temperature to permit a much easier purification procedure. The styrene analog was a white
crystalline solid, however, it was found that storage on the benchtop over the course of several
days led to decomposition to a yellow viscous oil that was assumed to be polymerization of the
olefin. Storage at 0 ºC kept olefin 31 analytically pure for over 6 months, thus addition of a
polymerization inhibitor was unnecessary.
With both reactants in hand the conditions for the initial palladium mediated reaction
were considered. In general Heck reactions prefer electron-poor (unactivated) aryl bromides and
electron-rich (activated) olefins.134, 151 In our case, however, the substituted 4-bromo phenols
were electron-rich and the 2-vinylbenzo[b]thiophene 31 was electron-poor. Because of this it
was assumed that heating would be necessary, so many solvents were initially tried at or above
their boiling points in sealed vessels.
Although base plays many roles in the Heck reaction, the most crucial role is removing
the acidic proton produced (in this case HBr) to permit the catalytic cycle to continue. Sodium
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acetate has found use in a number of Heck reactions and as a weaker base was unlikely to cause
problems with either the aryl bromide or olefin.
For palladium (II) species it was important to reduce the palladium to palladium (0) with
phosphine ligands to initiate the catalytic process. There is an extensive library of phosphine
ligands available and many are suited for specific reactions.152 In this trial only two simple
phosphine ligands were explored, triphenylphosphine and tri(o-tolyl)phosphine. The two ligands
are by far the most widely used ligands in palladium catalyzed coupling reactions. Palladium (0)
catalysts could be used with no additional ligand as they are already in the correct oxidation
state.
Solvents were chosen mainly with regard to their ability to dissolve the starting materials
as, in general, homogenous reactions are more likely to succeed. With these factors in mind, a
number of reaction trials were completed (Table 3-1).
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Table 3-1: Heck reaction trials.

Trial

Palladium

Ligand

Base

Solventa

Temp. (ºC)

Conversion (%)b

1

Pd(OAc)2

P(Ph)3

NaOAc

THF

70

0

2

""

P(o-tol)3

NaOAc

THF

70

0

3

""

P(Ph)3

NaOAc

ACN

95

0

4

""

P(o-tol)3

NaOAc

ACN

95

0

5

""

P(Ph)3

NaOAc

DMA

150

0d

6

""

P(o-tol)3

NaOAc

DMA

150

0d

7

PdCl2

P(Ph)3

NaOAc

THF

70

0

8

""

P(o-tol)3

NaOAc

THF

70

0

9

""

P(Ph)3

NaOAc

ACN

95

0

10

""

P(o-tol)3

NaOAc

ACN

95

0

11

""

P(Ph)3

NaOAc

DMA

150

0d

12

""

P(o-tol)3

NaOAc

DMA

150

3

13

PdP(Ph3)4

---

NaOAc

DMA

100

5

14

""

---

NaOAc

DMA

150

0d

15

H.Palladc

---

NaOAc

DMA

150

5

16

""

---

NaOAc

DMA/5% H2O

150

95

17

""

---

NaOAc

DMA/5% H2O

100

24

18

""

---

NaOH (aq.)

DMA/5% H2O

150

93

19

""

---

Cs2CO3

DMA/5% H2O

150

96

20

""

---

NaOAc

DMA/10% H2O

150

96

a

freshly distilled and degassed via freeze-thaw, b determined by HPLC, c Herrmann’s palladacycle, d large amounts
of palladium black – likely decomposition.

Analysis of the data in Table 3-1 indicated that under most conditions no conversion to
the stilbene analog was noted, however when a small amount of water was added to
dimethylacetamide as the solvent, there was nearly full conversion. The idea to add water to the
conditions was conceived from trials 12, 13, and 15 where a small but noted conversion took
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place. Of all the solvents tested, dimethylacetamide was the most hygroscopic, therefore, it was
thought that perhaps in the cases in which some conversion was noted, water may have somehow
entered the reaction. The role of water in the reaction is not fully understood, and indeed, reports
in the literature only posits that water may increase the rate of palladium catalyzed reactions in
some cases,153-155 although the reasons behind this are somewhat elusive. In general, it is thought
that water can stabilize intermediates and thus accelerate the reaction,156 although few reactions
were found where water was necessary for any conversion. In the case of this reaction, 5-10%
water was found to give almost full conversion. It is unclear how much water is necessary for
conversion and there was no attempt to quantify this amount.
Herrmann’s palladacycle (Figure 3-2) is a cyclopalladated complex discovered by
Herrmann in 1997.157 Since this catalyst exists as palladium (II) at room temperature, this
catalyst exhibits far greater air and temperature stability compared to other common palladium
catalysts such as palladium tetrakis which readily decomposes at room temperature. Herrmann’s
palladacycle has a unique property in that at elevated temperatures, approximately 80 ºC, the
catalyst reduces to a form of palladium (0) suitable for Heck reactions without any additional
ligand. Because of these properties, it was an interesting catalyst choice for the trial reaction.
Indeed, when palladium acetate with ligands or palladium tetrakis was heated over 100 ºC,
necessary for conversion, large quantities of palladium black resulted, which indicated
decomposition of the catalyst. When Herrmann’s palladacycle was used, however, the reaction
mixture only changed color after prolonged heating at 150 ºC, and in some cases never became
the dark black color which indicated catalyst decomposition.
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Figure 3-2: Herrmann’s palladacycle.

While the role of base is critical in Heck reactions, little difference was seen in switching
from the relatively weak base, sodium acetate, to the relatively strong base, sodium hydroxide. It
should be noted, however, that aryl bromides are not always stable in strongly basic solutions,
and in these cases heating was found to cause premature decomposition of some aryl bromides
which led to lower yields. In the trial case, however, the bromide was rather stable and
conversion was not greatly affected. Because high conversion was seen with sodium acetate and
in general the stability of aryl bromides was not investigated prior to submitting them to the
reaction conditions, sodium acetate seemed to be the best choice as the base. The nitrogen-based
bases are also often used in Heck reactions and many other palladium catalyzed reactions that
require base, however, at the high temperature conditions necessary for conversion, nitrogen
based bases were deemed too volatile and not worth investigating due to the already high
conversion rate observed with sodium acetate.
It should also be noted that Herrmann’s palladacycle employs P(o-tolyl)3 ligands, the
same ligands employed in trials 2,4,6,8,10, and 12. In fact, Herrmann’s palladacycle was
conveniently synthesized in the lab by treating palladium acetate with tri(o-tolyl)phosphine
under gentle heating (Scheme 3-10) on a 5 gram scale. The difference in the trials, however, was
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that the phosphine ligand was added in excess which drives the conversion to Pd(P(o-tolyl)3)4,
similar in structure to palladium tetrakis, which is also thermally unstable and readily
decomposes to palladium black when subjected to high temperatures. Because of the convenient
synthesis of the palladacycle and its relative stability, the attempt to use palladium acetate along
with just one molar equivalent of the phosphine ligand (synthesizing the palladacycle in situ) was
not attempted. It was assumed that such a reaction would result in similar conversion if the other
conditions for trial 20 were followed.
Scheme 3-10: Synthesis of Herrmann’s palladacycle.
Pd(OAc)2 (1 eq) + P(o-tolyl)3 (1 eq)

toluene, 50 ºC
0.5-1 h

Herrmann's palladacycle

Optimization of the palladium catalyzed reaction was successful and was next attempted
with a variety of other aryl bromides.

2.

New thianaphthene analogs and their SAR.

As discussed earlier, substituted 4-bromophenols are less expensive, easier to synthesize,
and generally more commercially available when compared to other aryl substitution patterns;
thus the initial focus of this SAR was this substitution pattern (Table 3-2). Heck reactions are
extremely versatile and it should be noted that this method, now optimized for substituted
phenols, should work with any substitution patterns given they are stable to the reaction
conditions. In the first series of reactions, most of them employed substituted 4-bromophenols as
starting materials, however, some other substitution patterns were also employed. In a later
section other substitution patterns will be discussed in more detail and are of critical importance
to provide potent antibacterial stilbenes.
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Table 3-2: First series of analogs synthesized.

a

RX
---------------------

Yield (%)a
91
91
90
95
93
89
92
90
91
80

Cl

R4 = Cl

93

OH

OMe

R3 = OMe

75

OH
OH
OH
OH
OMe

OCF3
OEt
OiPr
COOH
COOH

-----------

85
90
90
93
91

Compound
32
33
34
35
36
37
38
39
40
41

R1
OH
OH
OH
OH
OMe
OH
Cl
OH
OH

42

OH

43
44
45
46
47
48

R2
CHO
F
H
-OCH2OOMe
OH
Cl
OH
CN
NO2

Yield of isolated and purified product.

Four different compounds were prepared without a phenol in the R1 position; 35, 37, 39,
and 48. Additionally, compounds 42 and 43 are tri-substituted analogs, which illustrates some of
the versatility of the Heck reaction. Similarly to SK-03-92, these compounds could be further
purified after column chromatography by crystallization from isopropanol, however, this was
only done if a larger scale synthesis was employed. Indeed, when 36 and 38 were scaled up to a
1-gram scale using identical reaction conditions to their small-scale preparation, similarly
excellent yields were observed. Thus the Heck catalyzed reaction was not only an efficient
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process for constructing a library of stilbenoid analogs, but also for scale-up for pharmacological
studies when necessary.
From this first series of analogs several important antibacterials were identified with
activity against gram-positive bacteria, some of which were more active then lead compound
SK-03-92. Summarized in the following tables are the structures and MIC values for novel
antimicrobials synthesized utilizing Heck coupling detailed in Table 3-2.
Table 3-3: MICs for compounds 32, 33, and 34a.

Bacterial Strain

a

S. aureus

>128

>128

32

E. faecalis

>128

>128

32

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

>128

>128

>128

M. chelonae

>128

>128

>128

M. fortuitum

>128

>128

128

M. kansasii

>128

>128

>128

M. avium

>128

>128

>128

M. smegmatis

>128

>128

128

M. marinum

>128

>128

>128

Values in µg/mL
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Unfortunately, the trial ketone 32 previously discussed was not active against any
bacterial strains. The fluorine analog 33 was also inactive and the simple phenol 34
demonstrated only meager activity on the gram-positive strains. Initial setbacks such as this
were expected, however, and the SAR continued with another group of compounds (Table 3-4).
Table 3-4: MICs for compounds 35, 36, and 37a.

Bacterial Strain

O
O

a

35

S

S. aureus

>128

1

>128

E. faecalis

>128

1

128

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

>128

16

>128

M. chelonae

>128

16

>128

M. fortuitum

>128

8

>128

M. kansasii

>128

32

>128

M. avium

>128

16

>128

M. smegmatis

>128

8

>128

M. marinum

>128

8

>128

Values in µg/mL

Similarly to the prior SAR, lack of a phenol in the case of the 1,3-dioxole ligand 35
resulted in no activity. In general, a few compounds which lack phenolic groups were
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synthesized and screened to both validate the SAR, as well as test the theory that a phenol was
necessary for potency. Analog 36 is indeed very similar to SK-03-92, however, it differed in the
position of the phenol. However, the phenol in this position increased the activity about 2-4 fold
against gram-positive and mycobacterium species. Perhaps more interesting, however, was the
lack of activity of 37, which was very similar in structure to both SK-03-92 and 36. This small
change seemed to indicate that the target can accept the phenol changing position, but not the
methoxy group. This may indicate that the active site for these ligands has a larger space to
accommodate hydrogen bond donors, but has a conserved space for functional groups ortho to
the phenol.
The next set of analogs (Table 3-5) was prepared to determine the effects of changes in
the position of substituents as well. The chloro analog 38 represents one of the most active
compounds developed, to date. The chlorine group differs from methoxy group at the same
position in a number of notable fashions. First, chlorine is an electron withdrawing group by
induction while the methoxy group is an electron donating group by resonance. Secondly,
chlorine is at best a weak hydrogen bond acceptor while the methoxy group is a very strong
hydrogen bond acceptor. Thus, electronic character and H-bond acceptor character do not seem
to influence the activity in a meaningful way. Another difference between the chloro and
methoxy groups is size, with chloro being smaller; this may explain the similar activity between
these two compounds. Ligand 39, with a similar switching of positions of chloro and hydroxy
groups seen earlier, also exhibited a much weaker MIC value. The basis for this selective
activity is still undetermined, but it seems that it points to interactions between the small
molecule and a specific target in the bacteria. This is interesting as earlier findings suggested
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that these compounds may act on more than one target, however, extreme activity loss from a
simple substitution points to a specific target or selective metabolic step instead.
Table 3-5: MICs for compounds 38, 39, and 40a.

Bacterial Strain

a

S. aureus

0.5

64

32

E. faecalis

0.5

64

32

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

>128

>128

>128

M. chelonae

>128

>128

>128

M. fortuitum

>128

>128

>128

M. kansasii

>128

>128

>128

M. avium

>128

>128

>128

M. smegmatis

>128

>128

>128

M. marinum

>128

>128

>128

Values in µg/mL

In regard to active chloro 38, it is also of interest that the chloro substitution greatly
diminished activity against the mycobacterium species as compared to the similar methoxy
analog 36. This was interesting considering that activity against gram-positive bacteria from the
prior SAR almost always was followed by a linear-type activity against mycobacterium species.
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Given the similar nature of gram-positive bacteria and mycobacterium, this activity was not
surprising. Given that no compounds from the prior SAR were active against gram-negative
bacteria, it was hypothesized that the mode of action was somehow related to the cell walls of
both the gram-positive bacteria and mycobacteria. Thus the lack of activity of 38 to
mycobacterium could give some insight into the cellular target, whether it is a single target or
multiple targets.
Finally, synthesis of the cyano compound 40 was similar to the nitrile analog 26,
however, in this case the phenol was easy to prepare in one step. While it showed some activity,
it was not active enough to warrant synthesis of the nitrile at other positions at this time.
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Table 3-6: MICs for compounds 41, 42, and 43a.

Bacterial Strain

a

S. aureus

128

32

32

E. faecalis

128

8

32

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

>128

>128

>128

M. chelonae

>128

>128

>128

M. fortuitum

>128

>128

>128

M. kansasii

>128

>128

>128

M. avium

>128

>128

>128

M. smegmatis

>128

>128

>128

M. marinum

>128

>128

>128

Values in µg/mL

Outlined in Table 3-6 are the details of the SAR of three more analogs of interest. The
nitro analog 41 was synthesized to test whether or not a strong electron withdrawing group in the
R2 position increased activity similar to the chloro group. It was found, however, that the nitro
analog 41 was not very active at all with MIC’s of 128 µg/mL against the gram-positive strains.
Both 42 and 43 probe the idea of tri-substituted analogs. Both, however, exhibited weaker
activity then their disubstituted parent compounds. In future SAR studies it may be beneficial to
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try a range of tri-substituted analogs to improve solubility, metabolism, and other pharmaceutical
parameters, however, this remains to be seen.
The next set of compounds were prepared to attempt to demonstrate that size was directly
related to activity (Table 3-7).
Table 3-7: MICs for compounds 44, 45, and 46a.

Bacterial
Strain

a

S. aureus

>128

8

>128

E. faecalis

>128

8

>128

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M.
intracellulare

>128

32

16

M. chelonae

>128

32

16

M. fortuitum

>128

32

16

M. kansasii

>128

32

8

M. avium

>128

32

16

M. smegmatis

>128

16

32

M. marinum

8

16

4

Values in µg/mL

The trifluoromethoxy analog 44 was inactive in all assays except that of M. marinum,
however, this could be a case of experimental error or a bad strain. It was interesting that the
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trifluoromethoxy analog was far less active even though fluoride is generally a good bioisostere
for hydrogen, however, CF3 is more similar in size to isopropyl and thus sterics may play a large
role in the potency of this analog. The electronic character of trifluoromethoxy also differs from
that of a methoxy group, which may also explain the loss of activity.
The ethoxy analog 45 retained some activity, however was less active then both the
methoxy and chloro analogs. Ethoxy, similar to methoxy, also retained activity in the
mycobacterium assays, however.
Finally, the isopropoxy analog 46 was seemingly the most interesting of the set even
given it had no activity on the gram-positive strains tested. Ligand 46 was found to retain
mycobacterium activity even though it exhibited no gram-positive activity. Since the chloro
derivative was very active against gram-positive bacteria, but had no activity against
mycobacterium, the isopropoxy was inversely active against mycobacterium but not grampositive bacteria. This seems to suggest that the mode of action for gram-positive bacteria is
independent of the mycobacterium species.
This suggests, as suggested from earlier work, that some of these compounds act on
multiple targets. The targets in gram-positive and mycobacterium strains, however, could be
very similar as indeed they share an evolutionary past. Uncovering these targets, however,
remains a struggle and will be detailed in future sections.
The final table from this first series of compounds (Table 3-8) includes two carboxylic
acid derivatives 47 and 48. The third compound included, 49, is from the next series of
compounds discussed in Table 3-9.

80

Table 3-8: MICs for compounds 47, 48, and 49a.

Bacterial Strain

a

S. aureus

>128

8

>128

E. faecalis

>128

8

>128

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

>128

>128

>128

M. chelonae

>128

>128

>128

M. fortuitum

>128

>128

>128

M. kansasii

>128

>128

>128

M. avium

>128

>128

>128

M. smegmatis

>128

>128

>128

M. marinum

>128

>128

>128

Values in µg/mL

Similar to prior results, the non-phenolic analog 47 was not active. The para-phenolic
acid 48, however, was active against gram-positive bacteria, while similarly to the chloro
derivative lacked activity on the mycobacterium strains. Similarly to chloro, the carboxylic acid
is electron withdrawing, which may play a role in this activity profile.
The pyridine derivative 49, though inactive, led to the next series of compounds, the
pyridines. Pyridine analogs were synthesized in the hope of discovering a more water soluble
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active analog that would be more useful for future in vivo work. The optimized Heck reaction
was found to work with good to excellent yields of these pyridine derivatives. Only four
pyridine analogs were prepared for this study, but these pyridine analogs may prove useful for
future SAR studies, especially if more in vivo work is planned because of increased water
solubility which should enhance bioavailability.
Table 3-9: Pyridine series of analogs synthesized.

Compound
49
50
51
52

R1
COOMe
OMe
OH
COOH

Yield (%)
82
90
90
87

Although only four analogs were prepared, based on the yields it seems likely that a great
deal of other N-containing analogs are possible. It was found that phenolic analog 51 was rather
unstable and over the course of several days on the benchtop it was no longer analytically pure,
therefore it is best stored in the freezer. In general, the work-up procedure for the stilbenoid
derivatives involved washing with dilute acid; in the case of pyridines this would obviously be
problematic. However, washing with just water only led to a negligible loss of yield. Analysis
of the data in Table 3-8 illustrated pyridine 49 had no activity in any strains tested. Indeed it was
assumed that perhaps only the phenol derivative 51 would show activity based on the past SAR.
It was surprising to find that 51 also lacked activity, but the carboxylic acid derivative 52 was
still active in both gram-positive and mycobacterium strains (Table 3-10). In the case of the
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meta-phenol 51, it is conceivable that the unstable nature of this analog causes it to degrade prior
to exerting any antibacterial properties.
Table 3-10: MICs for compounds 50, 51, and 52a.

Bacterial Strain

a

S. aureus

>128

128

8

E. faecalis

>128

128

8

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

>128

>128

32

M. chelonae

>128

>128

32

M. fortuitum

>128

>128

64

M. kansasii

>128

>128

32

M. avium

>128

>128

64

M. smegmatis

>128

>128

64

M. marinum

>128

>128

32

Values in µg/mL

The meta-carboxy pyridine analog 52 was the first case of a non-phenolic derivative to
show activity. Two possibilities exist for this activity. First, perhaps the acidic -OH in the
carboxylate is a good replacement for the acidic phenolic -OH. Second, it is possible this
compound acts as a zwitterion and the NH+ mimics the phenol (Figure 3-3). This zwitterionic
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form may more closely mimic the structure of SK-03-92. In any case, an active pyridine analog
is promising for future SAR studies and if an ~8-fold more active pyridine analog is discovered,
and it has suitable PK properties, it may be a viable lead compound for preclinical studies.
Figure 3-3: Zwitterionic form of 52.

3.

New styrenes and substitution patterns.

Although this optimized Heck reaction was an excellent method to synthesize stilbenes
from a wide selection of aryl bromides, after a number of active analogs were discovered it was
prudent to again modify the ‘right-hand-side’ to see if potency could be further enhanced. As
previously described (Scheme 3-9) synthesis of styrenes was quick and in high yields from
aldehydes. Some styrenes of interest were even commercially available, for example 4-vinyl1,1'-biphenyl (58).

Thus a number of new styrenes were synthesized to be used in the Heck

reaction to provide a growing variety of stilbenoid compounds in rational drug design.
The first new styrene derivative investigated was the indole (Scheme 3-11). Indoles are
widely known for exhibiting excellent PK properties and are privileged substructures of a
number of pharmaceutical drugs.158-161 Because of the previously discussed poor ADME
properties of SK-03-92, analogs that can perhaps improve these properties were pursued.
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Scheme 3-11: Synthesis of 2-vinylindole.

Since the 1H-indole-2-carboxylic acid starting material was inexpensive, the first two
steps, first to the alcohol 53 and then to the aldehyde 54 were scaled up to gram-scale from the
start. Similarly to the thianaphthene analog 31, 2-vinylindole 55 was synthesized in high yield.
One striking difference between 31 and 53, however, was their acid stability. The indole 53
readily decomposed and gave a deep purple color when treated with even minimal amounts of
acid. This is commonly observed with benzylic alcohol analogs of indoles at position 2 via loss
of water.
The N-methyl derivative of aldehyde 54 was also synthesized, which gave the N-methyl
indole derivative 57 (Scheme 3-12). This was done to probe the substitution of the NH indole
position for future possible analogs.
Scheme 3-12: Synthesis of 1-methyl-2-vinyl-1H-indole 57.

Another styrene of interest was the 2-vinylbenzofuran (60), since it is very similar to the
lead styrene 2-vinylbenzo[b]thiophene 31 31. Synthesis of this analog followed similarly to the
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route for the thianaphthene derivative in that the aldehyde (59) was preferably synthesized since
it was expensive to purchase commercially (Scheme 3-13).
Scheme 3-13: Synthesis of 2-vinylbenzofuran 60.

Substitution of new groups on the original thianaphthene analog 31 itself was also
explored. The most easily substituted position seemed to be the 5-position and substitution with
both fluoro and chloro groups were explored. Unfortunately, substituted thianaphthenes are
expensive and it was necessary to synthesize them from substituted thiols (Scheme 3-14). These
reactions were found to be messy and low-yielding, however, the substituted thiols were
inexpensive enough to scale the reactions up to get enough material to continue on to the desired
final substituted styrenes.
Scheme 3-14: Synthesis of substituted thianaphthenes.

Once the substituted thianaphthenes were synthesized, synthesis of the 2-vinyl analogs
followed the same route to the lead vinyl analog 31 (Scheme 3-15). Similarly to 31, high yields
of the substituted 2-vinylthianaphthenes 61 and 62 were obtained and the material was similar in
terms of stability and appearance. Future SAR studies may also focus on substitution in both this
5-position and other positions based on availability of substituted thiols. It should be noted that
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3-substituted thiols will likely generate two different isomers when cyclized that may prove very
difficult to separate, thus focus initially on 4-substituted thiols (this work) or 2-substituted thiols
would be preferred.
Scheme 3-15: Synthesis of substituted styrenes.

Summarized in Figure 3-4 are the styrenes that are now available for synthesis of
stilbenes via the optimized Heck reaction.
Figure 3-4: Styrenes synthesized and/or commercially available.

Synthesis using a new substitution pattern was also investigated in this second series of
compounds. Using the convenient hydroxy/methoxy substitution pattern found to lead to active
compounds, depicted in Figure 3-5 below are all of the possible substitution patterns that can be
explored using the Heck reaction.
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Figure 3-5: Substitution patterns.

Previously it was shown that the methoxy group was preferably meta to the “R” group
(S1-S4), therefore, these were the preferred substitution patterns to try first. Pattern S1 was the
substitution pattern employed in the synthesis of SK-03-92 while S2 was the substitution pattern
employed for the optimized Heck reaction described in this chapter. Pattern S3 was a novel
substitution pattern and given the ortho/para directing nature of the phenol, synthesis of the
substituted aryl bromide was routine (Scheme 3-16). Synthesis of S4 was completed on a smallscale for another project, however, as of yet it has not been applied to this project. Pattern S9 has
also been partially explored with two compounds lacking activity, while S5-8 and S10 might be
considered for future SAR studies.
Scheme 3-16: Synthesis of 2-bromo-4-methoxyphenol.
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With these new starting materials in hand, the synthesis of another series of analogs was
accomplished. Summarized in Table 3-11 is the synthesis of these new analogs.
Table 3-11: Second series of analogs synthesized.

Compound
63
64
65

R1
OH
OH
OH

R2
OMe
OMe
Cl

RX
-------

Styrene
55
57
58

Yield (%)
83
89
84

66

H

OMe

R4 = OH

31

86

67

H

OMe

R4 = OH

55

81

68
69
70
71
72

H
OH
OH
OH
OH

OMe
OMe
Cl
Cl
OMe

R4 = OH
---------

60
61
61
62
62

86
87
87
92
88

73

NH2

OMe

R4 = Cl

31

75

74

H

OMe

R3 = OH

62

92

The indole analogs 63 and 67 were both not acid sensitive, unlike their parent styrene 55.
The N-methyl analog 57 was also not acid sensitive. This is of importance because acid stability
in vivo is an important quality for a drug-candidate. Compounds that readily decompose when
subjected to changes in pH are likely to quickly decompose in vivo (stomach, 2; gut, 9-10) and
likely not reach their target in time to elicit an effect. The relative instability of the styrene
indole, in this case, is likely simply related to the relative reactivity of the olefin, which is
quenched on annulation with the aryl bromides. Polymerization reactions with styrenes, likely
the major mode of decomposition, is well known.162-164
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Table 3-12: MICs for compounds 63, 64, and 65a.

Bacterial Strain

a

S. aureus

4

32

>128

E. faecalis

4

32

>128

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

32

32

>128

M. chelonae

32

32

>128

M. fortuitum

32

32

>128

M. kansasii

32

32

>128

M. avium

16

32

>128

M. smegmatis

16

32

>128

M. marinum

32

32

>128

Values in µg/mL

The major focus from this series of compounds were phenolic derivatives with either
methoxy or chloro substituents, since in the first series these were found to be the most potent.
Yields were generally high for all the analogs prepared, again showing the utility of the
optimized Heck reaction in the synthesis of a wide variety of analogs with Herrmann’s catalyst.
A number of new analogs were discovered that exhibited activity against gram-positive
bacteria from this second series. Based on these findings it is clear that the SAR is honing in on
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the, as of yet, unknown targets and future SAR studies should be successful in discovering even
more active analogs.
Described in Table 3-12, the indole derivative 63 had similar activity to the two lead
compounds 36 and 38. Although the activity of 63 is somewhere between 4-8-fold lower then
lead compounds 36 and 38, it is well within the margins for an antibiotic drug candidate. The
indole moiety may also prove to have better ADME properties and thus have better in vivo
performance compared to other analogs. The N-methyl analog 64 was much less active, and thus
it seems the N-methyl styrene is not a good choice for future SAR studies. The commercially
available styrene 58 was used to synthesize compound 65, which was found to have no activity
for any tested strains, thus this styrene is also a poor choice for future SAR studies.
It is also worth noting that like the other hydroxy/methoxy derivatives, both 63 and 64
retained mycobacterium activity. Interestingly, the mycobacterium activity of 64 was found to
be the same as its activity against gram-positive bacteria (32 µg/mL) and very similar to the
activity of 63 on these same mycobacterium species. This again may indicate that a similar yet
distinct mode of action is involved between the two different subspecies of bacteria.
Detailed in Table 3-13 are both a new substitution pattern as well as use of different
styrenes in an attempt to gain more insight into the SAR. Across the board these three analogs
(66, 67, and 68) seem to display similar activities with the different styrenes employed. In a
previous SAR, a derivative with the benzofuran substitution pattern was found to be inactive.
Regardless, benzofurans should also be explored in any future SAR based on these data.
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Table 3-13: MICs for compounds 66, 67, and 68a.

Bacterial Strain

a

S. aureus

4

4

4

E. faecalis

4

8

4

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

32

64

32

M. chelonae

64

32

64

M. fortuitum

32

64

32

M. kansasii

64

32

32

M. avium

64

64

64

M. smegmatis

32

64

32

M. marinum

32

64

32

Values in µg/mL

The new substitution pattern, phenol ortho to the bridge, was also found to retain activity.
Although the activity was slightly lower, again it is within the range of other pharmaceutical
antibiotics. Although not quantified, the solubility of this new substitution pattern in water and
aqueous acidic soliutions seemed to be higher than that of past compounds, perhaps due to the
influence of the phenol which is in close proximity to the hydrophobic side chain.
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Table 3-14: MICs for compounds 69, 70, and 71a.

Bacterial Strain

a

S. aureus

128

32

4

E. faecalis

128

4

2

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

>128

>128

>128

M. chelonae

>128

>128

>128

M. fortuitum

>128

>128

>128

M. kansasii

>128

>128

>128

M. avium

>128

>128

>128

M. smegmatis

>128

>128

>128

M. marinum

>128

>128

>128

Values in µg/mL

Detailed in Table 3-14 are some of the substituted thianaphthene analogs synthesized.
Interestingly the ring D chloro substituted 69 lost all activity when compared to the related active
analog 36. This may indicate that the molecular volume must not be increased too drastically.
Indeed 70 and 71 show similar trends. The ring D chloro analog 70 was less active then the ring
D fluoro analog 71, and both are less active then the related parent analog 38. It was also
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interesting to note that similar to what has been observed in the SAR, the ring A chloro analogs
70 and 71 again lack mycobacterium activity but still show gram-positive activity.
Table 3-15: MICs for compounds 72, 73, and 74a.
F

Bacterial Strain

MeO

72

HO

a

S

S. aureus

8

>128

0.5

E. faecalis

32

>128

0.5

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M. intracellulare

>128

>128

64

M. chelonae

>128

>128

64

M. fortuitum

>128

>128

32

M. kansasii

>128

>128

64

M. avium

>128

>128

64

M. smegmatis

>128

>128

32

M. marinum

>128

>128

64

Values in µg/mL

Detailed in Table 3-15 are the values for the final set of compounds from this second
series. The ring D fluoro analog 72 again seems to indicate that molecular volume is important
because it is more active than then ring D chloro analog 69, yet less active then the related
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compound 36. A more detailed analysis of molecular volume will be discussed in an upcoming
chapter. The analog 73 attempted to replace the phenolic function with a more soluble amine,
which lost all activity as the SAR would predict. Gratifyingly, ring D fluoro analog 74 showed
increased activity when compared to its parent compound SK-03-92 and similar activity to the
important lead compounds 36 and 38.

III.

CONCLUSION.

In summary, a new transition metal catalyzed Heck reaction was optimized for the
synthesis of novel stilbenoid analogs. This method was found to be extremely versatile in the
one-step synthesis of a number of structurally similar, yet distinct analogs. Moreover, the
starting materials necessary for the reaction were either commercially available or easily
synthesized in the lab with common starting materials.
This reaction was found to work best with ‘Herrmann’s palladacycle’, a cyclic palladium
dimer that, at room temperature, exists as the relatively stable and air tolerable palladium (II)
species. At elevated temperatures, generally over 80 ºC, studies indicated that the palladacycle
was altered and reduced to the active palladium (0) catalyst, which was found to be stable
enough for use at 150 ºC, a temperature at which other Pd catalysts readily decomposed.
A break-through in this reaction was the addition of water which permitted nearly full
conversion of the starting materials with Herrmann’s catalyst at 150 ºC. Without the addition of
water conversions were generally less than 10%, with many reactions resulting in zero
conversion.
Using this reaction, a number of new antibiotic analogs were prepared that had potent
activity less than 10 µg/mL against gram-positive bacterial strains, a general target for new drug
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candidates. These include analogs 36, 38, 45, 48, 52, 63, 66, 67, 68, 71, and 74. Many of these
new lead compounds were assayed against drug-resistant strains of gram-positive bacteria, the
results of which will be discussed in a later section.
A significant number of new analogs can be prepared via the method outlined in this
chapter and the general idea behind this SAR was both to advance our current understanding of
the SAR as well as provide potential new directions for future SAR work, with the final aim of a
clinical candidate with activity against MDR MRSA, VISA, VRSA, etc.

IV.
1.

EXPERIMENTAL
In vitro MIC assays.

In vitro minimum inhibitory concentration (MIC) determinations were performed
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines,115 for most of the
bacteria that were screened. Tetracycline, ciprofloxacin, and erythromycin controls were
included as control antibiotics for the gram-positive bacteria MICs and correlated with
established MIC values. All anti-Mycobacterium activity evaluations were performed using MIC
assays in Middlebrook 7H9 broth with 10% oleic acid albumin dextrose complex (OADC) as
previously described114. Rifampin was used as the positive control for the mycobacterial MICs.
All MIC numbers are a compilation of the geometric means from three separate runs. For the
broad characterization against S. aureus, strains that have been typed by a variety of means were
used116.

2.

General procedure for the optimized Heck reaction.

As previously noted Herrmann’s palladacycle is both air and temperature stable and thus
it was not necessary to weigh it under an inert atmosphere. All solid materials were charged to a
96

10 mL sealable reaction vessel under argon with a magnetic stir-bar. The vessel was purged by
vacuum three times, backfilling with argon after each evacuation.
In a separate flask dimethylacetamide mixed with 10% water was frozen under argon via
dry ice/acetone. Once frozen, the flask was evacuated with high vacuum and slowly warmed to
rt. Vigorous evolution of bubbles confirmed removal of gases from the solvent. This was
repeated three times or until minimal evolution of bubbles was observed. The solvent was kept
under argon and was found suitable for use over many weeks as long as it was kept under an
inert gas.
The solvent (3mL) was added to the reaction vessel under argon and the flask was
immediately heated to 150 ºC in an oil bath. In many cases the color of the reaction mixture
slowly darkened over a period of 3h, at which time it was generally a dark black color. After 3h
the reaction vessel was cooled to rt, diluted with EtOAc (10mL), filtered through a plug of celite,
washed with dilute acid (or water where acidic solutions were problematic), dried (Na2SO4), and
solvent was removed to a crude residue. In general compounds were purified by FCC as
described, but if necessary they could be further purified by crystallization from isopropanol.

3.

Characterization data.

Both 1H and 13C NMR spectra were recorded on a Bruker DPX-300 or DRX-500
instrument where noted. HRMS scans were recorded with a Shimadzu LCMS-IT-TOF or similar
instruments run at the Shimadzu Analytical Chemistry Center of Southeastern Wisconsin. In
silico cLogP values and topological polar surface area values (tPSA) were calculated with
ChemBioDraw Ultra v. 14.
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(E)-1-(5-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-hydroxyphenyl)ethan-1-one (32, Table 3-3,
entry 1)

The general procedure was followed (3 h). The 1-(5-bromo-2-hydroxyphenyl)ethan-1-one 30
(134.2 mg, 0.624 mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq),
sodium acetate (102.4 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016
mmol, 0.025 eq) were charged to a vial containing oxygen free solvent (10% water in
dimethylacetamide, 3 mL) under an argon atmosphere. The vial was sealed with a septum and
the mixture was heated to 150 ºC for 3h, cooled to rt, and EtOAc (10mL) was added in one
portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with 0.5 N aq HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and solvent was removed in vacuo to provide a crude red solid. The solid was purified
by flash column chromatography on silica gel (30% EtOAc in hexanes) to provide the pure
ketone 32 in 91% yield as an off-white solid (167 mg): 1H NMR (300 MHz, CDCl3) δ 12.36 (s,
1H), 7.81 (d, J = 1.7 Hz, 1H), 7.79 (d, J = 2.6 Hz, 1H), 7.72 (dd, J = 6.0, 2.8 Hz, 2H), 7.39 – 7.30
(m, 2H), 7.29 – 7.25 (m, 2H), 7.03 (d, J = 8.7 Hz, 1H), 6.96 (d, J = 16.0 Hz, 1H), 2.72 (s, 3H);
13

C NMR (75 MHz, CDCl3) δ 146.75, 145.98, 143.22, 140.33, 138.71, 130.90, 129.29, 124.54,

124.48, 123.25, 122.49, 122.19, 120.62, 120.21, 114.69, 108.39, 55.95; HRMS (ESI) (M - H),
Calcd. for C18H13O2S 293.0636; Found 293.0625.
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(E)-4-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-fluorophenol (33, Table 3-3, entry 2)

The general procedure was followed (3 h). The 4-bromo-2-fluorophenol (119.2 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL)
and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo
to provide a yellow solid. The solid was purified by flash column chromatography on silica gel
(20% EtOAc in hexanes) to provide the pure fluoro analog 33 in 91% yield as a white solid (153
mg): 1H NMR (500 MHz, DMSO) δ 10.14 (s, 1H), 7.96 – 7.85 (m, 1H), 7.84 – 7.74 (m, 1H),
7.51 (dd, J = 12.7, 1.9 Hz, 1H), 7.45 (d, J = 16.5 Hz, 1H), 7.42 (s, 1H), 7.34 (pd, J = 7.1, 1.4 Hz,
2H), 7.27 (dd, J = 8.3, 1.7 Hz, 1H), 6.98 (d, J = 8.8 Hz, 1H), 6.93 (d, J = 16.5 Hz, 1H); 13C NMR
(126 MHz, DMSO) δ 151.70 (d, J = 240.8 Hz), 145.60 (d, J = 12.5 Hz), 143.17 (s), 140.48 (s),
138.45 (s), 130.09 (s), 128.81 (d, J = 6.4 Hz), 125.26 (s), 125.18 (s), 124.15 (s), 123.92 (s),
123.52 (s), 122.81 (s), 121.24 (s), 118.33 (s), 114.31 (d, J = 18.6 Hz); HRMS (ESI) (M + H),
Calcd. for C16H12FOS 271.0593; Found 271.0599.
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(E)-4-(2-(Benzo[b]thiophen-2-yl)vinyl)phenol (34, Table 3-3, entry 3)

The general procedure was followed (3 h). The 4-bromophenol (108 mg, 0.624 mmol, 1 eq), 2vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4 mg, 1.248 mmol,
2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were charged to a vial
containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under an argon
atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC for 3h,
cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered through
a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL) and
brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to
provide an off-white solid. The solid was purified by flash column chromatography on silica gel
(20% EtOAc in hexanes) to provide the pure p-phenol 34 in 90% yield as a white solid (142 mg):
1

H NMR (300 MHz, DMSO-d6) δ 9.70 (s, 1H), 7.94 – 7.84 (m, 1H), 7.76 (dd, J = 6.4, 2.3 Hz,

1H), 7.47 (d, J = 8.5 Hz, 2H), 7.42 – 7.27 (m, 4H), 6.93 (d, J = 16.1 Hz, 1H), 6.79 (d, J = 8.5 Hz,
2H); 13C NMR (75 MHz, DMSO-d6) δ 158.26, 143.58, 140.55, 138.27, 131.19, 128.65, 127.74,
125.12, 125.06, 123.75, 122.88, 122.75, 119.63, 116.13; HRMS (ESI) (M + H), Calcd. for
C16H13OS 253.0687; Found 253.0681.
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(E)-5-(2-(Benzo[b]thiophen-2-yl)vinyl)benzo[d][1,3]dioxole (35, Table 3-4, entry 1)

The general procedure was followed (3 h). The 5-bromobenzo[d][1,3]dioxole (125.5 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL)
and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo
to provide a yellow solid. The solid was purified by flash column chromatography on silica gel
(10% EtOAc in hexanes) to provide the pure dioxole 35 in 95% yield as a white solid (166 mg):
1

H NMR (300 MHz, DMSO-d6) δ 7.96 – 7.86 (m, 1H), 7.79 (dd, J = 6.0, 2.8 Hz, 1H), 7.47 (d, J

= 16.1 Hz, 1H), 7.42 (s, 1H), 7.39 – 7.28 (m, 3H), 7.09 (d, J = 8.1 Hz, 1H), 6.97 (d, J = 10.1 Hz,
1H), 6.93 (d, J = 1.5 Hz, 1H), 6.06 (s, 2H); 13C NMR (75 MHz, DMSO-d6) δ 148.41, 147.86,
143.19, 140.46, 138.43, 131.23, 130.83, 125.25, 125.17, 123.90, 123.52, 122.79, 122.57, 121.19,
108.94, 105.93, 101.68; HRMS (ESI) (M - H), Calcd. for C17H13O2S 281.0636; Found 282.0638.
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(E)-4-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-methoxyphenol (36, Table 3-4, entry 2)

The general procedure was followed (3 h). The 4-bromo-2-methoxyphenol (126.7 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL)
and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo
to provide a yellow solid. The solid was purified by flash column chromatography on silica gel
(20% EtOAc in hexanes) to provide the pure methoxy phenol 36 in 93% yield as a white solid
(164 mg): 1H NMR (300 MHz, CDCl3) δ 7.83 – 7.77 (m, 1H), 7.75 – 7.66 (m, 1H), 7.40 – 7.29
(m, 2H), 7.23 (s, 1H), 7.20 (d, J = 16.2 Hz, 1H), 7.06 (d, J = 10.2 Hz, 2H), 6.95 (dd, J = 12.0, 3.9
Hz, 2H), 5.70 (s, 1H), 3.98 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 146.75, 145.98, 143.22,
140.33, 138.71, 130.90, 129.29, 124.54, 124.48, 123.25, 122.49, 122.19, 120.62, 120.21, 114.69,
108.39, 55.95; HRMS (ESI) (M - H), Calcd. for C17H13O2S 281.0636; Found 281.0629.
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(E)-5-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-methoxyphenol (37, Table 3-4, entry 3)

The general procedure was followed (3 h). The 5-bromo-2-methoxyphenol (126.7 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL)
and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo
to provide a yellow solid. The solid was purified by flash column chromatography on silica gel
(20% EtOAc in hexanes) to provide the pure methoxy phenol 37 in 89% yield as a white solid
(157 mg): 1H NMR (300 MHz, DMSO-d6) δ 9.11 (s, 1H), 7.89 (d, J = 7.0 Hz, 1H), 7.76 (d, J =
8.1 Hz, 1H), 7.42 (s, 1H), 7.38 – 7.25 (m, 3H), 7.07 (s, 1H), 7.02 (d, J = 8.4 Hz, 1H), 6.93 (d, J =
9.4 Hz, 1H), 6.88 (d, J = 16.2 Hz, 1H), 3.80 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 148.65,
147.11, 143.35, 140.50, 138.36, 131.12, 129.69, 125.16, 123.81, 123.29, 122.76, 120.48, 119.39,
113.39, 112.60, 56.08; HRMS (ESI) (M + H), Calcd. for C17H15O2S 283.0793; Found 283.0787
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(E)-4-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-chlorophenol (38, Table 3-5, entry 1)

The general procedure was followed (3 h). The 4-bromo-2-chlorophenol (129.5 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL)
and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo
to provide a yellow solid. The solid was purified by flash column chromatography on silica gel
(20% EtOAc in hexanes) to provide the pure chloro phenol 38 in 92% yield as a grey solid (164
mg): 1H NMR (300 MHz, DMSO-d6) δ 10.44 (s, 1H), 7.90 (d, J = 6.8 Hz, 1H), 7.85 – 7.73 (m,
1H), 7.68 (s, 1H), 7.46 (d, J = 16.3 Hz, 1H), 7.43 (m, 2H), 7.40 – 7.27 (m, 2H), 6.98 (d, J = 8.4
Hz, 1H), 6.92 (d, J = 16.1 Hz, 1H); 13C NMR (75 MHz, DMSO-d6) δ 153.57, 143.17, 140.45,
138.45, 129.70, 129.25, 128.42, 127.11, 125.25, 125.16, 123.91, 123.55, 122.80, 121.23, 120.69,
117.29; HRMS (ESI) (M + H), Calcd. for C16H12ClOS 287.0297; Found 287.0298.
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(E)-5-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-chlorophenol (39, Table 3-5, entry 2)

The general procedure was followed (3 h). The 5-bromo-2-chlorophenol (129.5 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL)
and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo
to provide a yellow solid. The solid was purified by flash column chromatography on silica gel
(20% EtOAc in hexanes) to provide the pure chloro phenol 39 in 90% yield as a yellow solid
(161 mg): 1H NMR (300 MHz, DMSO-d6) δ 10.28 (s, 1H), 7.98 – 7.85 (m, 1H), 7.85 – 7.74 (m,
1H), 7.52 (s, 1H), 7.49 (d, J = 16.4 Hz, 1H), 7.42 – 7.29 (m, 3H), 7.20 – 7.07 (m, 2H), 6.94 (d, J
= 16.1 Hz, 1H); 13C NMR (75 MHz, DMSO-d6) δ 153.65, 142.62, 140.34, 138.70, 136.77,
130.57, 129.99, 125.53, 125.24, 124.63, 124.11, 123.38, 122.87, 119.97, 118.93, 114.89; HRMS
(ESI) (M + H), Calcd. for C16H12ClOS 287.0297; Found 287.0291.
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(E)-5-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-hydroxybenzonitrile (40, Table 3-5, entry 3)

The general procedure was followed (3 h). The 5-bromo-2-hydroxybenzonitrile (123.6 mg,
0.624 mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate
(102.4 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq)
were charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL)
under an argon atmosphere. The vial was sealed with a septum and the mixture was heated to
150 ºC for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was
filtered through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x
10 mL) and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed
in vacuo to provide a yellow solid. The solid was purified by flash column chromatography on
silica gel (20% EtOAc in hexanes) to provide the pure nitrile 40 in 91% yield as a white solid
(157 mg): 1H NMR (300 MHz, DMSO-d6) δ 11.33 (s, 1H), 7.96 – 7.88 (m, 2H), 7.85 – 7.74 (m,
2H), 7.52 (d, J = 16.1 Hz, 1H), 7.43 (s, 1H), 7.40 – 7.28 (m, 2H), 7.04 (d, J = 8.7 Hz, 1H), 6.95
(d, J = 16.1 Hz, 1H); 13C NMR (75 MHz, DMSO-d6) δ 160.36, 142.91, 140.39, 138.52, 133.21,
131.87, 128.96, 128.70, 125.38, 125.20, 124.01, 123.94, 122.84, 122.05, 117.23, 117.07, 99.82;
HRMS (ESI) (M + H), Calcd. for C17H12NOS 278.0640; Found 278.0642.
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(E)-4-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-nitrophenol (41, Table 3-6, entry 1)

The general procedure was followed (3 h). The 4-bromo-2-nitrophenol (136.1 mg, 0.624 mmol,
1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4 mg,
1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were charged
to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under an argon
atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC for 3h,
cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered through
a plug of celite and the filtrate was washed successively with water (2 x 10 mL) and brine (2 x 10
mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to provide a
yellow solid. The solid was purified by flash column chromatography on silica gel (50% EtOAc
in hexanes) to provide the pure nitrophenol 41 in 80% yield as a brown solid (148 mg): 1H NMR
(300 MHz, DMSO-d6) δ 8.15 (d, J = 1.5 Hz, 1H), 7.96 – 7.89 (m, 1H), 7.86 (dd, J = 8.8, 1.7 Hz,
1H), 7.83 – 7.75 (m, 1H), 7.57 (d, J = 16.1 Hz, 1H), 7.47 (s, 1H), 7.41 – 7.30 (m, 2H), 7.15 (d, J
= 8.7 Hz, 1H), 7.03 (d, J = 16.1 Hz, 1H). [phenol 1H not observed]; 13C NMR (75 MHz, DMSOd6) δ 152.24 (phenolic), 142.79, 140.37, 138.62, 137.63, 133.16, 128.74, 128.43, 125.44, 125.21,
124.21, 124.06, 123.61, 122.86, 122.69, 119.99; HRMS (ESI) (M + H), Calcd. for C16H12NO3S
298.0538; Found 298.0535.
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(E)-4-(2-(Benzo[b]thiophen-2-yl)vinyl)-2,5-dichlorophenol (42, Table 3-6, entry 2)

The general procedure was followed (3 h). The 4-bromo-2,5-dichlorophenol (151 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL)
and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo
to provide a yellow/grey solid. The solid was purified by flash column chromatography on silica
gel (20% EtOAc in hexanes) to provide the pure dichlorophenol 42 in 93% yield as a grey solid
(186 mg): 1H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 7.97 (s, 1H), 7.94 – 7.89 (m, 1H),
7.85 – 7.79 (m, 1H), 7.63 (d, J = 16.0 Hz, 1H), 7.49 (s, 1H), 7.36 (p, J = 5.5 Hz, 2H), 7.09 (d, J =
16.3 Hz, 1H), 7.06 (s, 1H); 13C NMR (75 MHz, DMSO-d6) δ 154.12, 142.65, 140.36, 138.55,
131.36, 127.84, 126.20, 125.63, 125.29, 124.76, 124.47, 124.23, 124.20, 122.89, 120.48, 117.32;
HRMS (ESI) (M + H), Calcd. for C16H11Cl2OS 320.9908; Found 320.9912.
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(E)-4-(2-(Benzo[b]thiophen-2-yl)vinyl)-2,6-dimethoxyphenol (43, Table 3-6, entry 3)

The general procedure was followed (3 h). The 4-bromo-2,6-dimethoxyphenol (145.4 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL)
and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo
to provide a brown solid. The solid was purified by flash column chromatography on silica gel
(20% EtOAc in hexanes) to provide the pure dimethoxyphenol 43 in 75% yield as a yellow solid
(146 mg): 1H NMR (500 MHz, DMSO) δ 8.66 (s, 1H), 7.93 – 7.89 (m, 1H), 7.79 (dd, J = 7.1, 1.5
Hz, 1H), 7.48 (d, J = 15.7 Hz, 1H), 7.41 (s, 1H), 7.39 – 7.29 (m, 2H), 6.96 (s, 2H), 6.95 (d, J =
16.0 Hz, 1H), 3.84 (s, 6H); 13C NMR (126 MHz, DMSO) δ 148.62 (2C), 143.59, 140.59, 138.33,
136.73, 131.84, 127.19, 125.15, 125.12, 123.82, 122.93, 122.79, 120.28, 104.93 (2C), 56.51
(2C); HRMS (ESI) (M + H), Calcd. for C18H17O3S 313.0898; Found 313.0892.
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(E)-4-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-(trifluoromethoxy)phenol (44, Table 3-7, entry 1)

The general procedure was followed (3 h). The 4-bromo-2-(trifluoromethoxy)phenol (160.4 mg,
0.624 mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate
(102.4 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq)
were charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL)
under an argon atmosphere. The vial was sealed with a septum and the mixture was heated to
150 ºC for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was
filtered through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x
10 mL) and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed
in vacuo to provide a brown solid. The solid was purified by flash column chromatography on
silica gel (20% EtOAc in hexanes) to provide the pure trifluoromethoxy 44 in 85% yield as a
white solid (178 mg): 1H NMR (300 MHz, DMSO-d6) δ 10.45 (s, 1H), 7.91 (dd, J = 6.0, 2.9 Hz,
1H), 7.82 – 7.75 (m, 1H), 7.59 (s, 1H), 7.52-7.48 (m, 1H), 7.51-7.45 (d, J = 16.1 Hz, 1H), 7.44
(s, 1H), 7.39 – 7.29 (m, 2H), 7.03 (d, J = 8.5 Hz, 1H), 6.97 (d, J = 16.1 Hz, 1H); 13C NMR (75
MHz, DMSO-d6) δ 150.35, 143.07, 140.43, 138.49, 136.77, 129.66, 128.74, 127.34, 125.29,
125.17, 123.94, 123.70, 122.81, 122.57, 121.77, 121.53, 118.33; HRMS (ESI) (M + H), Calcd.
for C17H12F3O2S 337.0510; Found 337.0513.
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(E)-4-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-ethoxyphenol (45, Table 3-7, entry 2)

The general procedure was followed (3 h). The 4-bromo-2-ethoxyphenol (135.5 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL)
and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo
to provide a red solid. The solid was purified by flash column chromatography on silica gel
(20% EtOAc in hexanes) to provide the pure ethoxyphenol 45 in 90% yield as a yellow solid
(166 mg): 1H NMR (300 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.88 (d, J = 7.1 Hz, 1H), 7.76 (d, J =
7.6 Hz, 1H), 7.46 – 7.27 (m, 4H), 7.24 (s, 1H), 7.03 (d, J = 8.1 Hz, 1H), 6.92 (d, J = 16.1 Hz,
1H), 6.81 (d, J = 8.1 Hz, 1H), 4.10 (q, J = 6.9 Hz, 2H), 1.37 (t, J = 7.0 Hz, 3H); 13C NMR (75
MHz, DMSO-d6) δ 147.96, 147.50, 143.64, 140.58, 138.30, 131.54, 128.28, 125.11, 125.04,
123.75, 122.81, 122.75, 120.97, 119.85, 116.17, 111.85, 64.35, 15.25; HRMS (ESI) (M + H),
Calcd. for C18H17O2S 297.0949; Found 297.0957.
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(E)-4-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-isopropoxyphenol (46, Table 3-7, entry 3)

The general procedure was followed (3 h). The 4-bromo-2-isopropoxyphenol (144.2 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL)
and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo
to provide a yellow oil. The oil was purified by flash column chromatography on silica gel (20%
EtOAc in hexanes) to provide the pure isopropoxyphenol 46 in 90% yield as a yellow-white
solid (174 mg): 1H NMR (500 MHz, DMSO) δ 9.12 (s, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.77 (d, J
= 7.5 Hz, 1H), 7.40 (d, J = 15.9 Hz, 1H), 7.39 (s, 1H), 7.37 – 7.29 (m, 2H), 7.26 (s, 1H), 7.06 (d,
J = 8.2 Hz, 1H), 6.93 (d, J = 16.1 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 4.65 (dt, J = 12.1, 6.0 Hz,
1H), 1.30 (d, J = 6.0 Hz, 6H); 13C NMR (126 MHz, DMSO) δ 149.07, 146.10, 143.66, 140.59,
138.31, 131.49, 128.31, 125.13, 125.07, 123.77, 122.86, 122.77, 121.26, 119.89, 116.53, 114.81,
71.15, 22.44; HRMS (ESI) (M + H), Calcd. for C19H19O2S 311.1106; Found 311.1110.
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(E)-5-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-hydroxybenzoic acid (47, Table 3-8, entry 1)

The general procedure was followed (3 h). The 5-bromo-2-hydroxybenzoic acid (135.4 mg,
0.624 mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate
(102.4 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq)
were charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL)
under an argon atmosphere. The vial was sealed with a septum and the mixture was heated to
150 ºC for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was
filtered through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x
10 mL) and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed
in vacuo to provide a orange solid. The solid was purified by flash column chromatography on
silica gel (50% EtOAc in hexanes) to provide the pure acid phenol 47 in 93% yield as an offwhite solid (172 mg): 1H NMR (300 MHz, DMSO-d6) δ 8.01 (d, J = 1.4 Hz, 1H), 7.89 (d, J =
6.8 Hz, 1H), 7.83 – 7.64 (m, 2H), 7.43 (d, J = 16.1 Hz, 1H), 7.42 (s, 1H), 7.37 – 7.25 (m, 2H),
6.99 (d, J = 16.2 Hz, 1H), 6.90 (d, J = 8.6 Hz, 1H). [acidic and phenolic protons not observed];
13

C NMR (75 MHz, CDCl3) δ 172.13, 162.47, 143.40, 140.51, 138.42, 132.67, 130.54, 129.17,

127.02, 125.13, 125.12, 123.81, 123.30, 122.77, 120.45, 117.84, 116.20; HRMS (ESI) (M + H),
Calcd. for C17H13O3S 297.0585; Found 297.0589.
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(E)-5-(2-(benzo[b]thiophen-2-yl)vinyl)-2-methoxybenzoic acid (48, Table 3-8, entry 2)

The general procedure was followed (3 h). The 5-bromo-2-methoxybenzoic acid (144.2 mg,
0.624 mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate
(102.4 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq)
were charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL)
under an argon atmosphere. The vial was sealed with a septum and the mixture was heated to
150 ºC for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was
filtered through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x
10 mL) and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed
in vacuo to provide a yellow solid. The solid was purified by flash column chromatography on
silica gel (20% EtOAc in hexanes) to provide the pure acid methoxy 48 in 91% yield as an offwhite solid (176 mg): 1H NMR (300 MHz, DMSO-d6) δ 12.77 (s, 1H), 7.91 (d, J = 1.9 Hz, 2H),
7.78 (d, J = 6.9 Hz, 2H), 7.52 (d, J = 16.1 Hz, 1H), 7.45 (s, 1H), 7.34 (p, J = 7.3 Hz, 2H), 7.15
(d, J = 8.8 Hz, 1H), 7.02 (d, J = 16.1 Hz, 1H), 3.85 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ
167.67, 158.27, 143.14, 140.44, 138.53, 131.50, 129.75, 129.13, 128.89, 125.29, 125.16, 123.94,
123.81, 122.82, 122.31, 121.69, 113.29, 56.38; HRMS (ESI) (M + H), Calcd. for C18H15O3S
311.0742; Found 311.0743.
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Methyl (E)-5-(2-(benzo[b]thiophen-2-yl)vinyl)nicotinate (49, Table 3-8, entry 3)

The general procedure was followed (3 h). The methyl 5-bromonicotinate (134.8 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with water (2 x 10 mL) and
brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to
provide a brown/red solid. The solid was purified by flash column chromatography on silica gel
(49% EtOAc and 1% TEA in hexanes) to provide the pure pyridine methylester 49 in 82% yield
as a brown solid (151 mg): 1H NMR (300 MHz, CDCl3) δ 9.11 (s, 1H), 8.89 (s, 1H), 8.48 (t, J =
1.9 Hz, 1H), 7.81 (dd, J = 8.1, 5.1 Hz, 1H), 7.76 (dt, J = 5.5, 3.2 Hz, 1H), 7.51 (d, J = 16.1 Hz,
1H), 7.43 – 7.32 (m, 3H), 7.28 (s, 1H), 7.00 (d, J = 16.1 Hz, 1H), 4.02 (s, 3H); 13C NMR (75
MHz, DMSO-d6) δ 166.96, 152.21, 149.49, 142.36, 140.60, 139.12, 133.87, 132.73, 127.40,
126.25, 125.98, 125.84, 125.53, 125.36, 124.49, 123.06, 52.82; HRMS (ESI) (M + H), Calcd. for
C17H14NO2S 296.0745; Found 296.0739.
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(E)-3-(2-(Benzo[b]thiophen-2-yl)vinyl)-5-methoxypyridine (50, Table 3-9, entry 1)

The general procedure was followed (3 h). The 3-bromo-5-methoxypyridine (117.5 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with water (2 x 10 mL) and
brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to
provide a yellow solid. The solid was purified by flash column chromatography on silica gel
(19% EtOAc and 1% TEA in hexanes) to provide the pure methoxy pyridine 50 in 90% yield as
a red/brown solid (150 mg): 1H NMR (300 MHz, DMSO-d6) δ 8.41 (s, 1H), 8.21 (d, J = 2.6 Hz,
1H), 7.99 – 7.91 (m, 1H), 7.88 – 7.83 (m, 1H), 7.80 (d, J = 16.0 Hz, 1H), 7.70 (s, 1H), 7.57 –
7.49 (m, 1H), 7.41 – 7.32 (m, 2H), 7.06 (d, J = 16.2 Hz, 1H), 3.89 (s, 3H); 13C NMR (75 MHz,
CDCl3) δ 154.29, 142.54, 140.27, 139.96, 138.79, 138.11, 133.23, 127.48, 125.65, 125.27,
124.95, 124.70, 124.23, 122.91, 118.80; HRMS (ESI) (M + H), Calcd. for C16H14NOS 268.0796;
Found 268.0789.
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(E)-5-(2-(Benzo[b]thiophen-2-yl)vinyl)pyridin-3-ol (51, Table 3-9, entry 2)

The general procedure was followed (3 h). The 5-bromopyridin-3-ol (108.6 mg, 0.624 mmol, 1
eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4 mg, 1.248
mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were charged to a
vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under an argon
atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC for 3h,
cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered through
a plug of celite and the filtrate was washed successively with water (2 x 10 mL) and brine (2 x 10
mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to provide a
yellow solid. The solid was purified by flash column chromatography on silica gel (29% EtOAc
and 1% TEA in hexanes) to provide the pure pyridine phenol 51 in 90% yield as a brown solid
(142 mg): 1H NMR (300 MHz, DMSO-d6) δ 10.09 (s, 1H), 8.29 (s, 1H), 8.07 (s, 1H), 7.98 –
7.90 (m, 1H), 7.85 – 7.78 (m, 1H), 7.65 (d, J = 16.2 Hz, 1H), 7.53 (s, 1H), 7.38 (dd, J = 11.7, 7.6
Hz, 3H), 7.00 (d, J = 16.2 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 154.29, 142.54, 140.27,
139.96, 138.79, 138.11, 133.23, 127.48, 125.65, 125.27, 124.95, 124.70, 124.23, 122.91, 118.80;
HRMS (ESI) (M + H), Calcd. for C15H12NOS 254.0640; Found 254.0645.
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(E)-5-(2-(Benzo[b]thiophen-2-yl)vinyl)nicotinic acid (52, Table 3-9, entry 3)

The general procedure was followed (3 h). The 5-bromonicotinic acid (126.1 mg, 0.624 mmol, 1
eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4 mg, 1.248
mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were charged to a
vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under an argon
atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC for 3h,
cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered through
a plug of celite and the filtrate was washed successively with water (2 x 10 mL) and brine (2 x 10
mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to provide a
brown/red solid. The solid was purified by flash column chromatography on silica gel (49%
EtOAc and 1% TEA in hexanes) to provide the pure pyridine acid 52 in 87% yield as a light
brown solid (153 mg): 1H NMR (300 MHz, CDCl3) δ 13.59 (s, broad, 1H), 9.04 (s, 1H), 8.96 (s,
1H), 8.54 (s, 1H), 8.00 – 7.94 (m, 1H), 7.90 (d, J = 16.3 Hz, 1H), 7.87 – 7.82 (m, 1H), 7.58 (s,
1H), 7.38 (dd, J = 5.9, 3.2 Hz, 2H), 7.16 (d, J = 16.3 Hz, 1H); 13C NMR (75 MHz, DMSO-d6) δ
166.66, 152.15, 149.52, 142.33, 140.20, 138.98, 133.96, 132.75, 127.29, 126.22, 126.18, 125.82,
125.62, 125.30, 124.39, 122.96; HRMS (ESI) (M + H), Calcd. for C16H12NO2S 282.0589; Found
282.0582.
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2-vinylbenzo[b]thiophene 31 (31, Scheme 3-9)

The The sodium methoxide (406.6 mg, 7.53 mmol, 1.1eq), methyltriphenylphosphonium
bromide (2.69 g, 7.53 mmol, 1.1eq), and THF (25mL) were stirred under argon at rt for 0.5h.
The benzo[b]thiophene-2-carbaldehyde (1.11 g, 6.84 mmol, 1eq) was dissolved in THF (5mL)
and added dropwise to the solution. After 3h examination by TLC (10% EtOAc in hexanes)
indicated no starting aldehyde remained and the reaction was quenched with 0.5N aq HCl
(10mL). The organic layer was extracted and the aq layer was subsequently extracted with
EtOAc (15mL x 2). The organic layer was washed with brine (10mL x 2), dried (Na2SO4), and
the solvent removed in vacuo to yield an off-white solid. The solid was purified by flash column
chromatography on silica gel (hexanes) to provide the pure thiostyrene 31 in 98% yield as a
white solid (1076 mg): 1H NMR (500 MHz, CDCl3) δ 7.87 – 7.79 (m, 1H), 7.79 – 7.72 (m, 1H),
7.43 – 7.32 (m, 2H), 7.22 (s, 1H), 6.98 (dd, J = 17.3, 10.8 Hz, 1H), 5.74 (d, J = 17.3 Hz, 1H),
5.37 (d, J = 10.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 143.16, 140.08, 138.93, 130.66,
124.85, 124.48, 123.63, 123.14, 122.34, 116.00; HRMS (ESI) (M + H), Calcd. for C10H9S
161.0425; Found 161.0431.
2-Vinyl-1H-indole (55, Figure 3-4)
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The The sodium methoxide (406.6 mg, 7.53 mmol, 1.1eq), methyltriphenylphosphonium
bromide (2.69 g, 7.53 mmol, 1.1eq), and THF (25mL) were stirred under argon at rt for 0.5h.
The 1H-indole-2-carbaldehyde (993 mg, 6.84 mmol, 1eq) was dissolved in THF (5mL) and
added dropwise to the solution. After 3h analysis by TLC (10% EtOAc in hexanes) indicated no
starting aldehyde remained and the reaction mixture was quenched with water (10mL). The
organic layer was extracted and the aq layer was subsequently extracted with EtOAc (15mL x 2).
The organic layer was washed with brine (10mL x 2), dried (Na2SO4), and the solvent removed
in vacuo to yield a yellow solid. The solid was purified by flash column chromatography on
silica gel (hexanes, 1% TEA) to provide the pure indole styrene 55 in 92% yield as a yellow
solid (901 mg): 1H NMR (500 MHz, CDCl3) δ 8.08 (s, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.44 – 7.31
(m, 2H), 7.31 – 7.23 (m, 1H), 6.82 (dd, J = 17.8, 11.2 Hz, 1H), 6.66 (s, 1H), 5.60 (d, J = 17.8 Hz,
1H), 5.38 (d, J = 11.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 136.74, 136.48, 128.88, 127.66,
122.96, 120.96, 120.28, 112.44, 110.99, 103.20; HRMS (ESI) (M + H), Calcd. for C10H10N
144.0813; Found 144.0845.
1-Methyl-2-vinyl-1H-indole (57, Figure 3-4)

The sodium methoxide (406.6 mg, 7.53 mmol, 1.1eq), methyltriphenylphosphonium bromide
(2.69 g, 7.53 mmol, 1.1eq), and THF (25mL) were stirred under argon at rt for 0.5h. The 1methyl-2-vinyl-1H-indole (1.07 g, 6.84 mmol, 1eq) was dissolved in THF (5mL) and added
dropwise to the solution. After 3h examination by TLC (10% EtOAc in hexanes) indicated no
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starting aldehyde remained and the reaction was quenched with 0.5N aq HCl (10mL). The
organic layer was extracted and the aq layer was subsequently extracted with EtOAc (15mL x 2).
The organic layer was washed with brine (10mL x 2), dried (Na2SO4), and the solvent removed
in vacuo to yield an off-white solid. The solid was purified by flash column chromatography on
silica gel (hexanes) to provide the pure methylindole styrene 57 in 98% yield as a white solid
(1076 mg): 1H NMR (500 MHz, Acetone) δ 7.56 (d, J = 7.8 Hz, 1H), 7.36 (d, J = 8.2 Hz, 1H),
7.23 – 7.13 (m, 1H), 7.06 (t, J = 7.4 Hz, 1H), 6.92 (dd, J = 17.4, 11.3 Hz, 1H), 6.73 (s, 1H), 5.87
(dd, J = 17.4, 1.3 Hz, 1H), 5.36 (dd, J = 11.3, 1.2 Hz, 1H), 3.75 (s, 3H); 13C NMR (126 MHz,
Acetone) δ 138.39, 138.06, 127.91, 126.20, 121.55, 120.24, 119.57, 115.47, 109.42, 98.63,
29.15; HRMS (ESI) (M + H), Calcd. for C11H12N 158.0970; Found 158.0975.
2-Vinylbenzofuran (60, Figure 3-4)

The sodium methoxide (406.6 mg, 7.53 mmol, 1.1eq), methyltriphenylphosphonium bromide
(2.69 g, 7.53 mmol, 1.1eq), and THF (25mL) were stirred under argon at rt for 0.5h. The
benzofuran-2-carbaldehyde (1.00 g, 6.84 mmol, 1eq) was dissolved in THF (5mL) and added
dropwise to the solution. After 3h examination by TLC (10% EtOAc in hexanes) indicated no
starting aldehyde remained and the reaction was quenched with 0.5N aq HCl (10mL). The
organic layer was extracted and the aq layer was subsequently extracted with EtOAc (15mL x 2).
The organic layer was washed with brine (10mL x 2), dried (Na2SO4), and the solvent removed
in vacuo to yield a yellow oil. The oil was purified by flash column chromatography on silica
gel (hexanes) to provide the pure benzofuran styrene 60 in 85% yield as a clear oil that slowly
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solidifies in a freezer (838 mg): 1H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 7.6 Hz, 1H), 7.49 (d,
J = 8.1 Hz, 1H), 7.27 (m, 2H), 6.75 – 6.62 (dd, J = 17.4 Hz, J = 11.4 Hz, 1H), 6.63 (s, 1H), 6.00
(d, J = 17.4 Hz, 1H), 5.42 (d, J = 11.2 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 154.86, 154.78,
128.83, 125.30, 124.64, 122.79, 120.98, 115.71, 111.02, 104.74; HRMS (ESI) (M + H), Calcd.
for C10H9O 145.0653; Found 145.0652.
5-Chloro-2-vinylbenzo[b]thiophene 31 (61, Figure 3-4)

The sodium methoxide (406.6 mg, 7.53 mmol, 1.1eq), methyltriphenylphosphonium bromide
(2.69 g, 7.53 mmol, 1.1eq), and THF (25mL) were stirred under argon at rt for 0.5h. The 5chlorobenzo[b]thiophene-2-carbaldehyde (1.35 g, 6.84 mmol, 1eq) was dissolved in THF (5mL)
and added dropwise to the solution. After 3h examination by TLC (10% EtOAc in hexanes)
indicated no starting aldehyde remained and the reaction was quenched with 0.5N aq HCl
(10mL). The organic layer was extracted and the aq layer was subsequently extracted with
EtOAc (15mL x 2). The organic layer was washed with brine (10mL x 2), dried (Na2SO4), and
the solvent removed in vacuo to yield an off-white solid. The solid was purified by flash column
chromatography on silica gel (hexanes) to provide the pure chloro thiostyrene 61 in 96% yield as
a white solid (1278 mg): 1H NMR (300 MHz, CDCl3) δ 7.67 (dd, J = 5.1, 3.3 Hz, 2H), 7.29 (dt, J
= 4.8, 3.9 Hz, 1H), 7.08 (s, 1H), 6.91 (dd, J = 17.3, 10.8 Hz, 1H), 5.72 (d, J = 17.3 Hz, 1H), 5.37
(d, J = 10.8 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 145.06, 141.16, 136.96, 130.64, 130.29,
125.13, 123.22, 123.03, 122.15, 116.78; HRMS (ESI) (M + H), Calcd. for C10H8ClS 195.0035;
Found 195.0032.
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5-Fluoro-2-vinylbenzo[b]thiophene 31 (62, Figure 3-4)

The sodium methoxide (406.6 mg, 7.53 mmol, 1.1eq), methyltriphenylphosphonium bromide
(2.69 g, 7.53 mmol, 1.1eq), and THF (25mL) were stirred under argon at rt for 0.5h. The 5fluorobenzo[b]thiophene-2-carbaldehyde (1.23 g, 6.84 mmol, 1eq) was dissolved in THF (5mL)
and added dropwise to the solution. After 3h examination by TLC (10% EtOAc in hexanes)
indicated no starting aldehyde remained and the reaction was quenched with 0.5N aq HCl
(10mL). The organic layer was extracted and the aq layer was subsequently extracted with
EtOAc (15mL x 2). The organic layer was washed with brine (10mL x 2), dried (Na2SO4), and
the solvent removed in vacuo to yield an off-white solid. The solid was purified by flash column
chromatography on silica gel (hexanes) to provide the pure fluoro thiostyrene 62 in 95% yield as
a white solid (1159 mg): 1H NMR (300 MHz, CDCl3) δ 7.69 (dd, J = 8.8, 4.8 Hz, 1H), 7.38 (dd,
J = 9.4, 2.4 Hz, 1H), 7.12 (s, 1H), 7.08 (dd, J = 8.8, 2.5 Hz, 1H), 6.92 (dd, J = 17.3, 10.8 Hz,
1H), 5.72 (d, J = 17.3 Hz, 1H), 5.37 (d, J = 10.8 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 160.94
(d, J = 241.4 Hz), 145.56 (s), 141.02 (d, J = 9.5 Hz), 134.22 (d, J = 1.5 Hz), 130.40 (s), 123.32
(d, J = 9.3 Hz), 122.60 (d, J = 4.3 Hz), 116.60 (s), 113.44 (d, J = 25.2 Hz), 109.02 (d, J = 23.0
Hz); HRMS (ESI) (M + H), Calcd. for C10H8FS 179.0331; Found 179.0334.
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(E)-4-(2-(1H-Indol-2-yl)vinyl)-2-methoxyphenol (63, Table 3-11, entry 1)

The general procedure was followed (3 h). The 4-bromo-2-methoxyphenol (126.7 mg, 0.624
mmol, 1 eq), 2-vinyl-1H-indole (89.4 mg, 0.624 mmol, 1 eq), sodium acetate (102.4 mg, 1.248
mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were charged to a
vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under an argon
atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC for 3h,
cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered through
a plug of celite and the filtrate was washed successively with water (2 x 10 mL) and brine (2 x 10
mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to provide a
yellow solid. The solid was purified by flash column chromatography on silica gel (19% EtOAc
and 1% TEA in hexanes) to provide the pure indole stilbene 63 in 83% yield as a brown solid
(137 mg): 1H NMR (300 MHz, DMSO-d6) δ 11.27 (s, 1H), 9.18 (s, 1H), 7.47 (d, J = 7.7 Hz,
1H), 7.32 (d, J = 8.0 Hz, 1H), 7.16 (d, J = 1.4 Hz, 1H), 7.12 – 7.01 (m, 3H), 7.01 – 6.88 (m, 2H),
6.79 (d, J = 8.1 Hz, 1H), 6.49 (s, 1H), 3.85 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 148.43,
147.15, 137.79, 137.58, 129.01, 128.99, 128.17, 122.05, 120.57, 120.20, 119.55, 117.05, 116.12,
111.21, 109.60, 102.20, 56.05; HRMS (ESI) (M + H), Calcd. for C17H16NO2 266.1181; Found
266.1183.
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(E)-2-Methoxy-4-(2-(1-methyl-1H-indol-2-yl)vinyl)phenol (64, Table 3-11, entry 2)

The general procedure was followed (3 h). The 4-bromo-2-methoxyphenol (126.7 mg, 0.624
mmol, 1 eq), 1-methyl-2-vinyl-1H-indole (98 mg, 0.624 mmol, 1 eq), sodium acetate (102.4 mg,
1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were charged
to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under an argon
atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC for 3h,
cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered through
a plug of celite and the filtrate was washed successively with water (2 x 10 mL) and brine (2 x 10
mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to provide a
brown solid. The solid was purified by flash column chromatography on silica gel (19% EtOAc
and 1% TEA in hexanes) to provide the pure methylindole stilbene 64 in 89% yield as a brown
solid (155 mg): 1H NMR (300 MHz, DMSO-d6) δ 9.21 (s, 1H), 7.49 (d, J = 7.7 Hz, 1H), 7.42 (d,
J = 8.2 Hz, 1H), 7.29 (d, J = 1.5 Hz, 1H), 7.27 – 6.94 (m, 5H), 6.84 – 6.73 (m, 2H), 3.86 (s, 3H),
3.84 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 148.33, 147.36, 139.42, 138.09, 131.45, 129.11,
128.10, 121.38, 120.91, 120.07, 119.92, 116.02, 114.64, 110.50, 110.02, 97.71, 56.20, 30.16;
HRMS (ESI) (M + H), Calcd. for C18H18NO2 280.1338; Found 280.1345.
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(E)-4-(2-([1,1'-Biphenyl]-4-yl)vinyl)-2-chlorophenol (65, Table 3-11, entry 3)

Chemical Formula: C20H15ClO
Molecular Weight: 306.79
c Log P: 6.07
tPSA: 20.23

Cl

HO

The general procedure was followed (3 h). The 4-bromo-2-chlorophenol (129.5 mg, 0.624
mmol, 1 eq), 4-vinyl-1,1'-biphenyl (112.5 mg, 0.624 mmol, 1 eq), sodium acetate (102.4 mg,
1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were charged
to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under an argon
atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC for 3h,
cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered through
a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL) and
brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to
provide a yellow oil. The oil was purified by flash column chromatography on silica gel (20%
EtOAc in hexanes) to provide the pure biphenyl stilbene 65 in 84% yield as a white solid (164
mg): 1H NMR (300 MHz, DMSO-d6) δ 10.35 (s, 1H), 7.75 – 7.61 (m, 7H), 7.54 – 7.31 (m, 4H),
7.27 – 7.10 (m, 2H), 6.98 (d, J = 8.4 Hz, 1H); 13C NMR (75 MHz, DMSO-d6) δ 153.19, 140.13,
139.31, 136.91, 130.09, 129.41, 128.21, 127.88, 127.71, 127.33, 127.27, 126.88, 126.63, 120.59,
117.29; HRMS (ESI) (M + H), Calcd. for C20H16ClO 307.0890; Found 307.0885.
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(E)-2-(2-(Benzo[b]thiophen-2-yl)vinyl)-4-methoxyphenol (66, Table 3-12, entry 1)

The general procedure was followed (3 h). The 2-bromo-4-methoxyphenol (126.7 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL)
and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo
to provide a yellow solid. The solid was purified by flash column chromatography on silica gel
(20% EtOAc in hexanes) to provide the pure o-hydroxy stilbene 66 in 86% yield as a bright
yellow-green solid (151 mg): 1H NMR (300 MHz, DMSO-d6) δ 9.48 (s, 1H), 7.90 (d, J = 8.3 Hz,
1H), 7.84 – 7.73 (m, 1H), 7.59 (d, J = 16.2 Hz, 1H), 7.44 (s, 1H), 7.34 (p, J = 7.5 Hz, 2H), 7.21
(d, J = 16.1 Hz, 1H), 7.17 (s, 1H), 6.82 (d, J = 8.8 Hz, 1H), 6.75 (dd, J = 8.8, 2.7 Hz, 1H), 3.74
(s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 152.86, 149.69, 143.83, 140.53, 138.40, 126.27,
125.26, 125.16, 123.94, 123.70, 123.59, 122.81, 122.43, 117.19, 116.11, 110.99, 55.92; HRMS
(ESI) (M + H), Calcd. for C17H15O2S 283.0793; Found 283.0790.
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(E)-2-(2-(1H-Indol-2-yl)vinyl)-4-methoxyphenol (67, Table 3-12, entry 2)

The general procedure was followed (3 h). The 2-bromo-4-methoxyphenol (126.7 mg, 0.624
mmol, 1 eq), 2-vinyl-1H-indole (89.4 mg, 0.624 mmol, 1 eq), sodium acetate (102.4 mg, 1.248
mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were charged to a
vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under an argon
atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC for 3h,
cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered through
a plug of celite and the filtrate was washed successively with water (2 x 10 mL) and brine (2 x 10
mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to provide a
yellow solid. The solid was purified by flash column chromatography on silica gel (19% EtOAc
and 1% TEA in hexanes) to provide the pure indole stilbene 67 in 81% yield as a bright green
solid (134 mg): 1H NMR (300 MHz, DMSO-d6) δ 11.39 (s, 1H), 9.38 (s, 1H), 7.48 (d, J = 7.7
Hz, 1H), 7.39 (d, J = 16.7 Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 16.7 Hz, 1H), 7.16 –
7.02 (m, 1H), 6.96 (t, J = 7.3 Hz, 1H), 6.81 (d, J = 8.8 Hz, 1H), 6.71 (dd, J = 8.7, 2.7 Hz, 1H),
6.52 (s, 1H), 3.74 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 152.86, 149.45, 137.91, 137.79,
128.91, 124.68, 123.08, 122.18, 120.30, 119.61, 119.56, 117.01, 115.13, 111.37, 110.70, 102.84,
55.86; HRMS (ESI) (M + H), Calcd. for C17H16NO2 266.1181; Found 266.1178.
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(E)-2-(2-(Benzofuran-2-yl)vinyl)-4-methoxyphenol (68, Table 3-12, entry 3)

The general procedure was followed (3 h). The 2-bromo-4-methoxyphenol (126.7 mg, 0.624
mmol, 1 eq), 2-vinylbenzofuran (90 mg, 0.624 mmol, 1 eq), sodium acetate (102.4 mg, 1.248
mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were charged to a
vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under an argon
atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC for 3h,
cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered through
a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x 10 mL) and
brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to
provide a yellow solid. The solid was purified by flash column chromatography on silica gel
(20% EtOAc in hexanes) to provide the pure benzofuran stilbene 68 in 86% yield as a bright
yellow solid (143 mg): 1H NMR (500 MHz, DMSO) δ 9.53 (s, 1H), 7.61 (d, J = 7.4 Hz, 1H),
7.59 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 16.4 Hz, 1H), 7.32 (d, J = 16.4 Hz, 1H), 7.33 – 7.29 (m,
1H), 7.26 – 7.21 (m, 1H), 7.18 (d, J = 3.0 Hz, 1H), 6.92 (s, 1H), 6.83 (d, J = 8.8 Hz, 1H), 6.76
(dd, J = 8.8, 3.0 Hz, 1H), 3.75 (s, 3H); 13C NMR (126 MHz, DMSO) δ 155.89, 154.66, 152.85,
150.01, 129.38, 125.75, 125.10, 123.60, 123.54, 121.41, 117.24, 116.52, 116.37, 111.24, 111.06,
105.41, 55.91; HRMS (ESI) (M + H), Calcd. for C17H15O3 267.1021; Found 267.1026.
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(E)-4-(2-(5-Chlorobenzo[b]thiophen-2-yl)vinyl)-2-methoxyphenol (69, Table 3-13, entry 1)

The general procedure was followed (3 h). The 4-bromo-2-methoxyphenol (127 mg, 0.624
mmol, 1 eq), 5-chloro-2-vinylbenzo[b]thiophene 31 (121.5 mg, 0.624 mmol, 1 eq), sodium
acetate (102.4 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol,
0.025 eq) were charged to a vial containing oxygen free solvent (10% water in
dimethylacetamide, 3 mL) under an argon atmosphere. The vial was sealed with a septum and
the mixture was heated to 150 ºC for 3h, cooled to rt, and EtOAc (10mL) was added in one
portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with 0.5 N aq HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and solvent was removed in vacuo to provide a yellow solid. The solid was purified by
flash column chromatography on silica gel (20% EtOAc in hexanes) to provide the pure 5chlorothiophenyl analog 69 in 87% yield as a yellow solid (174 mg): 1H NMR (300 MHz,
DMSO-d6) δ 9.31 (s, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.86 (d, J = 1.4 Hz, 1H), 7.42 (d, J = 16.1
Hz, 1H), 7.37 (s, 1H), 7.33 (dd, J = 8.6, 1.7 Hz, 1H), 7.27 (s, 1H), 7.05 (d, J = 8.1 Hz, 1H), 6.97
(d, J = 16.1 Hz, 1H), 6.79 (d, J = 8.1 Hz, 1H), 3.85 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ
148.37, 147.89, 145.93, 141.99, 136.78, 132.40, 130.13, 128.10, 124.87, 124.37, 123.00, 121.94,
121.22, 119.52, 116.08, 110.61, 56.12; HRMS (ESI) (M + H), Calcd. for C17H14ClO2S 317.0403;
Found 317.0404.
130

(E)-2-Chloro-4-(2-(5-chlorobenzo[b]thiophen-2-yl)vinyl)phenol (70, Table 3-13, entry 2)

The general procedure was followed (3 h). The 4-bromo-2-chlorophenol (129.5 mg, 0.624
mmol, 1 eq), 5-chloro-2-vinylbenzo[b]thiophene 31 (121.5 mg, 0.624 mmol, 1 eq), sodium
acetate (102.4 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol,
0.025 eq) were charged to a vial containing oxygen free solvent (10% water in
dimethylacetamide, 3 mL) under an argon atmosphere. The vial was sealed with a septum and
the mixture was heated to 150 ºC for 3h, cooled to rt, and EtOAc (10mL) was added in one
portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with 0.5 N aq HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and solvent was removed in vacuo to provide a yellow solid. The solid was purified by
flash column chromatography on silica gel (20% EtOAc in hexanes) to provide the pure 5chlorothiophenyl analog 70 in 87% yield as an off-white solid (174 mg): 1H NMR (300 MHz,
DMSO-d6) δ 10.47 (s, 1H), 7.93 (d, J = 8.6 Hz, 1H), 7.87 (d, J = 1.9 Hz, 1H), 7.69 (d, J = 1.8
Hz, 1H), 7.54 – 7.28 (m, 4H), 6.98 (d, J = 8.4 Hz, 1H), 6.96 (d, J = 16.1 Hz, 1H); 13C NMR (75
MHz, DMSO-d6) δ 153.77, 145.47, 141.86, 136.94, 130.59, 130.16, 129.05, 128.59, 127.27,
125.07, 124.42, 123.14, 122.66, 120.85, 120.72, 117.29; HRMS (ESI) (M + H), Calcd. for
C16H11Cl2OS 320.9908; Found 320.9914.
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(E)-2-Chloro-4-(2-(5-fluorobenzo[b]thiophen-2-yl)vinyl)phenol (71, Table 3-13, entry 3)
F

Cl

Chemical Formula: C16H10ClFOS
Molecular Weight: 304.76
c Log P: 5.59
tPSA: 20.23

S

HO

The general procedure was followed (3 h). The 4-bromo-2-chlorophenol (129.5 mg, 0.624
mmol, 1 eq), 5-fluoro-2-vinylbenzo[b]thiophene 31 (111 mg, 0.624 mmol, 1 eq), sodium acetate
(102.4 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq)
were charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL)
under an argon atmosphere. The vial was sealed with a septum and the mixture was heated to
150 ºC for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was
filtered through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x
10 mL) and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed
in vacuo to provide a yellow solid. The solid was purified by flash column chromatography on
silica gel (20% EtOAc in hexanes) to provide the pure 5-fluorothiophenyl analog 71 in 92%
yield as an off-white solid (175 mg): 1H NMR (500 MHz, DMSO) δ 10.48 (s, 1H), 7.94 (dd, J =
8.8, 5.0 Hz, 1H), 7.70 (d, J = 2.0 Hz, 1H), 7.62 (dd, J = 9.8, 2.5 Hz, 1H), 7.47 (d, J = 15.9 Hz,
1H), 7.45 (dd, J = 8.3, 2.2 Hz, 1H), 7.40 (s, 1H), 7.20 (td, J = 9.0, 2.6 Hz, 1H), 6.99 (d, J = 8.4
Hz, 1H), 6.96 (d, J = 16.1 Hz, 1H); 13C NMR (126 MHz, DMSO) δ 160.87 (d, J = 239.2 Hz),
153.75 (s), 145.89 (s), 141.64 (d, J = 9.9 Hz), 134.15 (s), 130.38 (s), 129.11 (s), 128.57 (s),
127.28 (s), 124.41 (d, J = 9.5 Hz), 123.15 (d, J = 4.2 Hz), 121.02 (s), 120.73 (s), 117.30 (s),
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113.54 (d, J = 24.8 Hz), 109.32 (d, J = 23.0 Hz); HRMS (ESI) (M + H), Calcd. for C16H11ClFOS
305.0203; Found 305.0210.
(E)-4-(2-(5-Fluorobenzo[b]thiophen-2-yl)vinyl)-2-methoxyphenol (72, Table 3-14, entry 1)

The general procedure was followed (3 h). The 4-bromo-2-methoxyphenol (126.7 mg, 0.624
mmol, 1 eq), 5-fluoro-2-vinylbenzo[b]thiophene 31 (111 mg, 0.624 mmol, 1 eq), sodium acetate
(102.4 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq)
were charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL)
under an argon atmosphere. The vial was sealed with a septum and the mixture was heated to
150 ºC for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was
filtered through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x
10 mL) and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed
in vacuo to provide a yellow solid. The solid was purified by flash column chromatography on
silica gel (20% EtOAc in hexanes) to provide the pure 5-fluorothiophenyl analog 72 in 88%
yield as a yellow solid (165 mg): 1H NMR (300 MHz, DMSO-d6) δ 9.31 (s, 1H), 7.92 (dd, J =
8.7, 5.0 Hz, 1H), 7.60 (dd, J = 9.9, 2.1 Hz, 1H), 7.42 (d, J = 16.1 Hz, 1H), 7.37 (s, 1H), 7.26 (s,
1H), 7.18 (td, J = 9.1, 2.3 Hz, 1H), 7.05 (d, J = 8.2 Hz, 1H), 6.96 (d, J = 16.1 Hz, 1H), 6.79 (d, J
= 8.1 Hz, 1H), 3.85 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 160.86 (d, J = 239.0 Hz), 148.36
(s), 147.84 (s), 146.33 (s), 141.75 (d, J = 9.8 Hz), 133.97 (s), 132.18 (s), 128.13 (s), 124.33 (d, J
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= 9.4 Hz), 122.40 (d, J = 4.3 Hz), 121.17 (s), 119.65 (s), 116.07 (s), 113.29 (d, J = 25.1 Hz),
110.60 (s), 109.16 (d, J = 23.2 Hz), 56.11 (s); HRMS (ESI) (M + H), Calcd. for C17H14FO2S
301.0699; Found 301.0692.
(E)-4-(2-(Benzo[b]thiophen-2-yl)vinyl)-2-methoxyaniline (73, Table 3-14, entry 2)

The general procedure was followed (3 h). The 4-bromo-2-methoxyaniline (126.1 mg, 0.624
mmol, 1 eq), 2-vinylbenzo[b]thiophene 31 (100 mg, 0.624 mmol, 1 eq), sodium acetate (102.4
mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq) were
charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL) under
an argon atmosphere. The vial was sealed with a septum and the mixture was heated to 150 ºC
for 3h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was filtered
through a plug of celite and the filtrate was washed successively with water (2 x 10 mL) and
brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed in vacuo to
provide a yellow solid. The solid was purified by flash column chromatography on silica gel
(20% EtOAc in hexanes) to provide the pure amine 73 in 75% yield as a brown solid (131 mg):
1

H NMR (300 MHz, DMSO-d6) δ 7.87 (d, J = 7.2 Hz, 1H), 7.79 – 7.69 (m, 1H), 7.40 – 7.24 (m,

4H), 7.12 (s, 1H), 6.96 (d, J = 8.1 Hz, 1H), 6.88 (d, J = 16.1 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H),
5.09 (s, 2H), 3.84 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 146.80, 144.13, 140.72, 139.15,
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138.07, 132.32, 125.07, 124.91, 124.78, 123.53, 122.68, 121.85, 121.59, 117.66, 113.74, 108.72,
55.81; HRMS (ESI) (M + H), Calcd. for C17H16NOS 282.0953; Found 282.0956.
(E)-3-(2-(5-Fluorobenzo[b]thiophen-2-yl)vinyl)-5-methoxyphenol (74, Table 3-14, entry 3)
F

HO

Chemical Formula: C17H13FO2S
Molecular Weight: 300.35
c Log P: 4.9
tPSA: 29.46

S

OMe

The general procedure was followed (3 h). The 3-bromo-5-methoxyphenol (126.7 mg, 0.624
mmol, 1 eq), 5-fluoro-2-vinylbenzo[b]thiophene 31 (111 mg, 0.624 mmol, 1 eq), sodium acetate
(102.4 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.016 mmol, 0.025 eq)
were charged to a vial containing oxygen free solvent (10% water in dimethylacetamide, 3 mL)
under an argon atmosphere. The vial was sealed with a septum and the mixture was heated to
150 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added in one portion. The suspension was
filtered through a plug of celite and the filtrate was washed successively with 0.5 N aq HCl (2 x
10 mL) and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and solvent was removed
in vacuo to provide a yellow solid. The solid was purified by flash column chromatography on
silica gel (20% EtOAc in hexanes) to provide the pure 5-fluorothiophenyl analog 74 in 92%
yield as an off-white solid (172 mg): 1H NMR (300 MHz, DMSO-d6) δ 9.54 (s, 1H), 7.97 – 7.93
(m, 1H), 7.65 – 7.61 (m, 1H), 7.54 – 7.43 (m, 2H), 7.25 – 7.19 (m, 1H), 6.93 (d, J = 15.9 Hz,
1H), 6.70 (s, 1H), 6.62 (s, 1H), 6.31 (s, 1H), 3.75 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ
160.86 (d, J = 237.75 Hz), 161.15 (s), 159.14 (s), 145.55 (s), 141.54 (d, J = 9.75 Hz), 138.42 (s),
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134.31 (s), 131.87 (s), 124.46 (d, J = 9.75 Hz), 123.87 (d, J = 3.75 Hz), 122.78 (s), 113.74 (d, J =
24.75 Hz), 109.42 (d, J = 22.5 Hz), 106.94 (s), 103.63 (s), 102.18 (s), 55.53 (s); HRMS (ESI) (M
+ H), Calcd. for C17H14FO2S 301.0699; Found 301.0703.
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CHAPTER FOUR
ALDOL CONDENSATION PRODUCTS AND THEIR ANTIMICROBIAL
PROPERTIES: STRUCTURALLY SIMILAR TO BOTH STILBENOID AND
ACRYLATE ACTIVE COMPOUNDS
I.

INTRODUCTION AND BACKGROUND.
The aldol condensation is a carbon-carbon bond forming reaction in which an enol or

enolate anion reacts with a carbonyl compound, followed by dehydration to give a conjugated
enone (Scheme 4-1).165 This reaction was discovered in the late 19th century and is still one of
the most important C-C bond forming reactions in organic chemistry.165-166 It is particularly
useful for large-scale preparation of materials due to the inexpensive reagents involved.
Scheme 4-1: Aldol condensation mechanisms.

Earlier in the SAR of stilbenoid compounds it was discovered that another class of
compounds, acrylates, also showed activity against mycobacteria with lead compound SK-0457ac.120 These acrylates were further investigated through a second SAR and compounds with
potent activity against gram-positive bacteria and mycobacteria were discovered, the most active
being TI-01-37ac (Table 4-1).91
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Table 4-1: Acrylate activitya.

Bacterial Strain

a

S. aureus

>512

1

E. faecalis

>512

2

P. aeruginosa

>128

64

E. coli

>512

16

M. intracellulare

N.T.

4

M. chelonae

N.T.

8

M. fortuitum

N.T.

16

M. kansasii

N.T.

8

M. avium

N.T.

16

M. smegmatis

16

4

M. marinum

N.T.

4

Values in µg/mL, N.T. = not tested

Interestingly TI-01-37ac was the first compound synthesized that had broad activity
against gram-positive, gram-negative, and mycobacterium species. This activity, however, was
later linked to the cytotoxic nature of these compounds, which was likely due to the Michaelacceptor nature of the α,ß-unsaturated carbonyl system.167-170 In fact, when the carbon doublebond was saturated, the compound which resulted had no activity for all strains tested – unlike
saturation of the stilbene double-bond which, while it decreased potency, were still active (see
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Chapter 2). Analysis of further NMR studies confirmed that various anilines formed Michael
adducts with these acrylate compounds in an irreversible manner.
Regardless, modification of the stilbenoid core structure to include this α,ß-unsaturated
function was still explored to see if further modification of the bridge portion was advantageous,
accompanied by less cytotoxicity.

II.

CHEMISTRY AND RESULTS.
As discussed in the Introduction, the aldol condensation can lead to α,ß-unsaturated

compounds with a wide variety of substituents. In this case, the focus was on modification of the
current lead compounds by changing the ‘bridge’ portion to include this α,ß-unsaturated function
(Figure 4-1).
Figure 4-1: Target compounds.

Synthesis of such compounds would require an aldehyde and a methyl ketone, and since
benzo[b]thiophene-2-carbaldehyde (18) was already synthesized and the phenolic methyl
ketones were commercially available and relatively inexpensive, a series of three new analogs
were prepared (Table 4-2).
Synthesis of these analogs was found to proceed smoothly and purification by
crystallization from ethanol resulted in isolation of analytically pure material with no need of
flash column chromatography. These enone compounds, however, were found to be less soluble
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then the already rather insoluble stilbenoid compounds in suitable in vitro/in vivo solvent
preparations.
Table 4-2: Synthesis of enone analogs.

Compound
75
76

R
OMe
Cl

Yield (%)
89
93

77

NO2

81

Examination of the data in Table 4-3 details the activity of these enone analogs against
the standard bacterial strains tested. The methoxy analog 75 retained similar activity to its
related stilbenoid analog 36 while the chloro analog 76 does not retain activity compared to the
potent stilbenoid analog 38. This variability might be explained by the poor solubility of these
compounds, however, since considerable effort is required to keep them in solution. The nitro
analog 77, for example, readily precipitates out of a DMSO/water solution even at very low
concentrations which certainly could hinder MIC screens. However, it is important to note that
both the methoxy analog 75 and the nitro analog 77 were potent antimicrobials against S. aureus.
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Table 4-3: Enone analog activities.a

Bacterial
Strain

a

S. aureus

0.5

128

2

E. faecalis

1

64

128

P. aeruginosa

>128

>128

>128

E. coli

>128

>128

>128

M.
intracellulare

16

32

64

M. chelonae

32

32

64

M. fortuitum

16

64

128

M. kansasii

8

128

>128

M. avium

16

64

128

M. smegmatis

32

>128

128

M. marinum

4

16

64

Values in µg/mL

Synthesis of more analogs in this series was halted due to a number of reasons. First and
foremost, availability of substituted methyl ketones, although generally inexpensive, was low.
Secondly, the low solubility exhibited by these compounds was not promising, since they
seemed even less soluble then the related stilbenoid derivatives. Finally, cytotoxicity concerns
from both studies on 75 (to be discussed in the next chapter) and previous studies on SK-04-57ac
and TI-01-37ac were considered a hurdle based on the Michael acceptor pharmacophore in these
analogs.
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III.

CONCLUSION.

In conclusion, a synthesis of enone compounds structurally similar to the lead stilbenoid
compounds was accomplished using an aldol condensation reaction. Three different analogs
were synthesized, one of which had similar activity to the best current lead compounds. This
analog, 75, was structurally related to an earlier lead compound 36. Given this potent activity,
75 was also considered a lead compound in this work, however it may not be as desirable as the
related stilbene analogs due to cytotoxicity and solubility issues.
These issues, however, could be addressed in future SAR work by removing the α,ßunsaturated nature of this compound via various methods to determine whether or not activity
can be retained, especially if this substitution leads to better water solubility.
As also noted, selection of methyl ketones was rather low, however they could also be
conveniently synthesized via a Fries rearrangement reaction or other similar reactions. Attempts
to synthesize the enone analogs of the stilbenoids with different substitution patterns (66, 67, and
68 for example) may also prove useful in future work.

IV.
1.

EXPERIMENTAL.
In vitro MIC assays. (completed by Dr. Bill Schwan)

In vitro minimum inhibitory concentration (MIC) determinations were performed
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines,115 for most of the
bacteria that were screened. Tetracycline, ciprofloxacin, and erythromycin were included as
control antibiotics for the gram-positive bacterial MIC values and correlated with established
MIC values. All anti-Mycobacterium activity evaluations were performed using MIC assays in
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Middlebrook 7H9 broth with 10% oleic acid albumin dextrose complex (OADC) as previously
described.114 Rifampin was used as the positive control for the mycobacterial MIC values. All
MIC numbers are a compilation of the geometric means from three separate runs. For the broad
characterization against S. aureus, strains that have been typed by a variety of means were used
by Schwan et al116.

2.

Characterization data.

Both 1H and 13C NMR’s were recorded on a Bruker DPX-300 or DRX-500 instrument
where noted. HRMS scans were recorded on a Shimadzu LCMS-IT-TOF or similar instruments
run at the Shimadzu Analytical Chemistry Center of Southeastern Wisconsin. In silico cLogP
values and topological polar surface area values (tPSA) were calculated with ChemBioDraw
Ultra v. 14.
(E)-3-(Benzo[b]thiophen-2-yl)-1-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one (75, Table
4-3, entry 1)

The 1-(4-hydroxy-3-methoxyphenyl)ethan-1-one (500mg, 3 mmol, 1eq) and benzo[b]thiophene2-carbaldehyde (500mg, 3.08 mmol, 1.02eq) were dissolved in acetone (20mL) at rt. Potassium
hydroxide (338mg, 6 mmol, 2eq, crushed) was added in one portion and the slurry heated to
reflux. The reaction was followed by TLC (50% EtOAc in hexanes, silica gel) and was complete
after 3 h. The mixture was cooled with an ice bath and quenched with excess aq 0.5N HCl
(50mL). The solution which resulted was extracted with EtOAc (50mL x 2), washed with brine
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(50mL x 2), and the organic layer was dried (Na2SO4). The solvent was removed in vacuo which
resulted in in a yellow solid (921mg, 99% yield). The solid was further purified by
crystallization from hot EtOH to give yellow microcrystals of the enone 75 (834mg, 90.5%
recovery, 89% overall yield):1H NMR (300 MHz, DMSO-d6) δ 10.14 (s, 1H), 7.98 (d, J = 15.1
Hz, 1H), 8.04 – 7.92 (m, 2H), 7.92 – 7.84 (m, 1H), 7.74 (dd, J = 8.3, 1.8 Hz, 1H), 7.60 (d, J = 1.7
Hz, 1H), 7.60 (d, J = 15.3 Hz, 1H), 7.49 – 7.37 (m, 2H), 6.95 (d, J = 8.3 Hz, 1H), 3.88 (s, 3H);
13

C NMR (75 MHz, DMSO-d6) δ 186.84, 152.62, 148.35, 140.52, 140.11, 139.95, 136.35,

130.33, 129.62, 126.89, 125.54, 125.03, 124.20, 123.52, 123.16, 115.55, 111.97, 56.13; HRMS
(ESI) (M + H), Calcd. for C18H15O3S 311.0742; Found 311.0749.
(E)-3-(Benzo[b]thiophen-2-yl)-1-(3-chloro-4-hydroxyphenyl)prop-2-en-1-one (76, Table 4-3,
entry 2)

The 1-(3-chloro-4-hydroxyphenyl)ethan-1-one (512mg, 3 mmol, 1eq) and benzo[b]thiophene-2carbaldehyde (500mg, 3.08 mmol, 1.02eq) were dissolved in acetone (20mL) at rt. Potassium
hydroxide (338mg, 6 mmol, 2eq, crushed) was added in one portion and the slurry heated to
reflux. The reaction was followed by TLC (50% EtOAc in hexanes, silica gel) and was complete
after 3 h. The mixture was cooled with an ice bath and quenched with excess aq 0.5N HCl
(50mL). The solution which resulted was extracted with EtOAc (50mL x 2), washed with brine
(50mL x 2), and the organic layer was dried (Na2SO4). The solvent was removed in vacuo which
resulted in a yellow solid (932mg, 98.6% yield). The solid was further purified by crystallization
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from hot EtOH to give yellow microcrystals of enone 76 (878mg, 94% recovery, 93% overall
yield): 1H NMR (300 MHz, DMSO-d6) δ 11.32 (s, 1H), 8.16 (d, J = 2.0 Hz, 1H), 8.06 – 7.95 (m,
3H), 8.00 (d, J = 14.6 Hz, 1H), 7.95 – 7.85 (m, 1H), 7.61 (d, J = 15.3 Hz, 1H), 7.51 – 7.37 (m,
2H), 7.12 (d, J = 8.5 Hz, 1H); 13C NMR (75 MHz, DMSO-d6) δ 186.22, 158.46, 140.38, 140.31,
139.90, 137.07, 131.19, 130.67, 130.03, 129.89, 126.99, 125.57, 125.11, 123.20, 123.16, 120.87,
116.97; HRMS (ESI) (M + H), Calcd. for C17H12ClO2S 315.0247; Found 315.0243.
(E)-3-(Benzo[b]thiophen-2-yl)-1-(4-hydroxy-3-nitrophenyl)prop-2-en-1-one (77, Table 4-3,
entry 3)

The 1-(4-hydroxy-3-nitrophenyl)ethan-1-one (543.5mg, 3 mmol, 1eq) and benzo[b]thiophene-2carbaldehyde (500mg, 3.08 mmol, 1.02eq) were dissolved in acetone (20mL) at rt. Potassium
hydroxide (338mg, 6 mmol, 2eq, crushed) was added in one portion and the slurry heated to
reflux. The reaction was followed by TLC (50% EtOAc in hexanes, silica gel) and was complete
after 3 h. The mixture was cooled with an ice bath and quenched with excess aq 0.5N HCl
(50mL). The solution which resulted was extracted with EtOAc (50mL x 2), washed with brine
(50mL x 2), and the organic layer was dried (Na2SO4). The solvent was removed in vacuo which
resulted in a yellow solid (898mg, 92% yield). The solid was further purified by trituration in
hot EtOH to give a yellow powder of enone 77 (795mg, 88.5% recovery, 81% overall yield): 1H
NMR (300 MHz, DMSO-d6) δ 12.04 (s, 1H), 8.62 (d, J = 2.0 Hz, 1H), 8.27 (dd, J = 8.8, 2.1 Hz,
1H), 8.03 (d, J = 15.3 Hz, 1H), 7.98 (d, J = 10.2 Hz, 2H), 7.92 – 7.85 (m, 1H), 7.60 (d, J = 15.2
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Hz, 1H), 7.50 – 7.36 (m, 2H), 7.26 (d, J = 8.8 Hz, 1H); 13C NMR (75 MHz, DMSO-d6) δ
185.98, 156.13, 140.40, 140.22, 139.84, 137.75 (2C), 135.05, 131.09, 128.84, 127.08, 126.66,
125.56, 125.16, 123.18, 122.69, 119.63; HRMS (ESI) (M + H), Calcd. for C17H12NO4S
326.0487; Found 326.0483.
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CHAPTER FIVE
ACTIVITY OF THE MOST ACTIVE COMPOUNDS AGAINST RESISTANT
STRAINS, PRELIMINARY CYTOXICITY DATA, PRELIMINARY IN VIVO
DATA, MECHANISM OF ACTION STUDIES, AND PRELIMINARY
PHARMACOPHORE MODELING
I.

INTRODUCTION.
As previously discussed, twelve new compounds with activity averaging below 10

µg/mL for gram-positive strains were identified in this SAR study. These compounds, pictured
below (Figure 5-1), represent potential targets for further pharmaceutical development.
Figure 5-1: Most active compounds from this SAR.

The two gram-positive strains tested, however, were not antibiotic resistant strains and
are very susceptible to current antibiotics on the market. This necessitates screening these
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compounds against tested against drug-resistant strains to confirm they have potential use as a
new and novel therapy for bacterial infections which may not develop resistance.
A combination of eight antibiotic resistant strains were used by Schwan et al. in a followup assay to test many of the most active compounds from this series. These include three strains
of multi-drug resistant S. aureus (MDR-MRSA), rifampin resistant S. aureus (RifR-MRSA),
vancomycin intermediate resistant S. aureus (VISA-MRSA), community-acquired methicillin
resistant S. aureus (MW2-MRSA), and two strains of vancomycin resistant enterococci (VRE).
These strains represent some of the most highly virulent and deadly gram-positive bacterial
strains and many are contracted and isolated directly from hospitalized patients.
Controls in the form of commercial pharmaceutical antibiotics were also tested in these
same assays. These eight doctor-prescribed antibiotics are Gentamicin, Ampicillin, Oxacillin,
Ciprofloxacin, Vancomycin, Erythromycin, Tetracycline, and Rifampin. These drugs were
earlier described in Chapter 1 and represent some of the most prescribed drugs that are currently
on the market.
It was previously determined (Chapter 2) that SK-03-92, a parent compound to the
analogs described in this work, was not cytotoxic both in vitro and in vivo, even up to doses as
high as 2000 mg/kg. While these results only indicate that SK-03-92 is not cytotoxic, it also
implies that analogs of SK-03-92 should not be cytotoxic as well, especially if no known
cytotoxic moieties are introduced into the core structure. Preliminary cytotoxicity studies were
still initiated with five of the most active analogs along with vancomycin as a control. These
analogs were tested in a CellTiter-Glo toxicity assay to determine cell viability after incubation
with the compounds of interest.
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Preliminary in vivo work has also been done on both compounds 36 and 38. This work
involved a lung infection model with mice dosed either intranasal (IN) or intraperitoneal (IP).
The results from this preliminary work are somewhat promising, but it is clear much work has
yet to be done in this area to confirm it with a reasonable n value.
Mechanism/mode of action studies were also initiated on both compounds 36 and 38. In
general, the most convenient method of determining the mode of action is by first isolating
strains that acquire resistance via repeated sub-MIC dosing. Genomic information on these
resistant strains can then be used to determine the mode of action and perhaps even the
mechanism of action.
Finally, a preliminary pharmacophore model was constructed from compounds
synthesized in this work. Pharmacophore models can be extremely helpful in the design of new
compounds and in the elucidation of a binding site, if one exists.

II.

RESULTS AND DISCUSSION.
1.

In vitro data on resistant strains.

As mentioned five compounds were selected for preliminary cytotoxicity studies. These
five compounds were some of the mostactive compounds found via this new SAR and include
compounds 36, 38, 45, 48, and 75 (Table 5-1). Of these compounds 36, 38, and 75 are by far the
most active with MIC values around 1 µg/mL, rivaling that of Vancomycin and other
commercial antibiotics. Excitingly, all compounds tested were equipotent against the drugresistant strains, with no significant variability. In fact, for the particularly dangerous
Vancomycin resistant enterococci (VRE) strains, the analogs prepared via this SAR were
more active then every commercial antibiotic tested aside from Rifampin. As discussed
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earlier, Rifampin develops resistance very quickly and thus is used only in the most dire
situations, generally co-administered with another antibiotic.
The variability of commercialized antibiotics seen in Table 5-1 is also alarming and
speaks to the delicate nature of antibiotic use in infections. These strains are prevalent in
hospital settings and it is unnerving to know that a particularly resistant strain could be the cause
of an infection. It is not possible by visible inspection to discern whether or not a particular
infection is caused by drug-resistant bacteria or susceptible non-drug resistant strains. The
choice of the wrong treatment can both increase the likelihood of spreading the infection to other
patients, as well as conferring additional resistance to the bacteria in question. Doctors must
choose the best course of treatment and wait for biological testing of the bacterial strain in
question to determine whether it is drug-resistant or not; this is valuable time and, unfortunately,
the cause for the alarming number of deaths from MRSA infections.171-173
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1
8
8

0.5

1

8

8

8

32

4

>128

1

>128

32

0.015

38

75

45

47

Gentamicin

Ampicillin

Oxacillin

Ciprofloxacin

Vancomycin

Erythromycin

Tetracycline

Rifampin

>128

0.5

>128

1

>128

4

>128

32

0.5

1

1

36

0.003

64

128

1

32

4

>128

16

8

16

1

0.5

1

0.006

0.25

>128

4

128

4

8

32

8

8

1

1

1

ND

ND

ND

ND

ND

ND

ND

ND

4

8

0.5

0.5

0.5

ND

ND

ND

ND

ND

ND

ND

ND

8

8

0.5

0.5

0.5

0.25

4

>128

32

8

128

128

128

4

16

1

0.5

1

0.006

64

128

128

64

128

128

128

4

32

1

0.5

1

ND

ND

ND

>150

ND

ND

ND

ND

>150

>150

48.18

>150

>150

IC50 HEK293-T

Values in µM

Values in µg/mL
MC7769 RifR MRSA MC7606 MDR MRSA MC7846 VISA MRSA MC7583 MDR MRSA MW2 MRSA VRE 1 VRE 14

MC7827 MDR MRSA

Compound

Cell Viability

Minimum Inhibitory Concentration

Table 5-1: MICs and Cell Viability of some of the most active compounds developed in this work.

Examination of the data in Table 5-1 clearly indicated that of the five compounds tested,
all were very potent against the dangerous drug-resistant strains of gram-positive bacteria.
Particularly interesting is the potent activity against VRE strains of which only rifampin was
found to be more active than four of the five selected analogs. In fact, the MIC of chloro stilbene
analog 38 was almost universally under 1 µg/mL, better then all controls except for rifampin.
However, in the rifampin resistant strain, MC7769 RifR MRSA, compound 38 was 256-fold
more active than rifampin!
The methoxy enone analog 75 was also very active against all strains tested, similarly to
compound 38, however 75 was also slightly cytotoxic. This was almost certainly due to the
Michael-acceptor nature of this compound, similar to the acrylate compounds discussed earlier.
It should be noted, however, that 1 µg/mL for 75 is a MIC value of approximately 3 µM,
therefore the antimicrobial activity was still 16-fold greater than the IC50 of the cytotoxicity.
This indicated that while cytotoxicity might be a problem in vivo, the activity of the compound is
likely due, in major part, to the antibiotic properties rather than the cytotoxic properties.
Alternative analogs such as 36 and 38 are both very potent and also show no inherent
cytotoxicity, so they remain as promising treatment options which require further testing.
An additional thirteen analogs were also tested against these resistant strains (Table 5-2).
A number of these analogs were earlier found to be active against the non-resistant strains, but
some were also tested as negative controls, for example phenol analog 34 and chloro analog 39.
These compounds have not yet been tested for cytotoxicity, but again it is important to note that
prior data heavily implies that these compounds, none of which are Michael-acceptors, should be
safe and non-cytotoxic.
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Of these analogs, many were found to exhibit average MIC values of less than 10 µg/mL
against these resistant strains. This is potent enough to explore further. The ring D chloro
analogs 69 and 70 interestingly exhibited very potent activity against MC7606 MDR MRSA,
however, were clearly less active against the other strains. This strange behavior has not yet
been explained, however difficulty solubilizing these compounds was noted and perhaps the lack
of activity is due more to solubility issues, further testing of these compounds is on-going in
bacterial assays that do not rely upon aqueous dissolution of an analog prior to treatment. The
ring D fluoro analog 74 was the most active compound to date, with some MIC value in the 0.25
µg/mL range.
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154

>128
2
2
4

2
>128
32
4
8

>128

16

8

16

4

8

8

>128

128

8

16

0.25

39

42

63

64

66

67

68

69

70

71

72

74

0.5

4

1

>128

>128

34

0.25

1

0.5

0.25

1

4

2

2

2

1

16

>128

64

0.5

8

8

64

>128

4

4

2

4

2

32

>128

>128

0.5

4

4

64

16

16

8

8

16

16

16

>128

128

0.5

4

4

>128

8

4

4

4

4

1

32

>128

>128

Compound MC7827 MDR MRSA MC7769 RifR MRSA MC7606 MDR MRSA MC7846 VISA MRSA MC7583 MDR MRSA MW2 MRSA

Minimum Inhibitory Concentrations (values in µg/mL)

Table 5-2: MIC values of some other active (and inactive) compounds from this work.

1

32

4

4

>128

4

8

4

32

4

1

>128

>128

1

64

2

4

128

4

8

4

32

4

16

>128

>128

VRE 1 VRE 14

2.

Preliminary in vivo data on 36 and 38.

While this in vitro data is promising, in vivo data is also necessary since potential drugs
must be efficacious in mammalian systems. Preliminary in vivo studies were completed on two
of the most active compounds that were developed early in this SAR, 36 and 38.
These compounds were tested in a S. aureus lung infection model at a dosage of 10
mg/kg intranasally. The results from this preliminary in vivo exposure indicate that a number of
problems still exist with these compounds in vivo in regard to vehicle choice, similarly to SK-0392, however they seemed to be at least partially efficacious (Table 5-3).
Table 5-3: Preliminary in vivo data from a lung infection model.
Trial
Mouse 1 Mouse 2 Mouse 3 Mouse 4
Vehicle
0
0
0
‐‐‐
Vehicle + MRSA
D
D
D
4
36 + MRSA
D
3‐4
4
D
38 + MRSA
D
D
4
D
D = dead; 0=healthy; 1=less active; 2=hunched, less active;
3=ruffled, hunched, inactive; 4- ruffled, hunched, inactive, gaunt

A major problem in this experiment was dissolving the compound prior to treatment, as
mentioned. According to the team administering the compound, in this particular experiment
compound 36 seemed more soluble in the vehicle whereas 38 was not fully dissolved. For
intranasal exposure undissolved solids entering the lungs can cause lung trauma which can
actually increase the spread of infection and indeed 38 was found to not be particularly
efficacious in this experiment. The compound 36, which was seemingly more well-dissolved,
appeared to have a small effect on the outcome of the mice. Two mice survived as opposed to
just one and one of the mice had a better clinical score then what was seen in the MRSA control.
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Based on these findings, another preliminary in vivo experiment was planned using these two
compounds.
A second in vivo experiment followed in a similar fashion to the first, however in this
case compounds were also administered intraperitoneal (IP) as well as intranasal (IN) (Figure 52). Similarly to the first trial, our collaborators had issues fully dissolving the compounds, in this
case the ‘more soluble’ solution obtained was that of compound 38.
Figure 5-2: In vivo lung infection model data.

02-010 = 36; 02-063 = 38
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Our collaborators again noted that the poor results of IN exposure were likely due to
solids left undissolved in the administered vehicle. In this case, however, a modest decrease in
CFUs was noted when the ‘better dissolved’ 38 was administered IP. Although these results are
far from ideal, they at least show that these compounds have some efficacy in vivo and if
explored with a better vehicle or if more active compounds with a better pharmacokinetic profile
are discovered these could potentially lead to a drug that is efficacious in these in vivo lung
infection models.

3.

Mechanism of action studies.

One of the original goals of this work was to not only develop more potent analogs, but
also study the mode and/or mechanism of action (MoA) of these compounds. Mode of action
refers to the cellular site of action, such as cell walls or protein synthesis. Mechanism of action
refers to the actual cellular target, such as a specific protein target. As an example, penicillin’s
mode of action is inhibition of bacterial cell wall synthesis, while it is mechanism of action is
inhibition of penicillin-binding proteins (PBPs). This distinction is often not clarified in sources
and the acronym MoA is used interchangeably to discuss the cellular response to these
compounds. It should be noted that resistance to a mode of action for a specific compound is
never observed, but rather resistance to its mechanism of action. Consequently, there is an
important distinction between the two in terms of actual cellular response. In the case of this
work, no distinction is necessary since data on both mode and mechanism of action have proven
difficult to obtain for the reasons described below.
MoA studies are often carried out dosing a bacterial colony several times with the
compound of interest in a concentration slightly lower than its MIC value. In theory, the bacteria
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that survive these repeated exposures may have some desirable trait that permits them to be
resistant or at least partially resistant to the compounds employed. The repeated exposure helps
ensure that these resistant groups are allowed to reproduce and repopulate faster than the drug
susceptible groups.174-176 Once a resistant colony is grown, genomic testing can reveal definitive
differences between them and the wild-type susceptible strains, these differences can help
identify the mode of action and perhaps even the mechanism of action.177
Although this general method is useful for determining MoA, it has one critical problem
– if resistance can be easily conferred in vitro, it will inevitably be conferred in nature. This
indeed has been a major problem for antibiotics, as previously noted, the number of resistant
strains is growing at an incredible rate.
In the case of these novel stilbenoid compounds, however, many repeated in vitro
experiments have been attempted over the course of several years and resistant strains have not
been produced. This may indicate that these compounds act on a number of different
pathways and that when one builds resistance, the others are still susceptible to the
compounds. It may also indicate that the target itself cannot, or at least does not easily,
confer resistance.
While this is exciting in terms of actual pharmaceutical use, it has made determining the
mechanism of action much more difficult and in fact not possible, to date. As of yet, no MoA
has been determined for these compounds, however as mentioned earlier based on the lack of
activity against gram-negative bacteria they may prove to act on a target associated with cell
walls. One important result from this work, however, was the determination that both methoxy
analog 36 and chloro analog 38 were both bactericidal on all tested strains of S. aureus.
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Bactericidal non-cytotoxic agents are far more advantageous since they have the ability to clear
the infection rather than simply slowing it down in contrast to bacteriostatic agents.
A survey of recent literature178 suggests that “macromolecular synthesis assay” studies
can be used to help deduce plausible modes of action. Administration of an increasing in vitro
dose of a compound and measuring the bacterial production of key cellular products such as
DNA, RNA, protein, cell wall and lipid synthesis can be used along with a known control
antibiotic that acts on those pathways to help determine if the compound acts on any of those
specific sites. Methods such as these can potentially help lead to the discovery of the MoA for
this new and novel library of compounds. These studies rely on radioactive biomarkers, such as
tritiated thymidine, to determine bacterial uptake after treatment.
One potential target for these novel compounds, however, are tyrosinases. Tyrosinases
are enzymes that catalyze the formation of quinones, leading to a downstream process that ends
with the synthesis of melanin. Stilbenes and other similar structures are known tyrosinase
inhibitors179. In mammals, tyrosinases are known to be restrictive and selective to only L-form
tyrosines, however is other life forms, bacteria for example, they are much less restrictive180.
This mechanism can explain the similar activity seen with analogs 36 and SK-03-92 (see Scheme
5-1).
Scheme 5-1: Potential reaction of tyrosinase with 36 and SK-03-92.
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4.

Preliminary pharmacophore model and size/volume discussion.

It was previously noted that an increase/decrease in activity was seen when certain
characteristics such as substitution pattern or size of the molecule was altered in a number of
ways. A pharmacophore model can take these activities and correlate them with the structure of
the compound to help elucidate clear structural similarities between active compounds and
inactive compounds. This model can also estimate positions of key molecular sites, assuming
these compounds act on a specific target, which can permite a more directed SAR study. All of
the compounds from this work along with a number of compounds from the previous SAR were
used to create a preliminary pharmacophore model (Figure 5-3).
Figure 5-3: Pharmacophore model of all compounds described in this work.
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This model is based on a selection of 52 different ligands, many from this work,
including active and inactive ligands. The software used to construct this pharmacophore (MOE)
applies a binary selection process; consequently, for this study any compounds with activity
under 10 µg/mL were considered active while any compounds with activity over 10 µg/mL were
considered inactive. The consideration of all compounds with an MIC equal to or less than 32
µg/mL as active has resulted in much lower accuracy scores. Although the sample size is low
and it is still unclear whether or not these compounds act via a specific site, the pharmacophore
analysis still appears rather accurate. “Acc2” (teal) refers to an acceptor site, which satisfies the
phenolic H-bond donor seen in most active compounds. “Hyd” (green) refers to a hydrophobic
area while “Aro” (orange) refers to aromatic regions. Because the “bridge” portion and ring B/C
portion were for the most part kept static, it is not clear that these regions are necessarily
hydrophobic or aromatic regions in terms of the target.
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What is most interesting with the model is the orientation of ring A in comparison to ring
B/C. Analysis of the model indicated that these areas are preferably at a slight angle to each
other rather than planar. Earlier in Figure 2-6 the idea that orientation of rings B/C was briefly
discussed. It should be noted if a naphthene group were slightly rotated, as in the
pharmacophore model above, the fit would not be as strong as the 5-membered ring heterocycles.
This may explain the lower activity seen in the case of naphthene and other related 6-member
rings. This model is at best a coarse simplification of a potential binding site, assuming again
that it is only one specific site. However, if in the future a mode of action is determined,
pharmacophore analysis may be useful in determining the exact mechanism of action.
Additionally, this model can potentially help with future SAR studies.
Earlier the activities of 36, 44, 45, and 46 were compared based on the size of alkoxy
substituents; this is easier to view with 3D energy minimized conformers as shown in Figure 5-4.
The orientation of these ligands was calculated in a similar manner to the pharmacophore model
discussed above.
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Figure 5-4: Alkoxy size and activity comparison.

At the top-left is compound 36, one of the most active compounds discovered with an
MIC of 1 µg/mL. At the top-right is compound 44, the CF3 analog of 36 that was found to be
completely inactive. The CF3 group is of similar size to isopropyl, with some studies placing it
in between the size of ethyl and isopropyl groups.181 This is in agreement with the lack of
activity observed for this compound. The bottom-right is the ethoxy analog 45, which still
retains potent activity of 8 µg/mL. From the 3D structure one can see that the ethyl group is offset from ring A, however it is somewhat in-line with ring B/C, giving an overall smaller
molecular volume then the isopropoxy 46 (bottom-left). Based on this analysis, it seems that one
of the methyl groups in the isopropyl analog 46 may push out into an undesirable space that
greatly affects the activity, whereas the methyl group in the ethoxy analog 45 does not to such an
extent.
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It was also postulated earlier that the activity of the enone compounds was also based on
size or volume. Analysis of the energy minimization and alignment of these molecules indicated
that they are all relatively similar, thus the stark difference in activity (Table 4-3) is likely due to
electronic character or perhaps even solubility issues (Figure 5-5). Indeed, it was observed that
these compounds were very insoluble, and incomplete solvation prior to plating could lead to a
discrepancy in the results.
Figure 5-5: Overlay of enone compounds 75, 76, and 77.

The red with grey represents the OCH3 group from compound 75, green represents the
chloro group from compound 76, and blue with red represents the NO2 group from compound
77. Although the NO2 is slightly larger and out-of-plane, it was still found to retain activity
against S. aureus whereas the smaller chloro group was completely inactive. These factors may
revolve around solubility issues as well, so these compounds have also been sent to a screening
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system which should be able to perform the assay in 100% DMSO, limiting any issues related to
solubility. These results are still pending.

5.

Future SAR studies.

From the results gathered from this SAR, it is believed that further SAR development
should lead to both a more diverse selection of active compounds and even more potent analogs.
Preferably a new SAR should also focus on the solubility issues observed from this study.
Particular focus on the indole analogs may lead to active compounds with better overall PK
characteristics as well.
As discussed, this was the second SAR study executed on this antimicrobial project. In
the first SAR study, just four compounds were discovered with MIC values below 10 µg/mL. In
this work fourteen new analogs with average MIC values below 10 µg/mL have been developed.
As the SAR develops, it is clear a higher percentage of active compounds can be discovered,
hopefully with a better solubility profile.
Considerable effort was taken in this SAR to make broad new changes to discover the
scope of activity. It was found that two different new substitution patterns from this work
resulted in very active antimicrobials, while the original substitution patterns also retains activity.
These patterns, shown below (Figure 5-6), should be priorities for future SAR work.
Figure 5-6: Ring A lead fragments.
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Additionally, new ring B/C ligands were also tested with positive results. Benzofuran
substituted and indole substituted ligands both proved to provide active analogs, substituted
thianaphthenes also gave potent compounds. Substitution of the thianapthene at other positions
is of importance and awaits further study. Some of these ring B/C lead fragments are shown in
Figure 5-7.
Figure 5-7: Ring B/C lead fragments.

Based on this alone, many new compounds can be synthesized. The focus on more
soluble pyridine analogs may also be approached. Since analog 52 already exhibited some
activity, substitution on the various ring B/C fragments may prove valuable in the ring A
pyridine series (Figure 5-8).
Figure 5-8: Pyridine suggestions.

It was also earlier determined that SK-03-92 had poor metabolic stability and was rapidly
metabolized in rodents. A more thorough analysis of metabolic products through in vitro
metabolism studies may shed light on the positions which are most readily metabolized.
Techniques can be used to substitute these positions (F, for example) in the hope that a more
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metabolically stable analog still retains potent activity. These compounds may be more
advantageous in in vivo applications.

III.

CONCLUSION.

In conclusion, stilbenes with potent activity against wild-type gram-positive bacteria
were assayed against a number of resistant strains of gram-positive bacteria and were found to be
very potently active against all drug-resistant strains tested. Analysis of these results suggest that
these compounds may be a new class of antibiotics and perhaps even work by a novel
mechanism of action. Controls in the form of commercial antibiotics were also tested against the
same strains and the compounds synthesized in this work show a clear significance when
compared to each control.
Some preliminary in vivo testing of two of the most active compounds discovered in this
work was also initiated. The results from this preliminary work were mixed. The compounds
did seem to show efficacy in infection models, but solubility issues were a problem and currently
it is unknown whether the new compounds also have other poor PK properties similar to the first
lead compound SK-03-92. The results do indicate that further testing with different analogs may
prove beneficial, especially analogs with improved solubility. The metabolism of these
compounds should also be investigated to determine if other simple substitutions can both inhibit
metabolism while also retaining activity.
Pharmacophore analysis of the ligands discovered in this work was also explored. The
model itself seems accurate with respect to our SAR approach and can potentially help lead a
new SAR in developing more potent analogs. Additionally, 3D energy-minimized models can
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clearly identify activity relationships between different analogs. These issues must be constantly
weighed when deciding on which new analogs to synthesize.
Finally, this SAR has opened up a new pathway for further SAR development.
Suggestions on which compounds may prove to be potently active and/or more soluble were
discussed. A focus on the three main substitution patterns seems most prudent, along with the
active pyridine ring A substitution pattern. The coupling of these factors with a diverse set of
ring B/C ligands should both enrich the SAR and give rise to a number of new active compounds
with better clinical qualities.
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Part 2
SYNTHESIS OF DIHYDROBENZOFURANS VIA A NEW
TRANSITION METAL CATALYZED REACTION
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CHAPTER SIX
INTRODUCTION TO DIHYDROBENZOFURANS
I.

INTRODUCTION.
Dihydrobenzofurans are ubiquitous in nature and represent a vast array of natural

products, many that are also bioactive1. The dihydrobenzofuran skeleton is comprised of a
benzene ring fused to a 5-member oxygen heterocycle (Figure 6-1). In 2009 alone more than
500 dihydrobenzofuran-containing natural products were reported according to a reaxys search.2
Dihydrobenzofuran containing natural products have been reported to exhibit activity against a
number of diseases including, but not limited to, cancer3, tuberculosis4, malaria5, and cataracts.6
The compounds that act on direct targets such as HIF-17, α-glucosidase8, aldose reductase7, 5LOX9, COX-29, NF-κß10, and the muscarinic M3 receptor11 are also known. Some other
dihydrobenzofuran natural products have shown antioxidant behavior and cytoprotective
properties.12 A number of others exert insecticidal activity.13 A selection of some
dihydrobenzofuran natural products can be found in Figure 6-2.
Many synthetic dihydrobenzofurans have been found to possess biological activity, some
of which are currently used as pharmaceutical drugs. A selection of some synthetic
dihydrobenzofuran compounds are depicted below in Figure 6-3. This diverse biological activity
and ubiquity in nature make dihydrobenzofurans an interesting structural target for future
synthetic work.
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Figure 6-1: Structure of Dihydrobenzofuran.

Due to the diversity of dihydrobenzofuran natural products and a growing library of
bioactive synthetic dihydrobenzofurans, they represent an interesting avenue for studies of new
synthetic methods. Reviewed in this chapter is a summary of some of the current methods to
synthesize the dihydrobenzofuran skeleton, whereas the next chapter will detail a new and
interesting one-step route to novel dihydrobenzofurans.
Figure 6-2: Some dihydrobenzofuran natural products.
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Many of the natural products shown in Figure 2 possess bioactivity. Cedralin A is active
against two cancer cell lines (HL-60 and K562) and was isolated from Cedrela sinensis, a
broadleaf tree native to China and Korea.14 The leaves, fruit, and roots of this tree have been
used in oriental medicine since ancient times for a number of diseases.15 Benfur is a known
antimitotic agent active against a number of cancer cell lines and was isolated from a species of
shrub (Dracaena).16 The resin from these shrubs was used in traditional medicine as an
anticancer agent17, of which benfur was found to be the active component. It is particularly
interesting since it induces cell death in malignant T-cells, but does not harm primary T-cells.
Liliflol A was isolated from Magnolia liliiflora, a flowering tree native to China.18-19 It was
found to inhibit both COX-2 and 5-LOX, targets for non-steroidal anti-inflammatory drugs
(NSAIDs) and potential treatments for asthma, respectively.9 Fomannoxin was isolated from
Heterobasidion occidentale, a pathogenic fungus.20 It is a potent phytotoxin that aids in the root
rotting process associated with H. occidentale infection in trees.21 The last two
dihydrobenzofuran natural products are isolates from Senecio vulgaris and Microglossa pyrifolia
respectively, extracts of which both show bioactivity.22-23 These two recently isolated
dihydrobenzofurans have not been tested for bioactivity as of yet.
The biodiversity of dihydrobenzofurans also led to the synthesis of a diverse selection of
synthetic derivatives in which some are used as pharmaceutical drugs.
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Figure 6-3: Some synthetic dihydrobenzofurans.

The 5-APDB is a known psychoactive compound similar to MDMA (colloquially known
as ecstasy).24-26 In vitro studies show 5-APDB is a selective serotonin releasing agent (SSRA)
with an IC50 value of 130 nM.25 Although there are reports of recreational use, anecdotal reports
describe the effects of 5-APDB as much milder then related amphetamines and 5-APDB may
represent an interesting scaffold for future drug development. Efaroxan is an α2-adrenergic
receptor antagonist and imidazoline receptor antagonist that was initially thought to be useful in
the treatment of progressive supranuclear palsy.27 Later double-blind human trials showed no
significant cognitive enhancement in patients given the drug.28 It is still routinely used, however,
as an α2-blocker for in vitro/in vivo studies.29 Prucalopride is a first-in-class 5-HT4 receptor
agonist used in patients with chronic constipation.30 It is currently approved for use in Europe,
Canada, and Israel under the brand name Resolor.31 Other 5-HT4 receptor agonists have
experienced issues with selectivity at therapeutic dosages, many of which act on 5-HT1B/D or the
hERG channel and have associated cardiovascular side-effects.32 Prucalopride is effectively
selective for only 5-HT4 with >150-fold lower affinity for other receptors. The final compound
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listed as ‘anti-cancer’ has been found to be cytotoxic to a number of cancer cell lines. In vitro
studies have shown that this cytotoxic activity is even greater than the anti-cancer drug cisplatin,
routinely used for a number of chemotherapies.33
These are just a small selection of bioactive synthetic dihydrobenzofurans from the
literature. It should also be noted that natural and synthetic opiates, such as morphine, also
contain the dihydrobenzofuran skeleton (Figure 6-4). These represent some of the most
prescribed drugs on the market.34 While synthetic opiates are generally synthesized from a
natural opiate such as morphine or codeine, in which the dihydrobenzofuran skeleton has already
been formed through biological processes, the total synthesis of natural opiates often revolves
around formation of the benzofuran ring and will be discussed in this chapter as well.35
Figure 6-4: Structure of Morphine.

II.

SYNTHESIS OF DIHYDROBENZOFURANS.
Chemists have developed an array of methods for accessing the dihydrobenzofuran

skeleton. Many of which, however, require starting materials that are not commercially available
and must be synthesized through multi-step procedures. This review of the literature will focus
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on some of the main pathways to construct the dihydrobenzofuran skeleton, although the list is
not exhaustive by any means.

1.

Synthesis by Dehydration.

If a route begins with a molecule which contains both a phenol and an alcohol
functionality in the designated positions (1), intramolecular dehydration can yield
dihydrobenzofurans (Scheme 6-1). The use of a Mitsunobu type dehydration to perform this
transformation was first reported by Aristoff in 1984.36 The near complete inversion of
configuration together with high yields are major advantages of the Mitsunobu reaction.37 In the
case shown below, p-toluenesulfonic acid (p-TsOH) catalyzed the reaction giving an inseperable
68/32 mixture of diastereomeric cis and trans dihydrobenzofurans 2 and 3 respectively, whereas
the Mitsunobu protocol involving triphenylphosphine (PPh3) and diethyl azodicarboxylate
(DEAD) resulted in both a high yield (80%) and high diastereomeric control of 2 (95:5).38
Scheme 6-1: Mistunobu type dehydration/cyclization.

Disadvantages of the above reaction were the limited scope with substituted phenols and
the necessity to synthesize many of these phenols prior to the cyclization. DEAD is also
unstable and potentially explosive and the amount of by-products produced by this reaction,
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triphenylphosphine oxide and diethyl hydrazinedicarboxylate are of considerable mass and
render the reaction not suitable for scale-up because of waste disposal.
One solution to these issues was resolved with the use of a Vilsmeier reagent and this was
followed by trimethylamine (TEA) for the cyclization of hydroxyphenols to afford
dihydrobenzofurans via formation of an imidate ester, followed by displacement with
phenoxide.39 This method was particularly useful for scale-up, and has been used for the scaleup of the synthesis of 4-vinyl-2,3-dihydrobenzofuran by Bristol-Myers Squibb.40 Outlined in
Scheme 6-2 below is depicted an example of this reaction process.
Scheme 6-2: Vilsmeier cyclization method.

When the Mitsunobu cyclodehydration conditions were used with aldehyde 4 there was
no conversion to the desired dihyrobenzofuran 5. By contrast, the Vilsmeier method was
successful in the synthesis of the dihydrobenzofuran analog in 54% yield.41 Similarly to the
Mitsunobu method, the Vilsmeier method also requires highly specific starting materials that in
general are not commercially available, although it does offer an expanded scope in comparison.

2.

Synthesis by radical cyclizations.

An interesting radical reaction which involved substituted 2-bromophenols as starting
materials, which are also used in the new work to be discussed in the next chapter, is
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accomplished by first synthesis of 8, which was subsequently cyclized via a radical mechanism
to the dihydrobenzofuran 9 (Scheme 6-3).42
Scheme 6-3: Radical cyclization to dihydrobenzofurans.

The disadvantage to reactions of this nature are of course the toxicity of tin reagents and
the necessity to both synthesize bromide 8 prior to cyclization, as well as the necessity to prepare
6. Moreover, radical reactions are known to readily dimerize on some occasions. The 2bromophenols are advantageously commercially available, however, and used in the next chapter
to synthesize related dibydrobenzofurans using a very different transition metal catalyzed
prodedure.
It is important to note that the synthesis of bromide 8 required an electron-withdrawinggroup (EWG), typical of most Bayliss-Hillman reactions.43 This further limited the scope of
these reactions. In addition, it was noted by the authors that use of tributyltinhydride leads to tin
by-products that are sometimes difficult to separate from the reaction products; this is a common
problem when employing tributyltinhydride.44
Other radical type reactions involving similar pathways are also available in the
literature.45-48 Many of these reactions are low-yielding and/or have a restricted scope, similar to
the reaction detailed above.
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3.

Biomimetic synthesis.

Biomimetic synthesis aims to use the very same biosynthetic pathways that are used in
biological systems to synthesize compounds. Use of biomimetic synthesis has grown over the
years and is used extensively for the synthesis of many natural products.49-51 It is also a common
approach to form the distinct dihydrobenzofuran skeleton in a number of biologically active
compounds.52
Biological systems make extensive use of the ability of phenols and related analogs to
form reactive quinones in situ. This process can be extended to benchtop chemistry using
oxidants. Synthesis of benzofuran neo-lignans could be obtained in good yields and high
stereoselectivities by oxidation of para-methoxy substituted phenols with iodobenze bistrifluoroacetate in the presence of electron-rich styrene derivatives (Scheme 6-4).53 This
approach, which couples a quinone and a styryl moiety has been extensively adopted and has
been used in the preparation of a number of dihydrobenzofurans.54-57
Scheme 6-4: Quinone mediated synthesis.

As described earlier, a number of similar methods to synthesize dihydrobenzofurans via a
similar oxidative method exists. These methods, however, rely on formation of quinones and in
general low yields are observed when the substitution pattern of the phenol is altered in such a
way that formation of the quinone is supressed.
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4.

Synthesis by epoxide ring opening.

Asymmetric synthesis of epoxides is a well-known and versatile method of synthesizing
novel compounds pioneered by Sharpless and Jacobsen among others.58 In the case of
dihydrobenzofurans, it was found that ring opening in the presence of an intramolecular phenol
gave excellent yields and excellent ee of the corresponding dihydrobenzofurans. Detailed in
Scheme 6-5 is a reaction scheme in which Shi epoxidation led to the enantioenriched silane 14
which was subsequently deprotected with tetrabutylammonium fluoride (TBAF). The ring
opening was quickly followed by cyclization to the dihydrobenzofuran 15.59 This approach was
used in the total synthesis of the dihydrobenzofuran containing natural product (+)-marmesin
(Figure 6-5) found to be a novel inhibitor of angiogenesis.60
Scheme 6-5: Enantioselective synthesis using Shi epoxidation.
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Figure 6-5: Structure of (+)-marmesin.

In a similar manner, Sharpless asymmetric epoxidation (SAE) has also been used to
construct the dihydrobenzofuran skeleton by a ring opening cyclization method (Scheme 6-6).61
This method was successfully used in the total synthesis of the dihydrobenzofuran natural
product heliannuol G (Figure 6-6).62 These methods are advantageous for total synthesis,
however, as with other methods discussed thus far, they require very specialized starting
materials to form the 5-membered furan ring.
Scheme 6-6: Sharpless asymmetric epoxidation method.

After asymmetric induction, deprotection of the phenol followed by ring opening/closure
catalyzed by base gave the dihydrobenzofuran diol 18 in good yield with inversion of symmetry.
The natural product heliannuol G was originally identified in sunflower (Helianthus annuus)
seed extracts of which were found to be bioactive, however there is no evidence in the literature
that the dihydrobenzofuran is the bioactive component of the extract.63
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Figure 6-6: Structure of heliannuol G.

A final similar approach to the cyclization via the epoxidation ring opening is a method
which involved Sharpless asymmetric dihydroxylation (Scheme 6-7).64
Scheme 6-7: Synthesis of 23 via the Sharpless asymmetric dihydroxylation.
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This method was successful in the synthesis of 23, a core structure of a variety of natural
products including avicenol A65 and brosimacutin G.66

5.

Total synthesis of Morphine.

Morphine is an opioid alkaloid that acts directly on the central nervous system (CNS) to
reduce pain.67 In 2013 an estimated 523,000 kilograms of morphine were produced from natural
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sources, many of which were used to synthesize related analogs such as codeine and oxycodone.
These are pain medications routinely prescribed.68 Morphine, as earlier described, also contains
the dihydrobenzofuran skeleton and many total synthetic routes have been developed to construct
this functionality.
The first total synthesis of morphine was reported by Gates in 1952, with an overall yield
of 0.06% over 31 steps. The dihydrobenzofuran skeleton was introduced after the so-called
“Gates intermediate” was constructed; this is illustrated in Scheme 6-8.69 Bromination of the
“Gates Intermediate” followed by conversion to the hydrazino intermediate 24 was followed by
acid catalyzed conversion to the cyclized ether 25 in a yield of 8% over the three steps.
Scheme 6-8: Gates total synthesis of morphine, C-O bond forming step.

The “Gates Intermediate” was subsequently used in a number of total syntheses of
morphine.70 As shown, construction of the dihydrobenzofuran ring system occurred in very low
yield and this was subsequently improved by Rice from a similar starting position. The Rice
synthesis of the dihydrobenzofuran skeleton is illustrated in Scheme 6-9.71
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Scheme 6-9: Rice total synthesis of morphine, C-O bond forming step.

In this case, Rice formed the C-O ring of the ether by first brominating in the same
position as shown in hydrazone 24 followed by base catalyzed cyclization. This was followed by
debromination and N-methylation which resulted in an overall yield of 27 in 79% yield over the
three steps, a clear advantage compared to the prior synthesis by Gates.
This much higher yield of the dihydrobenzofuran system was an important factor in the
Rice synthesis which was known as the most efficient synthetic route to morphine.72 The Rice
synthesis was also a more efficient route with only 18 linear steps. Later, Rice developed the
famous NIH synthesis of morphine which was later licensed by Mallinkroft to prepare morphine
or codeine on kilogram scales, if necessary.
More recent examples of the total synthesis of morphine have focused attention on
transition metal catalyzed reactions.73 Trost reported an interesting route which involved an
intramolecular Heck coupling as a key step in formation of the dihydrobenzofuran skeleton
(Scheme 6-10).74 Trost’s synthesis included four transition metal catalyzed steps in a 13-step
linear synthesis, which illustrated the utility of transition metal catalyzed reactions as useful tools
for shortening synthetic routes. The Trost synthesis is one of the shortest total synthetic routes to
morphine, but employs toxic metals that may limit its use in pharmaceutical grade preparation.
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Scheme 6-10: Trost total synthesis of morphine, C-O bond forming step.

This traditional Heck-mediated intramolecular reaction from bromide 28 employed the
phosphine ligand 1,3-bis(diphenylphosphino)propane (dppp) to form the active palladium zero
catalyst; dihydrofuran 29 was formed in excellent yield of (91%). This led to the shortest
nonbiomimetic total synthesis of (-)-galanthamine to date.

6.

Synthesis via transition metal catalysis.

Since the reactions described in the next chapter are transition metal catalyzed, a more
thorough description of transition metal catalyzed reactions from the literature which led to
dihydrobenzofurans will be presented. This is also by no means an exhaustive list of transition
metal catalyzed reactions leading to dihydrobenzofurans, but is a description of some major
pathways.
The first reaction discussed will be the Ullman reaction, generally used to couple aryl
halides at high temperatures.75 It also represents a well-known and widely used method for the
synthesis of aryl ethers, although the intramolecular version of these reactions are less widely
used. In general, these reactions have a relatively small scope, however they do represent
possible strategies for the synthesis of dihydrobenzofurans. Described in Scheme 6-11 are an
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Ullman type reaction which employed catalytic copper chloride to provide an excellent yield of
dihydrobenzofuran 23.76
Scheme 6-11: Intramolecular Ullman cyclization.
Cl

Cl

30

Cl

OH

1. NaH
2. 5 mol% CuCl
toluene/EtOAc 115 ºC

O

31, 90%

Advances in this type of intramolecular conversion were reported more recently which
involved reactions between an aldehyde and a silane to furnish a silyl ether which could be
converted into the corresponding alkoxide (Scheme 6-12).77 This approach avoided the
formation of hydrated products, and greatly increased the overall yield of dihydrobenzofurans
compared to the earlier route (Scheme 6-11). This method also permitted construction of more
substituted dihydrobenzofurans as a variety of aldehydes could be employed. It should be noted,
however, that the overall scope of these reactions were still relatively small as the Ullman type
coupling conditions were rather harsh.
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Scheme 6-12: Advances in the Ullman reaction.
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While copper catalyzed reactions were ideal from a cost perspective, other transition
metals such as palladium gave access to a wider scope of transition metal catalyzed processes.78
Decades of research into palladium mediated reactions has led to an ever evolving number of
new reactions to synthesize interesting chemical entities.79 Two decades ago Buchwald
developed an intramolecular C-O bond formation process with an aryl bromide and an alcohol.
This reaction was carried out using catalytic amounts of palladium acetate along with a bidentate
phosphorous based ligand (generally Tol-BINAP or DPPF) and a base (generally K2CO3 or
tBuONa) in toluene between 80-100 ºC to give the corresponding heterocycles, including
dihydrobenzofurans (n = 1) in fair to very good yields (Scheme 6-13).80
This approach, however, was only efficient when tertiary alcohol substrates were used,
wherein R1 and R2 were both not hydrogen.
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Scheme 6-13: Buchwald C-O coupling.

When primary or secondary alcohols were used significant amounts of the corresponding
debrominated aldehydes (R1 = R2 = H) and ketones (R1 = H), respectively, were formed in place
of the cyclization. This occurred after coordination of palladium to the alcohol and ß-hydride
elimination took place, effectively stopping the reductive elimination to the desired cyclized
dihydobenzofuran 36. This process is illustrated in Scheme 6-14.
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Scheme 6-14: ß-Hydride elimination in primary/secondary alcohols.

This problem was overcome by the investigation of several different phosphorous based
ligands, of which it was found that bulky, electron-rich ligands could be successfully employed
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even with primary or secondary alcohols.81 The ligand of choice for this conversion was the tertbutyl binaphthyl ligand 38 depicted in Figure 6-7.
Figure 6-7: Buchwald ligand for use with primary/secondary alcohols.

Yields from 71-85% were reported using this ligand in similar reactions to those outlined
in Scheme 6-13 involving both primary and secondary alcohols, although it was noted that yields
with secondary alcohols were generally lower and required higher temperatures. Electron-rich
and bulky ligands are excellent choices for restricting ß-hydride elimination since reductive
elimination favors electron-rich ligands and bulky ligands can help prevent ß-hydride elimination
by shielding a coordination site from hydrogen.82
More recently, similar reactions which involved palladium-mediated C-H activation have
been reported. Similar to the original Buchwald method, these reactions work best with tertiary
alcohols and lower yields were observed for secondary alcohols.83 The report did not mention
the use of primary alcohols. Regardless, this is a novel method for the synthesis of
dihydrobenzofurans. This reaction process is illustrated in Scheme 6-15. Interestingly, this
method permits the use of aryl bromides, for example 39, which after C-H activation/cyclization
can permit further substitution on the aromatic ring via use of the bromide.84
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Scheme 6-15: C-H activation of homo-benzylic alcohols.

Heck-type chemistry was explored in part 1 of this work, however, it is also applicable in
the synthesis of dihydrobenzofurans. One interesting example is the reductive Heck cyclization
reaction, which permits stereoselective preparation of the framework for the natural product
furaquinocin A (Scheme 6-16).85
Scheme 6-16: Reductive Heck cyclization pathway to furaquinocin A.
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Oxidative Heck coupling generally involves the reaction of an unfunctionalized arene
directly with an olefin, which differs from the traditional Heck reaction in that a halogen is not
necessary.86 This is attractive for highly substituted arenes where halogenation may not proceed
smoothly. Recent work has expanded the scope of these reaction to include dihydrobenzofurans
and benzofurans from electron-rich arenes (Scheme 6-17).87
Scheme 6-17: Oxidative Heck reactions.

When tetrasubstituted olefins are employed (R ≠ H), synthesis of the dihydrobenzofuran
was favored, whereas when R = H, formation of the benzofuran was favored. Unfortunately,
because electrophilic Pd(II) is involved in the reaction mechanism, this method is limited to the
use of very electron-rich aromatic systems and low to 0% yields were reported with electron
deficient systems.
Detailed in Scheme 6-18 are four other Heck-type reactions that lead to
dihydrobenzofurans. The first reaction details the intramolecular coupling of an allylic ether of
o-halophenols, which advantageously leaves an unsaturated side chain that can be further
substituted if desired.88 The next reaction involves the intramolecular carbonylative Heck
cyclization of aryldiazonium salts leaving a carboxylic acid side chain that can be modified by
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various means.89 Aryl bromides, for example 42, were investigated in a number of
cyclization/coupling reactions. Heck cyclization followed by Stille coupling in the presence of
1,3-dimethyl-1,2-imidazolidinone (DMI) yielded the 3,3 disubstituted dihydrobenzofuran 43 in
good yield.90 Finally, a reaction involving Heck cyclization and concomitant cyanation with
K4Fe(CN)6 as a cyanide source was reported.91 In general, these reactions are important due to
the ability to further functionalize the products after formation of the dihydrobenzofuran
skeleton.
Scheme 6-18: Various Heck catalyzed dihydrobenzofuran reactions.
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6.

The Larock dihydrobenzofuran method.

In the early 1980’s Dieck reported that 1,3-dienes coordinated with palladium zero
complexes which permitted nucleophilic substitution to take place (Scheme 6-19).92 Larock
capitalized on this work and reported the heteroannulation of 1,3-dienes with substituted
iodophenols in the presence of catalytic amount of palladium acetate to give dihydrobenzofurans
in good yields in 1990.93 This reaction is perhaps the most similar to the work to be presented in
the next chapter, thus a more critical analysis of its mechanism and scope will be presented.
Scheme 6-19: Dieck’s 1,3-diene reaction.

Dieck also reported that reactions with an o-iodoaniline, in place of the iodobenzene and
an amine, gave the corresponding dihydroindoles (Scheme 6-20). This was the work that led
directly to the future work which resulted in the Larock indole synthesis.
Scheme 6-20: Dieck’s dihydroindole reaction.

An in-depth analysis of this reaction mechanism was not reported by Dieck, rather they
simply postulated that the close proximity of the amino group to the π-allylic moiety in the
intermediate complex was necessary for intramolecular cyclization since experiments with
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iodobenzene 46, isoprene 47, and aniline resulted in only the butadiene 48 with no amine
formation. As previously noted, Larock expanded on this cyclization involving 1,3-dienes and
synthesized a number of dihydrobenzofurans along with a few nitrogen-containing heterocycles.
Detailed in Scheme 6-21 is this reaction process and includes, as reported, a likely mechanism
for this transformation.
Scheme 6-21: Larock 1,3-diene cyclization.
XH

XH

XH

Pd(0)
61

R

62 PdI

I

R

63

XH

X

Base

PdI

64

PdI

PdI

65

R

R

Based on this work there was little doubt that the heteroannulation proceeded via the
intermediate aryl- and π-allylpalladium intermediates depicted in Scheme 6-21 (ligands on
palladium omitted for clarity). However, it was impossible to tell whether or not the
intramolecular palladium displacement was proceeding through a direct back-side displacement
(path A) or via front-side halide displacement and subsequent reductive elimination (path B).
From studies involving 1,3-cyclohexadienes it was determined, at least in the case of 1,3-
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cyclohexadiene, when 5-membered rings were formed, path B was the major pathway which
involved reductive elimination.
This study was revisited by Larock in 201094, at which point certain advancements were
made which permitted higher yields and an expanded scope. A more thorough mechanistic study
was also employed and a catalytic cycle was proposed for the formation of dihydrobenzofurans.
Outlined in Scheme 6-22 is this advancement, which principally revolved around the use of 2iodo acetates instead of the prior 2-iodophenols. A more advanced bidentate ligand (dppe) was
also employed in this reaction.
Scheme 6-22: Advancements in the Larock 1,3-diene cyclization.

It was shown that these new conditions which involved the acetate gave consistently
higher yields compared to the phenol under identical reaction conditions. The prior reaction
(Scheme 6-21) also suffered from a rather poor scope in which electron-rich aryl iodides either
gave low yields or did not react at all; with the acetates good yields with more electron-rich aryl
iodides were observed. For example, in the prior reaction 2-iodo-4-methoxyphenol afforded
mainly dehalogenated product and only negligible amounts of the desired dihydrobenzofuran 73.
However, 2-iodo-4-methoxyphenyl acetate with 72 gave a yield of 58% of the desired
dihydrobenzofuran 73 when used in the updated and optimized Larock process (Scheme 6-23).
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Scheme 6-23: Dihydrobenzofurans from electron-rich aryl iodides.

Similar results were obtained with other electron-rich aryl iodides in this report; however,
in the text only 2-iodo-4-methoxyphenol was mentioned in reference to failures with electronrich iodophenols. A proposed mechanism detailing the influence of these acetate groups was
also reported (Figure 6-8). It should be noted, however, that none of the proposed aryl-palladium
intermediates in this catalytic cycle have been isolated and confirmed.
Figure 6-8: Proposed catalytic cycle for the Larock’s synthesis of dihydrobenzofurans.94
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Initial oxidative addition of the iodoarene 61 to the palladium zero active catalyst
provides the aryl-palladium intermediate 62 after abstraction of the iodide by Ag2CO3. It was
postulated by Larock that this coordination led to higher reactivity towards alkene 63, which was
presumably responsible for the high yields observed in some trials. This cationic arylpalladium
complex 62 next adds to the 1,3-diene 63 in a syn-fashion to give the π-allylpalladium complex
64 which coordinated with the acetoxy oxygen atom leading to the formation of the cyclical aryl
palladium complex. This proposed coordination of the acetate was likely the mechanism that
slows formation of the undesired stilbene via a normal Heck coupling mechanism. This
coordination restricted rotation of the allyl C-C bonds, presumably, and was postulated to be
responsible for the stereoselectivity observed when trans-trans-2,4-hexadiene was utilized.
Deacylation of the starting iodoarene 61 was not observed under the reaction conditions, hence
why it was reported that deacylation occured between 64 and 65. A high correlation was seen
between the acidity of the phenolic precursors of the iodoarenes and annulation yields, which
further supported the deacylation at this step. Finally, complex 65 underwent reductive
elimination to give the desired dihydrobenzofuran 66 with regeneration of the palladium zero
catalyst.
It should be noted that of the 15 examples given in the report of Larock, many were under
70% yield. In general, these lower yields were associated with more electron-rich iodoarenes,
similar to issues seen prior to this method which involved the use of iodophenols instead of
iodoacetates. The byproducts of this reaction, similarly to the previous reaction, were the Hecktype stilbene products.
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III.

CONCLUSION.

In conclusion, a number of natural and synthetic dihydrobenzofurans have proven to
possess biological activity for a wide variety of disease indications; some are used as potent and
selective pharmaceutical drugs. Interest in the identification of natural dihydrobenzofurans, the
total synthesis of dihydrobenzofuran natural products, medicinal chemistry SAR applications
involving dihydrobenzofurans, and new methods for the synthesis of dihydrobenzofurans are
increasingly popular areas of study.
Detailed in this introduction are a number of both natural and synthetic
dihydrobenzofurans, many of which have biological activity. A scifinder search of the
dihydrobenzofuran skeleton revealed thousands of natural products with the dihydrobenzofuran
functionality, many of which also possess bioactivity. These compounds are novel scaffolds for
future research and methods for synthesis of these or similar analogs are of importance.
A number of methods for the synthesis of dihydrobenzofurans were also detailed. Some
of these methods were described only in reference to the synthesis of some natural products,
however, some were more general. Even in the general cases, many of these reactions had a
rather small scope due to the complex nature of the starting material employed. In many cases,
synthesis of the dihydrobenzofuran skeleton was only accomplished after a multi-step synthetic
procedure. In many of these cases the placement of substituents in the starting materials,
especially on the arene side chain of the dihydrobenzofuran, was either not explored or required
specific moieties. For example, in many cases, some presented here, methoxy groups in the 4position are necessary to help facilitate quinone formation. Although many natural
dihydrobenzofurans also contain a methoxy group in this position, and likely follow similar

220

biological processes for formation of the dihydrobenzofuran core structure, this restriction can be
resolved via transition metal catalyzed reactions.
Larock published a method very similar to the method to be described in this work;
however, there are many core differences that will be described below. Based on our findings, it
is unlikely that the mechanism involved in the work of Larock is the same as the mechanism to
be described herein, however the similarity in starting materials is interesting. Dieck and Larock
both reported that coordination of palladium to a phenolic system can influence the cyclization to
dihydrobenzofurans and other heteroannulations. This method led to a diverse selection of
dihydrobenzofurans, although issues with electron-rich arenes were noted. The work to be
presented in the next chapter aims to expand the scope of transition metal catalyzed reactions in a
similar manner to obtain dihydrobenzofurans, but by a 1-step mechanism which involves
commercially available and easily accessible starting materials.
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CHAPTER SEVEN
A NEW TRANSITION METAL CATALYZED PROCESS FOR THE
SYNTHESIS OF DIHYDROBENZOFURANS
I.

INTRODUCTION.
Detailed in Chapter 3 the Heck reaction was employed in the synthesis of a number of

stilbenoid compounds with antibiotic activity. The catalytic cycle for the Heck reaction was
studied in detail, but is shown again in Figure 7-1 for reference. For a more detailed explanation
of the steps depicted below please see Chapter 3.
Figure 7-1: General catalytic cycle of the Heck reaction.
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In summary, step a represents activation of a precatalyst to an active palladium zero
catalyst, this step can be avoided if a direct palladium zero source was used. Detailed in process
b was the oxidative addition, followed by syn-addition in step c. This was followed by ß-hydride
elimination d and reductive elimination e to give the desired compound while reactivating the
catalyst to continue in the catalytic cycle.
In general, as described in Chapter 3, both high conversion and excellent yields were
observed for many of the stilbenes synthesized. In a few particular cases, however, while yields
were still generally high, a prominent and easily purified dihydrobenzofuran byproduct was
observed. These cases involved the reaction of 2-bromo-4-methoxyphenol 67 with styrenes
under the same catalytic conditions employed for the synthesis of the stilbenes (Scheme 7-1).
Scheme 7-1: 2-bromo-4-methoxyphenol in the Heck reaction.
OH
Br

Herrmann's Palladacycle (2.5 mol%)
NaOAc, 150 ºC, DMA (10% H2O), 3h

+
80

81

S

OMe

OH

S
S

+

O

82, 86%

83, 7%

OMe
OMe

223

It should be noted that some of these compounds appear in part 1 of this work, however
they have been re-numbered for clarity in this section.
The interesting dihydrobenzofuran 83 was purified and was the only major byproduct in
this reaction. Since they were less polar than the stilbenoid derivatives, these
dihydrobenzofurans were easily purified by flash column chromatography. However, with only
a 7% yield this conversion was not high enough to be considered a new method for the synthesis
of dihydrobenzofurans.

II.

CHEMISTRY AND RESULTS.
It was originally thought that the reaction mechanism for this process was similar to that

which Larock had previously published.94 In this case, palladium would have inserted into the
heterocyclic aromatic thiophene ring system to form the aryl palladium species presented in
Chapter 6. Although this did not seem very plausible, synthesis of the methyl ester acetate 85,
used in Larock’s synthesis, was tested under the reaction conditions to ascertain whether or not it
affected the yield of the dihydrobenzofuran (Scheme 7-2).
Scheme 7-2: Synthesis of the Larock acetate 85.
OH

OAc
I

I

AcCl, pyridine, DCM
84

85, 81%

CO2Me

CO2Me

The acetate 85 was purified by crystallization from isopropanol and the 1H/13C NMR
spectra were identical to the published reports.94 When 85 was reacted under the same reaction
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conditions of Scheme 7-1, however, this resulted in only synthesis of the stilbenoid acetate
derivative 86 (Scheme 7-3) with no dihydrobenzofuran 87 observed even on examination of the
crude material by NMR spectroscopy. While this does not rule out a similar mechanism to prior
works reported by Larock, it certainly suggests a different mechanism may be operating in this
transformation.
Scheme 7-3: Palladium catalyzed reaction with acetate 85.

Following this work, a more thorough investigation of the reaction conditions was
initiated to attempt to improve the yield of the dihydrobenzofuran product while minimizing the
yield of the stilbene. The successful results from this study are detailed in Table 7-1 (see entry
13).
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Table 7-1: Optimization trials.

#

Pda

L

Base

Solventb

Temp (ºC)

82 (%)c

83 (%)c

1

H.P.d

---

NaOAc

DMA/10% H2O

150

86e

7e

2

""

---

NaOAc

DMA/10% H2O

200

84

9

3

""

---

NaOAc

DMA/10% H2O

100

0

0

4

""

---

NaOAc

DMA/10% H2O

130

45

22

5

""

---

NaOH (aq.)

DMA/10% H2O

130

42

15

6

""

---

NaOH (aq.)

DMA/10% H2O

100

0

0

7

PdCl2

---

NaOAc

DMA/10% H2O

150

10

trace

8

Pd(OAc)2

---

NaOAc

DMA/10% H2O

150

11

trace

9

PdP(Ph3)4

---

NaOAc

DMA/10% H2O

150

0

0

10

H.P.d

---

Cs2CO3

DMA/10% H2O

150

89

10

11

""

---

Cs2CO3

DMA/10% H2O

130

45

42

12

""

---

Cs2CO3

DMA

150

14

75

13
""
--Cs2CO3
DMA
130
trace
95
5 mol% Pd used, b all solvents were degassed by freeze/thaw prior to use, c conversion
determined by HPLC, d H.P. = Herrmann’s palladacycle, e isolated yield
a

Gratifyingly, optimization indicated that indeed the dihydrobenzofuran 83 could be
synthesized in excellent yields while minimizing the conversion of the undesired stilbene
byproduct. More surprisingly, however, was that the dihydrobenzofuran was synthesized more
readily at lower temperatures and without the inclusion of water, which was necessary for
optimal conversion to the stilbenes in the earlier work. It was interesting to note, however, that
conversion to the stilbene was noted in trial 12 even in the absence of water. It was presumed
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that the change in substitution pattern from earlier Heck trials in Chapter 3 permitted this
conversion to 82, although it was still rather low.
It was also interesting to note that in trials 7 and 8, palladium (II) species still gave the
desired stilbenoid product, although again in low yield. Palladium (II) species were not
investigated in the absence of a ligand in the original Heck reaction trials in Chapter 3, although
the low yield for these cases did not warrant further investigation. It was interesting to note,
however, that palladium (II) species were able to catalytically provide the stilbenes, whereas the
catalytic cycle dictates that palladium zero must be the active catalyst. This can be rationalized
by the ability of palladium (II) species to undergo conversion to palladium zero just prior to
formation of palladium black – which can essentially be described as clusters of ligandless
palladium. Just after de-ligation of ligands, but prior to clustering, these ligandless palladium
species have been previously shown to catalytically promote palladium zero reactions such as the
Heck reaction.95
Herrmann’s palladacycle (Figure 7-2) was again found to be the most suitable catalyst for
this conversion. It is apparent that this palladacycle is inherently well-suited for reactions with
these electron-rich aryl bromides.
Figure 7-2: Herrmann’s palladacycle.

227

Gratifyingly, nearly complete conversion to the desired dihydrobenzofuran was observed
by simply changing the base, removing water, and lowering the temperature slightly. It was
presumed that this effect of temperature was related to either the reductive elimination of the
stilbene or the ß-hydride elimination step, both of which would presumably lead to the stilbene
product. When that critical temperature was not reached, palladium had the ability to coordinate
with the phenol and conversion to the dihydrobenzofuran was accomplished. A more thorough
description of a proposed mechanism will be presented later in the Chapter.
In fact, it was found the influence of temperature was incredibly important for these
reactions. Four different styrenes were employed in this study (Figure 7-3) and it was found that
careful control of the temperature from 100-130 ºC was critical for high yields with minimization
of the undesired stilbene products.
Figure 7-3: Styrenes employed in this study.

Both styrenes 81 and 88 were used in the prior SAR study described in Part 1. Styrene
89 was commercially available and styrene 90 was conveniently synthesized from ethanone 91
(Scheme 7-4).
Scheme 7-4: Synthesis of 90.
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Three different aryl halides were also employed in the initial study, the previously
mentioned 2-bromo-4-methoxyphenol 80 along with 2-iodophenol 92 and the iodomethyl ester
93 (Figure 7-4). Thus twelve new and novel dihydrobenzofurans were synthesized via this
method. Further work and an interesting byproduct from the styrene 89 will also be described
below.
Figure 7-4: Aryl halides used in this study.
OH

OH
Br

OH

I
I

92

80
OMe

93
COOMe

It should be noted that 2-bromophenol was also employed in the process and works as
well as 2-iodophenol, however 2-bromophenol is a liquid which is more difficult to handle at
room temperature then the solid 2-iodophenol. In the case of the iodomethyl ester 93, it was
available in the lab from a previous project, consequently, the bromo derivative was not
employed. A subsequent study to be discussed later used three different aryl bromides similar to
80 with no issues, moreover, it seems that bromides are just as suitable as iodides for this new
reaction to dihydrobenzofurans. This is in contrast to method of Larock94 which only
employed aryl iodides, presumably out of necessity.
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Table 7-2: Scope of the reaction.a
Entry

Arene

Styrene

Temp. (ºC)

1

Yieldb

130

87%

2

80

110

75%

3

80

100

89%

4

80

130

90%

130

86%

5

6

92

110

73%

7

92

100

92%

8

92

130

94%

130

72%

9

a

Product

10

93

110

77%

11

93

100

82%

12

93

130

91%

Cs2CO3, DMA, Herrmann’s palladacycle

b

isolated yield
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The iodomethyl ester 93 was also an interesting substrate since it bears an electron
withdrawing group, in constrast to the electron donating nature of the methoxy analog 80. It
should also be noted that under the basic reaction conditions, the methyl ester remained intact in
all cases with no trace of the carboxylic acid even on examination of the crude material by NMR
spectroscopy. The acetate version of 93 was the most prominent aryl iodide employed in the
Larock publication (4 of 15 examples), therefore, it also served as a direct comparison to that
work.
Examination of the initial study illustrated the scope of this reaction (Table 7-2). Clearly
aryl bromides are applicable, as opposed to the report of Larock which seemingly required aryl
iodides94. Furthermore, excellent yields with electron-rich arenes are easily accessible with no
need to first synthesize the acetate of the phenol. Although this mechanism likely differs from
that in Larock’s work, these important distinctions were considered when developing the
reaction to assess its novelty and importance.
It was also important to note that the original hypothesis in the study by Larock that the
heterocyclic nature of the reactant was necessary for conversion with some coordination between
the aromatic 1,3 diene system seemed to be less plausible here, when the reactions between the
naphthyl styrenes 89 and 90 are considered. Although the thiophene and benzofuran systems are
aromatic in nature, they are considerably more reactive than naphthalene, and this fact was
considered early in the study here. The commercially available 2-vinylnaphthalene 89 was
reacted under a number of catalytic systems to attempt to determine the best possible conditions
and catalyst for the conversion. Subsequently it was determined that the original conditions
(Table 7-2 and 100 ºC) with Herrmann’s palladacycle gave the best yields of dihydrobenzofuran,
although even in this case low conversion to the stilbene was still observed.
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Detailed in Table 7-3 are some of the catalytic systems and conditions employed with 2vinylnaphthalene 89.
Table 7-3: Catalytic systems employed with naphthyl styrene 89.

#

Pda

L

Base

Additive

89 (%)b

106 (%)b

96 (%)b

1

H.P.c

---

Cs2CO3

---

1

5

86

2

Pd(OAc)2

p(otolyl)3

Cs2CO3

---

29

18

44

3

""

dppf

Cs2CO3

---

35

34

30

4

""

R-BINAP

Cs2CO3

---

45

15

25d

5

Pd(dba)2

---

Cs2CO3

---

75

15

10

6

PdCl2

---

Cs2CO3

---

41

11

44

7

PdCl2 (1 eq)

---

Cs2CO3

---

51

31

18

8

Wilk. cat.e

---

Cs2CO3

---

91

5

4

9

Pd(PPh3)4

---

Cs2CO3

---

72

20

8

---

Cs2CO3

LiCl

15

11

65

c

10

H.P.

11

""

---

NaH

---

50

0.5

0

12

""

---

Cs2CO3

K2S2O8

80

10

10

4-TBC
100
0
0
13
""
--Cs2CO3
b
c
5 mol% Pd used unless otherwise noted, conversion determined by HPLC, H.P. =
Herrmann’s palladacycle, d no asymmetric induction observed by chiral HPLC, e Wilk. cat. =
Wilkinson’s catalyst
a

Although analysis of all of the reactions in table 7-3 provide some insight into the
reaction mechanism and scope, none were as useful as the original conditions in Table 7-2,
which gave excellent conversion and yield of the naphthyl dihydrobenzofuran 96. It was
interesting to note that palladium zero catalysts such as Pd(dba)2 and Pd(PPh3)4 (trials 5 and 9)
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both gave low conversions to both the stilbene and the cyclized product, whereas palladium (II)
catalysts (trials 2, 3, 4, 6, and 7) with or without ligands gave better overall conversions. The use
of PdCl2 also exhibited little difference in conversion when used stoichiometrically or
catalytically, however, ratios of stilbene to dihydrobenzofuran were almost inverse to one
another. There is no current explanation for this behavior. Sodium hydride as a base was found
to decompose the starting styrene 89 and only trace conversion was noted. From examination of
the above data the future focus should center on Pd(OAc)2, PdCl2, and especially Herrmann’s
palladacycle as catalysts of choice.
Preliminary attempts to observe asymmetric induction using R-BINAP were also
unsuccessful leading to a 50:50 mixture of enantiomers (trial 4). It should be noted that in the RBINAP case, the reaction turned black after a few minutes at 100 ºC which presumably indicated
conversion to palladium black. As described earlier, palladium (II) can decompose to form
active palladium zero catalysts at elevated temperature. It is possible that the palladium BINAP
complex was not formed or decomposed under the reaction conditions and the conversion noted
was due to the formation of these palladium black active catalysts.
In parallel with this work, a novel new compound was also observed in the synthesis of
the dihydrobenzofuran 104, and is pictured below in Table 7-4. Strangely, the benzofuran 107
was observed in higher yields with lower reaction temperatures. This was not observed in other
cases and may represent an unusual characteristic of this specific reaction, however, it was still
interesting to note the formations of these different products based on temperatures changes
alone.
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Table 7-4: Reactions with methyl ester 93 and napthene 89.

a

Entry

Temp. (ºC)

107 (%)a

104 (%)a

108 (%)a

1

70

75

25

0

2

110

15

82

0

3
140
determined by HPLC

<5

<5

86

Because conversion to the benzofuran 107 at low temperatures was not expected, a
crystal structure was obtained to be certain that this was the material (Figure 7-5).
Figure 7-5: Crystal structure of 107.
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Examination of the crystal structure of benzofuran 107 indicated that the assigned
structure was correct, however as noted, similar behavior with other arenes and styrenes has not
yet been observed. This reaction was repeated with similar results and might represent a strange
case of palladium based chemistry. A plausible mechanism for ligand 107 will be discussed in a
future section.
Detailed in the introduction are a number of reactions that had restrictions on the
substitution patterns of the arene ring. Many of these reactions focus on the ability to form
quinones of phenols and required methoxy groups in the 4-position for good yields. It has been
shown that this new reaction process works well with 4-methoxy bromophenols, however,
substitution at other positions had not yet been evaluated. Based on the necessity of an orthohalophenol, there are four different suitable positions for mono-substitution of the ring system.
These are shown in Figure 7-6.
Figure 7-6: Possible substitution patterns for bromophenols.

For this initial study methoxy groups were chosen as the most suitable R-group due to
both the availability of the substituted phenols and its electronic characteristics. As previously
discussed, transition metal chemistry in general experiences problems with the oxidative addition
of electron-rich substrates, consequently the use of methoxy as a general guideline to test the
scope of this reaction was deemed appropriate.
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The 2-bromo-4-methoxyphenol 80 was already employed with a number of different
styrenes in excellent yields (Table 7-2), therefore R = methoxy 111 was already adequately
tested. This left R = methoxy 109, 110, and 112. Although these aryl bromides are
commercially available, the starting materials necessary for synthesis were already in hand for R
= methoxy 109 and 110, consequently while waiting to receive R = methoxy 112 the other
bromides were quickly and conveniently synthesized.
In general, synthesis of aryl bromides was carried out with a brominating agent. Given
the electronic character of phenols, the ortho and para positions were the most activated sites for
bromination. There are many literature reports for mono-bromination of phenols and a number
of pathways towards these compounds involve inexpensive reagents in high yields.96 The
synthesis of 2-bromo-6-methoxyphenol 114 was carried out with 2-methoxyphenol 113 by
slowly adding it to a suspension of tert-butylamine (tBuNH2) and bromine (Br2) at -78 ºC
(Scheme 7-5). The low temperature and addition of tert-butylamine slows the reaction down
considerably, halting the formation of other brominated derivatives while also promoting ortho
bromination. In contrast, the same reaction at room temperature in the absence of tertbutylamine resulted in almost full conversion to the para-directed bromide 4-bromo-2-methoxy
phenol, employed earlier in Part 1 for the synthesis of potent antimicrobials.
Scheme 7-5: Synthesis of ortho-substituted aryl bromide 114.
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The bromide was further purified by flash column chromatography with a final yield of
81%. It should be noted that column chromatography was only used as a precaution, since after
the work-up the bromide was nearly analytically pure. Palladium mediated reactions can
sometimes be poisoned by extremely small quantities of (in)organic materials97, consequently,
one had to insure the starting materials were as pure as possible prior to use; this was of utmost
importance for these trial reactions.
Synthesis of 116 was accomplished by starting with 3-methoxyphenol 115 and adding Nbromosuccinimide (NBS) (Scheme 7-6). To control the bromination, NBS was added in portions
over a period of 4 hours. The yields were similarly high, 92% for aryl bromide 116, even after
purification by flash column chromatography.
Scheme 7-6: Synthesis of aryl bromide 116.

It was determined that the best styrene to use for these trial reactions was 2vinylbenzo[b]thiophene 81, since these reactions produced the smallest amount of stilbenoid
byproduct and generally provided the best overall yields of the dihydrobenzofurans. As
illustrated in Table 7-2, high yields were afforded for all styrenes tested, therefore it was deemed
unnecessary to synthesize an exhaustive library using these new bromides. The details from
these experiments are depicted in Table 7-5.
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Table 7-5: Experiments between an ortho bromophenol and a thienyl styrene.
Entry

a

Arene

Styrene

Temp. (ºC)

Product

Yielda

1

130

87%

2

130

83%

3

130

84%

4

130

65%

isolated yield
Examination of the data in this Table illustrated that substitution on the arene ring was

well tolerated. The lowest yields were noted for arene 120, which was not surprising considering
the proximity of the electron-donating methoxy group to the site of coordination to palladium. In
this case more careful control of the temperature may lead to higher yields, however a
comprehensive optimization of this reaction was not investigated. It was clear from this process
that this reaction sequence exhibited a wide scope for arenes, even electron-rich substituted aryl
bromides, however, some difficulties were noted in the scope of the styrenes.
The natural product corsifuran 121 (Figure 7-7) was a prime target for a 1-step synthesis
via the reaction process detailed in this work. However, under these conditions, only the
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stilbenoid product was obtained. A number of different catalytic systems were attempted, but
none with much success, however, future work may uncover the right conditions for this
transformation.
Figure 7-7: Structure of corsifuran.

Earlier it was determined that careful reduction of the temperature could lead to
enrichment of the dihydrobenzofuran over the undesired stilbenoid. This was not successful in
this reaction as conversion to the stilbene was noted even at 70 ºC while no conversion was
observed prior to reaching this temperature. A number of different phosphine-based ligands
were also investigated; however, synthesis of the natural product has not been accomplished by
this method as of yet. Similar trials were also attempted with vinylbenzene with similarly
negative results. Presumably the 4-methoxystyrene is a poor substrate for this reaction sequence
and when employed high conversion to the stilbenoid byproduct was observed at all temperature
ranges tested.
It was postulated earlier that control of the temperature led to the dihydrobenzofurans and
points to an activation energy difference between the expected stilbenoid product (ß-hydride
elimination followed by reductive elimination) and the cyclized product. In the case of
unactivated styrenes, such as the styrenes employed in this study, presumably the activation
energy for formation of the cyclized product was slightly lower than the activation energy
necessary for ß-hydride elimination and thus the cyclized products are major products at lower
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temperatures. In contrast, more activated styrenes such as 4-methoxystyrene and vinylbenzene
may have lower activation energies for ß-hydride elimination, thus at any temperature the
stilbenoid products are the major products whereas the cyclized products are not observed.
Careful selection of reagents, especially phosphine-based ligands, may be able to alter
this behavior for more activated olefins. It is unclear which ligands might be most beneficial,
however, bulky ligands that may help block coordination of hydrogen might be of use. Currently
the exact mechanism by which this reaction occurs is not known, however future mechanistic
work may provide useful strategies for use of activated olefins.

III.

PROPOSED MECHANISM.

When first discovered, these reactions were thought to be correlated to the reactions
detailed earlier by Larock. Investigation into the scope of the reaction revealed this may not be
the case. In the reaction process of Larock, aryl iodides were necessary and conversion of the
phenol to an acetate facilitated better yields and a more extensive scope with electron-rich
arenes. The reaction developed here, however, was suitable for aryl bromides and electron-rich
phenols without the need to synthesize the acetates. In fact, the acetates themselves only led to
conversion to the undesired stilbene, with no conversion to the dihydrobenzofuran of interest.
Consideration of all these factors combined, it is believed that this reaction goes by a related, but
distinct mechanism.
Synthesis of the stilbene compounds likely occurred via the normal Heck reaction
mechanism discussed earlier. When the temperature was lowered, conversion to the stilbene was
retarded and conversion to the desired dihydrobenzofuran was observed. From this perspective,
this new mechanism certainly acts prior to the reductive elimination of the stilbene and also must
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occur after migratory insertion of the styrene. Between these steps it is clear that palladium must
coordinate to the phenol to help facilitate the formation of the 5-membered heterocyclic ring.
If this coordination occurred after migratory insertion, the dihydrobenzofuran can be
obtained. The palladium complex 122 exists after migratory insertion of the alkene. In a normal
Heck reaction this would be followed by ß-hydride elimination and reductive elimination to a
stilbene product. In this case, however, coordination of the phenol to palladium (123) followed
by base mediated abstraction of the phenolic hydrogen atom may lead to the palladium complex
124. Subsequent reductive elimination (r.e.) would lead to the desired dihydrobenzofuran 125.
This mechanism, however, does not account for the removal of the halide, which is generally
removed in Heck reactions by formation of H-X and neutralization with base. The Larock
mechanism presumes the removal of halide after oxidative addition of the arene (figure 6-7). If
this were the case in this reaction, it would seem a similar mechanism to that reported by Larock
would be plausible (Scheme 7-7).
Scheme 7-7: Coordination after migratory insertion.
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Accounting for hydrogen atoms is important for both this mechanistic process, and
attempts to discuss the mechanism of the benzofuran 107. In the dihydrobenzofuran case, the
reaction process starts with 4 hydrogen atoms and ends up with 3 (Scheme 7-8).
Scheme 7-8: Hydrogen accounting, dihydrobenzofuran.

The mechanism detailed in Scheme 7-7 assumes that the phenolic H1 is the lone hydrogen
atom that does not end up in the final product 100. This is logical since the phenolic hydrogen is
the most acidic hydrogen and it also presumes that ß-hydride elimination does not occur, giving
the dihydrobenzofuran. Accounting for hydrogens in the other reaction which resulted in the
synthesis of the benzofuran 107 is more difficult (Scheme 7-9).
Scheme 7-9: Hydrogen accounting, benzofuran 107.

As shown, 3 hydrogen atoms are lost under the reaction conditions and only 1 remains in
the final benzofuran product 107. It can be assumed that 1 hydrogen atom is lost via ß-hydride
elimination, and perhaps the phenolic hydrogen by base, however the loss of the third hydrogen
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atom is troubling. Another possibility is the loss of H2 by dehydrogenation, however subjecting
the cyclized dihydrobenzofuran product 104 to the identical reaction conditions does not result in
formation of the benzofuran product 107. Perhaps before reductive elimination, H2 is somehow
removed from the organo-complex and inserted into palladium, followed by reductive
elimination of the benzofuran. This would necessarily have to occur in the intermediate
palladium complex 126, since the cyclized product itself does not seem to dehydrogenate when
resubmitted to the reaction conditions.
Scheme 7-10: Benzofuran proposed mechanism.

Further work in this area must be carried out to understand this. Some support in the
literature for oxidation of phenols to dihydrobenzofurans and benzofurans has previously been
reported98, however, as discussed resubmission of the dihydrobenzofuran product 104 to the
reaction conditions did not result in formation of any benzofuran product 107 by HPLC,
therefore it would necessarily have to occur either when complexed to palladium prior to
reductive elimination or perhaps through some oxidative reaction that may occur during the
catalytic cycle.
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IV.

FUTURE WORK.

Methods that can help to prove the mechanism, both for the dihydrobenzofurans and the
more difficult benzofuran 107, might also help improve the scope of the reaction by directing
optimization of reaction conditions. One potential method for experimentally determining the
mechanism would be to subject deuterium labeled styrenes to the reaction conditions. This can
be accomplished using relatively inexpensive starting materials such as DMF-d7 and the readily
synthesized methyl-d3-triphenylphosphonium bromide. These starting materials can be used to
synthesize a wide variety of deuterated styrenes that can presumably shed light on the exact
reaction mechanism by monitoring the inclusion of deuterium in the final products. Some of the
more easily accessible deuterated sytrenes are shown below in Figure 7-8.
Figure 7-8: Deuterated styrenes.
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Furthermore, deuteration of the phenol, although very difficult because of exchange with
water in the air, might also be possible to ascertain the fate of the phenolic hydrogen atom in this
new reaction. This can perhaps be accomplished by heating the acidic phenol in deuterium oxide
and removing water in vacuo several times under vacuum. Since the solvent and base employed
are both aprotic, exchange back to hydrogen under the reaction conditions should not occur if
moisture is completely eliminated.
Elucidation of an accurate mechanism can also be pursued in parallel to attempts to
introduce asymmetry into the dihydrobenzofuran ring system. Palladium catalyzed reactions
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generally act via mechanisms that can permit asymmetric induction by careful selection of
asymmetric ligands and/or precatalysts.99 As detailed earlier, R-BINAP as a ligand was
employed without success. A large library of phosphine based asymmetric ligands exists,
however, and many asymmetric precatalysts are also routinely used. Particular focus on
asymmetric palladacycles like Herrmann’s palladacycle that have similar palladium (II) to
palladium zero chemistry presumably would be the most interesting selections.
Extending the scope of these reactions by introduction of new and interesting styrenes
may also be attempted. The current scope involves rather unactivated styrenes, and trials with
more activated styrenes were met with less success. Introduction of additives or different ligands
could help expand the scope of the styrenes to also include activated styrenes. This aim would
benefit greatly, however, from a mechanism that rests on more experimental proof.

V.

CONCLUSION.
In conclusion, a new and novel transition metal catalyzed reaction to form

dihydrobenzofurans was discovered in the process of synthesizing novel small molecule
antibiotics. This reaction was further successfully optimized to afford excellent yields of the
novel dihydrobenzofurans while minimizing the conversion to the less interesting stilbene byproducts. Synthesis of a variety of styrenes expanded the scope of the reaction process to
include both heterocyclic styrenes and carbocycles; an important distinction as initially it was
felt the reaction would only be applicable to heterocycles.
The proposed mechanism of this new reaction may be very similar to the mechanism
postulated in the prior work of Larock, however, if so it would represent a significant expansion
of the scope. The original reaction was only suitable for aryl iodides and focused solely on 1,3245

dienes, whereas the reaction detailed in this work gave excellent yields with aryl bromides and
styrenes.
Another new and interesting reaction was also discovered in the case of methyl ester 93
and the napthyl styrene 89. The benzofuran 107 was a major product under low temperature
reaction conditions whereas the dihydrobenzofuran 104 was obtained at slightly higher
temperatures. Furthermore, high temperature reactions favored the stilbene product 108 over
both the benzofuran 107 and the dihydrobenzofuran 104. A mechanism for this conversion was
proposed, however, with a word of caution as it does not seem to match any known mechanisms
of Pd chemistry, on the other hand it may be new.
Finally, substitution of the arene ring in the dihydrobenzofurans was tested by moving a
methoxy group around the ring. These electron-rich arenes all gave good yields, with only the
methoxy analog 117 giving a yield under 70%. This was likely due to the ortho positioning of
the methoxy group which may restrict oxidative addition to the palladium species, which is
seemingly unrelated to the ring forming mechanism of this reaction.
This reaction offers a new route to interesting dihydrobenzofurans and with further
optimization may lead to an expanded scope that includes a more diverse selection of styrenes as
well as asymmetric induction.

VI.

EXPERIMENTAL.

Both 1H and 13C NMR spectra were recorded on a Bruker DPX-300 or DRX-500
instrument where noted. HRMS scans were recorded with a Shimadzu LCMS-IT-TOF or similar
instruments.
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2-Vinylbenzo[b]thiophene (81, Figure 7-3)

The sodium methoxide (406.6 mg, 7.53 mmol, 1.1 eq), methyltriphenylphosphonium bromide
(2.69 g, 7.53 mmol, 1.1 eq), and THF (25mL) were stirred under argon at rt for 0.5h. The
benzo[b]thiophene-2-carbaldehyde (1.11 g, 6.84 mmol, 1 eq) was dissolved in THF (5mL) and
added dropwise to the solution. After 3h, analysis by TLC (10% EtOAc in hexanes, silica gel)
indicated no starting aldehyde remained and the reaction was quenched with aq 0.5N HCl
(10mL). The organic layer was extracted and the aq layer was subsequently extracted with
EtOAc (15mL x 2). The combined organic layers were washed with brine (10mL x 2), dried
(Na2SO4), and the solvent was removed in vacuo to give an off-white solid. The solid was
purified by flash column chromatography on silica gel (hexanes) to provide the pure 2vinylthianaphthene 81 in 98% yield as a white solid (1076 mg): 1H NMR (500 MHz, CDCl3) δ
7.87 – 7.79 (m, 1H), 7.79 – 7.72 (m, 1H), 7.43 – 7.32 (m, 2H), 7.22 (s, 1H), 6.98 (dd, J = 17.3,
10.8 Hz, 1H), 5.74 (d, J = 17.3 Hz, 1H), 5.37 (d, J = 10.8 Hz, 1H); 13C NMR (126 MHz, CDCl3)
δ 143.16, 140.08, 138.93, 130.66, 124.85, 124.48, 123.63, 123.14, 122.34, 116.00; HRMS (ESI)
(M + H), Calcd. for C10H9S 161.0425; Found 161.0431
2-Vinylbenzofuran (88, Figure 7-3)
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The sodium methoxide (406.6 mg, 7.53 mmol, 1.1 eq), methyltriphenylphosphonium bromide
(2.69 g, 7.53 mmol, 1.1 eq), and THF (25mL) were stirred under argon at rt for 0.5h. The
benzofuran-2-carbaldehyde (1.00 g, 6.84 mmol, 1 eq) was dissolved in THF (5mL) and added
dropwise to the solution. After 3h, analysis by TLC (10% EtOAc in hexanes, silica gel)
indicated no starting aldehyde remained and the reaction was quenched with aq 0.5N HCl
(10mL). The organic layer was extracted and the aq layer was subsequently extracted with
EtOAc (15mL x 2). The combined organic layers were washed with brine (10mL x 2), dried
(Na2SO4), and the solvent was removed in vacuo to give a yellow oil. The oil was purified by
flash column chromatography on silica gel (hexanes) to provide the pure 2-vinylbenzofuran 88 in
85% yield as a clear oil that slowly solidifies in a freezer to a white solid (838 mg): 1H NMR
(300 MHz, CDCl3) δ 7.56 (d, J = 7.6 Hz, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.27 (m, 2H), 6.75 – 6.62
(dd, J = 17.4 Hz, J = 11.4 Hz, 1H), 6.63 (s, 1H), 6.00 (d, J = 17.4 Hz, 1H), 5.42 (d, J = 11.2 Hz,
1H); 13C NMR (75 MHz, CDCl3) δ 154.86, 154.78, 128.83, 125.30, 124.64, 122.79, 120.98,
115.71, 111.02, 104.74; HRMS (ESI) (M + H), Calcd. for C10H9O 145.0653; Found 145.0652
2-(Prop-1-en-2-yl)naphthalene (90, Figure 7-3)

The sodium methoxide (406.6 mg, 7.53 mmol, 1.1 eq), methyltriphenylphosphonium bromide
(2.69 g, 7.53 mmol, 1.1eq), and THF (25mL) were stirred under argon at rt for 0.5hr. The 1(naphthalen-2-yl)ethan-1-one (1.16 g, 6.84 mmol, 1 eq) was dissolved in THF (5mL) and added
dropwise to the solution. After 3h analysis by TLC (10% EtOAc in hexanes, silica gel) indicated
248

no starting aldehyde remained and the reaction was quenched with aq 0.5N HCl (10mL). The
organic layer was extracted and the aq layer was subsequently extracted with EtOAc (15mL x 2).
The combined organic layers were washed with brine (10mL x 2), dried (Na2SO4), , and the
solvent was removed in vacuo to give an off-white solid. The solid was purified by flash column
chromatography on silica gel (hexanes) to provide the pure methyl naphthyl styrene 90 in 92%
yield as a white solid (1059 mg): 1H NMR (500 MHz, CDCl3) δ 7.97 – 7.83 (m, 4H), 7.79 –
7.73 (m, 1H), 7.57 – 7.49 (m, 2H), 5.62 (s, 1H), 5.28 (s, 1H), 2.35 (s, 3H); 13C NMR (126 MHz,
CDCl3) δ 143.06, 138.40, 133.45, 132.87, 128.31, 127.76, 127.58, 126.18, 125.89, 124.33,
123.96, 113.09, 21.95; HRMS (ESI) (M + H), Calcd. for C13H13 169.1017; Found 169.1012
Methyl 4-acetoxy-3-iodobenzoate (85, Scheme 7-2)

The methyl 4-hydroxy-3-iodobenzoate (84, 1.00g, 3.6 mmol, 1 eq) was stirred in DCM (10 mL)
at rt. Then pyridine (570mg, 7.2 mmol, 2 eq) was added in one portion and the solution was
stirred for 5 min. Acetyl chloride (314mg, 4 mmol, 1.1 eq) was then added dropwise by syringe
over a period of 30 min. The solution was stirred for 2 h, analyzed by TLC (30% EtOAc in
hexanes, silica gel) which indicated the starting material was consumed, and the mixture was
quenched by addition of water (10 mL). The organic layer was extracted and the aq layer was
extracted with DCM (10 mL x 2). The combined organic layers were washed with water (10

249

mL), brine (10 mL), dried over dried (Na2SO4), , and the solvent was removed in vacuo to give a
white solid. The white solid was recrystallized from IPA to give the acetate 85 as pure white
needles (935mg, 81%): mp: 153-156 ºC; 1H NMR (300 MHz, CDCl3) δ 8.26 (d, J = 1.9 Hz,
1H), 7.97 (dd, J = 8.4, 2.0 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 3.88 (s, 3H), 2.33 (s, 3H); 13C NMR
(75 MHz, CDCl3) δ 167.87, 164.99, 151.86, 134.68, 129.86, 129.30, 123.74, 116.36, 52.43,
20.71. The spectral data of 85 were identical to the reported values.94
2-Bromo-6-methoxyphenol (114, Scheme 7-5)

The tert-butylamine (3.53g, 0.048 mol, 2 eq) was dissolved in toluene (10 mL) at -30 ºC.
Bromine (3.86g, 0.024 mol, 1 eq) was slowly added to the solution at -30 ºC which resulted in a
slightly turbid solution. The solution was further cooled to -78 ºC with dry ice/acetone and the
2-methoxyphenol (113, 3.00g, 0.24 mol, 1 eq), dissolved in toluene (5 mL), was added dropwise
over 30 min. The reaction was monitored by TLC (10% EtOAc in hexanes, silica gel) and was
complete after 4 h at -78 ºC. The solution was warmed to rt, quenched with a sat. aq Na2S2O4
solution (2 mL) mixed with water (15 mL), and extracted. The aq layer was then extracted with
DCM (10 mL x 2). The combined organic layers were washed with water (15 mL), brine (15
mL), and dried (Na2SO4). The solvent was removed in vacuo to provide an off-white powder.
The solid was further purified by flash column chromatography (silica gel, 5% EtOAc in
hexanes) to furnish aryl bromide 114 in 81% yield as a white powder (4.0g). The mp (63ºC) was
in excellent agreement with the literature value.100
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2-Bromo-5-methoxyphenol (116, Scheme 7-6)

The 3-methoxyphenol (115, 3.00g, 0.24 mol, 1 eq) was dissolved in DCM (600 mL) and Nbromosuccinimide (NBS, 4.3 g, 0.024 mol, 1 eq) was added in 4 equal portions over a period of
2 h. After the final addition of NBS, the solution was stirred for 2 additional h and monitored by
TLC (20% EtOAc in hexanes). After 2 h analysis by TLC indicated the reaction was complete
and the solvent was removed in vacuo to give an off-white powder. The crude solid was purified
by flash column chromatography (silica gel, 20% EtOAc in hexanes) to furnish aryl bromide 116
in 92% yield as a white powder (4.5g): 1H NMR (300 MHz, CDCl3) δ 7.33 (d, J = 8.8 Hz, 1H),
6.62 (d, J = 2.9 Hz, 1H), 6.43 (dd, J = 8.8, 2.9 Hz, 1H), 5.64 (bs, 1H), 3.78 (s, 3H).
(E)-2-(2-(Benzo[b]thiophen-2-yl)vinyl)-4-methoxyphenol (82, Scheme 7-1)

The 2-bromo-4-methoxyphenol (126.7 mg, 0.624 mmol, 1 eq), 2-vinylbenzo[b]thiophene (100
mg, 0.624 mmol, 1 eq), sodium acetate (102.4 mg, 1.248 mmol, 2 eq), and Herrmann’s
palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq) were charged to a vial containing oxygen free
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solvent (10% water in dimethylacetamide, 3 mL) under an argon atmosphere. The vial was
sealed with a septum and the mixture was heated to 150 ºC for 3 h, cooled to rt, and EtOAc
(10mL) was added in one portion. The suspension was filtered through a plug of celite and the
filtrate was washed successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The
organic layer was dried (Na2SO4) and the solvent was removed in vacuo to provide a crude
yellow solid. The solid was purified by flash column chromatography on silica gel (20% EtOAc
in hexanes) to provide the pure hydroxyl stilbene 82 in 86% yield as a bright yellow-green solid
(151 mg): 1H NMR (300 MHz, DMSO) δ 9.48 (s, 1H), 7.90 (d, J = 8.3 Hz, 1H), 7.84 – 7.73 (m,
1H), 7.59 (d, J = 16.2 Hz, 1H), 7.44 (s, 1H), 7.34 (p, J = 7.5 Hz, 2H), 7.21 (d, J = 16.1 Hz, 1H),
7.17 (s, 1H), 6.82 (d, J = 8.8 Hz, 1H), 6.75 (dd, J = 8.8, 2.7 Hz, 1H), 3.74 (s, 3H); 13C NMR (75
MHz, DMSO) δ 152.86, 149.69, 143.83, 140.53, 138.40, 126.27, 125.26, 125.16, 123.94, 123.70,
123.59, 122.81, 122.43, 117.19, 116.11, 110.99, 55.92; HRMS (ESI) (M + H), Calcd. for
C17H15O2S 283.0793; Found 283.0790
2-(Benzo[b]thiophen-2-yl)-5-methoxy-2,3-dihydrobenzofuran (94, Table 7-2, entry 1)

The 2-bromo-4-methoxyphenol (126.7 mg, 0.624 mmol, 1 eq), 2-vinylbenzo[b]thiophene (100
mg, 0.624 mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s
palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq) were charged to a vial which contained dry and
oxygen free dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a
septum and the mixture was heated to 130 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added
in one portion. The suspension was filtered through a plug of celite and the filtrate was washed
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successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude yellow solid. The solid was
purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide the
pure methoxy dihydrobenzofuran 94 in 87% yield as a white solid (153 mg): mp: 100-102 ºC;
1

H NMR (300 MHz, CDCl3) δ 7.85 – 7.78 (m, 1H), 7.78 – 7.71 (m, 1H), 7.42 – 7.29 (m, 1H),

6.81 (d, J = 8.6 Hz, 1H), 6.74 (dd, J = 8.7, 2.5 Hz, 1H), 6.09 – 5.98 (m, 1H), 3.80 (s, 1H), 3.69
(dd, J = 15.7, 9.2 Hz, 1H), 3.41 (dd, J = 15.7, 7.3 Hz, 1H); 13C NMR (75 MHz, DMSO) δ
154.57, 152.84, 146.17, 139.39, 139.20, 127.67, 125.08, 125.00, 124.23, 123.06, 122.05, 113.57,
111.62, 109.68, 80.22, 56.05, 38.36; HRMS (ESI) (M + H), Calcd. for C17H15O2S 283.0793;
Found 283.0794
5-Methoxy-2,3-dihydro-2,2'-bibenzofuran (95, Table 7-2, entry 2)

The 2-bromo-4-methoxyphenol (126.7 mg, 0.624 mmol, 1 eq), 2-vinylbenzofuran (90 mg, 0.624
mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6
mg, 0.0156 mmol, 0.025 eq) were charged to a vial which contained dry and oxygen free
dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a septum and
the mixture was heated to 130 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added in one
portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude yellow solid. The solid was
purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide the

253

pure methoxy dihydrobenzofuran 95 in 75% yield as a white solid (125 mg): mp: 84-86 oC; 1H
NMR (500 MHz, CDCl3)  7.57 (d, J = 8.0 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.30-7.33 (m, 1H),
7.23-7.26 (m, 1H), 6.79-6.86 (m, 3H), 6.73 (dd, J = 2.5, 8.5 Hz, 1H). 5.89 (t, J = 8.5 Hz, 1H),
3.80 (s, 3H), 3.59 (d, J = 9.0 Hz, 2H); 13C NMR (75 MHz, CDCl3)  155.8, 155.2, 154.5, 153.1,
127.8, 126.9, 124.6, 122.9, 121.2, 113.1, 111.4, 111.1, 109.5, 109.5, 104.4, 77.4, 56.0, 35.0;
HRMS (ESI-TOF m/z) for C17H14O3 calcd 267.1010 found 267.1016 (M+H)+.
5-Methoxy-2-(naphthalen-2-yl)-2,3-dihydrobenzofuran (96, Table 7-2, entry 3)

2-bromo-4-methoxyphenol (126.7 mg, 0.624 mmol, 1 eq), 2-vinylnaphthalene (96 mg, 0.624
mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6
mg, 0.0156 mmol, 0.025 eq) were charged to a vial which contained dry and oxygen free
dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a septum and
the mixture was heated to 130 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added in one
portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude yellow solid. The solid was
purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide the
pure methoxy dihydrobenzofuran 96 in 89% yield as a white solid (153 mg): mp: 121-123 ºC; 1H
NMR (300 MHz, CDCl3) δ 7.92 – 7.81 (m, 4H), 7.59 – 7.45 (m, 3H), 6.84 (dt, J = 6.9, 4.9 Hz,
2H), 6.77 (dd, J = 8.5, 2.6 Hz, 1H), 5.94 (t, J = 8.8 Hz, 1H), 3.81 (s, 3H), 3.70 (dd, J = 15.8, 9.4
Hz, 1H), 3.30 (dd, J = 15.7, 8.2 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 154.39, 153.88, 139.32,
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133.23, 133.13, 128.67, 128.06, 127.73, 127.52, 126.30, 126.08, 124.68, 123.62, 113.11, 111.27,
109.29, 84.38, 56.07, 38.91; HRMS (ESI) (M + H), Calcd. for C19H17O2 277.1229; Found
277.1224
5-Methoxy-2-methyl-2-(naphthalen-2-yl)-2,3-dihydrobenzofuran (97, Table 7-2, entry 4)
O

Chemical Formula: C20H18O2
Molecular Weight: 290.36

MeO

The 2-bromo-4-methoxyphenol (126.7 mg, 0.624 mmol, 1 eq), 2-(prop-1-en-2-yl)naphthalene
(105 mg, 0.624 mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s
palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq) were charged to a vial which contained dry and
oxygen free dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a
septum and the mixture was heated to 110 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added
in one portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude off-white solid. The solid
was purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide
the pure methoxy dihydrobenzofuran 97 in 90% yield as a white solid (163 mg): mp: 125-127
ºC; 1H NMR (300 MHz, CDCl3) δ 8.01 – 7.80 (m, 4H), 7.62 – 7.43 (m, 3H), 6.88 (d, J = 8.3 Hz,
1H), 6.74 (d, J = 8.5 Hz, 2H), 3.77 (s, 3H), 3.53 (d, J = 15.6 Hz, 1H), 3.44 (d, J = 15.5 Hz, 1H),
1.87 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 154.20, 153.08, 144.00, 133.08, 132.46, 128.27,
128.19, 127.51, 127.44, 126.17, 125.86, 123.29, 122.88, 113.09, 111.40, 109.48, 89.30, 56.03,
45.07, 29.11; HRMS (ESI) (M + H), Calcd. for C20H19O2 291.1385; Found 291.1382
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2-(Benzo[b]thiophen-2-yl)-2,3-dihydrobenzofuran (98, Table 7-2, entry 5)

The 2-iodophenol (137.3 mg, 0.62 mmol, 1 eq), 2-vinylbenzo[b]thiophene (100 mg, 0.624 mmol,
1 eq), cesium carbonate (407 mg, 1.25 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg,
0.016 mmol, 0.025 eq) were charged to a vial which contained dry and oxygen free
dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a septum and
the mixture was heated to 130 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added in one
portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude yellow solid. The solid was
purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide the
pure dihydrobenofuran in 86% yield as a white solid (135.4 mg): mp: 95-96 oC; 1H NMR (500
MHz, CDCl3)  7.82 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.32-7.38 (m, 3H), 7.25 (d, J
= 7.0 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 6.91-6.96 (m, 2H), 6.07 (t, J = 8.5 Hz, 1H), 3.73 (dd, J =
9.5, 15.5 Hz, 1H), 3.47 (dd, J = 7.0, 15.5 Hz, 1H); 13C NMR (75 MHz, CDCl3)  158.9, 145.4,
139.6, 139.3, 128.4, 125.9, 124.9, 124.5, 124.4, 123.7, 122.5, 121.4, 121.0, 109.7, 80.3, 38.3;
HRMS (ESI-TOF m/z) for C16H12O3S calcd 253.0850 found 253.0859 (M+H)+.
2,3-Dihydro-2,2'-bibenzofuran (99, Table 7-2, entry 6)
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The 2-iodophenol (137.3 mg, 0.624 mmol, 1 eq), 2-vinylbenzofuran (90 mg, 0.624 mmol, 1 eq),
cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.0156
mmol, 0.025 eq) were charged to a vial which contained dry and oxygen free dimethylacetamide
(3 mL) under an argon atmosphere. The vial was sealed with a septum and the mixture was
heated to 130 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added in one portion. The
suspension was filtered through a plug of celite and the filtrate was washed successively with aq
0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and the
solvent was removed in vacuo to provide a crude yellow solid. The solid was purified by flash
column chromatography on silica gel (5% EtOAc in hexanes) to provide the pure
dihydrobenzofuran 99 in 73% yield as a white solid (107.6 mg): mp: 73-75 oC; 1H NMR (300
MHz, CDCl3)  7.58 (d, J = 7.2 Hz, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.17-7.34 (m, 4H), 6.88-6.96
(m, 2H), 6.80 (s, 1H), 5.90 (t, J = 8.4 Hz, 1H), 3.62 (d, J = 8.7 Hz, 2H); 13C NMR (75 MHz,
CDCl3)  159.0, 155.7, 155.2, 128.3, 127.8, 125.9, 124.8, 124.6, 122.9, 121.2, 120.9, 111.4,
109.7, 104.5, 77.4, 34.5; HRMS (ESI-TOF m/z) for C16H12O2 calcd 237.0900 found 237.0910
(M+H)+.
2-(Naphthalen-2-yl)-2,3-dihydrobenzofuran (100, Table 7-2, entry 7)

The 2-iodophenol (137 mg, 0.624 mmol, 1 eq), 2-vinylnaphthalene (96 mg, 0.624 mmol, 1 eq),
cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6 mg, 0.0156
mmol, 0.025 eq) were charged to a vial which contained dry and oxygen free dimethylacetamide
(3 mL) under an argon atmosphere. The vial was sealed with a septum and the mixture was
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heated to 130 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added in one portion. The
suspension was filtered through a plug of celite and the filtrate was washed successively with aq
0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried (Na2SO4) and the
solvent was removed in vacuo to provide a crude yellow solid. The solid was purified by flash
column chromatography on silica gel (5% EtOAc in hexanes) to provide the pure
dihydrobebzofuran 100 in 92% yield as a white solid (141 mg): mp: 95-97 ºC; 1H NMR (500
MHz, CDCl3) δ 7.94 – 7.83 (m, 4H), 7.53 (dd, J = 11.4, 6.3 Hz, 3H), 7.24 (dd, J = 12.5, 7.4 Hz,
2H), 6.95 (dd, J = 12.0, 7.7 Hz, 2H), 5.97 (t, J = 8.9 Hz, 1H), 3.74 (dd, J = 15.6, 9.6 Hz, 1H),
3.34 (dd, J = 15.6, 8.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 159.72, 139.27, 133.22, 133.15,
128.72, 128.30, 128.07, 127.75, 126.51, 126.34, 126.12, 124.95, 124.75, 123.63, 120.77, 109.48,
84.20, 38.47; HRMS (ESI) (M + H), Calcd. for C18H15O 247.1123; Found 247.1126
2-Methyl-2-(naphthalen-2-yl)-2,3-dihydrobenzofuran (101, Table 7-2, entry 8)

The 2-iodophenol (137.3 mg, 0.624 mmol, 1 eq), 2-(prop-1-en-2-yl)naphthalene (105 mg, 0.624
mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s palladacycle (14.6
mg, 0.0156 mmol, 0.025 eq) were charged to a vial which contained dry and oxygen free
dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a septum and
the mixture was heated to 110 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added in one
portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude off-white solid. The solid
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was purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide
the pure dihydrobenzofuran 101 in 94% yield as a white solid (152 mg): mp: 103-104 ºC; 1H
NMR (300 MHz, CDCl3) δ 7.99 (s, 1H), 7.86 (m, 3H), 7.59 (dd, J = 8.6, 1.6 Hz, 1H), 7.50 (p, J =
6.5 Hz, 2H), 7.23 – 7.13 (m, 2H), 6.99 (d, J = 7.9 Hz, 1H), 6.89 (t, J = 7.4 Hz, 1H), 3.57 (d, J =
15.5 Hz, 1H), 3.47 (d, J = 15.5 Hz, 1H), 1.90 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 158.91,
143.98, 133.12, 132.50, 128.33, 128.22, 127.55, 126.48, 126.22, 125.91, 125.11, 123.32, 122.91,
120.53, 109.68, 89.21, 44.67, 29.21; HRMS (ESI) (M + H), Calcd. for C19H17O 261.1279; Found
261.1281
Methyl 2-(benzo[b]thiophen-2-yl)-2,3-dihydrobenzofuran-5-carboxylate (102, Table 7-2,
entry 9)

The methyl 4-hydroxy-3-iodobenzoate (173.53 mg, 0.624 mmol, 1 eq), 2vinylbenzo[b]thiophene (100 mg, 0.624 mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2
eq), and Herrmann’s palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq) were charged to a vial
which contained dry and oxygen free dimethylacetamide (3 mL) under an argon atmosphere.
The vial was sealed with a septum and the mixture was heated to 130 ºC for 3 h, cooled to rt, and
EtOAc (10mL) was added in one portion. The suspension was filtered through a plug of celite
and the filtrate was washed successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL).
The organic layer was dried (Na2SO4) and the solvent was removed in vacuo to provide a crude
yellow solid. The solid was purified by flash column chromatography on silica gel (5% EtOAc
in hexanes) to provide the pure product in 72% yield as a white solid (140 mg): mp: 140-142 oC;
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1

H NMR (300 MHz, CDCl3)  7.95-7.97 (m, 2H), 7.52-7.83 (m, 2H), 7.32-7.40 (m, 3H), 6.91 (d,

J = 8.7 Hz, 1H), 6.16 (t, J = 7.8 Hz, 1H), 3.91 (s, 3H), 3.75 (dd, J = 9.3, 15.9 Hz, 1H), 3.47 (dd, J
= 7.2, 15.9 Hz, 1H); 13C NMR (75 MHz, CDCl3)  166.8, 162.8, 144.3, 139.6, 139.1, 131.4,
126.7, 126.4, 124.7, 124.5, 123.8, 123.3, 122.5, 121.8, 109.4, 81.4, 51.9, 37.5; HRMS (ESI-TOF
m/z) for C18H14O3S calcd 311.0730 found 311.0736 (M+H)+.
Methyl 2,3-dihydro-[2,2'-bibenzofuran]-5-carboxylate (103, Table 7-2, entry 10)

The methyl 4-hydroxy-3-iodobenzoate (173.53 mg, 0.624 mmol, 1 eq), 2-vinylbenzofuran (90
mg, 0.624 mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s
palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq) were charged to a vial which contained dry and
oxygen free dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a
septum and the mixture was heated to 130 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added
in one portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude yellow solid. The solid was
purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide the
pure methyl ester dihydrobenzofuran 103 in 77% yield as a white solid (142 mg): mp: 102-104
o

C; 1H NMR (300 MHz, CDCl3)  7.93-7.96 (m, 2H), 7.58 (d, J = 7.5 Hz, 1H), 7.48 (d, J = 7.8

Hz, 1H), 7.22-7.35 (m, 2H), 6.88 (d, J = 8.4 Hz, 1H), 6.81 (s, 1H), 5.98 (t, J = 8.7 Hz, 1H), 3.91
(s, 3H), 3.63 (d, J = 9.6 Hz, 2H); 13C NMR (75 MHz, CDCl3)  166.8, 162.9, 155.2, 154.7,
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131.3, 127.7, 127.6, 126.7, 126.5, 124.3, 123.3, 123.0, 121.3, 111.5, 109.3, 105.0, 78.4, 51.9,
33.7; HRMS (ESI-TOF m/z) for C18H14O4 calcd 295.0975 found 295.0965 (M+H)+.
Methyl 2-(naphthalen-2-yl)-2,3-dihydrobenzofuran-5-carboxylate (104, Table 7-2, entry 11)

The methyl 4-hydroxy-3-iodobenzoate (173.53 mg, 0.624 mmol, 1 eq), 2-vinylnaphthalene (96.3
mg, 0.624 mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s
palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq were charged to a vial which contained dry and
oxygen free dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a
septum and the mixture was heated to 110 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added
in one portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude yellow solid. The solid was
purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide the
pure product in 82% yield as a white solid (155 mg): mp: 120-122 oC; 1H NMR (300 MHz,
CDCl3)  7.84-7.96 (m, 6H), 7.44-7.48 (m, 3H), 6.92 (d, J = 8.4 Hz, 1H), 6.01 (t, J = 8.4 Hz,
1H), 3.89 (s, 3H), 3.74 (dd, J = 9.6, 15.6 Hz, 1H), 3.32 (dd, J = 7.5, 15.6 Hz, 1H); 13C NMR (75
MHz, CDCl3)  166.9, 163.7, 138.4, 133.2, 133.1, 131.3, 128.8, 128.1, 128.0, 127.7, 126.9,
126.7, 126.4, 126.2, 124.8, 124.7, 123.3, 123.0, 109.1, 85.3, 51.8, 37.6, 29.7; HRMS (ESI-TOF
m/z) for C20H16O3 calcd 305.1160 found 305.1172 (M+H)+.
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Methyl 2-methyl-2-(naphthalen-2-yl)-2,3-dihydrobenzofuran-5-carboxylate (105, Table 7-2,
entry 12)

The methyl 4-hydroxy-3-iodobenzoate (173.5 mg, 0.624 mmol, 1 eq), 2-(prop-1-en-2yl)naphthalene (105 mg, 0.624 mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and
Herrmann’s palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq) were charged to a vial which
contained dry and oxygen free dimethylacetamide (3 mL) under an argon atmosphere. The vial
was sealed with a septum and the mixture was heated to 110 ºC for 3 h, cooled to rt, and EtOAc
(10mL) was added in one portion. The suspension was filtered through a plug of celite and the
filtrate was washed successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The
organic layer was dried (Na2SO4) and the solvent was removed in vacuo to provide a crude offwhite solid. The solid was purified by flash column chromatography on silica gel (5% EtOAc in
hexanes) to provide the pure methyl ester dihydrobenzofuran 105 in 91% yield as a white solid
(181 mg): mp: 125-126 ºC; 1H NMR (300 MHz, CDCl3) δ 8.01 – 7.91 (m, 2H), 7.91 – 7.81 (m,
4H), 7.60 – 7.46 (m, 3H), 6.98 (d, J = 8.4 Hz, 1H), 3.90 (s, 3H), 3.58 (d, J = 15.6 Hz, 1H), 3.48
(d, J = 15.6 Hz, 1H), 1.90 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 166.98, 162.89, 143.15, 133.03,
132.55, 131.30, 128.49, 128.19, 127.55, 126.98, 126.94, 126.36, 126.09, 123.00, 122.83, 109.36,
90.95, 51.83, 43.93, 29.19; HRMS (ESI) (M + H), Calcd. for C21H19O3 319.1334; Found
319.1336
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Methyl 2-(naphthalen-2-yl)benzofuran-5-carboxylate (107, Table 7-4, entry 1)

The methyl 4-hydroxy-3-iodobenzoate (173.53 mg, 0.624 mmol, 1 eq), 2-vinylnaphthalene (96.3
mg, 0.624 mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s
palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq) were charged to a vial which contained dry and
oxygen free dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a
septum and the mixture was heated to 70 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added
in one portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude yellow solid. The solid was
purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide the
pure benzofuran 107 in 75% yield as a white solid (141.5 mg): mp: 188-190 oC; 1H NMR (300
MHz, CDCl3)  8.38 (s, 1H), 8.35 (s, 1H), 8.04 (dd, J = 1.5, 8.7 Hz, 1H), 7.84-7.95 (m, 4H),
7.49-7.60 (m, 3H), 7.18 (s, 1H), 3.96 (s, 3H); 13C NMR (75 MHz, CDCl3)  167.4, 157.6, 157.5,
133.6, 133.5, 129.4, 128.7, 128.6, 127.9, 127.2, 126.9, 126.3, 125.5, 124.3, 123.4, 122.8, 111.1,
102.2, 52.2; HRMS (ESI-TOF m/z) for C20H14O3 calcd 303.1006 found 303.1016 (M+H)+.
Methyl (E)-4-hydroxy-3-(2-(naphthalen-2-yl)vinyl)benzoate (108, Table 7-4, entry 3)
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The methyl 4-hydroxy-3-iodobenzoate (173.53 mg, 0.624 mmol, 1 eq), 2-vinylnaphthalene (96.3
mg, 0.624 mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s
palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq) were charged to a vial which contained dry and
oxygen free dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a
septum and the mixture was heated to 140 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added
in one portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude yellow solid. The solid was
purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide the
pure hydroxyl stilbene 108 in 86% yield as a white solid (163 mg): mp: 193-195 oC; 1H NMR
(300 MHz, DMSOD6)  10.81 (s, 1H), 8.23 (s, 1H), 8.05 (s, 1H), 7.84-7.93 (m, 4H), 7.75 (dd, J
= 1.5, 8.4 Hz, 1H), 7.45-7.54 (m, 4H), 7.00 (d, J = 8.4 Hz, 1H), 3.84 (s, 3H); 13C NMR (75 MHz,
CDCl3)  166.5, 159.7, 135.3, 133.7, 132.9, 130.4, 129.6, 128.7, 128.6, 128.3, 128.0, 126.8,
126.7, 126.4, 124.4, 124.0, 123.7, 121.1, 116.3, 51.9; HRMS (ESI-TOF m/z) for C20H16O3 calcd
305.1180 found 305.1172 (M+H)+.
2-(Benzo[b]thiophen-2-yl)-7-methoxy-2,3-dihydrobenzofuran (118, Table 7-5, entry 2)

The 2-bromo-6-methoxyphenol (126.7 mg, 0.624 mmol, 1 eq), 2-vinylbenzo[b]thiophene (100
mg, 0.624 mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s
palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq) were charged to a vial which contained dry and
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oxygen free dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a
septum and the mixture was heated to 130 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added
in one portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude yellow solid. The solid was
purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide the
pure methoxy dihydrobenzofuran 118 in 83% yield as a white solid (146 mg): mp: 106-107 ºC;
1

H NMR (300 MHz, CDCl3) δ 7.87 – 7.78 (m, 1H), 7.78 – 7.72 (m, 1H), 7.43 – 7.29 (m, 3H),

6.97 – 6.79 (m, 3H), 6.18 – 6.05 (m, 1H), 3.93 (s, 3H), 3.73 (dd, J = 15.5, 9.3 Hz, 1H), 3.48 (dd,
J = 15.5, 7.6 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 147.32, 145.08, 144.67, 139.68, 139.26,
127.18, 124.50, 124.36, 123.68, 122.47, 121.74, 121.69, 117.07, 111.81, 80.94, 56.12, 38.75;
HRMS (ESI) (M + H), Calcd. for C17H15O2S 283.0793; Found 283.0789
2-(Benzo[b]thiophen-2-yl)-6-methoxy-2,3-dihydrobenzofuran (119, Table 7-5, entry 3)

The 2-bromo-5-methoxyphenol (126.7 mg, 0.624 mmol, 1 eq), 2-vinylbenzo[b]thiophene (100
mg, 0.624 mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s
palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq) were charged to a vial which contained dry and
oxygen free dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a
septum and the mixture was heated to 130 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added
in one portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
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(Na2SO4) and the solvent was removed in vacuo to provide a crude yellow solid. The solid was
purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide the
pure methoxy dihydroxybenzofuran 119 in 84% yield as a white solid (148 mg): mp: 100-101
ºC; 1H NMR (300 MHz, CDCl3) δ 7.87 – 7.79 (m, 1H), 7.79 – 7.68 (m, 1H), 7.41 – 7.30 (m, 3H),
7.12 (d, J = 7.9 Hz, 1H), 6.56 – 6.46 (m, 2H), 6.08 (dd, J = 9.0, 7.4 Hz, 1H), 3.81 (s, 3H), 3.65
(dd, J = 15.1, 9.2 Hz, 1H), 3.37 (dd, J = 15.1, 7.1 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 160.64,
160.17, 145.38, 139.61, 139.24, 124.86, 124.52, 124.40, 123.67, 122.48, 121.38, 117.76, 106.65,
96.43, 81.25, 55.53, 37.64; HRMS (ESI) (M + H), Calcd. for C17H15O2S 283.0793; Found
283.0798
2-(Benzo[b]thiophen-2-yl)-4-methoxy-2,3-dihydrobenzofuran (120, Table 7-5, entry 4)

The 2-bromo-3-methoxyphenol (126.7 mg, 0.624 mmol, 1 eq), 2-vinylbenzo[b]thiophene (100
mg, 0.624 mmol, 1 eq), cesium carbonate (407 mg, 1.248 mmol, 2 eq), and Herrmann’s
palladacycle (14.6 mg, 0.0156 mmol, 0.025 eq) were charged to a vial which contained dry and
oxygen free dimethylacetamide (3 mL) under an argon atmosphere. The vial was sealed with a
septum and the mixture was heated to 130 ºC for 3 h, cooled to rt, and EtOAc (10mL) was added
in one portion. The suspension was filtered through a plug of celite and the filtrate was washed
successively with aq 0.5 N HCl (2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried
(Na2SO4) and the solvent was removed in vacuo to provide a crude yellow solid. The solid was
purified by flash column chromatography on silica gel (5% EtOAc in hexanes) to provide the
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pure product in 65% yield as a white solid (114 mg): mp: 110-112 ºC; 1H NMR (300 MHz,
CDCl3) δ 7.87 – 7.79 (m, 1H), 7.79 – 7.72 (m, 1H), 7.42 – 7.29 (m, 3H), 7.17 (t, J = 8.1 Hz, 1H),
6.58 (d, J = 8.0 Hz, 1H), 6.50 (d, J = 8.3 Hz, 1H), 6.15 – 6.04 (m, 1H), 3.87 (s, 3H), 3.67 (dd, J =
15.7, 9.4 Hz, 1H), 3.39 (dd, J = 15.7, 7.2 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 160.20, 156.53,
145.51, 139.66, 139.28, 129.47, 124.47, 124.37, 123.67, 122.47, 121.32, 112.91, 103.49, 102.96,
80.81, 55.43, 35.71; HRMS (ESI) (M + H), Calcd. for C17H15O2S 283.0793; Found 283.0794
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CHAPTER EIGHT
INTRODUCTION AND BACKGROUND
I.

INTRODUCTION TO GABA AND GABA RECEPTORS.
Gamma (γ)-aminobutyric acid (GABA, Figure 8-1) is the chief inhibitory

neurotransmitter in the mammalian central nervous system.1 GABA binding to specific
transmembrane receptors in the plasma membrane is associated with the opening of ion channels
that allow the flow of either negatively charged chloride ions into the cell or positively charged
potassium ions out of the cell.2 This negative change in transmembrane potential generally
causes hyperpolarization of the neuron.3 Three receptor classes for GABA are known, the
GABAA receptor4, in which the receptor is part of a ligand-gated ion channel complex and the
GABAB receptor5, G protein-coupled receptors that open or close ion channels via intermediary
G proteins. There are also GABAC receptors that are ligand gated, but devoid of the allosteric
benzodiazepine binding site of interest; GABAC receptors are also known as GABAA-rho
receptors and some consider them a subset of GABAA6. Discussed in this work are ligands that
selectively activate specific α6β3γ2 GABAA receptors via the allosteric benzodiazepine binding
site to provide important physiological effects.
Figure 8-1: Structure of Gamma (γ)-Aminobutyric acid (GABA).
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GABAergic neurons, neurons that produce GABA, exhibit chiefly inhibitory action at
receptors in adult vertebrates.7 Medium spiny neurons, depicted in Figure 8-2, are a typical
example of GABAergic cells in the central nervous system (CNS).8 GABA is synthesized in
these neurons and others via enzyme catalyzed decarboxylation of glutamic acid (Scheme 8-1)
and does not readily pass the blood-brain-barrier.9
Figure 8-2: Medium spiny cells (mouse brain).10 (Modified from the Figure in reference 10)

Scheme 8-1: Biosynthesis of GABA.
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The GABAA receptor, a transmembrane heteropentameric ion channel, has been shown to
affect a number of pharmacological responses when activated.11 These include, but are not
limited to, anxiety,12 epilepsy,13 insomnia,14 depression,15 bipolar disorder,16-17 schizophrenia,18
and Alzheimer’s disease19. The response is dependent on the specific composition of GABAA
subunits which make up the GABAA receptor.20-21 To date, there are currently 19 individual
GABAA receptor subunits which have been identified; α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-322 with
additional unidentified subunits plausible. These subunits can arrange in either a hetero- or
homo-pentameric ring. Currently, only a small handful of subunit formations have been
positively identified to form a functional receptor, with many others highly likely or plausible.2324

The most common and intensively studied arrangement of the GABAA receptor consists of α1-

6β1-3γ2

in a 2:2:1 stoichiometric ratio.25
The GABAA receptor, much like other members of the cys-loop superfamily, possesses a

characteristic loop formed by 13 highly conserved amino acids between two cysteine (Cys)
residues which form a disulfide bond near the N-terminal extracellular domain of the alpha
subunit pictured in Figure 8-3.12, 26 These monomeric units form the pentameric chloride ion
channel also pictured in Figure 8-3.
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Figure 8-3: Structure of the GABAA receptor.

The GABAA receptor has numerous binding sites located at the synaptic cleft and also
within the pore. Activation of the GABAA receptor complex can occur from the binding of a
variety of compound classes at these various sites including β-carbolines27, barbiturates28,
ethanol29, and benzodiazepines30, as well as pyrazoloquinolinones among others.31-32 Located at
the synaptic cleft of the abundant α1-6β1-3γ2 receptors, arranged αβαβγ clockwise when viewed
from the extracellular region (Figure 8-4), are the GABA binding sites at the α-β+ interfaces; the
benzodiazepine binding site (BZs) is found at the γ-α+ interface.33-35 The more recently
discovered CGS 9895 binding site is located at the β-α+ interface in which a number of
pyrazoloquinolinones have been shown to bind to and activate the GABAA receptor.36-37 In
addition, neurosteroids38, ethanol39, and other compounds may also bind in the interior of the
pore.
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Figure 8-4: Binding sites on the GABAA receptor.

Figure 8-5: Structures of diazepam and flumazenil.

Traditional benzodiazepines such as diazepam (Figure 8-5) which contain the pendent
phenyl C ring, tend to bind non-selectively to the α1-3,5β1-3γ2 GABAA receptors at the BZ site.34, 40
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This class of compounds has been frequently prescribed as a medication for various CNS
disorders such as anxiety and convulsions for over half a century.41-42 They offer many
advantages in drug therapy since they are rapidly absorbed though the gastrointestinal tract when
taken orally and generally reach maximum blood concentrations within a couple hours of
ingestion.43-44 In addition, benzodiazepines are able to readily cross the blood-brain-barrier and
be distributed throughout the brain.45 When used as an emergency anticonvulsant, certain
benzodiazepines can reach levels of detection within five minutes, but tolerance to this effect
develops very rapidly in humans.46 Other advantages of benzodiazepines include minimal liver
microsomal enzyme inhibition which can cause drug-drug interactions47, and they lack serious
toxicity concerns even at high concentrations48. Unfortunately, there are also a number of
adverse effects that can be produced by benzodiazepines such as drowsiness, sedation, ataxia,
muscle-relaxation, amnesia, dependence, withdrawal issues, as well as tolerance to the
anticonvulsant effects limiting their use for chronic treatment of convulsions.49-51 These adverse
effects are a result of benzodiazepines which are non-selective and activate multiple GABAA
receptor subtypes simultaneously.
The pharmacological response to the activation of the α1-6β1-3γ2-GABAA receptors is
dependent on the composition of the subunits that form the receptor (Table 8-1), where the α
subunit in regard to Bz modulation is the major determining factor.52 Over the past decades,
studies using GABAA receptor single-point knock-in mice have been able to identify the actions
of the different α subunits located within the brain by rendering particular benzodiazepine
receptors insensitive to modulation with benzodiazepines.23 These studies have been done by
replacing a single histidine amino acid of the α subunit with an arginine. In both α1 and α2
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subunits, the replacement is a H101R, while the replacements are H126R for α3 and H105R in α5
subunits.53
Table 8-1: Subtype selective effects of GABAA receptors.
Subtype


Associated Effect
Sedation, anterograde amnesia, some
anticonvulsant action, ataxia, tolerance,
and addiction.



Anxiolytic, perhaps hypnotic (EEG),
maybe some muscle relaxation at higher
doses, antihyperalgesic effects.



Some anxiolytic action, anticonvulsant
action at higher doses. Maybe some
muscle relaxation at higher doses.



Diazepam-insensitive (DI) site.



Cognition, temporal and spatial memory
(Maybe memory component of anxiety).



Diazepam-insensitive (DI) site.

GABAA receptors which contain the α1 subunit have been shown to mediate anterograde
amnesia, motor impairment, and sedative effects, as well as part of the anticonvulsant action.21
The anxiolytic action and some anticonvulsant activity stems from the activation of the α2
subunits54, while contribution to the anxiolytic-like effects and possible muscle relaxation at
higher receptor occupancy appear to involve agonist action at the α3 subunit.55 Memory and
spatial learning, as well as other cognitive effects, are influenced by the α5 subtype.56
Antihyperalgesic effects also stem from the α2 subunit57; however, the site of this action appears
to occur, at least with Hz-166, from activation of the GABAA receptors that are located primarily
in the spinal cord as opposed to the brain.57 A recent triple-point knock-in mutation study was
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carried out and was shown to confirm that the specific α2 subunit was the source of the
antihyperalgesic response.58
The abundance of specific α subtype of the α1-6β2/3γ2 GABAA receptors are not equally
distributed throughout the brain. Many studies have reported using [3H]-muscimol binding
studies that are followed by immunoprecipitation with specific subunit antibodies in rat brains59,
immunohistochemistry60, or by monitoring the total decrease in GABAA receptors after knockout
studies in mice61. The α1 subtype is the most prevalent throughout the brain and accounts for 4050% of the α GABAA subtypes.62 The α2 and α3 subtype assemblies account for up to, but not
more than, 35% and 14%, respectively and are found in the mesolimbic system.63 Receptors
containing the α5 subtype are the least abundant of the diazepam-sensitive GABAA receptors
accounting for about 5% of all α subtypes within the brain, the majority of which are located in
the hippocampus.64
In addition to the diazepam-sensitive GABAA receptor subtypes (α1-3,5β2/3γ2), there are
also two diazepam-insensitive sites in which the binding pocket cannot accommodate the
pendent phenyl (C) ring of various benzodiazepines. Benzodiazepines, such as flumazenil
(Figure 8-5), which lack the pendent C ring can bind to both the diazepam-sensitive and
diazepam-insensitive GABAA receptor binding sites. These two DI subtypes are the α4 and α6
subtypes and they account for a smaller percentage of functional GABAA receptors than the
diazepam-sensitive subtypes. The α4 subtype makes up 6% of all subtypes65 and the α6 subtype is
found primarily in the cerebellum and the olfactory bulb.66 Although these have been studied,
the pharmacological effects that are affected by benzodiazepines at these two subtypes are still
relatively unknown.67 GABAA receptors are also found in the peripheral nervous system. A
major effect of GABA here involves tonic inhibition,68 but potential uses of benzodiazepines
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targeting GABAA receptors in the peripheral nervous system have been noted within the lungs,
intestines, and other areas of the body.69-70
The diazepam-insensitive sites are of particular interest due to the lack of data on the role
they play in vivo. The work herein targets the α6 diazepam-insensitive site and aims to determine
the biological response of the first α6 selective compounds discovered, compounds originally
prepared at Milwaukee as potential selective GABAA receptor agents.71 These compounds are
related to the earlier discussed pyrazoloquinoline ‘CGS’ compounds discovered in the 1970’s
and 1980’s that were found to elicit similar effects to other GABAA receptor ligands. The CGS
8216 and CGS 9896 ligands (Figure 8-6) represent some of the most investigated
pyrazoloquinolines of the CGS series.72 Both were found to elicit long-lived anxiolytic effects
with less sedation when compared to traditional benzodiazepines. The radioligand binding
assays on CGS 8216 confirm potent binding at all receptor subtypes α1-6ß3γ2, with the least
potent Ki found to be at the α6 receptor subtype (Table 8-2). CGS 9896 was found to also bind
strongly to brain membranes, with an average Ki of 0.5 nM (Table 8-1).
Figure 8-6: Structures of CGS 8216 and CGS 9896.
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Table 8-2: Binding profiles of CGS compounds.

Compound
CGS 8216
CGS 9896

α1ß3γ2
0.05

α2ß3γ2
0.08

Ki (nM)
α3ß3γ2
α4ß3γ2
0.12
35
0.5 ± 0.1 (brain membranes)

α5ß3γ2
0.25

α6ß3γ2
17

Receptor binding, however, does not necessarily cause an allosteric change in the binding
site necessary for activation of the chloride ion channel. Based on in vivo data in mice, it was
determined that CGS 8216 exhibited the properties of a weak inverse agonist while CGS 9896
exhibited properties of a mixed agonist/antagonist, very different activities for compounds that
clearly bound well to most receptor subtypes. Further in vitro testing via frog oocytes revealed
that CGS 8216 activated the ion channel weakly across the spectrum of α1-5ß3γ2 subtypes while it
was somewhat selective for the α6ß3γ2 subtype (Figure 8-7). CGS 9896, on the other hand,
exhibited a lack of selectivity, which presumably leads to its classification as a mixed
agonist/antagonist in vivo (Figure 8-7).

The in vivo properties observed for both CGS 8216 and

CGS 9896 could also be mediated through other receptor subtypes that have not yet been tested.
Figure 8-7: Alpha selectivity of CGS 8216 and CGS 9896 at α1-6ß3γ2 GABAA receptors.
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The pharmacological response due to the modulation of ligands is dependent not only on
which α receptor subtype the ligand binds to, but also the effect it has on the concentration influx
of chloride ions through the receptor pore.21 Under normal physiological conditions, a neuron
may become hyperpolarized leading to an action potential and a signal is fired (Figure 8-8). As
GABA binds to the GABAA receptor and causes a conformational change in the receptor,
chloride ions are allowed to travel through the pore. These chloride ions flow into the
postsynaptic area and lower the membrane potential, which decreases the likelihood of an action
potential being reached and inhibits neuronal signaling. Benzodiazepines and other allosteric
ligands can influence the chloride ion flux in three separate ways; however, GABA must also be
present since these ligands alone cannot induce a channel opening themselves.73 A positive
allosteric modulator (PAM) alters the conformation of the GABAA receptor which results in an
increase of chloride ion flux, further inhibiting neuronal firing. PAMs are different from
orthosteric agonists such as muscimol, since agonists bind to the GABA binding site while all
allosteric modulators bind at a separate site.74 Negative allosteric modulators (NAMs) are also
termed “inverse agonists” because the influx of chloride ions is reduced, increasing the chance of
the action potential being reached and firing.75 The third class of ligands are null modulators,
more commonly referred to as antagonists, which have no discernable effect on the influx of
chloride ions. Instead, these antagonists generally have a strong binding affinity for the
benzodiazepine receptor and limit the ability for other ligands to bind and influence the
membrane potential.37
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Figure 8-8: Membrane potential over time.

II.

ALPHA 6 Bz/GABA(A) POTENTIAL BIOLOGICAL ACTIVITY.
Prior to the synthesis and discovery of α6 selective PAMs, which are to be discussed in

the next chapter, determination of the biological response attributed to α6 GABAA receptors was
generally accomplished by gene knockout experiments in mice.76 These gene-disruption
methods leave mice with the inability to construct the α6 polypeptide. Binding studies which
involved [3H]Ro15-4513 (Figure 8-9) revealed that the homozygous α6 knockout mice still have
many binding sites for benzodiazepines, however, the displacement via diazepam was markedly
different in the homozygous α6 knockout mice compared to wild-type (Figure 8-10).
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Figure 8-9: Structure and binding of Ro15-4513 to BZ/GABAA receptors.
N
N

O

O

N

N3
O

Ro15-4513

Compound
Ro15-4513

α1ß3γ2
4.8±1.2

α2ß3γ2
7.3±3.2

Ki (nM)
α3ß3γ2
α4ß3γ2
2.4±1.4
0.13±0.05

α5ß3γ2
5.1±0.9

α6ß3γ2
8.2±1.7

Examination of these binding data indicate that Ro15-4513 binds relatively strongly to all
α1-6ß3γ2 receptors, unlike diazepam which does not bind strongly to the diazepam-insensitive α4
and α6 sites.77 Saturation with diazepam can therefore help distinguish the presence of
diazepam-insensitive sites via displacement studies. Analysis of Figure 8-10 shows the
displacement of Ro15-4513 by diazepam in both wild-type (+/+), heterozygous α6 knockout
mice (+/-), and homozygous α6 knockout mice. Row “a” is total binding of [3H]Ro15-4513, row
“b” is displacement via diazepam, and row “c” is thionin staining.76 Examination of the results
show that in the homozygous knockout mice (-/-) Ro15-4513 was completely displaced by
diazepam whereas in the wild-type (+/+) mice Ro15-4513 was displaced in most regions, but not
in the cerebral granule cell layer. The cerebral granule layer is thought to contain the highest
concentration of α6 receptors. It is important to note, however, that data collected from the
homozygous α6 knockout mice suggested that the total number of GABAA receptors was not
significantly different from wild-type, which suggested that other GABAA subunits substitute for
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the missing α6 subunits via compensatory effects. This up-regulation of other subunits could
cause changes in the behavior of the mice that renders the genetic study incomplete.
Figure 8-10: [3H]Ro15-4513 binding and displacement with diazepam.

Many of these studies have focused on ethanol tolerance in mice, with mixed results.78
Some other studies have shown an increased level of ataxia and impairment from diazepam in
the α6 knockout mice.79
Identification of mutations in the α6 gene in humans has also led to possible disease
treatments for childhood absence epilepsy80, psychological stress81, alcoholism82, and obesity83.
These mutations effectively cause a down-regulation in the number of α6 receptors in the CNS,
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and the wide variety of diseases associated with these mutations suggests that the α6 site may be
an important target for future drug discovery research.84

III.

CONCLUSION.

GABAA receptors are a diverse set of receptors located in the CNS that mediate a number
of different biological processes. The pentameric transmembrane receptor consists of 5 subunits
arranged around a central pore. The pore opening and closing mediates the flow of chloride
anions into and out of the cells, causing an inhibitory response. The bulk of these receptors are
comprised of α1-6ß3γ2 subunits, and each α unit effects distinct biological effects. This work is
focused on the α6 receptor, a so-called diazepam-insensitive receptor subclass that has only been
studied by in vivo knockout experiments in mice or population studies that have identified
mutations in the α6 gene.
Novel pyrazoloquinolines ligands similar to the CGS series have been discovered that,
unlike the prior CGS series, are subtype selective for the α6ß3γ2 receptor. These ligands have
proven that the α6 subtype, much like the other GABAA subtypes, has a diverse and interesting
biological profile. The SAR and biological effects of these ligands will be presented in the next
chapter.
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CHAPTER NINE
DESIGN, SYNTHESIS, AND SCALE-UP OF NOVEL
PYRAZOLOQUINOLINONES: α6 SUBTYPE SELECTIVE POSITIVE
ALLOSTERIC MODULATORS
I.

INTRODUCTION TO PYRAZOLOQUINOLINONES
Drug discovery efforts into the CGS series of compounds led to a variety of

pyrazoloquinilones synthesized in an attempt to discover new and interesting subtype selective
ligands. Many of these compounds bound to BzR with extremely high affinity, some of which
with greater affinity then diazepam such as the previously discussed CGS 9896. After this
discovery, a wide range of pyrazoloquinolinones have been designed and synthesized to correlate
the substitution pattern and structure with the intrinsic activity of a ligand. Thienylpyrazoloquinolinone (S-135, Figure 9-1) was reported by Takada and Shindo as a potent and
orally active inverse agonist at BzR, however the related regioisomers S1 and S2 (Figure 9-1)
demonstrated weak inverse agonist and agonist activity, respectively. The agonistic activity of
S2 (R = methyl) was also less potent then CGS 9896. A more thorough structure-activity
relationship (SAR) study into introduction of alkyl substituents of increasing size onto the parent
thienyl-pyrazoloquinolinone nucleus indicated that activity varied from inverse agonist, to
antagonist/null modulator, to agonist depending on the size of the alkyl group.
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Figure 9-1: Structure of S-135 and other related thienyl-pyrazoloquinolinones.

Although many of these original pyrazoloquinolinone ligands were active in vivo as
anxiolytic/anticonvulsant agents and were well absorbed and crossed the blood-brain-barrier, the
future for this series as clinical agents was limited due to very poor water solubility. However,
the unique topology of the pyrazoloquinolinone core structure accompanied with potent in vitro
affinity made them an excellent template for further refinement of pharmacophore models for the
GABAA receptor. Depicted in Figure 9-2 is CGS 9896 (dotted line) and diazepam (thick line) in
a unified pharmacophore model based on the binding affinity of numerous other ligands.
Brackets (i.e. [A]) represent each ring system (see Figure 9-1) for clarity. Sites H1 and H2
represent hydrogen bond donor sites on the receptor protein complex while A2 represents a
hydrogen bond acceptor site necessary for potent inverse activity in vivo. L1, L2, L3 and LDi
are four lipophilic regions in the binding pharmacophore. Descriptors S1, S2, and S3 are regions
of negative steric repulsion with the protein.
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Figure 9-2: The Milwaukee-based unified pharmacophore model.

Based on this fit, the anchor points A2, H1, H2, and L1 could be employed to estimate
the distance between the various receptor descriptors. The pyrazoloquinilinones fit into this
model almost perfectly, compared to other ligands. Moreover, SAR studies aimed at modifying
the hydrogen bond donor characteristics of the NH in ring B gave compounds with 3 orders of
magnitude less binding affinity, reinforcing the idea that the A2 site is a hydrogen bond acceptor.
The H1 site, thought to be hydrogen bond donor site, was also investigated by an SAR by
replacing the carbonyl group in ring C with other non-hydrogen bond accepting functional
groups. This also resulted in a loss of binding affinity. This strong in silico based evidence
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prompted further SAR studies into novel pyrazoloquinilinones via use of the unified
pharmacophore/receptor model.68
Figure 9-3: Schematic representation of pyrazoloquinolinones in the receptor model.

H2 is 0.1 Å below the plane
of the pyrazoloquinoline
ring system

e

L1 is 0.5 Å above the plane
of the pyrazoloquinoline
ring system.

L1

H2

a
d
f
b
H1
c
A2 is on the plane of
the pyrazoloquinoline
ring system

H 1 is on the plane of the
pyrazoloquinoline ring
system

A2
a = 6.735Å; b = 9.980Å; c = 5.860Å
d = 5.734Å; e = 5.218Å; f = 7.317Å

Based on the strong fit of the pyrazoloquinilinone backbone to the A2, H1, H2, and L1
receptor descriptors, synthesis of ligands that probe the LDi and L2 regions were explored. A
number of ligands were prepared with different substituents on both ring A and ring D.
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1
2
3
4
5
6
7
8
9
10
11
12

Compound
CGS 8216
CGS 9896
PWZ-009A1
Xhe-II-087c
Xhe-III-006c
PWZ-II-029
Xhe-II-094
PWZ-007A
Xhe-III-24
Xhe-II-17
PZ-II-028
Xhe-II-019

R8
H
H
H
H
H
H
tBu
OMe
tBu
tBu
Cl
tBu

R7 R6
R4'
H
H
H
H
H
Cl
OMe H
H
H
tBu
Br
Br
H
Br
OMe H
OMe
H
H
C≡CSiMe3
H
H
H
H
H
F
H
H
C≡CH
H
H
OMe
H
H C≡C-C≡CtBu

Table 9-1: Binding affinity of some novel pyrazoloquinilinones.

1.3
7000
34
0.3
329
0.1
0.25
3.3
0.2
273

α1ß3γ2
0.05

Ki (nM)
α2ß3γ2 α3ß3γ2 α4ß3γ2 α5ß3γ2 α6ß3γ2
0.08
0.12
35
0.25
17
0.5 ± 0.1 (brain membranes)
1.3
1.3
ND
0.8
2
7000
2000
ND
4000
7000
44
29
210
23
319
ND
0.8
ND
0.5
10
1098
1156
>1000
2462
>3000
0.1
0.1
ND
0.2
>10
ND
8
ND
10
328
10
7
258
17
294
ND
0.2
ND
0.3
1.9
428
762
ND
1464
>3000

Depicted in Table 9-1 are a number of ligands which bound strongly to most receptor
subtypes, however selective binding was not observed. As previously discussed, binding affinity
data only accesses whether or not a ligand binds to a receptor, not the effect that the ligand has
on the receptor. Oocyte data, however, can distinguish between positive allosteric modulators,
negative allosteric modulators (inverse agonists), and antagonists/null modulators. The oocyte
graphs for CGS 8216 and CGS 9896 are found in Chapter 8, the graphs for the rest of the
compounds listed in Table 9-1 can be found below in Figure 9-4.
Figure 9-4: Oocyte graphs for compounds listed in Table 9-1.
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Based on examination of these oocyte graphs, a variety of compounds showed some
selectivity for α6 receptors including compounds 3, 4, 6, 7, 9, 10, and 11. However, in many
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cases these activities were either weak or only applicable at high concentrations. In the case of
Compound 6, however, this α6 selectivity was potent even down to the 100nM concentration,
clearly the most selective α6 ligand discovered so far. Importantly, 100-200nM was felt to be a
pharmacologically relevant concentration. Compound 11 was also of interest, although it was
clearly not as selective at α6 at high concentrations, the strong agonist effect on α6 receptors at or
around druggable ranges (100nM – 1 µM) also made it an interesting candidate for future work.

II.

SYNTHESIS OF PYRAZOLOQUINOLINONES
1.

Synthesis and scale-up of Compound 6 for pharmaceutical evaluation.

The pyrazoloquinilinones discussed thus far were all synthesized in the past via the same
method starting with the use of substituted amines followed later by heating with substituted aryl
hydrazines. This method is described in Scheme 9-1 below representing the synthesis of
Compound 6.
Scheme 9-1: Original synthesis of Compound 6.
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Since both Compound 6 and Compound 11 were of interest due to their α6 agonist
subtype selective activity, scale-up to multi-gram quantities for more extensive in vivo biological
screening was necessary. The original synthesis, however, suffered from low yields that made
scale-up difficult. Several strategies were employed to increase the yield to a degree at which it
was possible to synthesize multi-gram quantities of ligands 6 and 11 in a timely fashion.
The first process improvement, depicted in Scheme 9-2, centered around simply isolating
the intermediate product 18 in the first step. This was accomplished by heating amine 13 and
diester 14 at 120 ºC under vacuum to afford 18 in nearly stoichiometric amounts. After the
reaction was complete, the mixture was cooled, which led to the precipitation of the product.
This was followed by slurrying the solids in hexanes to permit filtration of the intermediate 18.
Scheme 9-2: Process improvement in the synthesis of Compound 6 – first step.

The intermediate 18 was then slurried in diphenyl ether and heated to 250 ºC with a small
amount of 4-tert-butylcatechol (4TBC) added as a potential antioxidant, which seemed to
increase the overall yields for this step (Scheme 9-3). The 4TBC also inhibits polymerization,
which may also play a role at such high temperatures.
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Scheme 9-3: Process improvements – second step.

Compound 15 was found to be incredibly insoluble in most solvents and was therefore
used as is without further purification. The original procedure involved heating in neat POCl3
which generally led to excellent yields, however on a larger scale the removal of POCl3 was less
practical and it was found that similarly excellent yields were obtained when using 2 equivalents
of POCl3 in toluene (Scheme 9-4). In this case, the chlorinated product 16, was simply isolated
by removal of toluene after the reaction was complete. Further purification could be
accomplished by column chromatography or crystallization from EtOAc/hexanes if necessary;
however, in general the product was pure enough at this stage to continue to the next step.
Scheme 9-4: Process improvements – third step.

In the original synthesis free-base phenyl hydrazines were used to form the 5-member
heterocyclic ring (Scheme 9-1). While this worked well for many new analogs on small-scale,
on scale-up low yields were observed and suspected to be due to decomposition of the phenyl
hydrazine prior to conversion to the product. Many phenylhydrazines, including 17, are more
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readily purchased as the hydrochloride salts which are far more stable at room temperature. It
was found that using the hydrochloride salt and generating the free-base in situ by the addition of
excess triethylamine (TEA) gave high yields of the final target ligand Compound 6 (Scheme 95). Problems associated with this step, however, included the production of 2 equivalents of
triethylamine hydrochloride which could be difficult to fully remove from the final product.
Scheme 9-5: Process improvements – final step.

Removal of triethylamine hydrochloride was generally accomplished via an aqueous
crystallization method. The Compound 6 was slurried and heated in ethanol (1g Compound 6
/10mL EtOH) and water was slowly titrated into the slurry at reflux until a clear solution was
obtained (generally 10-15% water by volume). The solution was then cooled to room
temperature and microcrystals began to form. At room temperature the volume was doubled by
addition of water, the slurry cooled to 0 ºC, and filtered. In most cases this removed all traces of
triethylamine hydrochloride. In the case of Compound 11, purification by dissolution in DMSO
and precipitation with water, however, was sometimes necessary to remove trace amounts of
triethylamine hydrochloride.
These improvements permitted the efficient scale-up of both Compound 6 and
Compound 11, necessary for synthesis of sufficient quantities for in vivo experiments to help
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elucidate the role α6 subtypes play in the central nervous system. In total, about 25 grams of
both Compound 6 and Compound 11 were prepared via these methods.

2.

Design and synthesis of new analogs.

This new process permitted a more efficient synthesis of a number of new ligands. These
new ligands were designed to enhance potency, enhance metabolic stability, and/or increase
water solubility by the addition of new functional groups to the ring A and/or ring D portions.
Earlier SAR work had shown the core ring B/C functionalities were necessary for potent binding
to the BZ receptor and thus were kept constant for this new SAR. As previously discussed,
based on the pharmacophore receptor model it seems as though functionalities in ring A and ring
D protrude into a lipophilic pocket that is, in general, more accepting of a variety of
functionalities. The ligands synthesized in this work are detailed in Table 9-2.
Table 9-2: New analogs synthesized for α6 subtype selective activity.

Compound
Compound 6
Compound 11
19 DK-I-56-1
20 RV-I-029
21 DK-I-60-3
22 DK-I-94-1
23 DK-I-88-1
24 DK-I-90-1

R8
H
Cl
H
H
H
H
H
H

R7
OCH3
H
OCH3
OCD3
OCD3
OCD3
OCH3
OCD3

R6
H
H
H
H
H
H
H
H

X9 X8 X7 X6
C C C C
C C C C
C C C C
C C C C
C C C C
C C C C
C C C C
C C C C
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R4’
R3’
R2’
X3’
OCH3
H
H
C
OCH3
H
H
C
OCD3
H
H
C
OCH3
H
H
C
OCD3
H
H
C
H
OCD3
H
C
H
H
OCD3 C
H
H
OCD3 C

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61

CW-03-030
DK-II-13-1
DK-I-86-1
DK-II-60-1
RV-I-37
MM-I-03
DK-I-93-1
LAU 159
DK-I-59-1
LAU 165
DK-I-87-1
DK-II-18-1
DK-II-59-1
LAU 463
DK-I-58-1
DK-I-92-1
DK-I-89-1
DK-II-48-1
DK-II-58-1
LAU 176
DK-I-95-3
DK-I-97-1
DK-98-1
RV-I-071
MM-I-06
MM-I-08
MM-I-09
MM-I-10
MM-I-11
MM-I-12
MM-I-13
MM-I-18
CW-02-073
CW-02-078
CW-02-079
CW-02-082
CW-03-033

H
H
H
H
H
Br
Cl
Cl
Cl
Cl
Cl
Cl
Cl
H
H
H
H
H
H
OCH3
OCD3
OCD3
OCD3
H
H
H
H
H
H
H
Br
Br
H
H
H
H
H

OCH3 H
OCH3 H
OCD3 H
OCH3 H
OCD3 H
H
F
H
H
H
H
H
H
H
H
H
H
H
H
H
H
Br
H
Br
H
Br
H
Br
H
Br
H
Br
H
H
H
H
H
H
H
H
H
H
H
CF3
H
CF3
H
CF3
H
CF3
H
CF3
H
CF3
H
H
F
H
F
OCH3 CH3
OCH3 CH3
OCH3 CH3
OCH3 H
Cl
H

C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
N
C
C
C
C
C
C
C
C
C
C
C
C
C
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N
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
N

C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C

C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C

OCH3
OCH3
OCH3
OCD3
H
OCH3
OCD3
H
H
H
H
OCH3
OCD3
OCH3
OCD3
H
H
OCH3
OCD3
OCH3
OCD3
H
H
OCH3
OCH3
Cl
NO2
OCF3
F
H
Cl
F
OCH3
H
OCF3
OCF3
OCH3

H
H
H
H
H
H
H
OCH3
OCD3
H
H
H
H
H
H
OCD3
H
H
H
H
H
OCD3
H
H
H
H
H
H
H
OCH3
H
H
H
H
H
H
H

H
H
H
H
H
H
H
H
H
OCH3
OCD3
H
H
H
H
H
OCD3
H
H
H
H
H
OCD3
H
H
H
H
H
H
H
H
H
H
H
H
H
H

C
N
N
N
C
C
C
C
C
C
C
N
N
C
C
C
C
N
N
C
C
C
C
H
C
C
C
C
C
C
C
C
C
C
C
C
C

Early efforts to enhance metabolic stability by introduction of a deuterated methoxy
group were gratifyingly successful, a more in-depth analysis of this increased stability will
be presented in Chapter 10. Ligands 19-24, 27-29, 31, 33, 35, 37, 39-41, 43, and 45-47 all
contain a deuterated methoxy group in either ring A, ring D, or both rings. Examination of early
in vitro experiments indicated that the deuterated methoxy analogs had the same/very similar
agonistic activity as the parent methoxy analogs (OCH3), as expected, thus many future analogs
included deuterated methoxy groups to enhance metabolic stability.
Introduction of pyridine rings in either ring A or ring D was also explored in the hope of
enhancing water solubility by synthesis of the hydrochloride salts, generally known to be more
water soluble. The pyridine analogs were indeed much more soluble in water then the related
parent ligand, however, as of this report synthesis of the hydrochloride salts has proven difficult.
Early in vitro testing, to also be presented in Chapter 10, showed that ring A pyridines, at least in
the case of compound 25, do not retain potent α6 activity/selectivity. Analogs substituted with
ring D pyridine groups have been shown to retain activity and selectivity to α6, which provides
potentially new more soluble compounds for in vivo experimentation. In general, the pyridine
analogs were found to ~20 times more soluble then the related analogs. This is thought to be
exclusively due to the polarity of the pyridine compounds, generally with in silico clogP values
much lower than their parent counterparts. For example, the clogP of Compound 6 is 2.06
while the pyridine analog 26 has a clogP of 1.43, a significant difference on a logarithmic scale.
In general, CNS drugs tend to have high clogP values (~3). This high lipophilicity
permits these drugs to more easily cross the blood-brain-barrier, thus lowering the clogP in the
case of pyridine analogs may influence in vivo activity negatively, however the rather rigid
nature of these small organic molecules may allow them to still easily cross the blood-brain311

barrier in lieu of lower lipophilicity, at which point the increased water solubility may prove
useful.
A variety of other analogs were also prepared that probe different sites on ring A and ring
D by substitution with typical medicinal chemistry techniques. These included altering the
electronic nature of the functionalities and/or altering the size of different functionalities.
It should be noted that this study is still in its infancy and many of the compounds
reported have not yet been tested yet in the in vitro oocyte assay to determine activity and
selectivity at α6 subtypes. All biological data compiled thus far will be presented in Chapter 10
for the compounds discussed above.

III.

CONCLUSION

In conclusion, ligands were discovered for the first time that are selectively active at α6
subtype selective GABA(A) receptors. These receptors, up to this point, exhibited a relatively
unknown function in the CNS that was only explored by experiments which involved mutations.
The lead compounds, Compound 6 and Compound 11 were scaled up in sufficient quantities
for extensive in vivo work and the important process improvements permitted for more efficient
preparation of the lead compounds as well as new analogs.
New analogs were designed with the goal of enhancing potency, metabolic stability, and
water solubility. The original CGS compounds (prepared by Ciba Geigy) discussed in Chapter 8
also had very poor water solubility, this was part of the reason they were never marketed as
replacements for benzodiazepines. Work on the in vitro activity of many of these compounds is
still on-going, however, a number of additional analogs with interesting in vitro properties have
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been discovered since the initial discovery of Compound 6 and Compound 11 in Milwaukee.
These new compounds will be discussed in the next chapter.
IV.

EXPERIMENTAL
Both 1H and 13C NMR spectra were recorded on a Bruker DPX-300 or DRX-500

instrument where noted. HRMS scans were recorded with a Shimadzu LCMS-IT-TOF mass
spectrometer or similar instruments. Silica gel, unless otherwise noted, was employed for flash
chromatography and TLC. Anhydrous solvents were employed unless otherwise noted.
Synthesis of Compounds by General Procedure A: A substituted aniline (1 mmol) was mixed
thoroughly with DEEMM (1 mmol) and heated under argon to 120 ºC, at which point ethanol
was distilled and removed from the reaction vessel. After heating the mixture for 2-3h and
examination by TLC (30% EtOAc in hexanes) indicated complete consumption of the starting
aniline, diphenyl ether was added and the reaction vessel was heated to 250 ºC for 2-3h. After
complete cyclization to the desired quinoline the reaction vessel wass cooled to rt, hexanes were
added, and the solid material which formed was filtered. No further purification was performed
on this material. To the quinoline (1 mmol) was added POCl3 (10 eq) and the mixture was stirred
at an appropriate temperature to give the chlorinated quinoline. The chlorinated quinoline was
further purified by flash column chromatography (20% EtOAc in hexanes, silica gel) generally to
furnish a white/off-white solid. The chlorinated quinoline (1 mmol) was mixed with xylene,
triethylamine (2.5 mmol), and an appropriate hydrazine hydrochloride salt (1.5 mmol) and
heated to reflux for 3-24h. When the reaction was complete by TLC (10% MeOH in EtOAc) the
mixture was cooled to 0 ºC, filtered, and the solid was washed with copious amounts of water.
The solid was then washed with hexanes and allowed to dry. The solid was then recrystallized,

313

generally from a 5:1 mixture of EtOH:water, to furnish fluffy yellow/orange/red microcrystals of
suitable purity for biological testing. Further purification can be accomplished by dissolving the
solid in DMSO and slowly adding water and/or dissolving it in a basic solution (pH > 10) and
slowly acidifying to pH < 6 to precipitate out the product.
Ethyl-4-hydroxy-7-methoxy (d3) quinolone-3-carboxylate. A mixture of 3-(methoxyd3)aniline (1.26 g, 0.01 mol) and diethyl ethoxy methylenemalonate (DEMM, 4.32 g, 0.02 mol)
in 50 mL of diphenyl ether were heated to 120°C for 1h. The ethanol which formed was distilled
off. The solution was then heated to 245-250°C. The heating was continued for 4h. The contents
were cooled to room temperature and hexane (50 mL) was added and the solids were collected
by filtration. The compound was washed with ethyl acetate:hexane [(2:1), 50 mL] and dried. The
yield was 2.37 g, 95%. Compound is off white and has very poor solubility. The compound was
used as such for the next reaction: 1H NMR (300 MHz, DMSO) 12.123 (s, 1H), 8.489(s, 1H),
8.072-8.040(d, 1H, J= 9.6), 7.018-6.996(s, 2H), 4.239-4.170(q, 2H, J= 6.9), 1.301-1.254(t, 3H,
J= 6.9), 3.876(s, 3H); 13C (75 MHz, DMSO) 165.29, 162.74, 145.27, 141.24, 127.99, 121.78,
114.63, 100.58, 59.95 and 14.80; HRMS m/z calculated for C13H11D3NO4 251.1111 found
251.1110.
4-Chloro-7-methoxy (d3) quinolin-3-carboxylate. The starting Ethyl-4-hydroxy-7-methoxy
(d3) quinolone-3-carboxylate (2.5 grams, 0.01 mol) was heated in neat POCl3 at 80°C for 2h.
The excess POCl3 was distilled off under reduced pressure. The residue was dissolved in dry
dichloromethane (25mL) and the solvent was distilled off under reduced pressure. The cycle was
repeated 3 times to remove all the HCl and POCl3. Due to unstable nature of this compound it
was used without further purification (2.55 g, 95%): 1H NMR (500 MHz, CDCl3) 9.19 (s, 1H),
8.32-8.30(d, 1H, J= 10.0), 7.48 (s, 1H), 7.36-7.34(t, 1H), 4.52-4.48(q, 2H, J= 10), 1.301-1.49314

1.46(t, 3H, J= 10); 13C (75 MHz, CDCl3)164.46, 162.87, 151.28, 150.63, 143.94, 126.86,
121.73, 121.36, 120.69, 107.27, 61.95, 55.14, 14.29; HRMS m/z calculated for C13H10D3ClNO3
269.0772 found 269.0770.
A general procedure for the synthesis of pyrazoloquinolinones. A mixture of 4-chloro-7methoxy(d3)quinolin-3-carboxylate 3 (0.01 mol, 0.324g), substituted phenylhydrazine
hydrochloride (0.012 mol) and TEA (0.012 m,0.12 g ) in xylene (40mL) was heated to reflux for
4h. The reaction mixture was cooled to rt. The precipitated compound was collected by filtration
and purified by crystallization.
Synthesis of LAU159, LAU165, and LAU463: 8-Chloro-2-(3-methoxyphenyl)-2Hpyrazolo[4,3-c]quinolin-3(5H)-one (LAU159). In a 8 mL-vial with magnetic stirrer and screw
cap, ethyl 4,8-dichloroquinoline-3- carboxylate (135mg, 0.5 mmol, 1 eq), 3-(methoxy)phenyl
hydrazine (83mg, 0.6 mmol, 1.2 eq) and triethylamine (61 mg, 0.6 mmol, 1.2 eq) were dissolved
in dry N,Ndimethylacetamide (3 mL). The reaction mixture was heated to 140°C for 16 hours.
After completion of the reaction the volatiles were removed by evaporation and the solid residue
was washed with acetone and water to afford the pure product as a yellow solid (108mg, 66%):
m.p.: ~ 340°C, with partial decomposition above 300°C; 1H NMR (200 MHz, DMSO-d6): 12.95
(bs, 1H), 8.72 (d, J = 5.2Hz, 1H), 8.15 (s, 1H), 7.84 - 7.70 (m, 4H), 7.33 (t, J = 8.1Hz, 1H), 6.75
(d, J = 8.1Hz, 1H), 3.80 (s, 3H); 13C NMR (50 MHz, DMSO-d6): δ= 161.5 (s), 159.5 (s), 141.9
(s), 141.0 (s), 139.5 (d), 134.2 (s), 130.6 (s), 130.2 (d), 129.5 (d), 121.6 (d), 121.1 (d), 119.9 (s),
110.9 (d), 109.5 (d), 106.3 (s), 104.4 (d), 55.1 (q); HRMS: [M+H]+ m/z (predicted) = 326.0691,
m/z (measured) = 326.0688.
8-Chloro-2-(2-methoxyphenyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one (LAU165). In an 8
mL vial with magnetic stirrer and screw cap, ethyl 4,6-dichloroquinoline- 3-carboxylate (135
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mg, 0.5 mmol, 1 eq), 2-methoxyphenylhydrazine (83 mg, 0.6 mmol, 1.2 eq) and triethylamine
(63 mg, 0.6 mmol, 1.2 eq) were dissolved in dry N,Ndimethylacetamide (3 mL). The reaction
mixture was heated to 140 °C for 16h. After completion of the reaction the reaction mixture was
evaporated to dryness. The crude product was purified by flash-column chromatography (45 g
silica 60, eluent EtOAc/MeOH 5%), the co-eluting triethylamine hydrochloride was
subsequently removed by washing with water. Yield: 28% (0.14 mmol, 46 mg, 28%) as a yellow
solid: m.p. 310 - 313 °C with partial decomposition; 1H-NMR (200 MHz, DMSO-d6) δ = 3.73
(s, 3H), 7.03 (t, J = 7.5 Hz, 1H), 7.16 (d, J = 8.2 Hz, 1H), 7.29-7.45 (m, 2H), 7.62-7.73 (m, 2H),
8.01 (d, J = 1.6 Hz, 1H), 8.65 (s, 1H), 12.78 (s, 1H); 13C-NMR (50 MHz, DMSO-d6) δ = 55.6
(q), 105.3 (s), 112.5 (d), 120.2 (d), 120.3 (s), 120.9 (d), 121.4 (d), 127.7 (s), 129.3 (d), 129.4 (d),
129.7 (d), 130.3 (s), 134.0 (s), 139.1 (d), 141.4 (s), 155.1 (s), 161.6 (s); HRMS: [M+H] calcd
326.0691 m/z 326.0678.
7-Bromo-2-(4-methoxyphenyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one (LAU463). The ethyl
7-bromo-4-chloroquinoline-3-carboxylate (200 mg, 0.64 mmol, 1 eq) and (4methoxyphenyl)hydrazine (110 mg, 0.80 mmol, 1.2 eq) were dissolved in dimethylacetamide
(5mL). The reaction was carefully purged with argon several times, triethylamine (1 eq) was
added, and the reaction was heated to 140°C for 24 hours. The solvent was removed via
Kugelrohr distillation of the crude mixture. Washing of the residue with acetone gave the
product as an orange-yellow solid (121mg, 51%): m.p.: >330 °C with decomposition; 1H NMR
(400 MHz, DMSO-d6) δ 12.78 (s, 1H), 8.74 (d, J = 5.8 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.06
(d, J = 8.6 Hz, 2H), 7.89 (d, J = 2.0 Hz, 1H), 7.69 (dd, J = 8.5, 2.0 Hz, 1H), 7.02 (d, J = 8.6 Hz,
2H), 3.79 (s, 3H); 13C NMR (101 MHz, DMSO) δ 161.3 (s), 156.5 (s), 142.4 (s), 140.1 (d),
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136.9 (s), 133.8 (s), 129.7(d), 124.5 (d), 123.0 (s), 122.2 (d), 120.9 (d), 118.2 (s), 114.3 (d),
107.2 (s), 55.7 (q).
7-Methoxy-2-(pyrazin-2-yl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3- one (DCBS126). In a
8 mL vial equipped with a magnetic stirrer and screw cap, the ethyl 4-chloro-7methoxyquinoline-3-carboxylate (70 mg, 0.26 mmol, 1 eq) and 2-hydrazinopyrazine (32 mg,
0.29 mmol, 1.1 eq) were dispersed in 1.5 mL ethanol, triethylamine (40 μL, 0.29 mmol, 1.1 eq)
was added, and the reaction mixture was heated to reflux under argon. After 20 h the reaction
mixture was rinsed with water (4mL), filtered, and the precipitate was washed with EtOAc:PE
(1:1, 15mL). The yellow solid was dried under reduced pressure to give the desired product
giving a yellow solid (45mg, 58%): m.p.: >300 °C with decomposition; 1H NMR (400 MHz,
DMSOd6) δ 3.88 (s, 3H), 7.16 – 7.23 (m, 2H), 8.13 (dd, J = 8.5, 0.8 Hz, 1H), 8.44 (d, J = 2.5 Hz,
1H), 8.56 (dd, J = 2.5, 1.5 Hz, 1H), 8.75 (s, 1H), 9.51 (d, J = 1.4 Hz, 1H), 12.74 (br s, 1H); 13C
NMR (101 MHz, DMSO-d6) δ 55.6 (q), 102.1 (d), 105.0 (s), 112.2 (s), 115.5 (d), 123.9 (d),
136.6 (d), 137.3 (s), 140.0 (d), 140.1 (d), 142.8 (d), 144.9 (s), 148.0 (s), 160.8 (s), 162.4 (s);
HRMS: Calc.[M+H]+ m/z 294.0992, m/z (measured) = 294.0992.
N-(4-Hydroxyphenyl)acetamide [DK-I-2-1]. To a mixture of 4-aminophenol (50.0 g, 458.2
mmol) and tetrahydrofuran (200 mL) acetic anhydride (49.1 g, 481.1 mmol) was added dropwise
over 30 min while keeping the temperature below 50 ºC. The reaction mixture was then stirred
for 30 min at 50 ºC and then cooled to rt. The reaction mixture was then diluted with hexanes
(200 mL) to precipitate the product. After stirring for 1 h, the solid product was filtered and
washed twice with hexanes (50 mL x 2). The solid was dried to afford the product as a white
crystalline solid DK-I-2-1 (62.7 g, 90.0%): mp 170-171 ºC; 1H NMR (300 MHz, DMSO) δ 9.64
(s, 1H), 9.13 (s, 1H), 7.34 (d, J = 8.8 Hz, 2H), 6.67 (d, J = 8.8 Hz, 2H), 1.98 (s, 3H); 13C NMR
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(75 MHz, DMSO) δ 167.95, 153.57, 131.49, 121.26, 115.44, 24.19; LRMS m/z calculated for
C8H10NO2 (M + H)+ 152.17 found 152.15. This material was used in a later step.
N-(3-Hydroxyphenyl)acetamide [DK-I-3-1]. To a mixture of 3- aminophenol (25.0 g, 229.1
mmol) and tetrahydrofuran (100 mL) acetic anhydride (24.5 g, 240.5 mmol) was added dropwise
over 30 min while keeping the temperature below 50 ºC. The reaction mixture was then stirred
for 30 min at 50ºC and then cooled to rt. The reaction mixture was then diluted with hexanes
(100 mL) to precipitate the product. After stirring for 1 h, the solid product was filtered and
washed twice with hexanes (25 mL x 2). The solid was dried to afford the product as a white
crystalline solid DK-I-3-1 (33.2 g, 96.0%): mp 145-148 ºC; 1H NMR (300 MHz, DMSO) δ 9.77
(s, 1H), 9.32 (s, 1H), 7.18 (s, 1H), 7.04 (t, J = 8.0 Hz, 1H), 6.92 (d, J = 8.1 Hz, 1H), 6.42 (dd, J =
7.9, 2.1 Hz, 1H), 2.01 (s, 3H); 13C NMR (75 MHz, DMSO) δ 168.60, 158.01, 140.81, 129.72,
110.55, 110.18, 106.60, 24.50; LRMS m/z calculated for C8H10NO2 (M + H)+ 152.17 found
152.15. This material was used in a later step.
N-(2-Hydroxyphenyl)acetamide [DK-I-30-1]. To a mixture of 2- aminophenol (25.0 g, 229.1
mmol) and tetrahydrofuran (100 mL) acetic anhydride (24.5 g, 240.5, mmol) was added
dropwise over 30 min while keeping the temperature below 50 ºC. The reaction mixture was then
stirred for 30 min at 50ºC and then cooled to rt. The reaction mixture was then diluted with
hexanes (100 mL) to precipitate the product. After stirring for 1 h, the solid product was filtered
and washed twice with hexanes (25 mL x 2). The solid was dried to afford the product as a light
brown solid DK-I-30-1 (33.1 g, 95.7%): mp 211-213 ºC; 1H NMR (300 MHz, DMSO) δ 9.75 (s,
1H), 9.31 (s, 1H), 7.67 (d, J = 7.7 Hz, 1H), 6.85 (ddd, J = 33.6, 14.6, 7.2 Hz, 3H), 2.10 (s, 3H);
13C NMR (75 MHz, DMSO) δ 169.44, 148.34, 126.88, 125.08, 122.80, 119.40, 116.38, 24.05;
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LRMS m/z calculated for C8H10NO2 (M + H)+ 152.17 found 152.15. This material was used in a
later step.
N-(4-Methoxy-d3-phenyl)acetamide [DK-I-6-1]. To a mixture of N-(4hydroxyphenyl)acetamide DK-I-2-1 (62.0 g, 410.1 mmol), potassium carbonate (113.4 g, 615.2
mmol) and acetone (230 mL) methyl iodide (D3) (100 g, 689.8 mmol) was added dropwise over
30 min. The reaction mixture was then stirred for 24 h at 20-25 ºC. The reaction mixture was
then diluted with ethyl acetate (300 mL) and water (300 mL). The biphasic mixture which
resulted was allowed to stand for 15 min and the layers were separated. The aq layer was
extracted with ethyl acetate (200 mL) and then the combined organic layers were washed with
10% potassium carbonate solution (200 mL). The organic layer was then dried over magnesium
sulfate. The solvents were then removed in vacuo and the product residue was slurried with
hexanes (200 mL). The solid product was then filtered and washed twice with hexanes (50 mL x
2). The solid was dried to afford the product as an off-white solid DK-I-6-1 (71.7 g, 99%): mp
125-126 ºC; 1H NMR (300 MHz, DMSO) δ 9.77 (s, 1H), 7.48 (d, J = 9.0 Hz, 2H), 6.85 (d, J =
9.0 Hz, 2H), 3.38 (s, 3H), 2.00 (s, 3H); 13C NMR (75 MHz, DMSO) δ 168.20, 155.48, 132.94,
121.01, 114.21, 24.23; LRMS m/z calculated for C9H9D3NO2 (M + H)+ 169.20 found 169.20.
This material was used in a later step.
N-(3-Methoxy-d3-phenyl)acetamide [DK-I-8-1]. To a mixture of N-(3hydroxyphenyl)acetamide DK-I-3-1 (35.0 g, 231.5 mmol), potassium carbonate (64.0 g, 463.1
mmol) and acetone (140 mL) methyl iodide (D3) (50.3 g, 347.3 mmol) was added dropwise over
30 min. The reaction mixture was then stirred for 24 h at 20-25 ºC. The reaction mixture was
then diluted with ethyl acetate (150 mL) and water (150 mL). The biphasic mixture which
resulted was allowed to stand for 15 min and the layers were separated. The aq layer was
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extracted with ethyl acetate (100 mL) and then the combined organic layers were washed with
10% potassium carbonate solution (100 mL). The organic layer was then dried over magnesium
sulfate. The solvents were then removed in vacuo and the product residue was slurried with
hexanes (100 mL). The solid product was then filtered and washed twice with hexanes (50 mL x
2). The solid was dried to afford the product as an off-white solid DK-I-8-1 (38.9 g, 99%): mp
89-91 ºC; 1H NMR (300 MHz, DMSO) δ 9.89 (s, 1H), 7.27 (s, 1H), 7.18 (t, J = 8.1 Hz, 1H),
7.10 (d, J = 8.2 Hz, 1H), 6.60 (dd, J = 7.8, 2.0 Hz, 1H), 2.03 (s, 3H); 13C NMR (75 MHz,
DMSO) δ 168.76, 159.93, 140.96, 129.89, 111.71, 108.76, 105.30, 24.53; LRMS m/z calculated
for C9H9D3NO2 (M + H)+ 166.20 found 166.15. This material was used in a later step.
N-(2-Methoxy-d3-phenyl)acetamide [DK-I-31-1]. To a mixture of N-(2hydroxyphenyl)acetamide DK-I-30-1 (30.0 g, 198.5 mmol), potassium carbonate (54.9 g, 396.9
mmol) and acetone (140 mL) methyl iodide (D3) (50.3 g, 347.3 mmol) was added dropwise over
30 min. The reaction mixture was then stirred for 24 h at 20-25 ºC. The reaction mixture was
then diluted with ethyl acetate (150 mL) and water (150 mL). The biphasic mixture which
resulted was allowed to stand for 15 min and the layers were separated. The aq layer was
extracted with ethyl acetate (100 mL) and then the combined organic layers were washed with
10% potassium carbonate solution (100 mL). The organic layer was then dried over magnesium
sulfate. The solvents were then removed in vacuo and the product residue was slurried with
hexanes (100 mL). The solid product was then filtered and washed twice with hexanes (50 mL x
2). The solid was dried to afford the product as an off-white solid DK-I-31-1 (31.9 g, 99%): mp
82-83 ºC; 1H NMR (300 MHz, DMSO) δ 9.10 (s, 1H), 7.93 (d, J = 7.8 Hz, 1H), 7.22 – 6.97 (m,
2H), 6.97 – 6.79 (m, 1H), 2.08 (s, 3H); 13C NMR (75 MHz, DMSO) δ 168.87, 149.98, 127.87,
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124.63, 122.45, 120.57, 111.50, 24.30; LRMS m/z calculated for C9H9D3NO2 (M + H)+ 166.20
found 169.19. This material was used in a later step.
4-Methoxy-d3-aniline [DK-I-67-1]. A mixture of N-(4-methoxy-d3- phenyl)acetamide DK-I-61 (20.0 g, 118.9 mmol), 12 M hydrochloric acid (20 mL, 240 mmol), and water (60 mL) was
heated at 90-95 ºC for 2 h. The reaction mixture was then cooled to 20-25 ºC and the pH was
adjusted to 14 with a solution of sodium hydroxide (20g, 500 mmol) and water (20 mL). The
product was then extracted from the aqueous layer four times with dichloromethane (50 mL x 4).
The combined organic layers were then dried over magnesium sulfate. Evaporation of the
solvents on a rotovap afforded the product as a dark orange oil DK-I-67-1 (14.4 g, 96%): 1H
NMR (300 MHz, DMSO) δ 5.75 – 5.62 (m, 2H), 5.62 – 5.47 (m, 2H), 3.50 (s, 2H); 13C NMR
(75 MHz, DMSO) δ 150.34, 141.51, 114.62, 113.89; LRMS m/z calculated for C7H7D3NO (M +
H)+ 127.25 found 127.25. This material was used in a later step.
3-Methoxy-d3-aniline [DK-I-41-1]. A mixture of N-(3-methoxy-d3- phenyl)acetamide DK-I-81 (20.0 g, 118.9 mmol), 12 M hydrochloric acid (20 mL, 240 mmol), and water (60 mL) was
heated at 90-95 ºC for 2 h. The reaction mixture was then cooled to 20-25 ºC and the pH was
adjusted to 14 with a solution of sodium hydroxide (20g, 500 mmol) and water (20 mL). The
product was then extracted from the aqueous layer four times with dichloromethane (50 mL x 4).
The combined organic layers were then dried over magnesium sulfate. Evaporation of the
solvents on a rotovap afforded the product as a golden yellow oil DK-I-41-1 (13.5 g, 90%): 1H
NMR (300 MHz, CDCl3) δ 7.10 (t, J = 8.0 Hz, 1H), 6.35 (dddd, J = 11.9, 11.2, 3.4, 2.0 Hz, 3H),
4.00 (s, 2H); 13C NMR (75 MHz, CDCl3) δ 160.78, 147.54, 130.16, 108.14, 104.22, 101.28;
LRMS m/z calculated for C7H6D3NO (M + H)+ 127.25 found 127.25. This material was used in
a later step.
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Ethyl-6-chloro-4-hydroxyquinoline-3-carboxylate [DK-I-34-1]. A mixture of 4-chloroaniline
(45.5 g, 356.7 mmol), diethyl ethoxymethylenemalonate (80.9 g, 374.1 mmol) and diphenyl
ether (200 mL) was slowly heated to 230 ºC. The evolved ethanol was collected in a Dean-Stark
trap. Once the ethanol formation ceased, the reaction mixture was heated for an additional 30
min at 230 ºC. The reaction mixture was then cooled to 80 ºC and diluted with ethanol (200 mL).
Upon cooling to 20-25ºC the solid product was collected by filtration and washed twice with
ethanol (50 mL x 2) and twice with hexanes (50 mL x 2). The solid was dried to afford the
product as an off-white crystalline solid DK-I-34-1 (85.1 g, 95%): 1H NMR (300 MHz, TFA) δ
11.66 (s, 1H), 9.32 (d, J = 4.5 Hz, 1H), 8.62 (d, J = 2.5 Hz, 1H), 8.12 (d, J = 13.0 Hz, 2H), 4.82 –
4.55 (m, 2H), 1.53 (dd, J = 11.8, 7.0 Hz, 3H); 13C NMR (75 MHz, TFA) δ 172.51, 167.19,
144.95, 138.35, 137.62, 137.58, 123.58, 121.35, 120.82, 105.30, 64.70, 11.96; LRMS m/z
calculated for C12H11ClNO3 (M+H)+ 252.10 found 252.10. This material was used in a later step.
Ethyl-4-hydroxy-7-methoxyquinoline-3-carboxylate [DK-I-39-1]. A mixture of 3methoxyaniline (50.0 g, 406.0 mmol), diethyl ethoxymethylenemalonate (87.8 g, 406.0 mmol)
and diphenyl ether (200 mL) was slowly heated to 230 ºC. The evolved ethanol was collected in
a Dean-Stark trap. Once the ethanol formation ceased, the reaction mixture was heated for an
additional 30 min at 230ºC. The reaction mixture was then cooled to 80 ºC and diluted with
ethanol (200 mL). Upon cooling to 20-25 ºC the solid product was collected by filtration and
washed twice with ethanol (50 mL x 2) and twice with hexanes (50 mL x 2). The solid was dried
to afford the product as a light brown solid DK-I-39-1 (37.1 g, 37%): 1H NMR (300 MHz, TFA)
δ 11.63 (s, 1H), 9.22 (d, J = 6.3 Hz, 1H), 8.56 (dd, J = 9.1, 6.7 Hz, 1H), 7.66 – 7.54 (m, 1H),
7.47 (d, J = 4.2 Hz, 1H), 4.69 (dd, J = 13.8, 6.9 Hz, 2H), 4.13 (d, J = 6.4 Hz, 3H), 1.57 (q, J =
6.8 Hz, 3H); 13C NMR (75 MHz, TFA) δ 171.88, 167.91, 167.62, 144.49, 142.43, 126.28,
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121.92, 114.05, 103.81, 99.24, 64.28, 55.45, 12.00; LRMS m/z calculated for C13H14NO4
(M+H)+ 248.15 found 248.15. This material was used in a later step.
Ethyl-7-bromo-4-hydroxyquinoline-3-carboxylate [DK-I-49-1]. A mixture of 3-bromoaniline
(8.7 g, 58.1 mmol), diethyl ethoxymethylenemalonate (10.9 g, 58.1 mmol) and diphenyl ether
(40 mL) was slowly heated to 230 ºC. The evolved ethanol was collected in a Dean-Stark trap.
Once the ethanol formation ceased, the reaction mixture was heated for an additional 30 min at
230 ºC. The reaction mixture was then cooled to 80 ºC and diluted with ethanol (40 mL). Upon
cooling to 20-25 ºC the solid product was collected by filtration and washed twice with ethanol
(10 mL x 2) and twice with hexanes (10 mL x 2). The solid was dried to afford the product as a
light brown solid DK-I-49-1 (11.5 g, 77%): 1H NMR (300 MHz, TFA) δ 11.64 (s, 1H), 9.38 (s,
1H), 8.57 (d, J = 8.9 Hz, 1H), 8.43 (s, 1H), 8.15 (d, J = 8.9 Hz, 1H), 4.75 (q, J = 7.1 Hz, 2H),
1.60 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, TFA) δ 173.48, 167.33, 145.75, 139.71, 134.19,
134.06, 125.60, 122.70, 118.57, 105.08, 64.74, 12.01; LRMS m/z calculated for C12H10BrNO3
(M+H)+ 296.12 found 296.05. This material was used in a later step.
Ethyl-4-hydroxy-7-methoxy-d3-quinoline-3-carboxylate [DK-I-54-1]. A mixture of 3methoxy-d3-aniline DK-I-41-1 (10 g, 81.2 mmol), diethyl ethoxymethylenemalonate (21.1 g,
97.4 mmol) and diphenyl ether (100 mL) was slowly heated to 230 ºC. The evolved ethanol was
collected in a Dean-Stark trap. Once the ethanol formation ceased, the reaction mixture was
heated for an additional 30 min at 230 ºC. The reaction mixture was then cooled to 80 ºC and
diluted with hexanes (100 mL). Upon cooling to 20-25 ºC the solid product was collected by
filtration and washed twice with hexanes (50 mL x 2). The solid was dried to afford the product
as a brown solid DK-I-54-1 (13.0 g, 64%): 1H NMR (300 MHz, TFA) δ 11.64 (s, 1H), 9.23 (s,
1H), 8.57 (d, J = 9.3 Hz, 1H), 7.59 (dd, J = 9.4, 2.3 Hz, 1H), 7.48 (d, J = 2.2 Hz, 1H), 4.71 (q, J
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= 7.2 Hz, 2H), 1.58 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, TFA) δ 171.89, 167.92, 167.64,
144.50, 142.44, 126.28, 121.93, 114.05, 103.81, 99.25, 64.29, 12.01; LRMS m/z calculated for
C13H11D3NO4 (M+H)+ 251.25 found 251.20. This material was used in a later step.
Ethyl-4-hydroxy-6-methoxy-d3-quinoline-3-carboxylate [DK-I-70-1]. A mixture of 4methoxy-d3-aniline DK-I-67-1 (10 g, 81.2 mmol), diethyl ethoxymethylenemalonate (21.1 g,
97.4 mmol) and diphenyl ether (100 mL) was slowly heated to 230 ºC. The evolved ethanol was
collected in a Dean-Stark trap. Once the ethanol formation ceased, the reaction mixture was
heated for an additional 30 min at 230 ºC. The reaction mixture was then cooled to 80 ºC and
diluted with hexanes (100 mL). Upon cooling to 20-25 ºC the solid product was collected by
filtration and washed twice with hexanes (50 mL x 2). The solid was dried to afford the product
as a light brown solid DK-I- 70-1 (9.9 g, 49%). 1H NMR (300 MHz, TFA) δ 11.66 (s, 1H), 9.15
(s, 1H), 8.05 (d, J = 9.2 Hz, 1H), 7.97 – 7.74 (m, 2H), 4.67 (q, J = 7.1 Hz, 2H), 1.67 – 1.39 (m,
3H); 13C NMR (75 MHz, TFA) δ 171.68, 167.54, 160.89, 141.86, 134.62, 129.91, 121.73,
121.28, 104.58, 102.17, 64.41, 11.97; LRMS m/z calculated for C13H11D3NO4 (M+H)+ 251.25
found 251.20. This material was used in a later step.
Ethyl 6-bromo-8-fluoro-4-hydroxyquinoline-3-carboxylate [MM-I-01]. 3- Bromo-5fluoroaniline (10 g, 52.6 mmol) was heated with diethyl ethoxymethylene malonate (11.2 mL,
55.3 mmol) at 125°C. After heating for 2 h, downtherm A (50 mL) was added and the mixture
was heated up to 255°C for 2 h. The reaction was cooled to rt and diluted with hexane (50 mL).
The mixture was stirred for 5 min. The precipitate was filtered and washed with hexane to yield
the product as a brown colored solid MM-I-01 (13.60 g, 82%): mp 285 – 286 °C; 1H NMR (300
MHz, DMSO) δ 12.65 (s, 1H; H- 11), 8.40 (s, 1H; H-8), 8.04 (s, 1H; H-6), 8.00 (dd, J = 10.1, 2.0
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Hz, 1H; H-2), 4.23 (q, J = 7.1 Hz, 2H; H-18), 1.28 (t, J = 7.1 Hz, 3H; H-17); HRMS m/z
calculated for C12H9NO3FBr 313.9823 found 313.9833. This material was used in a later step.
Ethyl 4-hydroxy-7-(trifluoromethyl)quinoline-3-carboxylate [MM-I-04]. 3(Trifluoromethyl)aniline (10 g, 62.1 mmol) was heated with diethyl ethoxymethylene malonate
(12.6 mL, 62 mmol) at 125 °C for 1 h. Then, downtherm A (50 mL) was added and the mixture
was heated up to 255 °C for 2.5 h. After heating, the reaction was cooled to rt and diluted with
hexane (50 mL). The mixture was stirred for 5 min. The precipitated was filtered and washed
with hexane to provide the product as a white colored solid MM-I-04 (16.51 g, 93%): mp 340 –
341 °C; 1H NMR (300 MHz, DMSO) δ 12.51 (s, 1H; H-11), 8.70 (s, 1H; H-8), 8.35 (d, J = 8.3
Hz, 1H; H-6), 8.00 (s, 1H; H-3), 7.72 (d, J = 8.1 Hz, 1H; H-1), 4.24 (q, J = 14.3, 7.1 Hz, 2H; H20), 1.29 (t, J = 7.0 Hz, 3H; H-19); HRMS m/z calculated for C13H10NO3F3 286.0686 found
286.0691. This material was used in a later step.
Ethyl-4,6-dichloroquinoline-3-carboxylate [DK-I-35-1]. A mixture of ethyl-6-chloro-4hydroxyquinoline-3-carboxylate DK-I-34-1 (85.1 g, 338.1 mmol), N,Ndimethylformamide (1.0
mL, 12.9 mmol), and dichloromethane (640 mL) was heated to 35- 40ºC. Oxalyl chloride (47.2
g, 371.9 mmol) was added dropwise to the reaction mixture over 30 min. The reaction mixture
was then heated for 6 h at reflux (38-40 ºC). The resulting pale yellow solution was then cooled
to 20-25 ºC. The reaction mixture was then neutralized by slowly adding a 25% solution of
potassium carbonate (75 g) in water (300 mL). The layers were then separated and the aqueous
layers extracted with dichloromethane (200 mL). The combined organic layers were then washed
with a 25% solution of potassium carbonate (50 g) in water (200 mL). The combined organic
layers were then dried over magnesium sulfate. The solvents were then removed in vacuo and the
product residue was slurried with hexanes (200 mL). The solid product was then filtered and
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washed twice with hexanes (50 mL x 2). The solid was dried to afford the product as an offwhite
solid DK-I-35-1 (81.9 g, 90%): 1H NMR (300 MHz, DMSO) δ 9.13 (s, 1H), 8.30 (d, J = 2.2 Hz,
1H), 8.14 (d, J = 9.0 Hz, 1H), 7.97 (dd, J = 9.0, 2.3 Hz, 1H), 4.44 (q, J = 7.1 Hz, 2H), 1.39 (t, J =
7.1 Hz, 3H); 13C NMR (75 MHz, DMSO) δ 164.01, 150.53, 147.73, 141.04, 134.30, 133.34,
132.20, 126.53, 124.37, 124.08, 62.59; LRMS m/z calculated for C12H9Cl2NO2 (M+H)+ 270.12
found 270.10. This material was used in a later step.
Ethyl-4-chloro-7-methoxyquinoline-3-carboxylate [DK-I-40-1]. A mixture of ethyl-4hydroxy-7-methoxyquinoline-3-carboxylate DK-I-39-1 (37.1 g, 150.0 mmol),
N,Ndimethylformamide (0.5 mL, 6.5 mmol), and dichloromethane (150 mL) was heated to 3540 ºC. Oxalyl chloride (20.9 g, 165.0 mmol) was added dropwise to the reaction mixture over 30
min. The reaction mixture was then heated for 2h at reflux (38-40 ºC). The resulting brown
solution was then cooled to 20-25 ºC. The reaction mixture was diluted with dichloromethane
(150 mL) and then neutralized by slowly adding a 25% solution of potassium carbonate (75 g) in
water (300 mL). The layers were then separated and the aqueous layers extracted with
dichloromethane (100 mL). The combined organic layers were then washed with a 25% solution
of potassium carbonate (75 g) in water (300 mL). The combined organic layers were then dried
over magnesium sulfate. The solvents were then removed in vacuo and the product residue was
slurried with hexanes (200 mL). The solid product was then filtered and washed twice with
hexanes (50 mL x 2). The solid was dried to afford the product as an off-white solid DK-I-40-1
(36.3 g, 91%): 1H NMR (300 MHz, DMSO) δ 9.08 (s, 1H), 8.25 (d, J = 9.2 Hz, 1H), 7.57 – 7.37
(m, 2H), 4.41 (q, J = 7.1 Hz, 2H), 3.98 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz,
DMSO) δ 164.32, 162.83, 151.62, 150.81, 142.02, 126.85, 122.12, 121.11, 120.56, 108.36,
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62.15, 56.45, 14.49; LRMS m/z calculated for C13H13ClNO3 (M+H)+ 266.70 found 266.15. This
material was used in a later step.
Ethyl-7-bromo-4-chloroquinoline-3-carboxylate [DK-I-52-1]. A mixture of ethyl-7-bromo-4hydroxyquinoline-3-carboxylate DK-I-49-1 (11.0 g, 37.1 mmol), N,Ndimethylformamide (0.1
mL, 1.3 mmol), and dichloromethane (50 mL) was heated to 35-40 ºC. Oxalyl chloride (5.2 g,
40.9 mmol) was added dropwise to the reaction mixture over 30 min. The reaction mixture was
then heated for 1h at reflux (38-40 ºC). The resulting brown solution was then cooled to 20-25
ºC. The reaction mixture was diluted with dichloromethane (150 mL) and then neutralized by
slowly adding a 25% solution of potassium carbonate (12.5 g) in water (50 mL). The layers were
then separated and the aqueous layers extracted with dichloromethane (50 mL). The combined
organic layers were then washed with a 25% solution of potassium carbonate (12.5 g) in water
(50 mL). The combined organic layers were then dried over magnesium sulfate. The solvents
were then removed in vacuo and the product residue was slurried with hexanes (50 mL). The
solid product was then filtered and washed twice with hexanes (25 mL x 2). The solid was dried
to afford the product as an off-white solid DK-I-54-1 (7.2 g, 61%): 1H NMR (300 MHz, DMSO)
δ 9.15 (s, 1H), 8.36 (d, J = 1.9 Hz, 1H), 8.28 (d, J = 9.0 Hz, 1H), 7.98 (dd, J = 9.0, 1.9 Hz, 1H),
4.44 (q, J = 7.1 Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, DMSO) δ 164.04, 151.40,
149.74, 142.34, 132.67, 131.88, 127.50, 126.64, 124.70, 123.96, 62.55, 14.46; LRMS m/z
calculated for C12H9BrClNO2 (M+H)+ 314.56 found 314.05. This material was used in a later
step.
Ethyl-4-chloro-7-methoxy-d3-quinoline-3-carboxylate [DK-I-57-1]. A mixture of ethyl-4hydroxy-7-methoxy-d3-quinoline-3-carboxylate DK-I-54-1 (13.0 g, 51.9 mmol), phosphorus
oxychloride (8.8 g, 57.1 mmol) and toluene (52 mL) was heated to 80-90 ºC. The reaction
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mixture was then held for 1 h at 80-90 ºC). The resulting brown solution was then cooled to 2025 ºC. The reaction mixture was then diluted with hexanes (50 mL). The solids were collected by
filtration and washed twice with hexanes (50 mL each). The solids were then dissolved in
dichloromethane (100 mL) and then neutralized by slowly adding a 25% solution of potassium
carbonate (12.5 g) in water (50 mL). The layers were then separated and the aqueous layers
extracted with dichloromethane (50 mL). The combined organic layers were then washed with a
25% solution of potassium carbonate (12.5 g) in water (50 mL). The combined organic layers
were then dried over magnesium sulfate. The solvents were then removed in vacuo and the
product residue was slurried with hexanes (50 mL). The solid product was then filtered and
washed twice with hexanes (25 mL x 2). The solid was dried to afford the product as an offwhite solid DK-I-57-1 (11.5 g, 82%): 1H NMR (300 MHz, DMSO) δ 9.07 (s, 1H), 8.23 (d, J =
9.2 Hz, 1H), 7.54 – 7.38 (m, 2H), 4.40 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H); 13C NMR
(75 MHz, DMSO) δ 164.29, 162.85, 151.53, 150.75, 142.41, 126.84, 122.11, 121.07, 120.56,
108.27, 62.15, 14.49; LRMS m/z calculated for C13H10D3ClNO3 (M+H)+ 269.70 found 269.15.
This material was used in a later step.
Ethyl-4-chloro-6-methoxy-d3-quinoline-3-carboxylate [DK-I-73-2]. A mixture of ethyl-4hydroxy-6-methoxy-d3-quinoline-3-carboxylate DK-I-70-1 (10.0 g, 40.0 mmol), phosphorus
oxychloride (6.7 g, 44.0 mmol) and toluene (40 mL) was heated to 80-90 ºC. The reaction
mixture was then held for 1 h at 80-90 ºC). The resulting brown solution was then cooled to 2025 ºC. The reaction mixture was then diluted with hexanes (40 mL). The solids were collected by
filtration and washed twice with hexanes (20 mL each). The solids were then dissolved in
dichloromethane (100 mL) and then neutralized by slowly adding a 25% solution of potassium
carbonate (10 g) in water (40 mL). The layers were then separated and the aqueous layers
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extracted with dichloromethane (50 mL). The combined organic layers were then washed with a
25% solution of potassium carbonate (10 g) in water (40 mL). The combined organic layers were
then dried over magnesium sulfate. The solvents were then removed in vacuo and the product
residue was slurried with hexanes (50 mL). The solid product was then filtered and washed twice
with hexanes (25 mL x 2). The solid was dried to afford the product as an off-white solid DK-I73- 2 (8.5 g, 79%): 1H NMR (300 MHz, DMSO) δ 8.95 (s, 1H), 8.03 (d, J = 9.1 Hz, 1H), 7.67 –
7.45 (m, 2H), 4.42 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, DMSO) δ
164.49, 159.57, 147.25, 145.36, 139.99, 131.67, 126.91, 125.20, 123.87, 102.96, 62.36, 14.47;
LRMS m/z calculated for C13H10D3ClNO3 (M+H)+ 269.70 found 269.15. This material was used
in a later step.
Ethyl 6-bromo-4-chloro-8-fluoroquinoline-3-carboxylate [MM-I-02]. The Ethyl 6-bromo-8fluoro-4-hydroxyquinoline-3-carboxylate MM-I-01 (1 g, 3.2 mmol) was placed in a flask with
POCl3 (4 mL). The mixture was heated at 70°C for 3 h. The excess of POCl3 was evaporated by
reduced pressure and the remaining oil was quenched with saturated solution of NaHCO3. Then,
the aqueous solution was extracted with CH2Cl2 (3 x 50 mL) and the combined organic layers
were dried (Na2SO4). The solvent was removed under reduce pressure and the residue was
purified by silica gel chromatography to give the compound as a white solid MM-I-02 (0.79 g,
75%): 1H NMR (300 MHz, CDCl3) δ 9.23 (s, 1H; H-8), 8.40 (s, 1H; H-6), 7.70 (dd, J = 9.1, 1.9
Hz, 1H; H-2), 4.54 (q, J = 7.1 Hz, 2H; H- 18), 1.49 (t, J = 7.1 Hz, 3H; H-17). HRMS m/z
calculated for C12H8NO2FClBr 331.9484 found 331.9487. This material was used in a later step.
Ethyl 4-chloro-7-(trifluoromethyl)quinoline-3-carboxylate [MM-I-05]. The reaction was
performed following the same procedure as for MM-I-02 except the reaction was performed in
bigger scale. Ethyl 4-hydroxy-7-(trifluoromethyl)quinoline-3- carboxylate MM-I-04 (5 g, 18
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mmol) was heated with POCl3 (10 mL) at 70°C for 3 h. MM-I- 05 was obtained as a white solid
(5.1 g, 93%): mp 71 – 73 °C; 1H NMR (300 MHz, CDCl3) δ 9.30 (s, 1H; H-8), 8.56 (d, J = 8.9
Hz, 1H; H-6), 8.46 (s, 1H; H-3), 7.89 (dd, J = 8.9, 1.5 Hz, 1H; H-1), 4.54 (q, J = 7.1 Hz, 2H; H20), 1.50 (t, J = 7.1 Hz, 3H; H-19); 13C NMR (75 MHz, CDCl3) δ 163.96 (s), 151.35 (s), 148.54
(s), 143.47 (s), 133.53 (q), 127.84 (s), 127.60 (q), 126.92 (s), 124.69 (s), 124.01 (q), 118.86 (s),
62.45 (s), 14.21 (s); HRMS m/z calculated for C13H9NO2F3Cl 304.0347 found 304.0353. This
material was used in a later step.
2-Methoxy-d3-5-nitropyridine [DK-II-44-1]. To a mixture of potassium tert-butoxide (13.3 g,
11.8 mmol) and methanol-d4 (50 mL) was slowly added 2-chloro-5- nitropyridine (15.0 g, 94.6
mmol). The exothermic reaction warmed to 50 ºC and then was refluxed at 65ºC for 2 h to
complete the reaction. The reaction mixture was then cooled to 20-25 ºC and poured into water
(750 mL). After stirring the mixture for 1 h the solid product was filtered and washed twice with
water (25 mL x 2). The solid was dried to afford the product as a light yellow powder DK-II-441 (13.0g, 87%). 1H NMR (300 MHz, DMSO) δ 9.08 (s, 1H), 8.47 (d, J = 9.1 Hz, 1H), 7.03 (d, J
= 9.1 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 167.45, 145.02, 139.99, 135.01, 111.67; LRMS
m/z calculated for C6H4D3N2O3 (M+H)+ 158.19 found 158.20. This material was used in a later
step.
5-Amino-2-methoxy-d3-pyridine [DK-II-45-1]. A mixture of 2-methoxy-d3- 5-nitropyridine
DK-II-44-1 (13.0 g, 82.7 mmol), iron powder (15.9 g, 284.7 mmol), water (5 mL) and ethanol
(50 mL) was heated to reflux (78 ºC). Once at reflux, concentrated hydrochloric acid (1 mL, 83.3
mmol) was added dropwise. The reaction mixture was then refluxed for 4 h to complete the
reaction. Upon cooling to 20-25 ºC, the mixture was filtered to remove the iron and the solids
were washed 3 times with ethanol (25 mL x 3). Sodium bicarbonate (5.0 g) was added to the
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filtrate and the ethanol was removed in vacuo. Water (50 mL) and dichloromethane (50 mL)
were added to dissolve the residue. The layers were separated and the aq layer was extracted
twice with dichloromethane (50 mL x 2). The combined organic layers were dried over
magnesium sulfate. The solvents were then removed in vacuo and the product was obtained as a
clear orange-red oil DK-II-45-1 (10.0 g, 95.1%): 1H NMR (300 MHz, DMSO) δ 7.57 (d, J = 2.7
Hz, 1H), 7.05 (dd, J = 8.6, 2.9 Hz, 1H), 6.56 (d, J = 8.7 Hz, 1H), 4.74 (s, 2H); 13C NMR (75
MHz, DMSO) δ 156.29, 139.77, 131.63, 126.85, 110.42; LRMS m/z calculated for C6H6D3N2O
(M+H)+ 128.15 found 128.15. This material was used in a later step.
4-Methoxy-d3-phenylhydrazine [DK-I-29-2]. A mixture of N-(4-methoxyd3phenyl)acetamide DK-I-6-1 (30 g, 178.4 mmol), concentrated hydrochloric acid (72 mL), and
water (72 mL) was heated to and held at 90 ºC for 2 h to hydrolyze the amide functionality. The
reaction mixture was then cooled to 0 to 5ºC and a solution of sodium nitrite (12.9 g, 187.7
mmol) and water (25 mL) was slowly added dropwise to the reaction mixture. Upon completion
of the addition, the reaction mixture was stirred for an additional 15 min at 0 to 5 ºC. The
reaction mixture was then cooled to -25 to -20ºC and a solution of tin (II) chloride (74.4 g, 392.4
mmol) and concentrated hydrochloric acid (150 mL) was added dropwise to the reaction mixture
over 30 min. Upon completion of the addition, the reaction mixture was stirred for an additional
4 h at -25 to -20 ºC. The reaction mixture was then diluted with diethyl ether (300 mL) and the
solids were filtered and washed three times with diethyl ether (100 mL x 3). The tin adduct of the
product was then dissolved in a mixture of sodium hydroxide (60 g), water (250 mL) and
dichloromethane (250 mL). After stirring for 2 h at 0 to 5 ºC, the solids completely dissolved.
The layers were separated and the aq layer was extracted three times with dichloromethane
(100mL x 3). The combined organic layers were then dried over magnesium sulfate. The
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solvents were then removed in vacuo and the product residue was slurried with hexanes (50 mL).
The solid product was then filtered and washed twice with hexanes (50 mL x 2). The solid was
dried to afford the product as a pale orange crystalline solid DK-I-29-2 (16.6 g, 66%): 1H NMR
(300 MHz, MeOD) δ 6.91 – 6.85 (m, 2H), 6.85 – 6.78 (m, 2H), 4.88 (s, 3H); 13C NMR (75
MHz, DMSO) δ 152.05, 147.27, 114.60, 113.38; LRMS m/z calculated for C7H8D3N2O (M+H)+
142.25 found 142.25. This material was used in a later step.
3-Methoxy-d3-phenylhydrazine [DK-I-26-3]. A mixture of N-(3-methoxyd3phenyl)acetamide DK-I-8-1 (25 g, 148.6 mmol), concentrated hydrochloric acid (60 mL), and
water (60 mL) was heated to and held at 90 ºC for 2 h to hydrolyze the amide functionality. The
reaction mixture was then cooled to 0 to 5 ºC and a solution of sodium nitrite (10.8 g, 156.1
mmol) and water (21 mL) was slowly added dropwise to the reaction mixture. Upon completion
of the addition, the reaction mixture was stirred for an additional 15 min at 0 to 5 ºC. The
reaction mixture was then cooled to -25 to -20 ºC and a solution of tin (II) chloride (62.0 g, 327.0
mmol) and concentrated hydrochloric acid (125 mL) was added dropwise to the reaction mixture
over 30 min. Upon completion of the addition, the reaction mixture was stirred for an additional
2 h at -25 to -20 ºC. The reaction mixture was then diluted with diethyl ether (250 mL) and the
solids were filtered and washed three times with diethyl ether (100 mL x 3). The tin adduct of the
product was then dissolved in a mixture of sodium hydroxide (20 g), water (100 mL) and
dichloromethane (100 mL). After stirring for 1 h at 0 to 5 ºC, the solids completely dissolved.
The layers were separated and the aq layer was extracted three times with dichloromethane
(50mL x 3). The combined organic layers were then dried over magnesium sulfate. The solvents
were then removed in vacuo to afford the product as an orange-red oil DK-I-26-3 (5.4 g, 26%):
1H NMR (300 MHz, DMSO) δ 6.98 (t, J = 8.0 Hz, 1H), 6.65 (s, 1H), 6.51 – 6.27 (m, 2H), 6.16
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(d, J = 7.9 Hz, 1H), 3.91 (s, 2H); 13C NMR (75 MHz, DMSO) δ 160.68, 154.54, 129.69, 104.96,
102.72, 97.52; LRMS m/z calculated for C7H8D3N2O (M+H)+ 142.14 found 142.15. This
material was used in a later step.
2-Methoxy-d3-phenylhydrazine [DK-I-43-3]. A mixture of N-(2-methoxyd3phenyl)acetamide DK-I-31-1 (25 g, 148.6 mmol), concentrated hydrochloric acid (60 mL), and
water (60 mL) was heated to and held at 90 ºC for 2 h to hydrolyze the amide functionality. The
reaction mixture was then cooled to 0 to 5 ºC and a solution of sodium nitrite (10.7 g, 156.1
mmol) and water (21 mL) was slowly added dropwise to the reaction mixture. Upon completion
of the addition, the reaction mixture was stirred for an additional 15 min at 0 to 5 ºC. The
reaction mixture was then cooled to -25 to -20 ºC and a solution of tin (II) chloride (62.0 g, 327.0
mmol) and concentrated hydrochloric acid (125 mL) was added dropwise to the reaction mixture
over 30 min. Upon completion of the addition, the reaction mixture was stirred for an additional
2 h at -25 to -20 ºC. The reaction mixture was then diluted with diethyl ether (300 mL) and the
solids were filtered and washed three times with diethyl ether (100 mL x 3). The tin adduct of the
product was then dissolved in a mixture of sodium hydroxide (20 g), water (100 mL) and
dichloromethane (100 mL). After stirring for 1 h at 0 to 5 ºC, the solids completely dissolved.
The layers were separated and the aq layer was extracted three times with dichloromethane
(100mL x 3). The combined organic layers were then dried over magnesium sulfate. The
solvents were then removed in vacuo and the product residue was slurried with hexanes (50 mL).
The solid product was then filtered and washed twice with hexanes (25 mL x 2). The solid was
dried to afford the product as a pale pink solid DK-I-43-3 (12.5 g, 60%): 1H NMR (300 MHz,
DMSO) δ 7.01 (dd, J = 7.8, 1.3 Hz, 1H), 6.92 – 6.71 (m, 2H), 6.61 (td, J = 7.7, 1.4 Hz, 1H), 5.92
(s, 1H), 3.92 (s, 2H); 13C NMR (75 MHz, DMSO) δ 146.33, 141.94, 121.26, 117.23, 111.20,
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110.07; LRMS m/z calculated for C7H8D3N2O (M+H)+ 142.30 found 142.30. This material was
used in a later step.
5-Hydrazinyl-2-methoxypyridine [DK-I-82-3]. A mixture of 5-amino-2- methoxypyridine (10
g, 80.6 mmol), concentrated hydrochloric acid (24 mL), and water (24 mL) was cooled to 0 to 5
ºC and a solution of sodium nitrite (5.8 g, 84.6 mmol) and water (12 mL) was slowly added
dropwise to the reaction mixture. Upon completion of the addition, the reaction mixture was
stirred for an additional 15 min at 0 to 5 ºC. The reaction mixture was then cooled to -25 to -20
ºC and a solution of tin (II) chloride (33.6 g, 177.2 mmol) and concentrated hydrochloric acid (70
mL) was added dropwise to the reaction mixture over 30 min. Upon completion of the addition,
the reaction mixture was stirred for an additional 2 h at -25 to -20 ºC. The reaction mixture was
then diluted with dichloromethane (100 mL). A solution of potassium hydroxide (100 g) in water
(200 mL) was added dropwise to the reaction mixture at 0 to 5 ºC over 30 min. After stirring for
1 h at 0 to 5 ºC, the solids completely dissolved. The layers were separated and the aq layer was
extracted four times with dichloromethane (50mL x 4). The combined organic layers were then
dried over magnesium sulfate. The solvents were then removed in vacuo and the product residue
was slurried with hexanes (20 mL). The slurry was placed in a freezer at -20 ºC for 24 h to fully
precipitate the product. The solid product was then filtered and washed twice with hexanes (10
mL x 2). The solid was dried to afford the product as a pale yellow-brown solid DK-I-82-3 (7.8
g, 70%): 1H NMR (300 MHz, DMSO) δ 7.70 (s, 1H), 7.20 (d, J = 8.7 Hz, 1H), 6.61 (d, J = 8.8
Hz, 1H), 6.41 (s, 1H), 3.97 (s, 2H), 3.73 (s, 3H); 13C NMR (75 MHz, DMSO) δ 156.98, 144.09,
129.85, 125.25, 110.22, 53.19; LRMS m/z calculated for C6H10N3O (M+H)+ 140.24 found
140.25. This material was used in a later step.
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5-Hydrazinyl-2-methoxy-d3-pyridine [DK-II-56-1]. A mixture of 5-amino- 2-methoxy-d3pyridine DK-II-45-1 (10 g, 78.6 mmol), concentrated hydrochloric acid (24 mL), and water (24
mL) was cooled to 0 to 5ºC and a solution of sodium nitrite (5.7 g, 82.5 mmol) in water (12 mL)
was slowly added dropwise to the reaction mixture. Upon completion of the addition, the
reaction mixture was stirred for an additional 15 min at 0 to 5 ºC. The reaction mixture was then
cooled to -25 to -20 ºC and a solution of tin (II) chloride (32.8 g, 173.0 mmol) and concentrated
hydrochloric acid (70 mL) was added dropwise to the reaction mixture over 30 min. Upon
completion of the addition, the reaction mixture was stirred for an additional 2 h at -25 to -20 ºC.
The reaction mixture was then diluted with dichloromethane (100 mL). A solution of potassium
hydroxide (100 g), water (200 mL) was added dropwise to the reaction mixture at 0 to 5 ºC over
30 min. After stirring for 1 h at 0 to 5 ºC, the solids completely dissolved. The layers were
separated and the aq layer was extracted four times with dichloromethane (50mL x 4). The
combined organic layers were then dried over magnesium sulfate. The solvents were then
removed in vacuo and the product residue was slurried with hexanes (20 mL). The slurry was
placed in a freezer at -20 ºC for 24 h to fully precipitate the product. The solid product was then
filtered and washed twice with hexanes (10 mL x 2). The solid was dried to afford the product as
a pale yellow-brown solid DK-II-56-1 (6.4 g, 57%): 1H NMR (300 MHz, DMSO) δ 7.70 (d, J =
2.8 Hz, 1H), 7.31 – 7.19 (m, 1H), 6.61 (d, J = 8.8 Hz, 1H), 6.42 (s, 1H), 4.00 (s, 2H); 13C NMR
(75 MHz, DMSO) δ 157.01, 144.07, 129.87, 125.27, 110.22; LRMS m/z calculated for C6H7D3O
(M+H)+ 143.25 found 143.25. This material was used in a later step.
7-Methoxy-2-(4-methoxyphenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[Compound 6]. A mixture of ethyl-4-chloro-7-methoxyquinoline-3-carboxylate DK-I-40-1 (4 g,
15.1 mmol), 4-methoxyphenylhydrazine hydrochloride (3.15 g, 18.1 mmol), triethylamine
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(3.66g, 36.1 mmol) and xylenes (32 mL) was heated to reflux (138 ºC) and held at reflux for 2 h.
The resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (32 mL). The
reaction mixture was then refluxed at 80ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder Compound 6 (2.0 g, 41%): 1H NMR (300 MHz, DMSO)
δ 12.59 (s, 1H), 8.65 (s, 1H), 8.10 (t, J = 8.7 Hz, 3H), 7.34 – 7.12 (m, 2H), 7.01 (d, J = 9.1 Hz,
2H), 3.87 (s, 3H), 3.78 (s, 3H); 13C NMR (75 MHz, DMSO) δ 161.45, 160.85, 156.22, 143.11,
139.33, 137.42, 134.10, 124.05, 120.68, 115.77, 114.25, 112.68, 106.87, 102.26, 55.98, 55.68;
LRMS m/z calculated for C18H16N3O3 (M+H)+ 322.25 found 322.25.
7-Methoxy-d3-2-(4-methoxyphenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [RV-I029]. A mixture of ethyl-4-chloro-7-methoxy-d3-quinoline-3- carboxylate DK-I-57-1 (2 g, 7.4
mmol), 4-methoxyphenylhydrazine hydrochloride (1.56 g, 8.9 mmol), triethylamine (1.81g, 17.6
mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The
resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder RV-I-029 (1.0 g, 41%): 1H NMR (300 MHz, DMSO) δ
12.59 (s, 1H), 8.65 (s, 1H), 8.10 (t, J = 8.7 Hz, 3H), 7.17 (d, J = 2.0 Hz, 2H), 7.01 (d, J = 8.9 Hz,
2H), 3.78 (s, 3H); 13C NMR (75 MHz, DMSO) δ 161.45, 160.86, 156.22, 143.11, 139.32,
137.42, 134.11, 124.05, 120.68, 115.76, 114.25, 112.66, 106.87, 102.25, 55.68; LRMS m/z
calculated for C18H13D3N3O3 (M+H)+ 325.30 found 325.30.
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7-Methoxy-2-(4-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [DK-I56-1]. A mixture of ethyl-4-chloro-7-methoxyquinoline-3-carboxylate DK-I-40-1 (2 g, 7.4
mmol), 4-methoxy-d3-phenylhydrazine DK-I-29-2 (1.25 g, 8.9 mmol), triethylamine (0.90g, 8.9
mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The
resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-I-56-1 (1.5 g, 62.5%): 1H NMR (300 MHz, DMSO) δ
12.60 (s, 1H), 8.66 (s, 1H), 8.10 (t, J = 9.7 Hz, 3H), 7.18 (s, 2H), 7.01 (d, J = 8.4 Hz, 2H), 3.88
(s, 3H); 13C NMR (75 MHz, DMSO) δ 160.73, 160.43, 156.39, 143.09, 139.34, 137.43, 134.08,
124.08, 120.68, 115.80, 114.24, 112.69, 106.87, 102.28, 56.00; LRMS m/z calculated for
C18H13D3N3O3 (M+H)+ 325.30 found 325.30.
7-Methoxy-d3-2-(4-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[DK-I-60-3]. A mixture of ethyl-4-chloro-7-methoxy-d3-quinoline-3- carboxylate DK-I-57-1 (2
g, 7.4 mmol), 4-methoxy-d3-phenylhydrazine DK-I-29-2 (1.26 g, 8.9 mmol), triethylamine
(0.90g, 8.9 mmol) and xylenes (16 mL) was heated to reflux (138ºC) and held at reflux for 2 h.
The resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-I-60-3 (1.2 g, 50.0%): 1H NMR (300 MHz, DMSO) δ
12.57 (s, 1H), 8.65 (s, 1H), 8.10 (t, J = 9.0 Hz, 3H), 7.17 (d, J = 5.7 Hz, 2H), 7.01 (d, J = 9.0 Hz,
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2H); 13C NMR (75 MHz, DMSO) δ 161.45, 160.85, 156.21, 143.12, 139.37, 137.48, 134.10,
124.05, 120.69, 115.76, 114.24, 112.68, 106.86, 102.30; LRMS m/z calculated for
C18H10D6N3O3 (M+H)+ 328.15 found 328.15.
7-Methoxy-d3-2-(3-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[DK-I-94-1]. A mixture of ethyl-4-chloro-7-methoxy-d3-quinoline-3- carboxylate DK-I-57-1 (2
g, 7.4 mmol), 3-methoxy-d3-phenylhydrazine DK-I-26-3 (1.26 g, 8.9 mmol), triethylamine
(0.90g, 8.9 mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h.
The resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-I-94-1 (1.5 g, 62.0%): 1H NMR (300 MHz, DMSO) δ
12.62 (s, 1H), 8.66 (s, 1H), 8.13 (d, J = 9.4 Hz, 1H), 7.93 – 7.73 (m, 2H), 7.34 (t, J = 8.2 Hz,
1H), 7.18 (d, J = 6.7 Hz, 2H), 6.74 (d, J = 8.2 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 162.13,
161.02, 159.97, 143.50, 141.73, 139.59, 137.58, 129.94, 124.18, 115.84, 112.56, 111.30, 109.60,
106.83, 104.81, 102.32; LRMS m/z calculated for C18H10D6N3O3 (M+H)+ 328.25 found 328.25.
7-Methoxy-d3-2-(2-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[DK-I-90-1]. A mixture of ethyl-4-chloro-7-methoxy-d3-quinoline-3- carboxylate DK-I-57-1 (2
g, 7.4 mmol), 2-methoxy-d3-phenylhydrazine DK-I-43-3 (1.26 g, 8.9 mmol), triethylamine
(0.90g, 8.9 mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h.
The resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
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hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-I-90-1 (1.8 g, 75.0%): 1H NMR (300 MHz, DMSO) δ
12.47 (s, 1H), 8.57 (s, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.51 – 7.24 (m, 2H), 7.22 – 6.93 (m, 4H);
13C NMR (75 MHz, DMSO) δ 162.19, 160.63, 155.66, 142.97, 139.04, 137.26, 129.88, 129.67,
128.51, 123.87, 120.65, 115.49, 112.96, 112.91, 105.83, 102.15; LRMS m/z calculated for
C18H10D6N3O3 (M+H)+ 328.30 found 328.30.
7-Methoxy-2-(2-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [DK-I88-1]. A mixture of ethyl-4-chloro-7-methoxy-quinoline-3- carboxylate DK-I-40-1 (2 g, 7.5
mmol), 2-methoxy-d3-phenylhydrazine DK-I-43-3 (1.28 g, 9.0 mmol), triethylamine (0.91g, 9.0
mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The
resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-I-88-1 (1.6 g, 65.6%): 1H NMR (300 MHz, DMSO) δ
12.46 (d, J = 4.9 Hz, 1H), 8.57 (d, J = 5.8 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.40 (t, J = 7.8 Hz,
1H), 7.31 (d, J = 7.6 Hz, 1H), 7.15 (dd, J = 9.7, 6.0 Hz, 3H), 7.03 (t, J = 7.5 Hz, 1H), 3.87 (s,
3H); 13C NMR (75 MHz, DMSO) δ 184.22, 162.19, 160.62, 155.66, 142.95, 139.04, 137.26,
129.88, 129.66, 128.51, 123.88, 120.65, 115.49, 112.97, 112.94, 105.83, 102.15, 55.94; LRMS
m/z calculated for C18H13D3N3O3 (M+H)+ 325.24 found 325.25.
8-Chloro-2-(4-methoxyphenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin- 3-one [Comp 11].
A mixture of ethyl-4,6-dichloro-quinoline-3-carboxylate DK-I-35-1 (2 g, 7.4 mmol), 4methoxyphenylhydrazine hydrochloride (1.55 g, 8.9 mmol), triethylamine (1.80g, 17.8 mmol)
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and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The resulting
yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The reaction
mixture was then refluxed at 80ºC for 30 min and then cooled to 20-25 ºC. The solids were
collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and hexanes
(2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to afford the
product as a yellow powder Comp 11 (1.7 g, 71.0%): 1H NMR (300 MHz, DMSO) δ 12.95 (d, J
= 5.6 Hz, 1H), 8.72 (d, J = 6.2 Hz, 1H), 8.14 (d, J = 2.1 Hz, 1H), 8.08 (d, J = 9.0 Hz, 2H), 7.70
(dt, J = 8.9, 5.5 Hz, 2H), 7.02 (d, J = 9.1 Hz, 2H), 3.79 (s, 3H); 13C NMR (75 MHz, DMSO) δ
161.37, 156.48, 141.97, 139.79, 134.59, 133.87, 131.04, 130.46, 122.08, 121.50, 120.89, 120.48,
114.29, 106.86, 55.71; LRMS m/z calculated for C17H13ClN3O2 (M+H)+ 326.25 found 326.25.
8-Chloro-2-(4-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [DK-I93-1]. A mixture of ethyl-4,6-dichloro-quinoline-3-carboxylate DK-I- 35-1 (2 g, 7.4 mmol), 4methoxy-d3-phenylhydrazine DK-I-29-2 (1.25 g, 8.9 mmol), triethylamine (0.90g, 8.9 mmol)
and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The resulting
yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The reaction
mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids were
collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and hexanes
(2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solids was dried to afford the
product as a yellow powder DK-I-93- 1 (1.3 g, 53.6%): 1H NMR (300 MHz, DMSO) δ 12.89 (s,
1H), 8.74 (s, 1H), 8.24 – 7.89 (m, 3H), 7.86 – 7.56 (m, 2H), 7.02 (d, J = 8.9 Hz, 2H); 13C NMR
(75 MHz, DMSO) δ 161.38, 156.49, 141.98, 139.86, 134.59, 133.84, 131.05, 130.49, 122.09,
121.52, 120.91, 120.49, 114.29, 106.88; LRMS m/z calculated for C17H10D3ClN3O2 (M+H)+
329.15 found 329.15.
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8-Chloro-2-(3-methoxyphenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin- 3-one [LAU 159].
A mixture of ethyl-4,6-dichloro-quinoline-3-carboxylate DK-I-35-1 (2 g, 7.4 mmol), 3methoxyphenylhydrazine hydrochloride (1.55 g, 8.9 mmol), triethylamine (1.80g, 17.8 mmol)
and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The resulting
yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The reaction
mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids were
collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and hexanes
(2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to afford the
product as a yellow powder LAU 159 (0.7 g, 30.0%): 1H NMR (300 MHz, DMSO) δ 12.85 (s,
1H), 8.69 (s, 1H), 8.15 (d, J = 1.9 Hz, 1H), 7.83 (d, J = 8.7 Hz, 2H), 7.70 (dt, J = 9.0, 5.4 Hz,
2H), 7.34 (t, J = 8.1 Hz, 1H), 6.83 – 6.65 (m, 1H), 3.81 (s, 3H); 13C NMR (75 MHz, DMSO) δ
161.99, 159.98, 142.44, 141.52, 140.02, 134.81, 131.11, 130.62, 129.97, 122.17, 121.62, 120.42,
111.47, 110.04, 106.80, 104.96, 55.59; LRMS m/z calculated for C17H13ClN3O2 (M+H)+ 326.20
found 326.20.
8-Chloro-2-(3-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [DK-I59-1]. A mixture of ethyl-4,6-dichloro-quinoline-3-carboxylate DK-I- 35-1 (2 g, 7.4 mmol), 3methoxy-d3-phenylhydrazine hydrochloride DK-I-26-2 (1.45 g, 8.1 mmol), triethylamine (1.87g,
18.5 mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The
resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-I-59-1 (2.0 g, 87.0%): 1H NMR (300 MHz, DMSO) δ

341

12.85 (s, 1H), 8.71 (s, 1H), 8.17 (s, 1H), 8.00 – 7.49 (m, 4H), 7.35 (t, J = 7.7 Hz, 1H), 6.77 (d, J
= 7.4 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 162.01, 160.01, 142.48, 141.54, 140.10, 134.76,
131.15, 130.72, 130.01, 122.14, 121.68, 120.45, 111.42, 110.04, 106.87, 104.95; LRMS m/z
calculated for C17H10D3ClN3O2 (M+H)+ 329.10 found 329.10.
8-Chloro-2-(2-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [DK-I87-1]. A mixture of ethyl-4,6-dichloro-quinoline-3-carboxylate DK-I- 35-1 (2 g, 7.4 mmol), 2methoxy-d3-phenylhydrazine DK-I-43-3 (1.25 g, 8.9 mmol), triethylamine (0.9g, 8.9 mmol) and
xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The resulting yelloworange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The reaction mixture was
then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids were collected by
filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and hexanes (2.5 mL x 2)
and then washed twice with hexanes (5 mL x 2). The solid was dried to afford the product as a
yellow powder DK-I-87-1 (1.0 g, 41.0%): 1H NMR (300 MHz, DMSO) δ 12.74 (s, 1H), 8.66 (s,
1H), 8.03 (s, 1H), 7.69 (p, J = 9.0 Hz, 2H), 7.42 (t, J = 7.8 Hz, 1H), 7.32 (d, J = 7.6 Hz, 1H), 7.17
(d, J = 8.3 Hz, 1H), 7.05 (t, J = 7.5 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 162.15, 155.64,
141.87, 139.59, 134.48, 130.83, 130.23, 129.91, 129.85, 128.22, 121.91, 121.40, 120.76, 120.68,
113.00, 105.81; LRMS m/z calculated for C17H10D3ClN3O2 (M+H)+ 329.0882 found 329.20.
7-Bromo-2-(4-methoxyphenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin- 3-one [LAU 463].
A mixture of ethyl-7-bromo-4-chloro-quinoline-3-carboxylate DK-I-52-1 (2 g, 6.3 mmol), 4methoxyphenylhydrazine hydrochloride (1.33 g, 7.6 mmol), triethylamine (1.54g, 15.3 mmol)
and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The resulting
yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The reaction
mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids were
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collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and hexanes
(2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to afford the
product as a yellow powder LAU 463 (1.4 g, 60.0%): 1H NMR (300 MHz, DMSO) δ 12.75 (s,
1H), 8.74 (s, 1H), 8.09 (dd, J = 17.7, 8.8 Hz, 3H), 7.89 (d, J = 1.6 Hz, 1H), 7.68 (dd, J = 8.6, 1.6
Hz, 1H), 7.02 (d, J = 9.1 Hz, 2H), 3.79 (s, 3H); 13C NMR (75 MHz, DMSO) δ 161.37, 156.47,
142.38, 140.08, 136.98, 133.85, 129.65, 124.51, 122.95, 122.22, 120.87, 118.22, 114.31, 107.21,
55.71; LRMS m/z calculated for C17H13BrN3O2 (M+H)+ 370.0191 found 370.15.
7-Bromo-2-(4-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [DK-I58-1]. A mixture of ethyl-7-bromo-4-chloro-quinoline-3-carboxylate DK-I-52-1 (2 g, 6.3 mmol),
4-methoxy-d3-phenylhydrazine DK-I-29-2 (1.08 g, 7.6 mmol), triethylamine (0.77g, 7.6 mmol)
and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The resulting
yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The reaction
mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids were
collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and hexanes
(2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to afford the
product as a yellow powder DK-I-58-1 (1.0 g, 42.0%): 1H NMR (300 MHz, DMSO) δ 12.75 (s,
1H), 8.74 (d, J = 4.9 Hz, 1H), 8.09 (dd, J = 17.8, 8.7 Hz, 3H), 7.88 (s, 1H), 7.69 (d, J = 8.4 Hz,
1H), 7.01 (d, J = 8.8 Hz, 2H); 13C NMR (75 MHz, DMSO) δ 161.35, 156.49, 141.88, 140.06,
136.95, 133.83, 129.65, 124.51, 122.93, 122.18, 120.86, 118.22, 114.24, 107.22; LRMS m/z
calculated for C17H10D3BrN3O2 (M+H)+ 373.0377 found 373.05.
7-Bromo-2-(3-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [DK-I92-1]. A mixture of ethyl-7-bromo-4-chloro-quinoline-3-carboxylate DK-I-52-1 (1.5 g, 4.8
mmol), 3-methoxy-d3-phenylhydrazine DK-I-26-3 (0.81 g, 5.7 mmol), triethylamine (0.58g, 5.7
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mmol) and xylenes (12 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The
resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (12 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-I-92-1 (0.7 g, 40.0%): 1H NMR (300 MHz, DMSO) δ
12.78 (s, 1H), 8.76 (s, 1H), 8.15 (d, J = 8.5 Hz, 1H), 7.95 – 7.76 (m, 3H), 7.71 (d, J = 8.6 Hz,
1H), 7.35 (t, J = 8.2 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 162.00,
160.00, 142.81, 141.51, 140.33, 137.11, 130.03, 129.75, 124.65, 123.22, 122.26, 118.16, 111.39,
109.98, 107.20, 104.92; LRMS m/z calculated for C17H10D3BrN3O2 (M+H)+ 373.0377 found
373.10.
7-Bromo-2-(2-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [DK-I89-1]. A mixture of ethyl-7-bromo-4-chloro-quinoline-3-carboxylate DK-I-52-1 (2 g, 6.3 mmol),
2-methoxy-d3-phenylhydrazine DK-I-43-3 (1.08 g, 7.6 mmol), triethylamine (0.77g, 7.6 mmol)
and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The resulting
yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The reaction
mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids were
collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and hexanes
(2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to afford the
product as a yellow powder DK-I-89-1 (1.2 g, 50.6%): 1H NMR (300 MHz, DMSO) δ 12.60 (s,
1H), 8.64 (d, J = 16.3 Hz, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.86 (s, 1H), 7.64 (d, J = 8.5 Hz, 1H),
7.41 (t, J = 7.8 Hz, 1H), 7.32 (d, J = 7.7 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 7.04 (t, J = 7.5 Hz,
1H); 13C NMR (75 MHz, DMSO) δ 162.14, 158.75, 155.64, 142.23, 139.79, 136.89, 129.84,

344

129.45, 128.23, 124.36, 122.64, 122.04, 120.69, 118.50, 112.99, 106.18; LRMS m/z calculated
for C17H10D3BrN3O2 (M+H)+ 373.0377 found 373.10.
8-Methoxy-d3-2-(4-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[DK-I-95-3]. A mixture of ethyl-4-chloro-6-methoxy-d3-quinoline-3- carboxylate DK-I-73-2 (2
g, 7.4 mmol), 4-methoxy-d3-phenylhydrazine DK-I-29-2 (1.26 g, 8.9 mmol), triethylamine
(0.90g, 8.9 mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h.
The resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-I-95-3 (0.9 g, 37.0%): 1H NMR (300 MHz, DMSO) δ
12.77 (s, 1H), 8.64 (s, 1H), 8.11 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 9.1 Hz, 1H), 7.57 (s, 1H), 7.28
(d, J = 9.1 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H); 13C NMR (75 MHz, DMSO) δ 161.59, 157.98,
156.34, 143.00, 138.11, 134.10, 130.13, 121.70, 120.92, 120.50, 119.95, 114.23, 105.70, 102.96;
LRMS m/z calculated for C18H10D6N3O3 (M+H)+ 328.1569 found 328.25.
8-Methoxy-d3-2-(3-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[DK-I-97-1]. A mixture of ethyl-4-chloro-6-methoxy-d3-quinoline-3- carboxylate DK-I-73-2 (2
g, 7.4 mmol), 3-methoxy-d3-phenylhydrazine DK-I-26-3 (1.26 g, 8.9 mmol), triethylamine
(0.90g, 8.9 mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h.
The resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
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afford the product as a yellow powder DK-I-97-1 (1.8 g, 74.0%): 1H NMR (300 MHz, DMSO) δ
12.80 (s, 1H), 8.65 (s, 1H), 7.99 – 7.80 (m, 2H), 7.67 (d, J = 9.1 Hz, 1H), 7.59 (s, 1H), 7.41 –
7.21 (m, 2H), 6.76 (d, J = 8.2 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 162.25, 159.98, 158.04,
143.42, 141.76, 138.36, 130.26, 129.94, 121.73, 120.45, 120.10, 111.53, 109.64, 105.70, 105.11,
103.16; LRMS m/z calculated for C18H10D6N3O3 (M+H)+ 328.1569 found 328.30.
8-Methoxy-d3-2-(2-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[DK-I-98-1]. A mixture of ethyl-4-chloro-6-methoxy-d3-quinoline-3- carboxylate DK-I-73-2 (2
g, 7.4 mmol), 2-methoxy-d3-phenylhydrazine DK-I-43-3 (1.26 g, 8.9 mmol), triethylamine
(0.90g, 8.9 mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h.
The resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-I-98-1 (0.5 g, 20.0%): 1H NMR (300 MHz, DMSO)
δ 12.65 (s, 1H), 8.57 (s, 1H), 7.65 (d, J = 9.1 Hz, 1H), 7.54 – 7.28 (m, 3H), 7.28 – 7.21 (m, 1H),
7.16 (d, J = 8.3 Hz, 1H), 7.05 (t, J = 7.5 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 162.38, 157.83,
155.76, 142.92, 137.98, 130.05, 129.94, 129.83, 128.54, 121.50, 120.75, 120.65, 119.64, 112.91,
104.61, 102.88; LRMS m/z calculated for C18H10D6N3O3 (M+H)+ 328.1569 found 328.30.
7-Methoxy-2-(6-methoxypyridin-3-yl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [DKII-13-1]. A mixture of ethyl-4-chloro-7-methoxy-quinoline-3- carboxylate DK-I-40-1 (2 g, 7.5
mmol), 5-hydrazinyl-2-methoxypyridine DK-I-82-3 (1.26 g, 9.0 mmol), triethylamine (0.91g, 9.0
mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The
resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
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reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-II-13-1 (1.2 g, 49.0%): 1H NMR (300 MHz, DMSO)
δ 12.65 (s, 1H), 8.92 (d, J = 2.4 Hz, 1H), 8.68 (s, 1H), 8.43 (dd, J = 9.0, 2.6 Hz, 1H), 8.24 – 7.91
(m, 1H), 7.29 – 7.02 (m, 2H), 6.92 (d, J = 9.0 Hz, 1H), 3.88 (s, 6H); 13C NMR (75 MHz,
DMSO) δ 161.74, 160.98, 160.43, 143.86, 139.71, 137.45, 137.37, 131.88, 130.77, 124.13,
115.94, 112.59, 110.56, 106.22, 102.30, 56.00, 53.71; LRMS m/z calculated for C17H15N4O3
(M+H)+ 323.1144 found 323.25.
7-Methoxy-d3-2-(6-methoxypyridin-3-yl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[DK-I-86-1]. A mixture of ethyl-4-chloro-7-methoxy-d3-quinoline-3- carboxylate DK-I-57-1 (2
g, 7.4 mmol), 5-hydrazinyl-2-methoxypyridine DK-I-82-3 (1.24 g, 8.9 mmol), triethylamine
(0.90 g, 8.9 mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h.
The resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-I-86-1 (1.0 g, 41.0%): 1H NMR (300 MHz, DMSO) δ
12.69 (s, 1H), 8.92 (s, 1H), 8.69 (s, 1H), 8.43 (d, J = 9.0 Hz, 1H), 8.12 (d, J = 9.4 Hz, 1H), 7.18
(s, 2H), 6.92 (d, J = 9.0 Hz, 1H), 3.88 (s, 3H); 13C NMR (75 MHz, DMSO) δ 161.75, 161.01,
160.44, 143.88, 139.73, 137.46, 137.39, 131.88, 130.79, 124.15, 115.96, 112.57, 110.58, 106.22,
102.31, 53.72; LRMS m/z calculated for C17H12D3N4O3 (M+H)+ 326.1330 found 326.20.
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7-Methoxy-2-(6-methoxy-d3-pyridin-3-yl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[DK-II-60-1]. A mixture of ethyl-4-chloro-7-methoxy-quinoline-3- carboxylate DK-I-40-1 (2 g,
7.5 mmol), 5-hydrazinyl-2-methoxy-d3-pyridine DK-II-56-1 (1.28 g, 9.0 mmol), triethylamine
(0.91 g, 9.0 mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h.
The resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-II-60-1 (1.2 g, 49.0%): 1H NMR (300 MHz, DMSO)
δ 12.68 (s, 1H), 8.91 (d, J = 2.1 Hz, 1H), 8.68 (s, 1H), 8.42 (dd, J = 9.0, 2.4 Hz, 1H), 8.16 – 8.03
(m, 1H), 7.18 (d, J = 5.9 Hz, 2H), 6.92 (d, J = 9.0 Hz, 1H), 3.87 (s, 3H); 13C NMR (75 MHz,
DMSO) δ 161.74, 160.98, 160.44, 143.85, 139.69, 137.44, 137.39, 131.86, 130.77, 124.13,
115.94, 112.58, 110.54, 106.22, 102.29, 56.00; LRMS m/z calculated for C17H12D3N4O3
(M+H)+ 326.1330 found 326.30.
8-Chloro-2-(6-methoxypyridin-3-yl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [DK-II18-1]. A mixture of ethyl-4,6-dichloro-7-methoxy-3-carboxylate DKI- 35-1 (2 g, 7.4 mmol), 5hydrazinyl-2-methoxypyridine DK-I-82-3 (1.24 g, 8.9 mmol), triethylamine (0.90 g, 8.9 mmol)
and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The resulting
yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The reaction
mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids were
collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and hexanes
(2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to afford the
product as a yellow powder DK-II-18-1 (1.0 g, 41.0%): 1H NMR (300 MHz, DMSO) δ 12.96 (s,
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1H), 8.92 (d, J = 2.6 Hz, 1H), 8.77 (s, 1H), 8.42 (dd, J = 8.9, 2.6 Hz, 1H), 8.14 (s, 1H), 7.89 –
7.60 (m, 2H), 6.93 (d, J = 9.0 Hz, 1H), 3.89 (s, 3H); 13C NMR (75 MHz, DMSO) δ 161.62,
160.64, 142.70, 140.12, 137.57, 134.58, 131.66, 131.15, 130.92, 130.64, 122.11, 121.58, 120.38,
110.59, 106.25, 53.74; LRMS m/z calculated for C16H12ClN4O2 (M+H)+ 327.0649 found 327.25.
8-Chloro-2-(6-methoxy-d3-pyridin-3-yl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[DK-II-59-1]. A mixture of ethyl-4,6-dichloro-quinoline-3-carboxylate DKI- 35-1 (2 g, 7.4
mmol), 5-hydrazinyl-2-methoxy-d3-pyridine DK-II-56-1 (1.26 g, 8.9 mmol), triethylamine (0.90
g, 8.9 mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The
resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-II-59-1 (1.4 g, 57.0%): 1H NMR (300 MHz, DMSO)
δ 12.92 (s, 1H), 8.90 (d, J = 1.7 Hz, 1H), 8.74 (d, J = 9.1 Hz, 1H), 8.40 (dd, J = 8.9, 2.4 Hz, 1H),
8.09 (s, 1H), 7.78 – 7.61 (m, 2H), 6.90 (d, J = 8.9 Hz, 1H); 13C NMR (75 MHz, DMSO) δ
161.60, 160.63, 142.67, 140.06, 137.55, 134.55, 131.64, 131.13, 130.87, 130.60, 122.07, 121.56,
120.37, 110.55, 106.26; LRMS m/z calculated for C16H9D3ClN4O2 (M+H)+ 330.25 found
330.25.
7-Bromo-2-(6-methoxypyridin-3-yl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one [DK-II48-1]. A mixture of ethyl-7-bromo-4-chloroquinoline-3-carboxylate DK-I-52-1 (2 g, 6.3 mmol),
5-hydrazinyl-2-methoxypyridine DK-I-82-3 (1.06 g, 7.6 mmol), triethylamine (0.77 g, 7.6 mmol)
and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h. The resulting
yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The reaction
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mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids were
collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and hexanes
(2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to afford the
product as a yellow powder DK-II-48-1 (1.6 g, 67.0%): 1H NMR (300 MHz, DMSO) δ 12.81 (s,
1H), 10.29 – 10.27 (m, 1H), 8.89 (s, 1H), 8.75 (s, 1H), 8.40 (dd, J = 8.9, 2.2 Hz, 1H), 8.09 (d, J =
8.5 Hz, 1H), 7.86 (s, 1H), 7.68 (d, J = 8.1 Hz, 1H), 6.91 (d, J = 8.9 Hz, 1H), 3.88 (s, 3H); 13C
NMR (75 MHz, DMSO) δ 161.63, 160.61, 143.11, 140.38, 137.53, 136.95, 131.65, 130.88,
129.74, 124.54, 123.15, 122.26, 118.12, 110.61, 106.58, 53.74; LRMS m/z calculated for
C16H12BrN4O2 (M+H)+ 371.19 found 371.20.
7-Bromo-2-(6-methoxy-d3-pyridin-3-yl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[DK-II-58-1]. A mixture of ethyl-7-bromo-4-chloroquinoline-3-carboxylate DK-I-52-1 (1.20 g,
3.8 mmol), 5-hydrazinyl-2-methoxy-d3-pyridine DK-II-56-1 (0.65 g, 4.6 mmol), triethylamine
(0.46 g, 4.6 mmol) and xylenes (16 mL) was heated to reflux (138 ºC) and held at reflux for 2 h.
The resulting yellow-orange slurry was cooled to 100 ºC and diluted with ethanol (16 mL). The
reaction mixture was then refluxed at 80 ºC for 30 min and then cooled to 20-25 ºC. The solids
were collected by filtration and washed twice with a 1:1 mixture of ethanol (2.5 mL x 2) and
hexanes (2.5 mL x 2) and then washed twice with hexanes (5 mL x 2). The solid was dried to
afford the product as a yellow powder DK-II-58-1 (0.5 g, 35.0%): 1H NMR (300 MHz, DMSO)
δ 12.77 (s, 1H), 8.88 (d, J = 2.3 Hz, 1H), 8.75 (d, J = 8.4 Hz, 1H), 8.39 (dd, J = 8.9, 2.5 Hz, 1H),
8.07 (d, J = 8.5 Hz, 1H), 7.83 (s, 1H), 7.65 (d, J = 8.6 Hz, 1H), 6.90 (d, J = 8.9 Hz, 1H); 13C
NMR (75 MHz, DMSO) δ 161.60, 160.60, 143.08, 140.33, 137.51, 136.93, 131.63, 130.83,
129.70, 124.50, 123.11, 122.24, 118.10, 110.56, 106.58; LRMS m/z calculated for
C16H9D3BrN4O2 (M+H)+ 374.19 found 374.20.
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7-Methoxy(d3)-2-(phenyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one [RV-I- 37]. A mixture of
ethyl-4-chloro-7-methoxy-d3-quinoline-3-carboxylate DK-I-57-1 (0.01 mol, 0.324g),
phenylhydrazine hydrochloride (0.012 mol, 0.172g ) and TEA (0.012 mol, 0.12 g ) in 40 mL
xylene was refluxed for 4h, cooled to room temperature. The precipitated compound was
collected by filtration. The compound was recrystallized from methanol as a yellow colored
compound RV-I-37, yield 75 %, 0.22 g: mp > 260°C dec. 1H NMR (500 MHz, MeOD) 8.5 (s,
1H), 8.236(d, 1H, J=9.0Hz), 8.102(d, 2H, J= 9.0), 7.492-7.236(m, 5H,); 13C (125 MHz, MeOD)
161.4, 160.8, 156.2, 143.1, 139.3, 137.4, 137.1, 134.1, 124.0, 120.6, 115.8, 114.2, 112.6, 106.8,
102.2, 78.5, 55.69; HRMS m/z calculated for C17H11D3N3O2 295.1274 found 295.1272.
2-(4-Methoxyphenyl)-2H-pyrazolo[4,3-c][1,5]naphthyridin-3(5H)-one [RV-I-071]. A
mixture of ethyl 4-chloro-1,5-naphthyridine-3-carboxylate (0.01 mol, 0.236 g), 4methoxyphenylhydrazine hydrochloride (0.012 mol, 0.153g), triethylamine (0.012mol, 0.12 g)
and xylenes (40 mL) was heated to reflux (138ºC) and held at reflux for 4 hours. The resulting
yellow-orange slurry was cooled to room temperature and the solids were collected by filtration.
The solids washed twice with 20 ml water. Drying of the solid afforded the product as a yellow
powder RV-I-071 (0.268 g): 1H NMR (300 MHz, DMSO) δ 12.9 (s, 1H), 8.79 (s, 1H), 8.77 (s,
1H), 8.11-8.10(d, 2H, J= 9.0), 8.08 (s, 1H), 7.70-7.68 (m, 1H), 7.05- 7.03(d, 2H, J= 9.0), 3.80 (s,
3H); 13C NMR (75 MHz, DMSO) δ 161.49, 160.85, 156.56, 148.79.11, 143.06, 139.81, 136.60,
133.97,132.95, 127.93, 125.21, 120.91, 114.33, 109.42, 55.72; HRMS m/z calculated for
C16H12N4O2 (M+H)+ 293.1039 found 293.1037.
8-Bromo-6-fluoro-2-(4-methoxyphenyl)-2H-pyrazolo[4,3-c]quinolin- 3(5H)-one [MM-I-03].
A mixture of 0.5 g (1.5 mmol) of ethyl 6-bromo-4-chloro-8- fluoroquinoline-3-carboxylate MMI-02, 0.31 g (1.8 mmol) of (4-methoxyphenyl)hydrazine hydrochloride and Et3N (2 mL) was
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placed in a flask with xylene (8 mL) and heated for 4 h. The reaction was cooled at rt and
filtered. The solid was washed several times with hexane and water. Then, the solid was
dissolved in a base solution 3 N NaOH and stirred for 15 min. The base solution was neutralized
with 3 N HCl and filtrated. The solid was recrystallized using hot ethanol and dried in vacuo,
affording a yellow solid MM-I-03 (0.28 g, 48%): mp 333-334°C; 1H NMR (300 MHz, DMSO) δ
8.51 (s, 1H; H-6), 8.09 (s, 1H; H-8), 8.03 (d, J = 8.9 Hz, 2H; H-15 and H-19), 7.89 (d, J = 10.5
Hz, 1H; H-2), 7.01 (d, J = 9.0 Hz, 2H; H-16 and H-18), 3.78 (s, 3H; H-24); 13C NMR (75 MHz,
DMSO) δ 161.11 (s), 156.65 (s), 140.93 (s), 139.49 (s), 133.57 (s), 124.37 (s), 124.19 (s), 122.02
(s), 121.00 (s), 120.61 (s), 119.08 (q, J = 3.3, 1.9 Hz), 118.82 (s), 118.34 (s), 118.22 (s), 114.32
(s), 107.83 (s), 55.73 (s); HRMS m/z calculated for C17H11N3O2FBr 388.0091 found 388.0094.
2-(4-Methoxyphenyl)-7-(trifluoromethyl)-2H-pyrazolo[4,3-c]quinolin- 3(5H)-one [MM-I06]. Treatment of ethyl 4-chloro-7-(trifluoromethyl)quinoline-3-carboxylate MM-I-05 (0.5 g, 1.5
mmol) with (4-methoxyphenyl)hydrazine hydrochloride (0.57 g, 1.8 mmol) and TEA (2 mL) in 8
mL of xylene under reflux for 4 h afforded the corresponding product. The reaction was cooled
at rt and filtered. The solid was washed several times with hexane and water. An acid-base
crystallization was needed to remove the triethylamine salt, and it afforded yellow crystals MMI-06 (0.51 g, 82 %): mp 315 – 316°C; 1H NMR (300 MHz, DMSO) δ 12.93 (s, 1H; H-7), 8.84
(s, 1H; H-8), 8.40 (d, J = 8.4 Hz, 1H; H-6), 8.08 (d, J = 9.1 Hz, 2H; H-15 and H-19), 8.03 (s, 1H;
H-3), 7.83 (d, J = 8.1 Hz, 1H; H-1), 7.03 (d, J = 9.1 Hz, 2H; H-16 and H-18), 3.79 (s, 3H; H-22);
13C NMR (75 MHz, DMSO) δ 161.38 (s), 156.60 (s), 141.99 (s), 140.79 (s), 135.83 (s), 133.75
(s), 130.23 (s), 129.80 (s), 125.96 (s), 124.05 (s), 122.66 (q), 122.35 (s), 122.12 (s), 121.00 (s),
117.21 (q), 114.34 (s), 107.42 (s), 55.71 (s); HRMS m/z calculated for C18H12N3O2F3 360.0954
found 360.0943.
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2-(4-Chlorophenyl)-7-(trifluoromethyl)-2H-pyrazolo[4,3-c]quinolin- 3(5H)-one [MM-I-08].
The reaction of 0.5 g (1.6 mmol) of ethyl 4-chloro-7-(trifluoromethyl)quinoline-3-carboxylate
MM-I-05 with (4-chlorophenyl)hydrazine hydrochloride (0.47 g, 3.2 mmol) and 2 mL of Et3N in
8 mL of xylene at reflux for overnight afforded the product. The recrystallization of solid gave
yellow crystals MM-I-08 (0.44 g, 75%): mp 346 – 347°C; 1H NMR (300 MHz, DMSO) δ 12.98
(s, 1H; H-7), 8.84 (s, 1H; H-8), 8.34 (d, J = 8.3 Hz, 1H; H-1), 8.21 (d, J = 8.9 Hz, 2H; H-15 and
H-19), 7.98 (s, 1H; H-3), 7.80 (d, J = 8.3 Hz, 1H; H-6), 7.47 (d, J = 8.9 Hz, 2H; H-18 and H-16);
13C NMR (75 MHz, DMSO) δ 161.92 (s), 142.71 (s), 141.03 (s), 139.11 (s), 135.84 (s), 130.51
(s), 130.08 (s), 129.08 (s), 128.45 (s), 125.88 (s), 124.11 (s), 122.72 (q), 122.27 (s), 121.92 (s),
120.40 (s), 117.15 (q), 107.15 (s). HRMS m/z calculated for C17H9N3OF3Cl 364.0459 found
364.0453.
2-(4-Nitrophenyl)-7-(trifluoromethyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)- one [MM-I-09]. In
a flask containing ethyl 4-chloro-7-(trifluoromethyl)quinoline-3-carboxylate MM-I-05 (0.2 g,
0.66 mmol), (4-nitrophenyl)hydrazine (0.25 g, 1.3 mmol) and xylene (8 mL), was added 2 mL of
Et3N and the flask was immediately placed in oil bath previously heated at 150°C. After 4 h of
heating, the solid was collected by filtration and washed with hexane and water. The same
procedure of acid-base crystallization was used affording reddish solid MM-I-09 (0.035 g, 15
%): mp > 350°C; 1H NMR (300 MHz, DMSO) δ 13.09 (s, 1H; H-7), 8.89 (s, 1H; H-8), 8.41 (d, J
= 9.1 Hz, 2H; H-16 and H-18), 8.35 (d, J = 8.4 Hz, 1H; H-6), 8.27 (d, J = 9.1 Hz, 2H; H-15 and
H-19), 7.95 (s, 1H; H-3), 7.82 (d, J = 8.2 Hz, 1H; H-1); HRMS m/z calculated for C17H9N4O3F3
375.0700 found 375.0695.
2-(4-(Trifluoromethoxy)phenyl)-7-(trifluoromethyl)-2H-pyrazolo[4,3- c]quinolin-3(5H)-one
[MM-I-10]. A mixture of ethyl 4-chloro-7-(trifluoromethyl)quinoline-3- carboxylate MM-I-05
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(0.3 g, 1 mmol) with (4-(trifluoromethoxy)phenyl)hydrazine hydrochloride (0.48 g, 2 mmol) and
Et3N (2 mL) in 8 mL of xylene was heated at reflux for overnight. The solid was collected by
filtration and washed with hexane and water. The solid was dissolved in 3 N NaOH solution (10
mL) and precipitated with 3 N HCl (11 mL) solution. Then, a recrystallization using 15 mL
EtOH and 2 mL of water was used and afforded yellow crystals MM-I-10 (0.25 g, 60%): mp 286
– 287°C; 1H NMR (300 MHz, DMSO) δ 8.86 (s, 1H; H-8), 8.36 (d, J = 8.4 Hz, 1H; H-6), 8.29
(d, J = 9.0 Hz, 2H; H-15 and H-19), 7.99 (s, 1H; H- 3), 7.81 (d, J = 8.3 Hz, 1H; H-1), 7.43 (d, J =
8.8 Hz, 2H; H-16 and H-18); 13C NMR (75 MHz, DMSO) δ 161.98 (s), 144.85 (s), 142.85 (s),
141.22 (s), 139.27 (s), 135.96 (s), 130.54 (s), 130.11 (s), 124.12 (s), 122.78 (s), 122.29 (q, J = 2.8
Hz), 121.98 (s), 120.37 (s), 117.25 (q, J = 8.4, 4.7 Hz), 107.07 (s); HRMS m/z calculated for
C18H9N3O2F6 414.0672 found 414.0674.
2-(4-Fluorophenyl)-7-(trifluoromethyl)-2H-pyrazolo[4,3-c]quinolin- 3(5H)-one [MM-I-11].
Treatment of ethyl 4-chloro-7-(trifluoromethyl)quinoline-3-carboxylate MM-I-05 (0.2 g, 0.66
mmol) with (4-fluorophenyl)hydrazine hydrochloride (0.22 g, 1.3 mmol) and Et3N (2 mL) in 8
mL of xylene under reflux for overnight afforded the corresponding product. The yellow crystals
MM-I-11 (0.15 g, 65%) were obtained by recrystallization with hot EtOH: mp 296 – 297 °C; 1H
NMR (300 MHz, DMSO) δ 12.98 (s, 11H; H-7), 8.84 (s, 11H; H-8), 8.36 (d, J = 8.3 Hz, 1H; H6), 8.19 (dd, J = 9.0, 5.1 Hz, 2H; H-15 and H-19), 8.00 (s, 1H; H-3), 7.81 (d, J = 8.4 Hz, 1H; H1), 7.27 (t, J = 8.9 Hz, 2H; H-16 and H-18); 13C NMR (75 MHz, DMSO) δ 161.69 (s), 160.85
(s), 157.66 (s), 142.41 (s), 140.94 (s), 136.74 (s), 135.78 (s), 130.21 (q), 124.09 (d), 124.07 (s),
122.73 (q), 121.99 (s), 120.97 (d), 117.14 (q), 115.95 (s), 115.65 (s), 107.21 (s); HRMS m/z
calculated for C17H9N3OF4 348.0755 found 348.0766.
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2-(3-Methoxyphenyl)-7-(trifluoromethyl)-2H-pyrazolo[4,3-c]quinolin- 3(5H)-one [MM-I12]. The reaction of 0.5 g (1.6 mmol) of ethyl 4-chloro-7- (trifluoromethyl)quinoline-3carboxylate MM-I-05 with (3-methoxyphenyl)hydrazine hydrochloride (0.575 g, 4.1 mmol) and
2 mL of Et3N in 15 mL of xylene at reflux for overnight afforded the product. Recrystallization
gave yellow crystals MM-I-12 (0.762 g, 46 %): mp > 350 °C; 1H NMR (500 MHz, DMSO) δ
8.85 (s, 1H, H-8), 8.43 (d, J = 8.3 Hz, 1H, H-6), 8.04 (s, 1H, H-15), 7.88 – 7.80 (m, 3H, H-1 H-3
and H-19), 7.37 (t, J = 8.2 Hz, 1H, H-18), 6.79 (dd, J = 8.2, 2.4 Hz, 1H, H-17), 3.82 (s, 3H, H22).
8-Bromo-2-(4-chlorophenyl)-6-fluoro-2H-pyrazolo[4,3-c]quinolin-3(5H)- one [MM-I-13]. A
mixture of ethyl 6-bromo-4-chloro-8-fluoroquinoline-3-carboxylate MM-I-02 (0.2 g, 0.64 mmol)
with (4-chlorophenyl)hydrazine hydrochloride (0.18 g, 1.2 mmol) and Et3N (2 mL) in 8 mL of
xylene was heated at reflux for overnight. The solid was collected by filtration and washed with
hexane and water. The solid was dissolved in 10 mL of DMSO. The solution was poured in 30
mL of H2O, and filtered in order to remove the triethylamine salt. Then, a recrystallization using
15 mL EtOH and 2 mL of water was used and afforded yellow crystals MM-I-13 (0.17 g, 70%):
1H NMR (300 MHz, DMSO) δ 8.54 (s, 1H, H-8), 8.22 (d, J = 8.9 Hz, 2H, H-15 and H-19), 8.11
(s, 1H, H-6), 7.92 (dd, J = 10.6, 1.8 Hz, 1H, H-2), 7.50 (d, J = 8.9 Hz, 2H, H-16 and H-18).
8-Bromo-6-fluoro-2-(4-fluorophenyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)- one [MM-I-18].
Treatment of ethyl 6-bromo-4-chloro-8-fluoroquinoline-3-carboxylate MM-I- 02 (0.2 g, 0.64
mmol) with (4-fluorophenyl)hydrazine hydrochloride (0.22 g, 1.3 mmol) and Et3N (2 mL) in 8
mL of xylene under reflux overnight afforded the corresponding product. The yellow crystals
MM-I-18 (0.120 g, 50 %) were obtained by recrystallization with hot EtOH: 1H NMR (300
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MHz, DMSO) δ 13.02 (s, 1H, H-7), 8.55 (s, 1H, H-8), 8.25 – 8.15 (m, 2H, H-15 and H-19), 8.12
(s, 1H, H-6), 7.93 (dd, J = 10.6, 1.9 Hz, 1H, H-2), 7.29 (t, J = 8.9 Hz, 2H, H-16 and H-18).
7-Methoxy-2-(4-(trifluoromethoxy)phenyl)-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[CW-02-082]. To a clean and dry flask ethyl 4-chloro-7-methoxyquinoline- 3-carboxylate DK-I40-1 (531 mg, 2 mmol, 1 eq), (4-(trifluoromethoxy)phenyl)hydrazine hydrochloride (686 mg, 3
mmol, 1.5 eq), xylene (10 mL), and TEA (607 mg, 6 mmol, 3 eq) were charged. The mixture
was immediately transferred to pre-heated oil bath (150 ºC) and heated for 12h at which point it
was cooled to 0 ºC via ice/water bath and hexanes (20 mL) were added in one portion. The
yellow solid was filtered and dried (1.35g product + TEA*HCl). The mixture was purified via
general purification method A and B. The solid was dried overnight under high vacuum
obtaining the pure product in 75% yield (563 mg) as a yellow powder CW-02-082: 1H NMR
(300 MHz, DMSO) δ 12.71 (s, 1H), 8.71 (s, 1H), 8.33 (s, 2H), 8.12 (s, 1H), 7.45 (s, 2H), 7.18 (s,
2H), 3.88 (s, 3H); 13C NMR (75 MHz, DMSO) δ 162.18, 161.10, 144.50, 144.48, 143.97,
139.93, 139.60, 137.61, 124.15, 121.98, 120.12, 115.95, 112.52, 106.45, 102.37, 56.00; HRMS
(ESI) (M + H),Calcd. for C18H13F3N3O3 376.0909, Found 376.0914.
7-Methoxy-2-(4-methoxyphenyl)-6-methyl-2,5-dihydro-3H-pyrazolo[4,3- c]quinolin-3-one
[CW-02-073]. To a clean and dry flask ethyl 4-chloro-7-methoxy-8- methylquinoline-3carboxylate (560 mg, 2 mmol, 1 eq), (4-methoxyphenyl) hydrazine hydrochloride (524 mg, 3
mmol, 1.5 eq), xylene (10 mL), and TEA (607 mg, 6 mmol, 3 eq) were charged. The mixture
was immediately transferred to pre-heated oil bath (150 ºC) and heated overnight at which point
it was cooled to 0 ºC via ice/water bath and hexanes (20 mL) were added in one portion. The
yellow solid was filtered and dried (1.15g product + TEA*HCl). The mixture was purified via
general purification method B. The solid was dried for 12h under high vacuum obtaining the
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pure product in 70% yield (470 mg) as a yellow solid: 1H NMR (300 MHz, DMSO) δ 11.80 (s,
1H), 8.37 (s, 1H), 8.08 (dd, J = 8.9, 5.1 Hz, 3H), 7.29 (d, J = 9.0 Hz, 1H), 7.01 (d, J = 9.1 Hz,
2H), 3.92 (s, 3H), 3.78 (s, 3H), 2.36 (s, 3H); 13C NMR (75 MHz, DMSO) δ 161.39, 158.24,
156.22, 143.58, 139.11, 135.37, 134.09, 121.18, 120.66, 114.33, 114.25, 112.80, 111.11, 106.53,
56.65, 55.68, 10.03; HRMS (ESI) (M + H), Calcd. for C19H18N3O3 336.1348; Found 336.1240.
7-Methoxy-6-methyl-2-phenyl-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin- 3-one [CW-02-078].
To a clean and dry flask ethyl 4-chloro-7-methoxy-8-methylquinoline-3- carboxylate (560 mg, 2
mmol, 1 eq), phenylhydrazine hydrochloride (434 mg, 3 mmol, 1.5 eq), xylene (10 mL), and
TEA (607 mg, 6 mmol, 3 eq) were charged. The mixture was immediately transferred to preheated oil bath (150 ºC) and heated overnight at which point it was cooled to 0 ºC via ice/water
bath and hexanes (20 mL) were added in one portion. The yellow solid was filtered and dried
(1.17g product + TEA*HCl). The mixture was purified via general purification method A. The
solid was dried overnight under high vacuum obtaining the pure product in 84% yield (513 mg)
as yellow crystals: 1H NMR (500 MHz, DMSO) δ 11.86 (s, 1H), 8.42 (s, 1H), 8.22 (d, J = 8.2
Hz, 2H), 8.11 (d, J = 8.8 Hz, 1H), 7.45 (t, J = 7.9 Hz, 2H), 7.33 (d, J = 8.9 Hz, 1H), 7.17 (t, J =
7.3 Hz, 1H), 3.95 (s, 3H), 2.39 (s, 3H); 13C NMR (126 MHz, DMSO) δ 162.00, 158.41, 144.04,
140.60, 139.43, 135.49, 129.15, 124.29, 121.32, 118.98, 114.42, 112.77, 111.22, 106.48, 56.71,
10.08; HRMS (ESI) (M + H), Calcd. for C18H16N3O2 306.1243; Found 306.1237.
7-Methoxy-6-methyl-2-(4-(trifluoromethoxy)phenyl)-2,5-dihydro-3Hpyrazolo[ 4,3c]quinolin-3-one [CW-02-079]. To a clean and dry flask ethyl 4-chloro-7- methoxy-8methylquinoline-3-carboxylate (560 mg, 2 mmol, 1 EQ), (4-(trifluoromethoxy) phenyl)
hydrazine (689 mg, 3 mmol, 1.5 eq), xylene (10 mL), and TEA (607 mg, 6 mmol, 3 eq) were
charged. The mixture was immediately transferred to pre-heated oil bath (150 ºC) and heated
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overnight at which point it was cooled to 0 ºC via ice/water bath and hexanes (20 mL) were
added in one portion. The yellow solid was filtered and dried (1.14g product + TEA*HCl). The
mixture was purified via general purification method B. The solid was dried overnight under
high vacuum obtaining the pure product in 68% yield (530 mg) as a yellow powder: 1H NMR
(300 MHz, DMSO) δ 11.92 (d, J = 5.8 Hz, 1H), 8.44 (d, J = 6.3 Hz, 1H), 8.33 (d, J = 9.1 Hz,
2H), 8.09 (d, J = 8.9 Hz, 1H), 7.45 (d, J = 8.9 Hz, 2H), 7.32 (d, J = 9.0 Hz, 1H), 3.94 (s, 3H),
2.37 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 162.11, 158.52, 144.48, 144.44, 139.74, 139.57,
135.51, 122.35, 122.00, 121.34, 120.10, 114.51, 112.64, 111.31, 106.11, 56.70, 10.05; HRMS
(ESI) (M + H), Calcd. for C19H15F3N3O3 390.1066; Found 390.1068.
7-Methoxy-2-(4-methoxyphenyl)-2,5-dihydro-3H-pyrazolo[4,3- c][1,6]naphthyridin-3-one
[CW-03-030]. To a clean and dry flask ethyl 4-chloro-7- methoxy-1,6-naphthyridine-3carboxylate (78 mg, 0.29 mmol, 1 eq), (4- methoxyphenyl)hydrazine hydrochloride (76 mg,
0.435 mmol, 1.5 eq), xylene (5 mL), and TEA (89 mg, 0.87 mmol, 3 eq) were charged. The
mixture was immediately transferred to pre-heated oil bath (150 ºC) and heated overnight at
which point it was cooled to 0 ºC via ice/water bath and hexanes (20 mL) were added in one
portion. The yellow solid was filtered and dried (product + TEA*HCl). The mixture was purified
via FCC (7% MeOH in DCM) and general purification method A. The solid was dried overnight
under high vacuum obtaining the pure product in 47% yield (44 mg) as orange crystals: 1H NMR
(300 MHz, DMSO) δ 12.60 (s, 1H), 9.06 (s, 1H), 8.67 (s, 1H), 8.02 (d, J = 9.1 Hz, 2H), 7.02 (d,
J = 9.1 Hz, 2H), 6.89 (s, 1H), 3.96 (s, 3H), 3.79 (s, 3H); 13C NMR (75 MHz, DMSO) δ 164.59,
161.30, 156.46, 144.09, 143.92, 141.36, 141.25, 133.63, 120.84, 114.32, 110.13, 108.40, 96.94,
55.72, 54.49; HRMS (ESI) (M + H), Calcd. for C17H15N4O3 323.1144; Found 323.1138.
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7-Chloro-2-(4-methoxyphenyl)-2,5-dihydro-3H-pyrazolo[4,3- c][1,6]naphthyridin-3-one
[CW-03-033]. To a clean and dry flask ethyl 4,7-dichloro-1,6- naphthyridine-3-carboxylate (120
mg, 0.443 mmol, 1 eq), (4-methoxyphenyl)hydrazine hydrochloride (116 mg, 0.664 mmol, 1.5
eq), xylene (5 mL), and TEA (135 mg, 1.33 mmol, 3 eq) were charged. The mixture was
immediately transferred to pre-heated oil bath (150 ºC) and heated overnight at which point it
was cooled to 0 ºC via ice/water bath and hexanes (15 mL) were added in one portion. The
yellow solid was filtered and dried (product + TEA*HCl). The mixture was purified via FCC
(7% MeOH in DCM) and general purification method B. The solid was dried overnight under
high vacuum obtaining the pure product in 61% yield (88 mg) as an orange solid: 1H NMR (300
MHz, DMSO) δ 12.87 (s, 1H), 9.21 (s, 1H), 8.81 (s, 1H), 8.03 (d, J = 9.1 Hz, 2H), 7.61 (s, 1H),
7.03 (d, J = 9.1 Hz, 2H), 3.79 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 161.08, 156.70, 150.07,
146.16, 143.21, 141.60, 140.52, 133.41, 121.00, 114.38, 114.10, 113.06, 109.77, 55.73; HRMS
(ESI) (M + H), Calcd. for C16H12ClN4O2 327.0649; Found 327.0654.
Purification Method A: The crude compound was heated to reflux in ethanol (10mL/g) and a
solution of ethanol/water (50% H2O, 50% ethanol) was slowly added until all the compound was
completely dissolved at reflux. Once dissolved, water was added dropwise at reflux until the
solution became slightly cloudy. The solution was cooled slowly to rt and in most cases
microcrystals began to accumulate. The solution was further cooled to 0ºC via an ice-bath,
filtered, and the solids were washed with cold aq solution of ethanol/water (50% H2O, 50%
ethanol) and dried overnight. If necessary, compounds were further dried under high vacuum.
Purification Method B: The crude compound was dissolved in a minimal amount of DMSO and
water was added until the compound was completely precipitated from the DMSO solution. The
product was filtered and washed with water. The amorphous powder was ground with a mortar
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and pestle and dried under high vacuum for 24h or until little trace of water was present in the
HNMR spectrum.
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CHAPTER TEN
IN VITRO AND IN VIVO CHARACTERISTICS OF NOVEL, SELECTIVE,
AND POTENT α6 POSITIVE ALLOSTERIC MODULATORS
I.

IN VITRO EXPERIMENTS AND RESULTS.
The first step in the determination of whether or not these novel pyrazoloquinlinones

have the necessary activity/selectivity at the α6ß3γ2 receptor is to complete oocyte assays on the
α1-6ß3γ2 receptors. Unfortunately, these oocyte assays are very time consuming, thus data on the
novel compounds prepared in the earlier section is still incomplete. However, data on a number
of compounds has been completed and more compounds selective to α6 receptors have been
discovered.
Where oocyte data has not yet been possible or is incomplete, other in vitro assays are
also being used to determine other pharmalogical characteristics of these novel ligands.
Currently, assays to determine water solubility and metabolic rate of these novel ligands are
routinely run on new analogs. In the future, a more complete pharmacokintetic (PK) analysis of
ligands identified as strong leads will also be accomplished.

1.

Oocyte data.

The oocyte data for compounds 6 and 11 are presented in Figures 10-1 and 10-2,
respectively, for comparison. As described in chapter 9, Compound 6 acts almost exclusively at
α6 receptors while it is nearly silent at α1-5ß3γ2. Compound 11, while not as selective as
Compound 6, exhibited much more potent activity on α6 receptor subtypes in vitro.
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Figure 10-1: Compound 6, oocyte efficacy data.

Figure 10-2: Compound 11, oocyte efficacy data.
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New compounds with complete oocyte data include LAU 159 (32) and LAU 463 (38).
These compounds along with their oocyte efficacy data are presented in Figures 10-3 and 10-4
respectively.
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Figure 10-3: LAU 159, oocyte efficacy data.

Figure 10-4: LAU 463, oocyte efficacy data.

Incomplete efficacy data, that is n < 3 and/or only α6ß3γ2 receptors have been determined
on a variety of other novel analogs (Table 10-1). A number of these ligands act as selective α6
agonists, including DK-I-56-1 (19) and RV-I-29 (20). Both of which are deuterated derivatives
of the lead ligand Compound 6. The slightly lower and statistically relevant efficacy of 20 is
thought to be due to a slightly impure sample. Prior to in vivo testing 20 was more thoroughly
purified. Compound 6 is included for reference.
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Table 10-1: Oocyte efficacy data obtained; to date.
Compound at 1mM
10 mM
Compound 6
DK-I-56-1 (19)
RV-I-29 (20)
DK-I-60-3 (21)
DK-I-94-1 (22)
CW-03-030a (25)
DK-I-86-1 (27)
DK-I-59-I (33)
DK-I-87-1 (35)
DK-I-58-1 (39)
DK-I-92-1 (40)

α6ß3γ2
300±30
570±100
270±30
500±80
190±20
370±40
280±40
600±100
NT
~220
120±10
210±15
160±15
230±30
NT
160±30
~100
NT
150±15
400±60
NT
~220

α1ß3γ2

α1ß3

α5ß3γ2

NT
NT
NT
140±30 180±30 220±20
NT
NT
NT
170±15 140±20
NT

NT

NT

NT
NT
NT
200±10 180±70 390±40
NT
NT
NT
~200
NT
NT
NT
220±20
NT
NT
NT
100±10 ~110
80±10
NT
NT
NT
~110
~80
NT
NT
NT
NT
NT
NT
NT
~140 400±25
NT

~200

NT

NT = not tested

While it is clear that the deuterated analogs of lead ligand Compound 6 retain α6 activity,
of the other novel ligands tested so far many are only weakly efficacious at α6 subtypes. This
adds valuable information for future SAR studies, for example comparison of 25 and 27 show a
statistically relevant difference in selectivity dependent upon the position of the pyridine ring
(Figure 10-5).
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Figure 10-5: Pyridine ring positioning.

Although 27 is a deuterated analog, it has been previously shown that the deuterium
atoms do not influence efficacy nor the subtype selectivity in a statistically relevant fashion.
However, the position of the pyridines rings, ring A in 25 and ring D in 27, effects a relevant
change in selectivity for α6. While both show only mild efficacy at α6, 27 retains selectivity
whereas pyridine 25 was found to also exhibit mild efficacy at the α1 receptor subtype, which
could lead to some negative side effects including sedation, ataxia, and addiction. This valuable
information will aid in the future design of ring D analogs, which should lead to more soluble
compounds that retain both activity and α6 selectivity.

2.

Solubility data.

The pyridine analogs discussed above were synthesized for the sole basis to improve
water solubility for future in vivo studies. Since the ring A pyridine 25 was found to be
nonselective in preliminary in vitro oocyte efficacy assays, the solubility of this compound was
not tested. The first four compounds examined were tested to show the enhanced solubility of
pyridine analog 27; in the future the solubility of many more analogs will be tested.
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Table 10-2: Solubility data on select compounds.

Compounds
DK-I-56-1 (19)
DK-I-60-3 (21)
DK-I-86-1 (27)
DK-I-58-1 (39)

Water solubility (ng/µL)
11.40
16.00
211.00
9.20

Determined by HPLC

From these data it can be seen that the pyridine analog 27 is nearly 20 times more water
soluble then the other analogs. As described earlier, the oocyte efficacy of 27 indicated that
selectivity at α6 was retained, however, it was less efficacious then the related α6 selective
ligands discovered thus far. The increase in solubility, however, may be a crucial component for
future in vivo work. Moreover, this indicated that pyridine analogs are an important target for
future SAR studies since these pyridine analogs may have better oral bioavailability then other
lead compounds. Unfortunately, synthesis of the hydrochloride salts of these pyridine analogs
has been complicated because demethylation of the pyridine OCH3 group has been observed
when the compound was subjected to acidic conditions. Analogs with the pyridine nitrogen and
methoxy group meta to one another are currently being prepared; synthesis of the hydrochloride
salts of these analogs may be more straightforward.
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3.

Metabolic data.

Deuterated methoxy groups have been shown to slow down metabolism for a number of
different drug candidates. The methoxy groups present in Compound 6 were thought to likely
contribute to metabolism of these compounds. Illustrated in Table 10-3 and 10-4 are metabolic
data obtained in vitro on both human liver microsomes and mouse liver microsomes,
respectively. It was shown that deuterated analogs exhibit a significantly longer half-life then
the non-deuterated analogs. The first 4 compounds in each table 10-3 and 10-4, compounds 6,
19, 20, and 21 are perhaps the most indicative of this increase in metabolic stability. Illustrated
in Figure 10-6 are the structures of these ligands.
Figure 10-6: Analogs with key metabolic stability.
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As described in Table 10-3, lead ligand Compound 6 was shown to have a half-life of
~200 minutes, whereas the ring D mono-deuterated analog 19 was shown to have a half-life of
~500 minutes – nearly double that of the parent compound. The ring A mono-deuterated analog
20 was found to have a half-life of ~3000 minutes and the di-deuterated analog 21 was fond to
have a half-life of ~700 minutes. This increase in metabolic stability is relevant and important
for in vivo work, which should lead to a longer time of effect in vivo compared to Compound 6.
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Day

Half-Life
(min)

Compound 6

HLM

1
175.00
2
250.00
1
516.39
DK-I-56-1 (19)
HLM
2
522.62
1
3387.00
RV-I-029 (20)
HLM
2
2558.00
1
875.33
DK-I-60-3 (21)
HLM
2
686.13
1
759.00
DK-II-13-1 (26)
HLM
2
828.05
1
915.33
DK-I-86-1 (27)
HLM
2
589.28
1
204.18
LAU 159 (32)
HLM
2
209.36
1
622.64
DK-I-59-1 (33)
HLM
2
675.43
1
96.85
LAU 463 (38)
HLM
2
110.88
1
194.28
DK-I-58-1 (39)
HLM
2
214.95
HLM: Human Liver Microsomes, NT: not tested

Compound

Microsome
Type

50.10
53.16
693.00
792.00
313.00
164.00
187.40
177.70
260.00
261.93
15.23
15.73
60.00
103.00
2.63
5.19
9.48
11.18

NT

STD (+/min)

Intrinsic
Clearance
(mL/min/mg)
0.4
0.277
0.1342
0.1326
0.02
0.027
0.07917
0.101
0.09131
0.08369
0.07571
0.1176
0.3394
0.331
0.1113
0.1026
0.7155
0.625
0.3567
0.3224

Table 10-3: In vitro metabolic stability on Human Liver Microsomes (HLM).

8
5.6
2.684
2.652
0.4
0.4
1.5834
2.02
1.8262
1.6738
1.5142
2.352
6.7888
6.62
2.226
2.052
14.31
12.5
7.134
6.448

Metabolic Rate
(nmol/min/mg)

%
remaining
at 60min
87.00
85.20
91.65
91.74
95.20
95.50
91.74
91.28
92.29
93.41
93.03
91.56
81.53
81.36
92.85
93.13
65.23
68.50
80.55
82.35

1.00
1.00
0.14
0.10
1.00
1.00
0.20
0.17
0.16
0.13
0.16
0.11
0.16
0.16
0.07
0.11
0.10
0.17
0.11
0.11

STD
(+/- %)
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MLM
MLM
MLM

DK-I-59-1 (33)

LAU 463 (38)

DK-I-58-1 (39)

MLM: Mouse Liver Microsomes

MLM

DK-I-60-3 (21)

LAU 159 (32)

MLM

RV-I-029 (20)

MLM

MLM

DK-I-56-1 (19)

DK-I-86-1 (27)

MLM

Compound 6

MLM

MLM

Compound

DK-II-13-1 (26)

Microsome
Type
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2

202.39
186.14
641.07
616.54
913.88
801.80
836.35
857.35
136.05
142.35
581.37
519.88
89.72
88.42
154.92
176.56
107.69
118.66
138.10
140.85

10.45
12.37
77.00
69.00
280.85
189.52
280.00
273.00
5.41
6.08
93.00
63.57
5.12
5.32
7.40
7.85
3.82
6.48
8.25
6.11

Half-Life STD (+/Day
(min)
min)

Intrinsic
Clearance
(mL/min/mg)
0.3424
0.3723
0.1081
0.1124
0.07583
0.08643
0.08286
0.0803
0.5095
0.4868
0.1192
0.1333
0.7724
0.7837
0.4473
0.3925
0.6435
0.584
0.5018
0.492

Table 10-4: In vitro metabolic stability on Mouse Liver Microsomes (MLM).

6.848
7.446
2.161
2.248
1.5116
1.7286
1.6572
1.6166
10.19
9.736
2.384
2.666
15.448
15.674
8.946
7.85
12.87
11.68
10.036
9.84

Metabolic Rate
(nmol/min/mg)

%
remaining
at 60min
81.20
79.51
92.66
92.94
93.31
93.03
93.13
93.03
74.14
75.40
91.65
91.10
60.34
59.32
75.48
77.70
67.22
70.70
73.40
74.29

0.12
0.16
0.10
0.09
0.17
0.15
0.20
0.19
0.12
0.13
0.14
0.11
0.23
0.24
0.13
0.10
0.13
0.19
0.18
0.13

STD
(+/- %)

II.

IN VIVO EXPERIMENTS AND RESULTS.
Novel pyrazoloquinolinones with α6 efficacy and α6 subtype selectivity were chosen for

in vivo studies in a number of mouse assays to probe the neurological activity of these ligands
(Figure 10-7). The first assay to be discussed is the measurement of the concentration
distribution between plasma and brain of each ligand in mice. This pharmacokinetic (PK)
analysis helps determine the uptake of the drug when injected intraperitoneally (i.p.), as well as
the free concentration reached in the brain of the mouse. Since these ligands are presumed to
only act on the central nervous system, crossing the blood-brain-barrier is necessary for a
pharmacological response. The free fraction in the brain is what binds to the receptor, thus this
fraction is also very important.
Since these compound bind and act via the BZ site at α6ß3γ2 receptors, it was also
extremely important to determine whether or not these novel selective ligands have the usual
effects that are associated with benzodiazepines such as diazepam. These effects include ataxia,
dependence, and sedation among others. These effects are viewed as negative side-effects for a
number of indications, including those under study here. Assays that help determine whether or
not benzodiazepine-like effects were seen with these novel pyrazoloquinolinone analogs were
thus completed. These will also be discussed in detail in the sections to follow.
Assays that have helped elucidate the role of α6 receptors tested for this study include
pre-pulse inhibition assays, migraine assays, and IoN-CCL rat assays. These assays will be
described in detail in this section. Future assays that are currently being completed or planned
will also be discussed.
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Figure 10-7: Ligands chosen for in vivo studies.

1.

Plasma/Brain distribution data.

As described earlier, blood-brain-barrier penetration is essential to potent activity for all
CNS active ligands. This can be measured in vivo by dosing animals and at predetermined time
intervals collecting blood samples from both the body and the brain. Moreover, estimates of the
free brain concentration, that is the ligand not bound to proteins, can also be determined by these
assays. While protein binding is a common phenomenon in CNS drugs for transport; on the
other hand, when bound to protein it is unlikely that the ligand will bind to the α6ß3γ2 receptor
subtype in question. This binding, however, is generally reversible and often in equilibrium with
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the ‘free fraction’ of ligand, thus moderate protein binding is often not a major concern for CNS
drugs.
Figure 10-8: Plasma/Brain distribution of Compound 6 in rats.

The lead compound, Compound 6, was found to have adequate brain concentration for a
candidate to target the CNS. Moreover, it was found that a steady concentration of ligand was
still present 12 hours post dosing. This may signify these compounds will be long-lasting in
vivo. Analysis of the data for the deuterated analog DK-I-56-1 indicated a similar concentration
in vivo to Compound 6 when dosed i.p., however, with a slightly lower half-life (Figure 10-9).
Estimation of the free brain concentration indicated that a substantial amount of ligand was not
protein bound.
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Figure 10-9: Plasma/Brain distribution of DK-I-56-1 in rats.

Figure 10-10: Plasma/Brain distribution of DK-I-86-1 in rats.
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Unlike Compound 6 and DK-I-56-1, examination of the data for the ring D pyridine
analog DK-I-86-1 indicated a much lower plasma concentration with a Cmax of just 1256
ng/mL. This is compared to Compound 6 which had a Cmax of 3667 ng/mL, nearly 3 times
higher. However, analysis of the data indicated DK-I-86-1 still obtains a substantial brain
concentration (Cmax = 215 ng/mL) with the longest half-life of all ligands tested (9 hours).
These beneficial characteristics, along with better water solubility, make DK-I-86-1 an
interesting candidate for future in vivo studies.
Figure 10-11: Plasma/Brain distribution of DK-I-56-1 in mice.
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Studies of DK-I-56-1 in mice have shown a dose dependence relating to the
concentration of ligand in both plasma and brain (Figure 10-11). Interesting to note is the
extreme increase of brain concentration of DK-I-56-1 when a 30 mg/kg dosage was used. While
these results clearly show that DK-I-56-1 is a suitable drug candidate for both rats and mice, it is
clear that in mice higher doses, such as 30 mg/kg as used in this study, provided higher brain
concentrations in a dose response curve manner.

2.

Battery of common BZ ligand in vivo studies.

Since ligands that activate the BZ site have been known to elicit a number of undesirable
side-effects, it was important to determine if these novel α6 selective ligands also exhibited some
of these negative side-effects especially from activation of α1ß2/3γ2 subtypes. A number of assays
have been carried out to help determine these effects and the rotorod assay is one of the most
important assays to test for the α1 receptor-mediated ataxia and sedation (Figure 10-12). While
not only measuring the ability of the mouse/rat to stay on the rod, grip strength can be measured
as well in regard to muscle relaxation (Figure 10-13).
Figure 10-12: Rotarod performance with Compound 6.
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Figure 10-13: Grip strength performance with Compound 6.

Analysis of the data from these initial tests indicated that at a dose of 3 mg/kg there was
essentially no difference in rotarod timing or grip strength seen on administration of Compound
6. These positive results indicate that unlike a number of typical benzodiazepine drugs,
Compound 6 is unlikely to be ataxic or cause any gross motor coordination difficulties.
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Figure 10-14: Test for a sedation effect of Compound 6.

Figure 10-15: Open arms distance in elevated plus maze.
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Figure 10-16: Open arms duration in elevated plus maze.

Figure 10-17: Rearing number.
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Analysis of the assays described above in Figures 10-14, 10-15, 10-16, and 10-17 detail
common assays for benzodiazepine ligands. Analysis of the sedation data in Figure 10-14
confirmed that Compound 6 has no sedative effect, in agreement with the data from the rotarod
assay. The elevated plus maze assay is an attempt to assay anxiety in mice. Mice that spend
more time in the “open arm” section of the elevated maze are thought to feel less anxiety then
mice that stay in the “closed arm” portion. From these data, it was shown that Compound 6
exhibited a dose-response anti-anxiety effect on mice, clearly a beneficial effect. The rearing in
a closed maze pertains to the number of times a mouse goes on their rear legs to view their
surroundings; analysis of the data in Figure 10-17 indicated that Compound 6 at both 3 and 10
mg/kg exhibited little difference from vehicle.
These assays together show that Compound 6, and likely α6 receptors in general, have
positive biological effects while at the same time do not include the negative effects exhibited by
other non-selective benzodiazepines – specifically α1 ligands which are known to be sedative,
addictive, ataxic, amnesic, and cause tolerance and addiction. The anti-anxiety effect of
Compound 6 was unexpected, since this usually emanates in mice via α2 and α3 receptor
subtypes and will have to be verified in a Vogel conflict test of anxiolysis.

3.

Studies of prepulse inhibition (PPI).

Prepulse inhibition (PPI) is a neurological phenomenon in which a weaker pulse,
generally acoustic, inhibits the startle response to a subsequent stronger pulse. In this study,
sensorimotor gating deficits which manifest themselves in neurological diseases such as
schizophrenia, OCD, and Tourette syndrome were studied by impairing mice with
methamphetamine and subsequently measuring the effect on PPI. Methamphetamine is a
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recreational and addictive stimulant drug that when administered can result in a behavior similar
to symptoms of schizophrenia or other sensorimotor gating deficits. In terms of PPI, when under
the effects of methamphetamine, the ‘prepulse’ no longer inhibits the response to the ‘pulse’
showing the mice to be experiencing more erratic behavior. Rescuing the PPI is thus defined as
reducing this erratic behavior to the point where the ‘prepulse’ is again able to inhibit a response
to the ‘pulse’ in a significant fashion. Illustrated in Figure 10-18 is an example of the
methamphetamine PPI mouse model. The designation C6 refers to Compound 6 and C11 refers
to Compound 11.
Figure 10-18: PPI results with Compound 6 and Compound 11.

The white bars under the label “Vehicle” represent the prepulse inhibition % seen in mice
when a short prepulse (71 dB or 77 dB) was played followed by a louder pulse (115 dB). To put
the difference in noise levels in perspective 71 dB is similar to a normal conversation, 77 dB is
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similar to the sound of a vacuum cleaner, and 115 dB is similar to a car horn at a short distance.
From analysis of the graph it is clear that the short prepulse inhibited the response in mice to the
louder pulse by about 55% for 71-115 dB and about 70% for 77-115 dB, indicating that the
measured ‘startle’ from mice was 55-70% less intense when a prepulse was played versus when
the louder 115 dB pulse was played without the prepulse.
The black bars under the label “Vehicle” represent the inhibition when mice were treated
with methamphetamine. It is clear that under the effects of methamphetamine, the prepulse does
not cause a significant inhibition response to the louder pulse. This more erratic behavior is what
can be attributed to patients with schizophrenia, in fact studies support that almost all
schizophrenic patients have a lower PPI% then non-schizophrenic control groups (eye blink test).
The grey bars labeled “Furo” represent administration of furosemide, a known GABAA
antagonist/NAM that acts particularly strongly at the α6 site. Furosemide was used as a control
to assess whether or not the effects seen were the results of α6 modulation or interactions with
other sites in the brain. It was shown that furosemide given directly into the brain slightly
rescued PPI% in mice under the effects of methamphetamine; however, these effects may be
explained by the method in which furosemide was administered. Furosemide (pictured in Figure
10-19) does not readily cross the blood-brain-barrier because it is a very hydrophilic molecule
thus necessitating direct injection into the brain. This can perhaps effect the concentration of
methamphetamine in the brain which could explain the modest rescue of PPI. More importantly,
however, administration of furosemide negatively affected the rescue response seen from the
administration of Compound 6 and Compound 11, especially in the 77-115 dB assay. This
suggests that the PPI effects of Compound 6 and Compound 11 are mediated by α6 subtypes.
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This is an important result in terms of psychiatric diseases such as schizophrenia, OCD, and tic
diseases including Tourette syndrome among a number of other potential applications.
Figure 10-19: Structure of furosemide, an α6ß3γ2 receptor antagonist.

It was shown that both Compound 6 and Compound 11 administered i.p. at 10 mg/kg
were able to rescue PPI to a significant margin in mice under the influence of methamphetamine.
Prior data has shown that Compound 6 was not sedative or motor impairing (Chapter 10 section
2), consequently, these results indicate that Compound 6, or α6 subtypes in general, have the
ability to rescue PPI in animals with sensorimotor gating deficits. A similar assay was
subsequently completed comparing these results to some of the other new and novel α6 selective
ligands discovered thus far (Figure 10-20).
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Figure 10-20: PPI rescue of other α6 PAM’s.

Examination of this assay indicated that the α6 ligands administered i.p. at 10 mg/kg had
no effect on mice that were not under the influence of methamphetamine, again showing that
these selective and potent ligands have very little, if any, negative side-effects. This ability to
rescue PPI while at the same time showing no negative side-effects is strong evidence that these
ligands may be important pharmaceutical agents for patients with sensorimotor gating deficits.
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4.

Studies on the effects of Compound 6 on migraines.

It has been demonstrated that c-Fos-ir neurons in the trigeminal nucleus caudalis (TNC)
are associated with pain related to migraines. Specifically, the location of the TNC may offer an
anatomical explanation to the ‘back-of-the-head’ pain associated with severe migraines.85
Depicted in Figure 10-21 are data that show c-Fos positive numbers can be influenced by cranial
injection of capsaicin, the chemical component of hot peppers that causes the associated burning
sensation. It was found that i.p. injection of Compound 6 at both 3 mg/kg and 10 mg/kg
significantly reduced the c-Fos positive number, essentially lowering the pain sensation
associated with the capsaicin vehicle. This demonstrates that these novel α6 ligands can play a
potential role in negating the effects of a severe migraine.
The GABAA α6 receptor has been implicated in the past as a potential inhibitor of
trigeminal nociceptive pain based on gene knockout studies; these results confirm this with a true
α6 selective ligand with pharmaceutical potential. Examination of these results proompted
further testing in an IoN-CCI model which tests for the possibility that these ligands could treat
trigeminal neuralgia and trigeminal neuropathy.86
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Figure 10-21: Reduction of c-Fos positive numbers increased by injection of capsaisin.

5.

IoN-CCI studies.

Infraorbital nerve chronic constriction injury (IoN-CCI) is a common neuropathic pain
model. The unilateral ligature of the infraorbital nerve (IoN) in rats, as an animal model of
peripheral neuropathic pain, and more specifically, trigeminal neuralgia and trigeminal
neuropathy, was performed as described by Desuere and Hans.87 The effects of subchronic
treatment were tested with a nanoemulsion formulation of DK-I-56-1 (19) injected i.p. at 10
mg/kg. Examination of Figure 10-22 illustrates the results of this experiment.
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Figure 10-22: IoN-CCI experiment results.

Rats were injected daily for 14 consecutive days post-surgery with DK-I-56-1 and
positive effects were seen through day 21, indicating that the novel α6 selective deuterated
analog of Compound 6 (DK-I-56-1) effectively modulated pain in IoN-CCI rats. Sham
surgeries (circles) represent rats that went through the entire surgical process, however, the
infraorbital nerve was not ligated, thus pain associated with the surgery itself can be accounted
for in the control.

386

Over the course of this assay face grooming in mice was also measured (Figure 10-23),
another assay to assess whether or not negative side-effects of these ligands were present. It was
found that the mice treated with DK-I-56-1 did not differ significantly to the other control mice.
This is more confirmation that these selective ligands show no signs of the usual benzodiazepine
related side-effects.
Figure 10-23: Face grooming in DK-I-56-1 treated IoN-CCI rats.

III.

CONCLUSION.

In conclusion, it has been shown that subtype selective α6 ligands have potential as novel
and selective pharmaceutical agents to treat a number of neurological disorders including
nociceptive pain, OCD, Tourette syndrome, schizophrenia, and anxiety disorders among others.
In vitro studies have shown potent efficacy at the specific α6ß3γ2 subtype in oocytes, increased
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solubility by addition of a pyridine ring while maintaining selectivity, and a significant increase
in metabolic stability with the introduction of deuterium to ring-A or ring-D methoxy groups.
These in vitro studies laid the ground work for in vivo testing in mice and rats.
The first in vivo studies described herein were initiated to determine some of the
pharmacokinetic parameters of these compounds, principally the concentration reached in
plasma and brain tissue when administered i.p. in mice. Analysis of these data indicated that
these selective ligands readily passed the blood-brain-barrier and were thus good candidates for
further in vivo work. Studies were then initiated to determine whether or not these subtype
selective α6 ligands showed any of the usual negative effects seen with benzodiazepines such as
diazepam. Analysis of these studies indicated that Compound 6, the first reported α6 subtype
selective ligand, exhibited little or no negative side-effects when dosed i.p. in mice. In fact, a
potential anti-anxiety indication was the only result that differed from vehicle (Figures 10-15 and
10-16), clearly a positive effect.
These promising results led to further in vivo testing in models of prepulse inhibition,
migraine, and IoN-CCI assays. Analysis of all three assays showed novel potential use of these
selective α6 ligands for the treatment of different neurological diseases. Future work will include
improving solubility as well as a more thorough PK study to assess drugable characteristics of
these ligands. While Compound 6 and its related deuterated analogs already show great
promise in delivering a CNS drug with little to no negative side-effects, efforts to discover more
soluble, selective, and potent drug candidates is still ongoing. In particular, future assays to test
oral bioavailability and the design of new analogs with enhance bioavailability are particularly
exciting.
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